EP4043440A1 - Substituted nitrogen heterocyclic compound and anesthetic effect thereof - Google Patents

Substituted nitrogen heterocyclic compound and anesthetic effect thereof Download PDF

Info

Publication number
EP4043440A1
EP4043440A1 EP20875415.0A EP20875415A EP4043440A1 EP 4043440 A1 EP4043440 A1 EP 4043440A1 EP 20875415 A EP20875415 A EP 20875415A EP 4043440 A1 EP4043440 A1 EP 4043440A1
Authority
EP
European Patent Office
Prior art keywords
alkyls
halogenated
substituted
unsubstituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20875415.0A
Other languages
German (de)
French (fr)
Other versions
EP4043440A4 (en
Inventor
Jin Liu
Wensheng Zhang
Haijun Ma
Changhua WANG
Zhenbiao XIE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Mfs Pharma Co Ltd
Original Assignee
Chengdu Mfs Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201910964601.7A external-priority patent/CN110724106B/en
Priority claimed from CN201910965229.1A external-priority patent/CN110669017B/en
Priority claimed from CN202011074987.3A external-priority patent/CN112239428B/en
Priority claimed from CN202011073826.2A external-priority patent/CN112174890B/en
Application filed by Chengdu Mfs Pharma Co Ltd filed Critical Chengdu Mfs Pharma Co Ltd
Publication of EP4043440A1 publication Critical patent/EP4043440A1/en
Publication of EP4043440A4 publication Critical patent/EP4043440A4/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention belongs to the field of medicinal chemistry, and in particular relates to a novel substituted nitrogen heterocyclic compounds, as well as the use of the compound in the preparation of drugs with sedative, hypnotic and/or general anesthetic effects, as well as drugs capable of controlling the status epilepticus.
  • Heterocyclic compounds are a class of cyclic organic compounds in which the atoms constituting the ring contain atoms other than carbon (including but not limited to N, O and S). Heterocyclic compounds are widely existed in nature. Most important compounds related to biology are heterocyclic compounds, such as nucleic acids, antibiotics, hormones, pigments and alkaloids etc. Heterocyclic compounds have various of structures, Common heterocyclic compounds include furan and its derivatives, thiophene and its derivatives, pyridine and its derivatives, pyrrole and its derivatives, benzofuran and its derivatives, benzothiophene and its derivatives etc. Due to the diverse structure of heterocyclic compounds, they have been widely used in many fields, such as drugs, fungicides, protease inhibitors etc.
  • Heterocyclic compound have fastly the anesthetic effect, and it has the effect of long-term local anesthesia after a single administration, and the sensory nerve block time is greater than the motor nerve block time, and it has both long-acting local anesthesia and selective local anesthesia, and can be used as a long-acting local anesthetic.
  • general anesthetics are needed to suppress the patient's central nervous system and make the patient's consciousness disappear.
  • Etomidate is containing 5-membered heterocyclic group of imidazole derivative, which has the effects of sedation, hypnosis and anesthesia. It has been one of the commonly used drugs for anesthesia induction, and has been used in clinical practice for more than 30 years. Its pharmacological characteristics are outstanding: rapid induction of anesthesia, little impact on respiration and stable hemodynamics during single or continuous infusion. ( Br J Anaesth. 1976; 48(3): 213-6. PubMed: 1259887 ; Arch Int Pharmacodyn Ther. 1975; 214(1): 92 -132. PubMed: 1156027 ; Acad Emerg Med. 2006; 13(4): 378-83. PubMed: 16531603 ).
  • the structure of etomidate is as follows, it is a ester substituted heterocyclic compound:
  • the present invention provides a novel series of substituted nitrogen heterocyclic compounds.
  • the present invention further provides that the substituted nitrogen heterocyclic derivatives can use in the preparation of drugs with sedative, hypnotic and/or anesthetic effects, together with drugs capable of controlling the status epilepticus.
  • the present invention provides compounds of formula I, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof:
  • R C4a is selected from the group consisting of substituted or unsubstituted C 2-6 alkenyls, substituted or unsubstituted C 2-6 alkynyls, substituted or unsubstituted 3 ⁇ 6-membered saturated or unsaturated heterocyclyls, substituted or unsubstituted 3 ⁇ 6-membered saturated or unsaturated cycloalkyls; Said substituents are independently of each other selected from the group consisting of C 1-5 alkyls, C 1-5 alkoxyl, halogen, hydroxyl;
  • X C is O or S
  • R C4a is selected from the group consisting of substituted or unsubstituted C 2-3 alkenyls, substituted or unsubstituted C 2-3 alkynyls, substituted or unsubstituted 3 ⁇ 4-membered saturated epoxyls; said substituents are independently of each other selected from C 1-3 alkyls;
  • L C3 is selected from substituted or unsubstituted C 1-3 alkylenyls, said substituents is selected from the group consisting of C 1-3 alkyls, C 1 ⁇ 5 alkoxyl;
  • n is an integer of 0 ⁇ 3;
  • X D is O or S
  • R D7 is selected from hydrogen or X Dc R D4c ;
  • R D7 is selected from hydrogen, X Dc R D4c ;
  • X D is O or S, preferable selection is O;
  • R D7 is selected from hydrogen or X Dc R D4c ;
  • the present invention also provides a drug, it is prepared by anyone of the above compounds, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, or their combinations as active ingredients, with addition of pharmaceutically acceptable excipients.
  • the present invention also provides the use of anyone of the above compounds , or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, or their combinations in preparation of drugs having sedative, hypnotic, and/or anesthetic effects and/or drugs that can be used to control epileptic status.
  • the said "sedative drug” in the present invention is a kind of drug thathas a sedative effect and can effectively help sleep and improve sleep, and this drug can avoid the serious harm of insomnia to human body, treat insomnia and improve sleep quality.
  • the said "hypnotic drug” in the present invention denotes a drug that has a hypnotic effect, which can induce drowsiness and promote sleep.
  • the drug has an effect of the central nervous system inhibition, and small dose causes sedation and excessive dose results in general anesthesia.
  • the said "anesthetic drug” in the present invention denotes a kind of drug that has a hypnotic effect, which canproduce a reversible functional inhibition of the central nervous system and / or peripheral nervous system and this inhibiton is mainly characterized by loss of sensation, especially sense of pain.
  • the anesthesia is general anesthesia.
  • the "general anesthesia” mentioned in the present invention denotes that the anesthetics inside the vivo cause the temporary inhibition of central nervous system.
  • the clinical manifestations are loss of consciouseness, disappearance of generalized sense of pain, amnesia, inhibitory reflex and skeletal muscle relaxation.
  • the "status epilepticus.” mentioned in the present invention denotes the epilepsy frequently recurs without complete recovery of consciousness between successive seizures and or does not stop automatically after the seizure lasts for more than 30 minutes .
  • Long-lastingseizure of epilepsy if not be treated in time, would lead to irreversible brain injury due to high fever, circulatory failure or neuronal excitotoxic injury with high disability rate and mortality, so epilepsy is a common emergency in internal medicine.
  • the present invention provides a drug, that is prepared by using compounds mentioned above, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof as active ingredients, with addition of pharmaceutically acceptable excipients.
  • the compounds and derivatives provided in the present invention can be named according to IUPAC (International Union of Pure and Applied Chemistry) or CAS (Chemical Abstracting Service, Columbus, OH) naming system.
  • substitution means that one or more hydrogen atoms in a molecule are replaced by other atoms or molecules that are not hydrogen, including one or more substitutions on the homotopic atoms or heterotopic atoms in the molecule.
  • the structures of the compounds mentioned in the present invention denote the stable existence structures.
  • Deuterium denotes the isotope of hydrogen (H), also known as heavy hydrogen, and the elemental symbol is generally D or 2H.
  • the minimum and the maximum number of carbon atoms in hydrocarbon groups are represented by prefixes, for example, the prefix (C a ⁇ C b ) alkyls indicate any alkyls containing "a" ⁇ "b" carbon atoms. Therefore, for example, C 1 ⁇ C 8 alkyls denote alkyls containing 1 ⁇ 8 carbon atoms. C 1 ⁇ C 8 alkyls arelinear or branched hydrocarbon chains containing 1 ⁇ 8 carbon atoms.
  • Alkyls is a hydrocarbon group formed by losing one hydrogen in an alkane molecule, such as methyl -CH 3 , ethyl -CH 3 CH 2 , etc.
  • Alkylenyls denotes the hydrocarbon group formed by losing two hydrogens in the alkane molecule, such as methylene-CH 2 -, ethylidene-CH 2 CH 2 -, etc.
  • C 1-8 alkylenyls denotes a linear or branched hydrocarbon chain containing 1 ⁇ 8 carbon atoms.
  • Substituted or unsubstituted C 1-8 alkyls denotes C 1-8 alkyls that can be substituted or not be substituted.
  • Ring A is none of in the present invention denotes L 1 and L 2 are connected directly by chemical bonds.
  • 3 ⁇ 6-membered saturated carbocycles in “ring A is 3 ⁇ 6-membered saturated carbocycles” mentioned in the present invention denotes a carbocycle consisting of 3 ⁇ 6 carbons, in which no double bond exists.
  • 3 ⁇ 6-membered unsaturated carbocycles in “ring A is 3 ⁇ 6-membered unsaturated carbocycles” mentioned in the present invention denotes a carbocycle consisting of 3 ⁇ 6 carbons, in which double bond exists.
  • 3 ⁇ 6-membered saturated heterocycles in “ring A is 3 ⁇ 6-membered saturated heterocycles” mentioned in the present invention denotes a saturated heterocycle without double bonds, in which there is at least one atom selected from O, S, or substituted N, and the remaining ring atoms are carbons.
  • 3 ⁇ 6-membered unsaturated heterocycles in “ring A is 3 ⁇ 6-membered unsaturated heterocycles” mentioned in the present invention denotes a saturated heterocycle without double bonds, in which there is at least one atom selected from O, S, or substituted N, and the remaining ring atoms are carbons.
  • Alkynyls denotes aliphatic hydrocarbon groups with at least one C ⁇ C triple bond. Said alkynyls can be linear or branched chain. When there is a limited carbon numbers before alkynyls (such as C 2-8 alkynyls), for example, the term “C 2-8 alkynyls” denotes a linear or branched alkynyls with 2 ⁇ 8 carbons.
  • dienyls denotes aliphatic hydrocarbon groups with two double bonds among carbons. Said dienyls could be linear or branched chain. When there is a limited carbon numbers before “dienyls”, for example, “C 3-6 dienyls” denotes a linear or branched dienyls with 3 ⁇ 6 carbons ,such as the structures of "propadienyls" are
  • Halogen is fluorine, chlorine, bromine, or iodine.
  • Aryls denote all-carbon monocyclic or fused polycyclic (i.e. ring sharing adjacent carbon atom pairs) groups with conjugated ⁇ electron system, such as phenyl and naphthyl. Said aryl ring can be fused to other cyclic groups (including saturated and unsaturated rings), but can not contain hetero atoms such as nitrogen, oxygen, or sulfur. At the same time, the site connected with the parent must be on the carbon in the ring having the conjugated ⁇ electron system. Aryls can be substituted or unsubstituted.
  • Heteroaryls denote the heteroaromatic group containing one or more heteroatoms.
  • the heteroatoms mentioned herein include oxygen, sulfur, and nitrogen.
  • the heteroaromatic ring can be fused to aryls, heterocyclic group or cycloalkyl ring, in which the ring connected with the parent structure is heteroaromatic ring.
  • Heteroaryls can be substituted or unsubstituted.
  • Cycloalkyls denote saturated or unsaturated cyclic hydrocarbon substituents; cyclic hydrocarbon can have one or more rings.
  • C 3-8 cycloalkyls denote cycloalkyls having 3 ⁇ 8 carbons.
  • Heterocyclyls denotes saturated or unsaturated cyclic hydrocarbon substituents; cyclic hydrocarbon can have one or more rings with at least one heteroatom (including but not limited to O, S or N).
  • C 3-8 heterocyclyls denote saturated or unsaturated cyclic hydrocarbon substituents; cyclic hydrocarbon could be mono cyclic and poly cyclic containing at least one atom selected from O, S or substituted N, other ring atioms are carbons.
  • C 1-4 alkyls, or halogenated or deuterated derivatives thereof denots C 1-4 alkyls, halogenated or deuterated C 1-4 alkyls.
  • Other related terms "or halogenated or deuterated derivatives thereof” have the similar definition.
  • each chiral carbon atom (chiral center) can be optionally R-configurated or S-configurated, or a mixture of R-configuration and S-configuration.
  • “Pharmaceutically acceptable carriers” denote one or more compatible solid or liquid filling materials or gel substances, which are suitable for human use and must be of sufficient purity and low toxicity. "Compatibility” herein means that each component in the composition can be mixed with the compounds of the present invention without reducing the efficacy of the compounds obviously.
  • Some examples of pharmaceutically acceptable carriers are cellulose and its derivatives (such as carboxymethylcellulose sodium, ethylcellulose sodium, cellulose acetate, etc.), gelatin, talcum, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oil (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifier (such as Tween ® ), wetting agent (such as sodium dodecyl sulfate), colorant, seasoning agent, stabilizer, antioxidant, preservative, pyrogen free water, etc.
  • solid lubricants such as stearic acid, magnesium stearate
  • calcium sulfate such as soybean oil, sesame oil, peanut oil, olive oil, etc.
  • polyols such as propylene glycol, glycerin,
  • pharmaceutically acceptable salt denotes the salt formed by the compounds of the present invention and pharmaceutically acceptable inorganic and organic acids, which is suitable for contacting the tissue of the object (e.g. human) without undue side effects.
  • the preferred inorganic acids include (but not limited to) hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid;
  • the preferred organic acids include (but not limited to) formic acid, acetic acid, propionic acid, succinic acid, naphthalene disulfonic acid (1,5), asiatic acid, oxalic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, valeric acid, diethylacetic acid, malonic acid, succinic acid, fumaric acid, pimelic acid, adipic acid, maleic acid, malic acid, sulfamic acid, phenylpropionic acid, gluconic acid, ascorbic acid, niaci
  • pharmaceutically acceptable solvate denotes the solvate formed by the compounds of the present invention and pharmaceutically acceptable solvents, in which the pharmaceutically acceptable solvent includes (but not limited to) water, ethanol, methanol, isopropanol, propylene glycol, tetrahydrofuran, and dichloromethane.
  • the term "pharmaceutically acceptable stereoisomer” means that the chiral carbon atom involved in the compounds of the present invention may be R-configuration, S-configuration, or a combination thereof.
  • the compounds of the present invention or composition thereof, as well as the use method thereof The compounds of the present invention, and various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates thereof, as well as the pharmaceutical composition containing the compounds of the present invention as the main active ingredients can be used for sedation, hypnosis and/or general anesthesia.
  • the compounds of the present invention can also be used for controlling epileptic persistent state and the like.
  • the pharmaceutical composition of the present invention includes a compound of the present invention or a pharmaceutically acceptable salt thereof within a safe and effective amount, as well as a pharmaceutically acceptable excipient or carrier thereof.
  • the administration ways for the compound or pharmaceutical composition of the present invention include (but not limited to) intragastric, intraintestinal, extragastrointestinal (intravenous, intramuscular or subcutaneous), oral and various local administration.
  • composition for extragastrointestinal injection may contain physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powder used for reconstitution into sterile injectable solutions or dispersions.
  • Suitable aqueous and nonaqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and their suitable mixtures.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or mixed with following ingredients: (a) bulking agent or compatibilizer, such as starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binding agent, such as hydroxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and gum arabic; (c) moisturing agent, such as glycerin; (d) disintegrating agent, such as agar, calcium carbonate, potato starch or cassava starch, alginate, some complex silicates, and sodium carbonate; (e) solvents, such as paraffin; (f) absorption accelerators, such as quaternary amine compounds; (g) wetting agents, such as cetyl alcohol and glycerin monostearate; (h)
  • the dosage form may also include buffers.
  • the liquid dosage forms used for oral administration include pharmaceutically acceptable emulsion, solution, suspension, syrup or tincture.
  • the liquid dosage form may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide and oil, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or the mixture thereof, etc.
  • Solid dosage forms such as tablets, sugar pills, capsules, pills and granules can be prepared by coating and shell materials, such as casing and other materials known in the art. They may comprise an opaque agent, and the release of the active compound or compound in the composition may be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymers and waxes. If necessary, the active compound may also form a microcapsule form with one or more of above excipients.
  • the dosage form of the compound of the present invention for local administration includes ointment, powder, patch, spray and inhalant.
  • the active ingredient is mixed in sterile conditions with a biologically acceptable carrier and any preservatives, buffers, or propellants that may be required if necessary.
  • the composition may also include auxiliaries such as wetting agents, emulsifiers and suspensions, sweeteners, flavoring agents and perfumes.
  • the suspension may contain a suspending agent, such as ethoxylated isooctadecanol, polyoxyethylene sorbitol and dehydrated sorbitol ester, microcrystalline cellulose, aluminum methoxide and agar or the mixture thereof, etc.
  • the compound of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds.
  • the safe and effective amount of the compound of the present invention is administrated to the mammal (such as human) in need thereof, in which the dosage is the pharmaceutically acceptable safe and effective dosage.
  • the safe and effective amount of the compound of the present invention is administrated to the mammal (such as human) that need to be treated, in which the pharmaceutically effective dosage is given.
  • the daily dosage is usually 1-2000 mg, preferably 5-500 mg.
  • the specific dose should be adjusted dependent on the route of administration, the health status of patients and other factors, that are all within the scope of technical skill of practical physicians.
  • Said "room temperature" of the present invention is 25 ⁇ 5°C.
  • Said "overnight" of the present invention is 12 ⁇ 1 hours.
  • Said " 1N HCl" of the invention is 1 mol/L HCl.
  • the experimental results show that the present invention of substituted nitrogen heterocyclic compounds have better depressant effects on the central nervous system and produce sedative, hypnotic and/or anesthetic action as well as control of epilepsy persistence;
  • the substituted nitrogen heterocyclic compounds not only maintain excellent anesthetic activity, but also has the characteristics of rapid onset and rapid recovery;
  • the substituted nitrogen heterocyclic compounds have almost no inhibitory effect on the function of adrenal cortex and has little side effects, which solves the technical problems in the field.
  • the present invention provides a new choice for clinically screening and /or preparing sedative, hypnotic and/or general anesthesia drugs and drugs for controlling status epilepticus.
  • Agilent LCMS 1260-6110 was used in the present invention.
  • the mobile phases were composed of 0.05% TFA in water (A) and 0.05% TFA in Acetonitrile (B).
  • a gradient elution was applied from 95% A and 5% B to 0% A and 100% B within 3 mins, then extended for another 1 min, and at end changed back to 95% A and 5% B within 0.05 mins and kept eluting for another 0.7 mins.
  • the silica gel plate (HSGF254) for thin layer chromatography was bought from Yantai Xinnuo Chemical Co., Ltd, with the thickness of 1 mm.
  • Thin layer chromatography was bought from Yantai Jiangyou silicone Development Co., Ltd., with the thickness of 0.2 ⁇ 0.03 mm.
  • Silica gel used for column chromatography was mostly made by Rushan Sun Desiccant Co., Ltd. (Weihai, Shandong) with 100-200 meshes or 200-300 meshes.
  • the target compounds A3 ⁇ A48 were prepared according to the general procedure A , using A (100 mg, 0.41 mmol) and corresponding alcohol (0.61 mmol) as starting materials.
  • the target compounds A51 ⁇ A69 were prepared according to the general procedure A , using B (100 mg, 0.43 mmol) and corresponding alcohol (0.64 mmol) as starting materials.
  • the target compounds A72 ⁇ A90 were prepared according to the general procedure A, using C (100 mg, 0.43 mmol) and corresponding alcohol (0.64 mmol) as starting materials.
  • (S)-1-phenylethan-1-ol ( 1-1) (20 g, 164 mmol) and PPh 3 (85.9 g, 328 mmol) were dissolved in THF (300 mL) at 0°C.
  • DEAD (57.1 g, 328 mmol) in THF (50 mL) was added dropwise into the mixture at the rate of 10 mmol/min, then DPPA (54.1 g, 197 mmol) was added dropwise into the mixture at the rate of 6 mmol/min.
  • the mixture was warmed to room temperature slowly and allowed to react for overnight.
  • the target compounds B3 ⁇ B32 were prepared according to the general procedure A, using (R)-1-(1-phenylethyl)-1 H -1,2,3-triazole-5-carboxylic acid A (100 mg, 0.46 mmol) and corresponding alcohols (0.69 mmol) as starting materials.
  • the target compounds B35 ⁇ B64 were prepared according to the general procedure A, using (R)-4-fluoro-1-(1-phenylethyl)-1 H -1,2,3-triazole-5-carboxylic acid B (100 mg, 0.46 mmol) and corresponding alcohols (0.69 mmol) as starting materials.
  • Ethyl 3-chloropropiolate ( 65-1) and (R)-(1-azidoethyl)benzene 1-2 (3.2 g, 21.7 mmol) were dissolved in toluene (100 mL), then the mixture was refluxed for 14 hrs. The reaction was monitored by TLC until completion. The mixture was quenched with the saturated brine (30 mL) and extracted with ethyl acetate (3 ⁇ 30 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
  • the target compounds B67 ⁇ B98 were prepared according to the general procedure A, using (R)-4-chloro-1-(1-phenylethyl)-1 H -1,2,3-triazole-5-carboxylic acid C (80 mg, 0.32 mmol) and corresponding alcohols (0.48 mmol) as starting materials.
  • the target compounds B101 ⁇ B126 were prepared according to the general procedure A, using (R)-4-bromo-1-(1-phenylethyl)-1 H -1,2,3-triazole-5-carboxylic acid ( D ) (100 mg, 0.34 mmol) and corresponding alcohols (0.51 mmol) as starting materials.
  • the target compounds B129 ⁇ B144 were prepared according to the general procedure A, using (R)-4-iodo-1-(1-phenylethyl)-1 H -1,2,3-triazole-5-carboxylic acid ( E) (100 mg, 0.29 mmol) and corresponding alcohols (0.44 mmol) as starting materials.
  • PTSA.H 2 O 99 mg, 0.52 mmol was added into the solution of the crude product 1-1 (171 mg) in acetone (5 mL). Then the mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC until completion, the ice-water (10 mL) was added slowly into the mixture and extracted with ethyl acetate (3 ⁇ 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
  • the target compounds C2 ⁇ C7 were prepared according to the operation method of preparing compound C1 .
  • Compound A reacted with corresponding halides under NaH condition to give intermediate compounds 2-1 ⁇ 7-1, which were deprotected with PTSA.H 2 O to give target compounds C2 ⁇ C7 .
  • the target compound C10 were prepared according to the operation method of preparing compound C9.
  • compound 9-1 reacted with sodium cyclobutyl methanethiolate to give the compound C10 (87 mg, yield 43%).
  • (R)-1-(1-phenylethyl)-1 H -pyrazole-5-carbaldehyde 11-2 (451 mg, 2.25 mmol) was dissolved in anhydrous THF (20 mL). The mixture was replaced with nitrogen and cooled to -15°C with an ice-brine bath. Prop-1-yn-1-ylmagnesium bromide (3.4 mL, 0.5 mol/L in THF, 2.70 mmol) was added dropwise into the mixture at the rate of 0.5 mmol/min at -15°C. Then the mixture was warmed to room temperature slowly and allowed to react for 2 hrs.
  • reaction was monitored by TLC until completion, then it was cooled to 0°C with an ice-water bath, quenched with saturated ammonium chloride (50 mL) and extracted with ethyl acetate (3 ⁇ 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure.
  • the target compounds C14 and C15 were prepared according to the operation method of preparing compound C1 .
  • Compound B reacted with corresponding halides under NaH condition to give intermediate compounds 14-1 and 15-1, which were deprotected with PTSA.H 2 O to give target compounds C14 and C15.
  • the target compounds C17 ⁇ C24 were prepared according to the operation method of preparing compound C1 .
  • Compound C reacted with corresponding halides under NaH condition to give intermediate compounds 17-1 ⁇ 24-1, which were deprotected with PTSA.H 2 O to give target compounds C17 ⁇ C24 .
  • the target compounds C26 ⁇ C49 were prepared according to the operation method of preparing compound C1 .
  • Compound D reacted with corresponding halides under NaH condition to give intermediate compounds 26-1 ⁇ 49-1, which were deprotected with PTSA.H 2 O to give target compounds C26 ⁇ C49.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed in the present invention are a substituted nitrogen heterocyclic compound and anesthetic action thereof. Specifically provided a chemical compound as shown in formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, a prodrug thereof, a metabolite thereof or a deuterated derivative thereof. The substituted nitrogen heterocyclic compound provided in the present application has good central nervous system inhibition effects, capable of generating sedative, hypnotic and/or general anesthetic effects, and capable of controlling status epilepticus; said substituted nitrogen heterocyclic compound is also characterized by rapid onset of action and rapid recovery, while maintaining positive anesthetic activity; in addition, said substituted nitrogen heterocyclic compound has almost no inhibitory effect on adrenocortical function, low side effects, and resolves technical difficulties in the art. The present invention provides a new selection for clinical screening and/or preparation of sedative, hypnotic and/or general anesthetic drugs and drugs controlling status epilepticus.

Description

    Technical field
  • The present invention belongs to the field of medicinal chemistry, and in particular relates to a novel substituted nitrogen heterocyclic compounds, as well as the use of the compound in the preparation of drugs with sedative, hypnotic and/or general anesthetic effects, as well as drugs capable of controlling the status epilepticus.
    • Background art
  • Heterocyclic compounds are a class of cyclic organic compounds in which the atoms constituting the ring contain atoms other than carbon (including but not limited to N, O and S). Heterocyclic compounds are widely existed in nature. Most important compounds related to biology are heterocyclic compounds, such as nucleic acids, antibiotics, hormones, pigments and alkaloids etc. Heterocyclic compounds have various of structures, Common heterocyclic compounds include furan and its derivatives, thiophene and its derivatives, pyridine and its derivatives, pyrrole and its derivatives, benzofuran and its derivatives, benzothiophene and its derivatives etc. Due to the diverse structure of heterocyclic compounds, they have been widely used in many fields, such as drugs, fungicides, protease inhibitors etc.
  • Studies have found that some heterocyclic compounds with special structures have the effect of sedation and anesthesia. CN111153851A disclosed a quaternary ammonium salt heterocyclic compound and preparation method and use thereof. Heterocyclic compound have fastly the anesthetic effect, and it has the effect of long-term local anesthesia after a single administration, and the sensory nerve block time is greater than the motor nerve block time, and it has both long-acting local anesthesia and selective local anesthesia, and can be used as a long-acting local anesthetic. However, for some patients who require major surgery, general anesthetics are needed to suppress the patient's central nervous system and make the patient's consciousness disappear. Etomidate is containing 5-membered heterocyclic group of imidazole derivative, which has the effects of sedation, hypnosis and anesthesia. It has been one of the commonly used drugs for anesthesia induction, and has been used in clinical practice for more than 30 years. Its pharmacological characteristics are outstanding: rapid induction of anesthesia, little impact on respiration and stable hemodynamics during single or continuous infusion. (Br J Anaesth. 1976; 48(3): 213-6. PubMed: 1259887; Arch Int Pharmacodyn Ther. 1975; 214(1): 92 -132. PubMed: 1156027; Acad Emerg Med. 2006; 13(4): 378-83. PubMed: 16531603). The structure of etomidate is as follows, it is a ester substituted heterocyclic compound:
    Figure imgb0001
    • However, the disadvantages of etomidate gradually was appeared when use in the clinical, which limits its application. For example, it's awakening quality is slightly worse than that of another general anesthetic propofol, which can reduce the survival rate of critically ill patients by inhibiting the function of adrenal cortex(Lancet. 1983; 1(8339): 1434. PubMed: 6134189; Crit Care. 2007; 11(3): 145. PubMed: 17610749; Anesthesiology. 2011; 114(3): 695-707. PubMed: 21263301); (Cochrane Database Syst Rev. 2015; 1: CD010225. PubMed: 25568981). It has been reported that a single injection of etomidate can also inhibit adrenal cortex function for up to 6 to 8 hours, increasing mortality in hospitalized patients(Klin Wochenschr. 1984; 62 (21): 1014-7. PubMed: 6096626) (Crit Care Med. 2012; 40(11): 2945-53. PubMed: 22971586; Anesth Analg. 2013; 117(6): 1329-37. PubMed: 24257383);
    • The literature suggests that etomidate can inhibit the key enzymes in the synthesis pathway of adrenocortical hormone (11 β- Hydroxylase) to inhibit adrenocortical function (n Engl J Med. 1984; 310 (22): 1415-21 PubMed: 6325910; J Clin Endocrinol Metab. 1984; 59(6): 1143-7. PubMed: 6092411)∘ Further studies showed that the inhibition was mainly due to the fact that the basic nitrogen on the imidazole ring in the molecular structure of etomidate could interact with 11 β- Heme iron on hydroxylase binds to inhibit the activity of the enzyme (J compute aided mol des. 2007; 21 (8): 455-71 PubMed: 48126)∘ However, in fact, not all heterocyclic compounds containing imidazole rings can inhibit the function of adrenal cortex, such as etomidate acid, the metabolite of etomidate, cyclopropyl methoxycarbonyl metamidate (CPMM), etc. (Anesthesiology. 2016; 125 (5): 943-951 PubMed: 27541316)∘
  • Therefore, it is of great clinical significance and wide application prospect to design a new compound which can not only keep the excellent characteristics of etomidate general anesthesia activity, but also not inhibit the synthesis of adrenocortical hormone.
    • Content of the present invention
  • In order to solve above problems, the present invention provides a novel series of substituted nitrogen heterocyclic compounds. The present invention further provides that the substituted nitrogen heterocyclic derivatives can use in the preparation of drugs with sedative, hypnotic and/or anesthetic effects, together with drugs capable of controlling the status epilepticus.
  • The present invention provides compounds of formula I, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof:
    Figure imgb0002
    • R1 is independently selected from the group consisting of deuterium, halogen, - CN, -NO2, -OR32, -C(O)R31, -CO2R31, -CON(R32)2, -N(R32)2, -OC(O)R31, -SO2R31, substituted or unsubstituted 3~8-membered heterocyclic groups, substituted or unsubstituted C1-8 alkyls, substituted or unsubstituted C1-8 alkoxyl, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls;
    • Wherein, R31 is independently of each other selected from the group consisting of deuterium, R32, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls; R32 is independently of each other selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyls, substituted or unsubstituted C3-8 cycloalkyls, substituted or unsubstituted 3~8-membered heterocyclic groups, substituted or unsubstituted aryls, and substituted or unsubstituted heteroaryls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclic groups or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, and heteroaryls or their halogenated or deuterated derivatives;
    • For above R1, R31, R32, said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclic groups or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    • n is an integer of 0~5;
    • R2 is selected from the group consisting of hydrogen, deuterium, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C1-8 alkoxyl or their halogenated or deuterated derivatives, C2-8 alkenyls or their halogenated or deuterated derivatives, C2-8 alkynyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclic groups or their halogenated or deuterated derivatives;
    • K1 is selected from N or CRk1, K2 is selected from N or CRk2;
    • K3 is CRk3, R is selected from
      Figure imgb0003
    • or, K3 is CRk0, R is Rk3, Rk0 is selected from
      Figure imgb0004
      Figure imgb0005
    • Rk1, Rk2, Rk3 are independently selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-8 alkyls, N(R3k)2; said substituents are deuterium, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C1-8 alkoxyls or their halogenated or deuterated derivatives, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclic groups or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives, -N(R3k)2, R3k is H or C1-8 alkyls;
    • X is selected from O, S or NR30, wherein, R30 is selected from hydrogen or C1-8 alkyls; L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-8 alkylenyls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C2-8 alkenyls or their halogenated or deuterated derivatives, C2-8 alkynyls or their halogenated or deuterated derivatives, C1-8 alkoxyls or their halogenated or deuterated derivatives, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclic groups or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    • L1 and L2 can be connected to the homotopic or heterotopic atoms on the A ring; m is an integer of 0~4;
    • Ring A is none, or, ring A is selected from 3~8-membered saturated carbocycles, 3~8-membered unsaturated carbocycles, 3~8-membered saturated heterocycles or 3~8-membered unsaturated heterocycles;
    • R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl,
      Figure imgb0006
       substituted or unsubstituted C1-8 alkyls, -OR33, -SR33, -OC(O)R14, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls aryls, heteroaryls, -N(R33)2, - C(O)R34, -C(S)R34, -S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls, cyano, isocyano, isothiocyano, nitro, -L33-R36 or =R39;
    • L33 is selected from C1-4 alkylenyls;
    • R36 is selected from cyano, nitro, -OC(O)R34, -C(O)R34, -S(O)R34, -C(O)N(R33)2;
    • R33 is selected from the group consisting of hydrogen, methylsulfonyl, -L31-COO-L32, and the following substituted or unsubstituted groups: C1-8 alkyls, C3-8 cycloalkyls, 3~8-membered heterocyclylss, aryls, heteroaryls;
    • R34 is selected from the group consisting of R33, deuterium, and the following substituted or unsubstituted groups: C1-8 alkoxyl, C2-8 alkenyls, C2-8 alkynyls, or - S-C1-8 alkyls;
    • L31 is selected from the substituted or unsubstituted C1-8 alkylenyls; L32 is selected from the substituted or unsubstituted C1-8 alkyls;
    • For above R5, R33, R34, said substituents are selected from group consisting of deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives, -S-C1-4 alkyls, di-substituted cyclic carbonyls, =R39, C2-8 alkenyls or C2-8 alkynyls;
    • R39 is selected from O, S, NR40 or C(R41)2; R40 is selected from hydrogen, halogen, C1-4 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
    • R0 is selected from LC3RC4, LC1XCLC2RC5;
    • LC3 is selected from none, substituted or unsubstituted C1~4 alkylenyls, said substituents in C1~4 alkylenyls are selected from the group consisting of C1-5 alkyls, C1~5 alkoxyl, halogen, hydroxyl;
    • RC4 is selected from the group consisting of substituted or unsubstituted C2~6 alkenyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted 3~6-membered saturated or unsaturated heterocyclyls, substituted or unsubstituted 3~6-membered saturated or unsaturated cycloalkyls, COR4d; said substituents are independently of each other selected from LC4R4e; R4d is selected from C1~6 alkyls; LC4 is selected from the group consisting of none, substituted or unsubstituted C1-4 alkylenyls; R4e is selected from the group consisting of C1~5 alkyls, C1~5 alkoxyl, halogen, hydroxyl;
    • LC1 is selected from substituted or unsubstituted C1~3 alkylenyls, said substituents is selected from C1-5 alkyls;
    • XC is O or S;
    • LC2 is selected from none, substituted or unsubstituted C1-3 alkylenyls, said substituents are selected from the group consisting of C1-4 alkyls, C1~4 alkoxyl, L2aR5g; L2a is selected from none, C1~2 alkylenyls; R5g is selected from halogen, C1~4 alkoxyls;
    • RC5 is selected from the group consisting of hydrogen, halogen, C1~5 alkyls, C2~4 alkenyls, C2~4 alkynyls, COR4d, C3~6 di-alkenyls, C1~5 alkoxyl, 3~6-membered saturated or unsaturated heterocyclyls all of which are substituted by one or more R5c, 3~6-membered saturated or unsaturated cycloalkyls all of which are substituted by one or more R5c; R4d is selected C1~6 alkyls, R5c is selected from the group consisting of halogen, =R5d, L1aR5e, C3~6 di-alkenyls; R5d is CH2, O or S, L1a is C1~3 alkylenyls, R5e is C1~5 alkyls, C1~5 alkoxyl;
    • MD is selected from CO or CRD6RD7, RD6 is selected from hydrogen, XDbRD4b, RD7 is selected from hydrogen, XDcRD4c;
    • XD is O or S; XDb is O or S; XDc is O or S;
    • Ra is selected from the group consisting of substituted or unsubstituted C1~6 alkyls, substituted or unsubstituted C2~6 alkynyls, substituted or unsubstituted C2~6 alkenyls, substituted or unsubstituted 3~6-membered saturated or unsaturated heterocyclyls, substituted or unsubstituted 3~6-membered saturated or unsaturated cycloalkyls; said substituents are independently of each other selected from the group consisting of C3~6 di-alkenyls, C1~5 alkyls, C1~5 alkoxyl, halogen, hydroxyl;
    • RD4b, RD4c are independently of each other selected from the group consisting of substituted or unsubstituted C1~6 alkyls, substituted or unsubstituted C2~6 alkynyls, substituted or unsubstituted C2~6 alkenyls, CORDf, substituted or unsubstituted 3~6-membered saturated or unsaturated heterocyclyls groups, substituted or unsubstituted 3~6-membered saturated or unsaturated cycloalkyls; said substituents are independently of each other selected from the group consisting of C3~6 di-alkenyls, C1~5 alkyls, C1~5 alkoxyl, halogen, hydroxyl; RDf is selected from C1~5 alkyls; Or, when MD is CRD6RD7and RD6 is XDbRD4b, RD4b and Ra is connected to get the substituted or unsubstituted 3~6-membered saturated or unsaturated heterocyclyls said saturated or unsaturated heterocyclic substituents is selected from the group consisting of halogenated or un-halogenated C1~6 alkyls, halogenated or un-halogenated C2~6 alkynyls, halogenated or un-halogenated C2~6 alkenyls, CORDf; RD7 is selected from the group consisting of hydrogen, XDcRD4c, XDc is O or S, RD4c is selected from the group consisting of substituted or unsubstituted C1~6 alkyls, substituted or unsubstituted C2~6 alkynyls, substituted or unsubstituted C2~6 alkenyls, CORDf, substituted or unsubstituted 3~6-membered saturated or unsaturated heterocycyls, substituted or unsubstituted 3~6-membered saturated or unsaturated cycloalkyls; said substituents are independently of each other selected from the group consisting of C3~6 di-alkenyl, C1~5 alkyls, C1~5 alkoxyl, halogen, hydroxyl; RDf is selected from C1~5 alkyls.
  • Further, said compound is represented by formula A-I:
    Figure imgb0007
    • R1 is independently of each other selected from the group consisting of deuterium, halogen, -CN, -NO2,-OR32, -C(O)R31, -CO2R31, -CON(R32)2, -N(R32)2, -OC(O)R31, -SO2R31, substituted or unsubstituted 3~8-membered heterocyclyls, substituted or unsubstituted C1-8 alkyls, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls;
    • Wherein, R31 is independently of each other selected from the group consisting of deuterium, R32, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls, R32 is independently of each other selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyls, substituted or unsubstituted C3-8 cycloalkyls, substituted or unsubstituted 3~8-membered heterocyclyls, substituted or unsubstituted aryls, and substituted or unsubstituted heteroaryls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    • For above R1, R31, R32, said substituents are selected from the group consisting of deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclylss or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    • n is an integer of 0~5;
    • R2 is selected from the group consisting of hydrogen, deuterium, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C1-8 alkoxyl or their halogenated or deuterated derivatives, C2-8 alkenyls or their halogenated or deuterated derivatives, C2-8 alkynyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives;
    • R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-8 alkyls; said substituents is deuterium, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C1-8 alkoxyl or their halogenated or deuterated derivatives, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    • X is selected from O, S or NR30, wherein, R30 is selected from hydrogen, deuterium or C1-8 alkyls;
    • L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-8 alkylenyls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C2-8 alkenyls or their halogenated or deuterated derivatives, C2-8 alkynyls or their halogenated or deuterated derivatives, C1-8 alkoxyls or their halogenated or deuterated derivatives, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    • L1 and L2 can be connected to thehomotopic or heterotopic atoms on the A ring; m is an integer of 0~4;
    • Ring A is none, or, ring A is selected from 3~8-membered saturated carbocycles, 3~8-membered unsaturated carbocycles, 3~8-membered saturated heterocycles or 3~8-membered unsaturated heterocycles;
    • R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl,
      Figure imgb0008
       substituted or unsubstituted C1-8 alkyls, -OR33, -SR33, -OC(O)R14, C3-8-membered cycloalkyls, 3~8-membered heterocycyls, aryls, heteroaryls, -N(R33)2, - C(O)R34, -C(S)R34, -S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls, cyano, isocyano, isothiocyano, nitro, -L33-R36 or =R39;
    • L33 is selected from C1-4 alkylenyls;
    • R36 is selected from cyano, nitro, -OC(O)R34, -C(O)R34, -S(O)R34, -C(O)N(R33)2;
    • R33 is selected from the group consisting of hydrogen, methylsulfonyl, -L31-COO-L32, the following substituted or unsubstituted groups: C1-8 alkyls, C3-8 cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls;
    • R34 is selected from the group consisting of R33, deuterium, the following substituted or unsubstituted groups: C1-8 alkoxyl, C2-8 alkenyls, C2-8 alkynyls or - S-C1-8 alkyls;
    • L31 is selected from the substituted or unsubstituted C1-8 alkylenyls; L32 is selected from the substituted or unsubstituted C1-8 alkyls;
    • For above R5, R33, R34, said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives, -S-C1-4 alkyls, di-substituted cyclic carbonyl, =R39, C2-8 alkenyls or C2-8 alkynyls;
    • R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-4 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
    • Preferably:
      • Above R1 is independently of each other selected from the group consisting of deuterium, halogen, -CN, -NO2,-OR32, -C(O)R31, -CO2R31, -CON(R32)2, -N(R32)2, -OC(O)R31, C1-3 alkyls, C2-3 alkenyls, C2-3 alkynyls;
      • Wherein, R31 is independently of each other selected from the group consisting of deuterium, R32, C2-3 alkenyls, C2-3 alkynyls; R32 is independently of each other selected from the group consisting of hydrogen, C1-3 alkyls;
      • Or, n is an integer of 0~2;
      • Or, R2 is selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyls or their halogenated or deuterated derivatives.
  • Further, said compound is represented by formula A-II:
    Figure imgb0009
    • R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-4 alkyls; said substituents is deuterium, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-6 cycloalkyls or their halogenated or deuterated derivatives, 3~6-membered heterocyclyls or their halogenated or deuterated derivatives;
    • X is selected from O or S;
    • L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-4 alkylenyls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C2-4 alkenyls or their halogenated or deuterated derivatives, C2-4 alkynyls or their halogenated or deuterated derivatives, C1-4 alkoxyls or their halogenated or deuterated derivatives, C3-5 cycloalkyls or their halogenated or deuterated derivatives, 3~5-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    • L1 and L2 can be connected to the homotopic or heterotopic atoms on the A ring; m is an integer of 0~4;
    • Ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles, 3~6-membered saturated heterocycles or 3~6-membered unsaturated heterocycles;
    • R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl,
      Figure imgb0010
       substituted or unsubstituted C1-8 alkyls, -OR33, -SR33, -OC(O)R14, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, -C(O)R34, -C(S)R34, -S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls, cyano, isocyano, isothiocyano, nitro, -L33-R36 or =R39;
    • L33 is selected from C1-4 alkylenyls;
    • R36 is selected from cyano, nitro, -OC(O) R34, -C(O)R34, -S(O)R34, -C(O)N(R33)2;
    • R33 is selected from the group consisting of hydrogen, methyl sulfonyl, the following substituted or unsubstituted groups: C1-8 alkyls, C3-8 cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls;
    • R34 is selected from the group consisting of R33, deuterium, the following substituted or unsubstituted groups: C1-8 alkoxyl, C2-8 alkenyls, C2-8 alkynyls; For above R5, R33, R34, said substituents thereof are selected from the group consisting of deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives, -S-C1-4 alkyls, di-substituted cyclic carbonyl, =R39, C2-6 alkenyls or C2-6 alkynyls;
    • R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-4 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
    • Further, R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-4 alkyls; said substituents is deuterium, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-6 cycloalkyls or their halogenated or deuterated derivatives, 3~6-membered heterocycles or their halogenated or deuterated derivatives;
    • Or, L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-4 alkylenyls; said substituents are deuterium, cyano, hudroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C2-4 alkenyls or their halogenated or deuterated derivatives, C2-4 alkynyls or their halogenated or deuterated derivatives, C1-4 alkoxyls or their halogenated or deuterated derivatives, C3-5 cycloalkyls or their halogenated or deuterated derivatives, 3~5-membered heterocycles or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    • m is an integer of 0~4;
    • Or, ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles, 3~6-membered saturated heterocycles or 3~6-membered unsaturated heterocycles;
    • Or, R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl ,
      Figure imgb0011
       , substituted or unsubstituted C1-6 alkyls, -OR33, -SR33, - OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, -C(O)R34, -C(S)R34, -C(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-6 alkenyls, substituted or unsubstituted C2-6 alkynyls, cyano, isocyano, isothiocyano, =R39;
    • R33 is selected from the group consisting of hydrogen, methylsulfonyl, the following substituted or unsubstituted groups: C1-4 alkyls, C3-8 cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls;
    • R34 is selected from the group consisting of R33, deuterium, the following substituted or unsubstituted groups: C1-4 alkoxyl, C2-4 alkenyls, C2-4 alkynyls; For above R5, R33, R34, said substituents are selected from the group consisting of deuterium, cyano, hudroxyl, carboxyl, halogen, C1-4 alkyls, C1-4 alkoxyl, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -S-C1-4 alkyls, di-substituted carbonyls, =R39, C2-4 alkenyls or C2-4 alkynyls;
    • R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-4 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
    • Preferably:
      • For above R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-2 alkyls; said substituents are deuterium, halogen, C1-2 alkyls or their halogenated or deuterated derivatives, C1-2 alkoxyl or their halogenated or deuterated derivatives;
      • Or, L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-3 alkylenyls; said substituents are deuterium, halogen, C1-3 alkyls or their halogenated or deuterated derivatives, C2-3 alkenyls or their halogenated or deuterated derivatives, C2-3 alkynyls or their halogenated or deuterated derivatives, C1-3 alkoxyl or their halogenated or deuterated derivatives;
      • m is an integer of 0~3;
      • or, ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles, 3~6-membered saturated heterocycles;
      • or, R5 is selected from the group consisting of hydrogen, deuterium, halogen,
      • propadienyl ,
        Figure imgb0012
         substituted or unsubstituted C1-4 alkyls, -OR33, -SR33, - OC(O)R34, C3-8-membered cycloalkyls, C3-8-membered cycloalkyls, 3~8-membered heterocyclylss, aryls, heteroaryls, -N(R33)2, -C(O)R34, -C(S)R34, -S(O)R34, - CON(R33)2, -SO2R34, substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, cyano, isocyano, isothiocyano, =R39;
      • R33 is selected from the group consisting of hydrogen, methylsulfonyl, the following substituted or unsubstituted groups: C1-3 alkyls, C3-6 cycloalkyls, 3~6-membered heterocyclyls, aryls, heteroaryls;
      • R34 is selected from the group consisting of R33, deuterium, substituted or unsubstituted C1-3 alkoxyl;
      • For above R5 ,R33,R34, said substituents are selected from the group consisting of deuterium, halogen, cyano, C1-2 alkyls, C1-2 alkoxyl, C3-6-membered cycloalkyls, 3~6-membered heterocycyls, aryls, heteroaryls, -S-C1-2 alkyls, di-substituted cyclic carbonyl, =R39, C2-4 alkenyls or C2-4 alkynyls;
      • R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-3 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
      • More Preferably:
        • For above R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyl groups;
        • Or, L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-2 alkylenyls; said substituents are deuterium, halogen, C1-2 alkyls, C2-3 alkenyls, C2-3 alkynyls;
        • m is an integer of 0~2;
        • or, ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles or 3~6-membered saturated heterocycles;
        • Or, R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl ,
          Figure imgb0013
           , substituted or unsubstituted C1-3 alkyls, -OR33, -SR33, - OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, -C(O)R34, -C(S)R34, -S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-3 alkenyls, substituted or unsubstituted C2-3 alkynyls, cyano, isocyano, isothiocyano, =R39;
        • R33 is selected from the group consisting of hydrogen, methylsulfonyl, acetyl, C1-3 alkyls;
        • R34 is selected from the group consisting of R33, deuterium, C1-3 alkoxyl;
        • For above R5, said substituents are selected from the group consisting of deuterium, halogen, cyano, C1-2 alkyls, 3~5-membered heterocyclyls, -S-CH3, di-substituted carbonyl, =R39, C2-4 alkenyls or C2-4 alkynyls;
        • R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-3 alkyls; R41 is selected from R40 or deuterium;
        • Further, the compound is represented by formula A-II:
          Figure imgb0014
  • In formula A-II:
    • Ring A is 3~6-membered saturated carbocycles;
    • X is selected from O, S; m is an integer of 0~2;
    • R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyl, preferably, R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, F, Cl, CF3;
    • L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted methylene; said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
    • L1 and L2 can be connected to the homotopic or heterotopic atoms on the A ring; R5 is selected from the group consisting of hydrogen, deuterium, C1-2 alkyls, propadienyl, substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, -OR33, -C(O)R34, halogen, =R39;
    • R33 is selected from the C1-3 alkyls;
    • R34 is selected from the group consisting of R33, deuterium, C1-3 alkoxyl;
    • Said substituents of R5 are selected from the group consisting of =R39, C2-4 alkenyls or C2-4 alkynyls;
    • R39 is selected from O, S, CH2;
    • Or, in formula A-II:
      • Ring A is selected from 3~6-membered saturated heterocycles; preferably, ring A is
        Figure imgb0015
         M is O or S;
      • X is selected from O or S; m is an integer of 0~2;
      • R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyl, preferably,
      • R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, F, Cl, CF3;
      • L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted methylene; said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
      • R5 is selected from the group consisting of hydrogen, deuterium, C1-2 alkyls, propadienyl, substituted or unsubstituted C2-4 alkenyls, substituted or
      • unsubstituted C2-4 alkynyls, -OR33, -C(O)R34, halogen, =R39;
      • R33 is selected from C1-3 alkyls;
      • R34 is selected from the group consisting of R33, deuterium, C1-3 alkoxyl;
      • Said substituents R5 are selected from the group consisting of =R39, C2-4 alkenyls or C2-4 alkynyls;
      • R39 is selected from O, S, CH2;
      • or, in formula A-II:
        • Ring A is 5~6-membered unsaturated carbocycles; preferably, ring A is
          Figure imgb0016
           or
          Figure imgb0017
        • X is selected from O, S; m is an integer of 0~1;
        • R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyl, preferably, R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, F, Cl, CF3;
        • L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted methylene; said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
        • R5 is selected from -C(O)R34, R34 is selected from the group consisting of deuterium, R33, C1-2 alkoxyl, R33 is selected from the group consisting hydrogen, C1-2 alkyl; Or, in formula formula A-II:
          • Ring A is none;
          • X is selected from O, S; m is an integer of 0~1;
          • R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyl, preferably, R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, F, Cl, CF3;
          • L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted methylene; said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
          • R5 is selected from the group consisting of hydrogen, deuterium, C1-4 alkyls, propadienyl,
            Figure imgb0018
             , substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, -OR33, -OC(O)R34;
          • R33 is selected from C1-3 alkyls;
          • R34 is selected from the group consisting of deuterium, R33, C1-3 alkoxyl;
          • Said substituents of R5are selected from the group consisting ofdi-substituted cyclic carbonyls, =R39, C2-4 alkenyls or C2-4 alkynyls, R39 is selected from O, S, CH2. Further, the compound is represented by formula B-I:
            Figure imgb0019
            • R1 is independently of each other selected from the group consisting of deuterium, halogen, -CN, -NO2,-OR32, -C(O)R31, -CO2R31, -CON(R32)2, -N(R32)2, -OC(O)R31, -SO2R31, substituted or unsubstituted 3~8-membered heterocyclyls, substituted or unsubstituted C1-8 alkyls, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls;
            • Wherein, R31 is independently of each other selected from the group consisting of deuterium, R32, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls, R32 is independently of each other selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyls, substituted or unsubstituted C3-8 cycloalkyls, substituted or unsubstituted 3~8-membered heterocyclyls, substituted or unsubstituted aryls, substituted or unsubstituted heteroaryls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
            • For above R1, R31, R32, said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
            • n is an integer of 0~5;
            • R2 is selected from the group consisting of hydrogen, deuterium, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C1-8 alkoxyl or their halogenated or deuterated derivatives, C2-8 alkenyls or their halogenated or deuterated derivatives, C2-8 alkynyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives;
            • In R4a and R4b, one is R4, other is
              Figure imgb0020
            • Wherein, R4 is selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-8 alkyls, N(R3)2; said substituents are deuterium, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C1-8 alkoxyls or their halogenated or deuterated derivatives, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyl or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives, - N(R3)2, R3 is H or C1-8 alkyls;
            • X is selected from O, S, or NR30, wherein, R30 is selected from hydrogen or C1-8 alkyls; L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-8 alkylenyls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C2-8 alkenyls or their halogenated or deuterated derivatives, C2-8 alkynyls or their halogenated or deuterated derivatives, C1-8 alkoxyls or their halogenated or deuterated derivatives, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
            • L1 and L2 can be connected to the homotopic or heterotopic atoms on the A ring; m is an integer of 0~4;
            • Ring A is none, or, ring A is selected from 3~8-membered saturated carbocycles, 3~8-membered unsaturated carbocycles, 3~8-membered saturated heterocycles or 3~8-membered unsaturated heterocycles;
            • R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl,
              Figure imgb0021
               substituted or unsubstituted C1-8 alkyls, -OR33, -SR33, -OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, - C(O)R34, -C(S)R34, -S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls, cyano, isocyano, isothiocyano, nitro, -L33-R36 or =R39;
            • L33 is selected from C1-4 alkylenyls;
            • R36 is selected from cyano, nitro, -OC(O)R34, -C(O)R34, -S(O)R34, -C(O)N(R33)2;
            • R33 is selected from the group consisting of hydrogen, methylsulfonyl, -L31-COO-L32, the following substituted or unsubstituted groups: C1-8 alkyls, C3-8 cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls;
            • R34 is selected from the group consisting of R33, deuterium, the following substituted or unsubstituted groups: C1-8 alkoxyl, C2-8 alkenyls, C2-8 alkynyls, or - S-C1-8 alkyls;
            • L31 is selected from the substituted or unsubstituted C1-8 alkylenyls; L32 is selected from the substituted or unsubstituted C1-8 alkyls;
            • For above R5, R33, R34, said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives, -S-C1-4 alkyls, di-substituted cyclic carbonyl, =R39, C2-8 alkenyls or C2-8 alkynyls;
            • R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-4 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
            • Preferably:
              • For above R1 is independently of each other selected from the group consisting of deuterium, halogen, -CN, -NO2,-OR32, -C(O)R31, -CO2R31, -CON(R32)2, -N(R32)2, -OC(O)R31, C1-3 alkyls, C2-3 alkenyls, C2-3 alkynyls;
              • Wherein, R31 is independently of each other selected from the group consisting of deuterium, R32, C2-3 alkenyls, C2-3 alkynyls; R32 is independently of each other selected from of hydrogen, C1-3 alkyls;
              • Or, n is an integer of 0~2;
              • Or, R2 is selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyls or their halogenated or deuterated derivatives;
              • Further, said the compound is represented by formula B-II-1 or B-II-2:
                Figure imgb0022
              • R4 is selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-4 alkyls, N(R3)2; Said substituents are deuterium, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-6 cycloalkyls or their halogenated or deuterated derivatives, 3~6-membered heterocyclyls or their halogenated or deuterated derivatives, -N(R3)2, R3 is H or C1-4 alkyls;
              • X is selected from O or S;
              • L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-4 alkylenyls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C2-4 alkenyls or their halogenated or deuterated derivatives, C2-4 alkynyls or their halogenated or deuterated derivatives, C1-4 alkoxyls or their halogenated or deuterated derivatives, C3-5 cycloalkyls or their halogenated or deuterated derivatives, 3~5-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
              • L1 and L2 can be connected to the homotopic or heterotopic atoms on the A ring; m is an integer of 0~4;
              • Ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles, 3~6-membered saturated heterocycles or 3~6-membered unsaturated heterocycles;
              • R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl,
                Figure imgb0023
                 substituted or unsubstituted C1-8 alkyls, -OR33, -SR33, -OC(O)R14, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, - C(O)R34, -C(S)R34, -S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls, cyano, isocyano, isothiocyano, nitro, -L33-R36 or =R39;
              • L33 is selected from C1-4 alkylenyls;
              • R36 is selected from cyano, nitro, -OC(O) R34, -C(O)R34, -S(O)R34, -C(O)N(R33)2;
              • R34 is selected from the group consisting of deuterium or R33, R33 is selected from the group consisting of hydrogen, methyl sulfonyl, the following substituted or unsubstituted groups: C1-8 alkyls, C3-8 cycloalkyls, 3~8-membered heterocyclyls, heteroaryls;
              • R34 is selected from the group consisting of R33, deuterium, the following substituted or unsubstituted groups: C1-8 alkoxyl, C2-8 alkenyls, C2-8 alkynyls;
              • For above R5, R33, R34, said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives, -S-C1-4 alkyls, si-substituted carbonyl, =R39, C2-6 alkenyls or C2-6 alkynyls;
              • R39 is selected from O, S, NR40 or C(R41)2; R40 is selected from hydrogen, halogen, C1-4 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium.
              • Further, R4 is selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-4 alkyls, N(R3)2; Said substituents is deuterium, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-6 cycloalkyls or their halogenated or deuterated derivatives, 3~6-membered heterocyclyls or their halogenated or deuterated derivatives, -N(R3)2, R3 is H or C1-4 alkyls;
              • Or, L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-4 alkylenyls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C2-4 alkenyls or their halogenated or deuterated derivatives, C2-4 alkynyls or their halogenated or deuterated derivatives, C3-5 cycloalkyls or their halogenated or deuterated derivatives, 3~5-membered heterocyclyls or their halogenated or deuterated derivative, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
              • m is an integer of 0~4;
              • Or, ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles, 3~6-membered saturated heterocycles or 3~6-membered unsaturated heterocycles;
              • or, R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl,
                Figure imgb0024
                 substituted or unsubstituted C1-6 alkyls, -OR33, -SR33, - OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, C(O)R34, -C(S)R34, C(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-6 alkenyls, substituted or unsubstituted C2-6 alkynyls, cyano, isocyano, isothiocyano, =R39;
              • R33 is selected from the group consisting of hydrogen, methyl sulfonyl, the following substituted or unsubstituted groups: C1-4 alkyls, C3-8 cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls;
              • R34 is selected from the group consisting of R33, deuterium, the following substituted or unsubstituted groups: C1-4 alkoxyl, C2-4 alkenyls, C2-4 alkynyls;
              • For above R5, R33, R34, said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls, C1-4 alkoxyl, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -S-C1-4 alkyls, di-substituted cyclic carbonyl, =R39, C2-4 alkenyls or C2-4 alkynyls;
              • R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-4 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
              • Preferably:
                • For above R4 is selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-2 alkyls, -N(R3)2; Said substituents is deuterium, halogen, C1-2 alkyls or their halogenated or deuterated derivatives, C1-2 alkoxyl or their halogenated or deuterated derivatives, -N(R3)2, R3 is H or C1-4 alkyls;
                • Or, L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-3 alkylenyls; said substituents is deuterium, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C2-3 alkenyls or
                • their halogenated or deuterated derivatives, C2-3 alkynyls or their halogenated or
                • deuterated derivatives, C1-3 alkoxyl or their halogenated or deuterated derivatives;
                • m is an integer of 0~3;
                • or, ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles or 3~6-membered saturated heterocycles;
                • or, R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl,
                  Figure imgb0025
                   substituted or unsubstituted C1-4 alkyls, -OR33, -SR33, - OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, C(O)R34, -C(S)R34, S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, cyano, isocyano, isothiocyano, =R39;
                • R33 is selected from the group consisting of hydrogen, methylsulfonyl, the following substituted or unsubstituted groups: C1-3 alkyls, C3-6 cycloalkyls, 3~6-membered heterocyclyls, aryls, heteroaryls;
                • R34 is selected from the group consisting of R33, deuterium, substituted or unsubstituted C1-3 alkoxyl;
                • For above R5, R33 and R34, said substituents are deuterium, halogen, cyano, C1-2 alkyls, C1-2 alkoxyls, C3-6-membered cycloalkyls, 3~6-membered heterocyclyls, aryls, heteroaryls, -S-C1-2 alkyls, di-substituted cyclic carbonyl, =R39, C2-4 alkenyls or C2-4 alkynyls;
                • R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-3 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
                • More Preferably:
                  • For above R4 is selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyl, - N(R3)2, R3 is H or C1-2 alkyl;
                  • Or, L1 and L2 are independently of each other selected from none, substituted or unsubstituted C1-2 alkylenyls; said substituents are deuterium, halogen, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
                  • m is an integer of 0~2;
                  • Or, ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles, 3~6-membered saturated heterocycles;
                  • or, R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl ,
                    Figure imgb0026
                     , substituted or unsubstituted C1-3 alkyls, -OR33, -SR33, - OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, C(O)R34, -C(S)R34, C(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-3 alkenyls, substituted or unsubstituted C2-3 alkynyls, cyano, isocyano, isothiocyano, =R39;
                  • R33 is selected from the group consisting of hydrogen, methyl sulfonyl, acetyl, C1-3 alkyls;
                  • R34 is selected from the group consisting of R33, deuterium, C1-3 alkoxyl;
                  • For above R5 is selected from of the group deuterium, halogen, cyano, C1-2 alkyls, 3~5-membered heterocyclyls, -S-CH3, di-substituted cyclic carbonyl, =R39, C2-4 alkenyls or C2-4 alkynyls;
                  • R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-3 alkyls; R41 is selected from R40 or deuterium;
                  • Further, said the compound is represented by formula B-II-1 or B-II-2:
                    Figure imgb0027
                     Wherein:
                    • Ring A is 3~6-membered saturated carbocycles;
                    • X is selected from O, S; m is an integer of 0~2;
                    • R4 is selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyls, N(R3)2; R3 is H or C1-2 alkyls; preferably, R4 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, CF3, -N(CH3)2;
                    • L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted methylenes; said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
                    • L1 and L2 can be connected to the homotopic or heterotopic atoms on the A ring; R5 is selected from the group consisting of hydrogen, deuterium, C1-2 alkyls, propadienyl, substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, -OR33, -SR33, -C(O)R34, halogen, =R39;
                    • R33 is selected from the C1-3 alkyls;
                    • R34 is selected from the group consisting of R33, deuterium, C1-3 alkoxyls;
                    • R5 said substituents are selected from the group consisting of =R39, C2-4 alkenyls or C2-4 alkynyls;
                    • Or, wherein:
                      • Ring A is selected from 3~6-membered saturated heterocycles; preferably, ring A is
                        Figure imgb0028
                         , M is s O or S;
                      • X is selected from O or S; m is an integer of 0~2;
                      • R4 is selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyls, N(R3)2, R3 is H or C1-2 alkyls; preferably, R4 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, CF3, -N(CH3)2;
                      • L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted C1-2 methylene; Said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
                      • R5 is selected from the group consisting of hydrogen, deuterium, C1-2 alkyls, propadienyl, substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, -OR33, -SR33, -C(O)R34, halogen, =R39;
                      • R33 is selected from the C1-3 alkyls;
                      • R34 is selected from the group consisting of R33, deuterium, C1-3 alkoxyl;
                      • R5 said substituents is selected from the group consisting of =R39, C2-4 alkenyls or C2-4 alkynyls;
                      • R39 is selected from the O, S, CH2;
                      • Or, wherein:
                        • Ring A is selected from 5~6-membered unsaturated carbocycles; preferably, Ring A is
                          Figure imgb0029
                        • X is selected from O or S; m is an integer of 0~1;
                        • R4 is selected from the group consisting of hydrogen, deuterium, halogen,
                        • halogenated or un-halogenated methyls, N(R3)2; R3 is H or C1-2 alkyls; Preferably,
                        • R4 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, CF3, -N(CH3)2;
                        • L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted C1-2 methylene; said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
                        • R5 is selected from -C(O)R34, R34 is selected from the group consisting of deuterium, R33, C1-2 alkoxyl; R33 is selected from hydrogen, C1-2 alkyls;
                        • Or, wherein:
                          • Ring A is none,
                          • X is selected from O, S; m is an integer of 0~1;
                          • R4 is independently of each other selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyl, -N(R3)2, R3 is H or C1-2 alkyls; Preferably, R4 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, CF3, -N(CH3)2;
                          • L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted C1-2 methylene; said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
                          • R5 is selected from the group consisting of hydrogen, deuterium, C1-4 alkyls , substituted by 1~3 halogens alkyls , propadienyl,
                            Figure imgb0030
                             , substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, -OR33, -SR33, -C(O)R34;
                          • R33 is selected from the C1-3 alkyls;
                          • R34 is selected from the group consisting of deuterium, R33, C1-3 alkoxyls;
                          • Said substituents of R5 are selected from the group consisting of di-substituted cyclopentanoyls, =R39, C2-4 alkenyls or C2-4 alkynyls, R39 is selected from O, S, CH2; Further, said the compound is represented by formula C-I:
                            Figure imgb0031
                          • Wherein, n is an integer of 0~3;
                          • R1 is selected from the group consisting of halogens, C1-5 alkyls , C1-5 alkoxyls; R2 is selected from the group consisting of halogens, C1-5 alkyls, C1-5 alkoxyls; Y1 is selected from N or CRc5a, Y2 is selected from N or CRc5b;
                          • Rc5a, Rc5b, Rc3 are independently selected from the group consisting of hydrogen, halogens, C1-5 alkyls;
                          • R0 is selected from LC3RC4, LC1XCLC2RC5;
                          • LC3 is selected from the group consisting of none, substituted or unsubstituted C1-4 alkylenyls; said substituents of C1-4 alkylenyls are selected from the group consisting of C1-5 alkyls, C1-5 alkoxyls, halogens, hydroxyl;
                          • RC4 is selected from the group consisting of substituted or unsubstituted C2-6 alkenyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted 3~6-membered saturated or unsaturated heterocyclyls, substituted or unsubstituted 3~6-membered saturated or unsaturated cycloalkyls, COR4d; said substituents independently of each other selected from LC4R4e; R4d is selected C1-6 alkyls; LC4 is selected from the group consisting of none, substituted or unsubstituted C1-4 alkylenyl; R4e is selected from the group consisting of C1-5 alkyls, C1-5 alkoxyl, halogen, hydroxyl;
                          • LC1 is selected from the substituted or unsubstituted C1-3 alkylenyls, said substituents are selected from the C1-5 alkyls;
                          • XC is O or S;
                          • LC2 is selected from the group consisting of none, substituted or unsubstituted C1-3 alkylenyls, said substituents are selected from the C1-4 alkyls, C1-4 alkoxyls, L2aR5g; L2a is selected from the group consisting of none, C1-2 alkylenyls, R5g is selected from halogen, C1-4 alkoxyls;
                          • Rc5 is selected from the group consisting of hydrogen, halogen, C1-5 alkyls, C2-4 alkenyls, C2-4 alkynyls, COR4d, C3~6 dienyls, C1∼5 alkoxyl, substituted by one or more R 5c 3~6-membered saturated or unsaturated heterocyclyls; substituted by one or more R 5c 3~6-membered saturated or unsaturated cycloalkyls; R4d is selected from C1-6 alkyls, R5c is selected from the group consisting of halogen, =R5d, L1aR5e, C3~6 dienyls; R5d is CH2, O or S; L1a is C1-3 alkylenyls; R5e is C1-5 alkyls, C1-5 alkoxyls.
                          • Further, said the compound is represented by formula C- II:
                            Figure imgb0032
  • In formula C- II, RC4a is selected from the group consisting of substituted or unsubstituted C2-6 alkenyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted 3~6-membered saturated or unsaturated heterocyclyls, substituted or unsubstituted 3~6-membered saturated or unsaturated cycloalkyls; Said substituents are independently of each other selected from the group consisting of C1-5 alkyls, C1-5 alkoxyl, halogen, hydroxyl;
    • Y1 is selected from N or CRC5a, Y2 is selected from N or CRC5b; Preferably, Y1 and Y2 aren't N at the same time;
    • RC5a, RC5b, RC3 are independently of each other selected from the group consisting of hydrogen, halogen, C1-5 alkyls;
    • Or, said the compounds are represented by formula C-III-a or formula C-III-b:
      Figure imgb0033
      Figure imgb0034
    Wherein, XC is O or S;
    • LC1 is selected from substituted or unsubstituted C1-3 alkylenyls, said substituents are selected from the C1-3 alkyls; preferably, LC1 is methylene;
    • LC2 is selected from the group consisting of none, substituted or unsubstituted C1-2 alkylenyls, said substituents are selected from the C1-3 alkyls;
    • Ring C is selected from 3~4-membered saturated heterocyclyls, 3~4-membered saturated cycloalkyls;
    • m1 is selected from 0, 1, 2; R5c is selected from the group consisting of halogen, =R5d, L1aR5e, propadienyl; R5d is CH2; L1a is C1∼5 alkylenyls, R5e is C1∼5 alkyls, C1∼5 alkoxyls; said halogen is selected to be F preferably;
    • RC5a, RC5b, RC3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼5 alkyls; said halogen is selected to be F preferably;
    • or, said the compounds are represented by formula C-III-c or formula C-III-d:
      Figure imgb0035
  • Wherein, XC is O or S;
    • LC1 is selected from substituted or unsubstituted C1-3 alkylenyls, said substituents are selected from the C1-3 alkyls, preferably, LC1 is selected from C1-2 alkylenyls;
    • LC2 is selected from the group consisting of none, substituted or unsubstituted C1-2 alkylenyls, said substituents are selected from the C1-4 alkyls, C1-4 alkoxyls, L2aR5g; L2a is selected from none, C1-2 alkylenyls; R5g is selected from halogen, C1-4 alkoxyls;
    • R5f is selected from the group consisting of hydrogen, halogen, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls, COR4d, propadienyl, C1∼4 alkoxyls; R4d is selected from C1∼4 alkyls;
    • RC5a, RC5b, RC3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼5 alkyls; said halogen is selected to be F preferably;
    • or, said the compounds are represented by formula C-IV:
      Figure imgb0036
    • In formula C-IV, LC3 is selected from substituted or unsubstituted C1∼4 alkylenyls, said substituents are selected from the group consisting of C1-5 alkyls, C1∼5 alkoxyl, halogen, hydroxyl;
    • R4c is selected from the group consisting of substituted or unsubstituted C2-6 alkenyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted 3~6-membered saturated cycloalkyls, substituted or unsubstituted 3~6-membered saturated heterocyclyls, COR4d; said substituents are independently of each other selected from LC4R4e; R4d is selected from C1-5 alkyls, LC4 is selected from none or C1-3 alkylenyls; R4e is selected from the group consisting of C1∼5 alkyls, C1∼5 alkoxyls, halogen, hydroxyl;
    • Y1 is selected from N or CRC5a, Y2 is selected from N or CRC5b; preferably, Y1 and Y2 aren't N at the same time.
    • RC5a, RC5b, RC3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼5 alkyls;
    • Further, Said the compound C-II is represented by formula C-II-a or formula C-II-b:
      Figure imgb0037
  • Wherein, RC4a is selected from the group consisting of substituted or unsubstituted C2-3 alkenyls, substituted or unsubstituted C2-3 alkynyls, substituted or unsubstituted 3~4-membered saturated epoxyls; said substituents are independently of each other selected from C1-3 alkyls;
    • RC5a, RC5b, RC3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼5 alkyls; said halogen is selected to be F preferably;
    • Or, the said compound C-IV is represented by formula C-IV-a or formula C-IV-b:
      Figure imgb0038
  • Wherein, LC3 is selected from substituted or unsubstituted C1-3 alkylenyls, said substituents is selected from the group consisting of C1-3 alkyls, C1∼5 alkoxyl;
    • R4c is selected from the group consisting of substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, substituted or unsubstituted 4-membered saturated cycloalkyls, COR4d; Said substituents are independently of each other selected from LC4R4e; R4d is selected from C1∼5 alkyls, LC4 is selected from the group consisting of none or C1-2 alkylenyls; R4e is selected from C1∼5 alkyls, C1∼5 alkoxyl;
    • RC5a, RC5b, RC3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼5 alkyls; said halogen is selected to be F preferably. Further, said the compound is represented by formula D-I:
      Figure imgb0039
  • Wherein, n is an integer of 0~3;
    • R1 is selected from the group consisting of halogen, C1-5 alkyls, C1-5 alkoxyls;
    • R2 is selected from the group consisting of halogen, C1-5 alkyls, C1-5 alkoxyls;
    • Y1 is selected from N or CRD5a, Y2 is selected from N or CRD5b;
    • RD5a, RD5b, RD3 are independently selected from the group consisting of hydrogen, halogen, C1-5 alkyls;
    • MD is selected from CO or CRD6 RD7; RD6 is selected from hydrogen, XDbRD4b; R7 is selected from hydrogen, XDcRD4c;
    • XD is O or S; XDb is O or S; XDc is O or S;
    • Ra is selected from the group consisting of substituted or unsubstituted C1-6 alkyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted C2-6 alkenyls, substituted or unsubstituted 3~6-membered saturated or unsatutated hererocyclyls, substituted or unsubstituted 3~6-membered saturated or unsatutated cycloalkyls; said substituents are independently of each other selected from the group consisting of C3-6dienyls, C1∼5 alkyls, C1∼5 alkoxyl, halogen, hydroxyl;
    • RD4b, RD4c are independently of each other selected from the group consisting of substituted or unsubstituted C1∼6 alkyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted C2-6 alkenyls, CORDf, substituted or unsubstituted 3~6-membered saturated or unsatutated hererocyclyls, substituted or unsubstituted 3~6-membered saturated or unsatutated cycloalkyls; said substituents are independently of each other selected from the group consisting of C3-6dienyls, C1∼5 alkyls, C1∼5 alkoxyl, halogen, hydroxyl; RDf is selected from C1∼5 alkyls;
    • Or, when MD is CRD6RD7 and RD6 is XDbRD4b, RD4b and Ra are connected to get substituted or unsubstituted 3~6-membered saturated or unsatutated hererocyclyls, said substituents of saturated or unsatutated hererocyclyls are selected from halogenated or unhalogenated C1∼6 alkyls, halogenated or unhalogenated C2-6 alkynyls, halogenated or unhalogenated C2-6 alkenyls, CORDf;
    • RD7 is selected from hydrogen, XDcRD4c; XDc is O or S, RD4c is selected from the group consisting of substituted or unsubstituted C1-6 alkyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted C2-6 alkenyls, CORDf, substituted or unsubstituted 3~6-membered saturated or unsatutated hererocyclyls, substituted or unsubstituted 3~6-membered saturated or unsatutated cycloalkyls, said substituents are independently of each other selected from the group consisting of C3-6dienyls, C1∼5 alkyls, C1∼5 alkoxyl, halogen, hydroxyl; RDf is selected from C1∼5 alkyls;
    • Further, said the compound is represented by formula D-II:
      Figure imgb0040
  • In formula D-II, XD is O or S;
    • Ra is selected from the group consisting of substituted or unsubstituted C1-6 alkyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted C2-6 alkenyls, substituted or unsubstituted 3~6-membered saturated or unsatutated hererocyclyls, substituted or unsubstituted 3~6-membered saturated or unsatutated cycloalkyls; said substituents are independently of each other selected from the group consisting of C3-6dienyls, C1∼5 alkyls, C1∼5 alkoxyls, halogen, hydroxyl;
    • Y1 is selected from N or CRC5a, Y2 is selected from N or CRC5b;
    • RD5a, RD5b, RD3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼5 alkyls;
    • Or, said the compound is represented by formula D-III:
      Figure imgb0041
  • Wherein, RD7 is selected from hydrogen or XDcRD4c;
    • XD, XDb, XDc are independently selected from O or S;
    • Ra, RD4b, RD4c are independently of each other selected from the group consisting of C1-6 alkyls, C2-6 alkynyls, C2-6 alkenyls, substituted or unsubstituted 3~6-membered saturated or unsatutated hererocyclyls, substituted or unsubstituted 3~6-membered saturated or unsatutated cycloalkyls; said substituents are independently of each other selected from the group consisting of C1∼5 alkyls, C1∼5 alkoxyl, halogen, hydroxyl;
    • Y1 is selected from N or CRD5a, Y2 is selected from N or CRD5b;
    • RD5a, RD5b, RD3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼5 alkyls;
    • Or, said the compound is represented by formula D-IV:
      Figure imgb0042
  • In formula D-IV, RD7 is selected from hydrogen, XDcRD4c;
    • XDb, XD, XD4c are independently selected from O or S;
    • RD4c is selected from the group consisting of C1-6 alkyls, C2-6 alkynyls, C2-6 alkenyls, CORDf; RDf is selected from C1-5 alkyls;
    • Rd1 and Re1 are independently of each other selected from the group consisting of hydrogen, halogenated or un-halogenated C1-6 alkyls, C2-6 alkynyls, C2-6 alkenyls, CORDf; RDf is selected from C1-5 alkyls;
    • Rd2 and Re2 are independently of each other selected from the group consisting of none, hydrogen, halogenated or un-halogenated C1-6 alkyls, C2-6 alkynyls, C2-6 alkenyls, CORDf; RDf is selected from C1-5 alkyls;
      Figure imgb0043
       is single bond or double bond;when
      Figure imgb0044
       is double bond, Rd2 and Re2 are none;
    • Y1 is selected from N or CRD5a, Y2 is selected from N or CRD5b;
    • RD5a, RD5b, RD3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼5 alkyls.
  • Further, Said the compound D-II is represented by formula D-II-1, formula D-II-2, formula D-II-3 or formula D-II-4:
    Figure imgb0045
    Figure imgb0046
  • Wherein, XD is O or S, preferable selection is O;
    • Ra is selected from the group consisting of substituted or unsubstituted C1-5 alkyls, substituted or unsubstituted C2-4 alkynyls, substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted 4-membered saturated epoxyls groups , substituted or unsubstituted 4-membered saturated cycloalkyls; Said substituents are independently of each other selected from the group consisting of propadienyl, C1∼5 alkyls, C1∼5 alkoxys;
    • RD5a, RD5b, RD3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼5 alkyls; Said halogen is selected to be F, Cl, Br preferably;
    • Or, said the compound D-III is represented by formula D-III-1, formula D-III-2, formula D-III-3 or formula D-III-4:
      Figure imgb0047
      Figure imgb0048
  • Wherein, RD7 is selected from hydrogen or XDcRD4c;
    • XD, XDb, XDc are independently selected from O or S;
    • Ra, RD4b, RD4c are independently of each other selected from the group consisting of C1-5 alkyls, C2-4 alkynyls, C2-3 alkenyls, 4-membered saturated cycloalkyls; RD5a, RD5b, RD3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼5 alkyls; Said halogen is selected to be F, Cl, Br preferably;
    • Or, said the compound D-IV is represented by formula D-IV-1, formula D-IV-2, formula D-IV-3 or formula D-IV-4:
      Figure imgb0049
      Figure imgb0050
      Figure imgb0051
  • Wherein, RD7 is selected from hydrogen, XDcRD4c;
    • XDb, XD, XDc are independently of each other selected from O or S;
    • RD4c is selected from the group consisting of C1-5 alkyls, C2-4 alkynyls, C2-3 alkenyls;
    • Rd1 and Re1 are independently of each other selected from the group consisting of hydrogen, halogenated or un-halogenated C1-5 alkyls, CORDf; RDf is selected from C1-3 alkyls; Preferably, said halogenated C1-5 alkyls are CF3;
    • Rd2 and Re2 are independently of each other selected from the group consisting of none, hydrogen, halogenated or un-halogenated C1-5 alkyls, CORDf; RDf is selected from C1-3 alkyls; Preferably, said halogenated C1-5 alkyls are CF3;
      Figure imgb0052
       is single bond or double bond; when is double bond,
      Figure imgb0053
       is double, Rd2 and Re2 are none;
    • RD5a, RD5b, RD3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼5 alkyls; said halogen is selected to be F, Cl, Br preferably. Further, the compound is one of the following compounds:
      Figure imgb0054
      Figure imgb0055
      Figure imgb0056
      Figure imgb0057
      Figure imgb0058
      Figure imgb0059
      Figure imgb0060
      Figure imgb0061
      Figure imgb0062
      Figure imgb0063
      Figure imgb0064
      Figure imgb0065
      Figure imgb0066
      Figure imgb0067
      Figure imgb0068
      Figure imgb0069
      Figure imgb0070
      Figure imgb0071
      Figure imgb0072
      Figure imgb0073
      Figure imgb0074
      Figure imgb0075
      Figure imgb0076
      Figure imgb0077
      Figure imgb0078
      Figure imgb0079
      Figure imgb0080
      Figure imgb0081
      Figure imgb0082
      Figure imgb0083
      Figure imgb0084
      Figure imgb0085
      Figure imgb0086
      Figure imgb0087
      Figure imgb0088
      Figure imgb0089
      Figure imgb0090
      Figure imgb0091
      Figure imgb0092
      Figure imgb0093
      Figure imgb0094
      Figure imgb0095
      Figure imgb0096
      Figure imgb0097
      Figure imgb0098
      Figure imgb0099
      Figure imgb0100
      Figure imgb0101
      Figure imgb0102
      Figure imgb0103
      Figure imgb0104
      Figure imgb0105
      Figure imgb0106
      Figure imgb0107
      Figure imgb0108
      Figure imgb0109
      Figure imgb0110
      Figure imgb0111
      Figure imgb0112
      Figure imgb0113
      Figure imgb0114
      Figure imgb0115
      Figure imgb0116
      Figure imgb0117
      Figure imgb0118
      Figure imgb0119
      Figure imgb0120
      Figure imgb0121
      Figure imgb0122
      Figure imgb0123
      Figure imgb0124
      Figure imgb0125
      Figure imgb0126
      Figure imgb0127
      Figure imgb0128
      Figure imgb0129
      Figure imgb0130
      Figure imgb0131
      Figure imgb0132
      Figure imgb0133
      Figure imgb0134
      Figure imgb0135
      Figure imgb0136
      Figure imgb0137
      Figure imgb0138
      Figure imgb0139
      Figure imgb0140
      Figure imgb0141
      Figure imgb0142
      Figure imgb0143
      Figure imgb0144
      Figure imgb0145
      Figure imgb0146
      Figure imgb0147
      Figure imgb0148
      Figure imgb0149
      Figure imgb0150
      Figure imgb0151
      Figure imgb0152
      Figure imgb0153
      Figure imgb0154
      Figure imgb0155
      Figure imgb0156
      Figure imgb0157
      Figure imgb0158
      Figure imgb0159
      Figure imgb0160
      Figure imgb0161
      Figure imgb0162
      Figure imgb0163
      Figure imgb0164
      Figure imgb0165
      Figure imgb0166
      Figure imgb0167
      Figure imgb0168
      Figure imgb0169
      Figure imgb0170
      Figure imgb0171
      Figure imgb0172
      Figure imgb0173
      Figure imgb0174
      Figure imgb0175
      Figure imgb0176
      Figure imgb0177
      Figure imgb0178
      Figure imgb0179
      Figure imgb0180
      Figure imgb0181
      Figure imgb0182
      Figure imgb0183
      Figure imgb0184
      Figure imgb0185
      Figure imgb0186
      Figure imgb0187
      Figure imgb0188
      Figure imgb0189
      Figure imgb0190
      Figure imgb0191
      Figure imgb0192
      Figure imgb0193
      Figure imgb0194
      Figure imgb0195
      Figure imgb0196
      Figure imgb0197
      Figure imgb0198
      Figure imgb0199
      Figure imgb0200
      Figure imgb0201
      Figure imgb0202
      Figure imgb0203
      Figure imgb0204
      Figure imgb0205
      Figure imgb0206
      Figure imgb0207
      Figure imgb0208
      Figure imgb0209
      Figure imgb0210
      Figure imgb0211
      Figure imgb0212
      Figure imgb0213
      Figure imgb0214
      Figure imgb0215
      Figure imgb0216
      Figure imgb0217
  • The present invention also provides a drug, it is prepared by anyone of the above compounds, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, or their combinations as active ingredients, with addition of pharmaceutically acceptable excipients.
  • The present invention also provides the use of anyone of the above compounds , or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, or their combinations in preparation of drugs having sedative, hypnotic, and/or anesthetic effects and/or drugs that can be used to control epileptic status.
  • The said "sedative drug" in the present invention is a kind of drug thathas a sedative effect and can effectively help sleep and improve sleep, and this drug can avoid the serious harm of insomnia to human body, treat insomnia and improve sleep quality. The said "hypnotic drug" in the present invention denotes a drug that has a hypnotic effect, which can induce drowsiness and promote sleep. The drug has an effect of the central nervous system inhibition, and small dose causes sedation and excessive dose results in general anesthesia.
  • The said "anesthetic drug" in the present invention denotes a kind of drug that has a hypnotic effect, which canproduce a reversible functional inhibition of the central nervous system and / or peripheral nervous system and this inhibiton is mainly characterized by loss of sensation, especially sense of pain.
  • Preferably, the anesthesia is general anesthesia.
  • The "general anesthesia" mentioned in the present invention denotes that the anesthetics inside the vivo cause the temporary inhibition of central nervous system. The clinical manifestations are loss of consciouseness, disappearance of generalized sense of pain, amnesia, inhibitory reflex and skeletal muscle relaxation.
  • The compounds mentioned above, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof are used in preparation of the drugs that could control the status epilepticus.
  • The "status epilepticus." mentioned in the present invention denotes the epilepsy frequently recurs without complete recovery of consciousness between successive seizures and or does not stop automatically after the seizure lasts for more than 30 minutes . Long-lastingseizure of epilepsy, if not be treated in time, would lead to irreversible brain injury due to high fever, circulatory failure or neuronal excitotoxic injury with high disability rate and mortality, so epilepsy is a common emergency in internal medicine.
  • The present invention provides a drug, that is prepared by using compounds mentioned above, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof as active ingredients, with addition of pharmaceutically acceptable excipients. The compounds and derivatives provided in the present invention can be named according to IUPAC (International Union of Pure and Applied Chemistry) or CAS (Chemical Abstracting Service, Columbus, OH) naming system.
  • For the definition of term used in the present invention: unless otherwise specified, the initial definition provided for the group or the term herein is applicable to those in the whole specification; for terms not specifically defined herein, according to the disclosure content and the context, the term should have the meaning commonly given by those skilled in the field.
  • "Substitution" means that one or more hydrogen atoms in a molecule are replaced by other atoms or molecules that are not hydrogen, including one or more substitutions on the homotopic atoms or heterotopic atoms in the molecule.
  • The structures of the compounds mentioned in the present invention denote the stable existence structures.
  • "Deuterium" denotes the isotope of hydrogen (H), also known as heavy hydrogen, and the elemental symbol is generally D or 2H.
  • In the present invention, the structure of substituent "-C(O)R32" is:
    Figure imgb0218
  • In the present invention, the structure of substituent "-CO2R32" is:
    Figure imgb0219
  • In the present invention, the structure of substituent "-CON(R32)2" is:
    Figure imgb0220
  • In the present invention, the structure of substituent "-OC(O)R32" is:
    Figure imgb0221
  • In the present invention, the structure of substituent "-SO2R32" is:
    Figure imgb0222
  • In the present invention, the structure of substituent "-C(S)R34" is:
    Figure imgb0223
  • In the present invention, the structure of substituent "-S(O)R34" is:
    Figure imgb0224
  • The minimum and the maximum number of carbon atoms in hydrocarbon groups are represented by prefixes, for example, the prefix (Ca~Cb) alkyls indicate any alkyls containing "a"~"b" carbon atoms. Therefore, for example, C1~C8 alkyls denote alkyls containing 1~8 carbon atoms. C1~C8 alkyls arelinear or branched hydrocarbon chains containing 1~8 carbon atoms.
  • "Alkyls" is a hydrocarbon group formed by losing one hydrogen in an alkane molecule, such as methyl -CH3, ethyl -CH3CH2, etc.
  • "Alkylenyls" denotes the hydrocarbon group formed by losing two hydrogens in the alkane molecule, such as methylene-CH2-, ethylidene-CH2CH2-, etc. "C1-8 alkylenyls" denotes a linear or branched hydrocarbon chain containing 1~8 carbon atoms. "Substituted or unsubstituted C1-8 alkyls"denotes C1-8 alkyls that can be substituted or not be substituted.
  • When the ring A of the compounds in the present invention is
    Figure imgb0225
     "
    Figure imgb0226
    " indicate the separate linkage sites of L1 and L2Similarly, when the ring A of the compounds in the present invention is
    Figure imgb0227
     "
    Figure imgb0226
    " indicate the separate linkage sites of L1 and L2.
  • "Ring A is none of" in the present invention denotes L1 and L2 are connected directly by chemical bonds.
  • "3~6-membered saturated carbocycles" in "ring A is 3~6-membered saturated carbocycles" mentioned in the present invention denotes a carbocycle consisting of 3~6 carbons, in which no double bond exists.
  • "3~6-membered unsaturated carbocycles" in "ring A is 3~6-membered unsaturated carbocycles" mentioned in the present invention denotes a carbocycle consisting of 3~6 carbons, in which double bond exists.
  • "3~6-membered saturated heterocycles" in "ring A is 3~6-membered saturated heterocycles" mentioned in the present invention denotes a saturated heterocycle without double bonds, in which there is at least one atom selected from O, S, or substituted N, and the remaining ring atoms are carbons.
  • "3~6-membered unsaturated heterocycles" in "ring A is 3~6-membered unsaturated heterocycles" mentioned in the present invention denotes a saturated heterocycle without double bonds, in which there is at least one atom selected from O, S, or substituted N, and the remaining ring atoms are carbons.
  • "Alkynyls" denotes aliphatic hydrocarbon groups with at least one C≡C triple bond. Said alkynyls can be linear or branched chain. When there is a limited carbon numbers before alkynyls (such as C2-8 alkynyls), for example, the term "C2-8 alkynyls" denotes a linear or branched alkynyls with 2~8 carbons.
  • "Alkenyls" denotes aliphatic hydrocarbon groups with at least one C=C double bond. Said alkenyls can be linear or branched chain. When there is a limited carbon numbers beforealkenyls (such as C2-8 alkenyls), for example, the term "C2-8 alkenyls" denotes a linear or branched alkenyls with 2~8 carbons.
  • "dienyls" denotes aliphatic hydrocarbon groups with two double bonds among carbons. Said dienyls could be linear or branched chain. When there is a limited carbon numbers before "dienyls", for example, "C3-6 dienyls" denotes a linear or branched dienyls with 3~6 carbons ,such as the structures of "propadienyls" are
    Figure imgb0229
  • Halogen is fluorine, chlorine, bromine, or iodine.
  • "Aryls" denote all-carbon monocyclic or fused polycyclic (i.e. ring sharing adjacent carbon atom pairs) groups with conjugated π electron system, such as phenyl and naphthyl. Said aryl ring can be fused to other cyclic groups (including saturated and unsaturated rings), but can not contain hetero atoms such as nitrogen, oxygen, or sulfur. At the same time, the site connected with the parent must be on the carbon in the ring having the conjugated π electron system. Aryls can be substituted or unsubstituted.
  • "Heteroaryls" denote the heteroaromatic group containing one or more heteroatoms. The heteroatoms mentioned herein include oxygen, sulfur, and nitrogen. For example, furanyl, thienyl, pyridinyl, pyrazolyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaromatic ring can be fused to aryls, heterocyclic group or cycloalkyl ring, in which the ring connected with the parent structure is heteroaromatic ring. Heteroaryls can be substituted or unsubstituted.
  • "Cycloalkyls" denote saturated or unsaturated cyclic hydrocarbon substituents; cyclic hydrocarbon can have one or more rings. For example, "C3-8 cycloalkyls" denote cycloalkyls having 3~8 carbons.Heterocyclyls denotes saturated or unsaturated cyclic hydrocarbon substituents; cyclic hydrocarbon can have one or more rings with at least one heteroatom (including but not limited to O, S or N). For example, "C3-8 heterocyclyls" denote saturated or unsaturated cyclic hydrocarbon substituents; cyclic hydrocarbon could be mono cyclic and poly cyclic containing at least one atom selected from O, S or substituted N, other ring atioms are carbons.
  • "C1-4 alkyls, or halogenated or deuterated derivatives thereof" denots C1-4 alkyls, halogenated or deuterated C1-4 alkyls. Other related terms "or halogenated or deuterated derivatives thereof" have the similar definition.
  • For all the compounds of the present invention, each chiral carbon atom (chiral center) can be optionally R-configurated or S-configurated, or a mixture of R-configuration and S-configuration.
  • "Pharmaceutically acceptable carriers" denote one or more compatible solid or liquid filling materials or gel substances, which are suitable for human use and must be of sufficient purity and low toxicity. "Compatibility" herein means that each component in the composition can be mixed with the compounds of the present invention without reducing the efficacy of the compounds obviously. Some examples of pharmaceutically acceptable carriers are cellulose and its derivatives (such as carboxymethylcellulose sodium, ethylcellulose sodium, cellulose acetate, etc.), gelatin, talcum, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oil (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifier (such as Tween®), wetting agent (such as sodium dodecyl sulfate), colorant, seasoning agent, stabilizer, antioxidant, preservative, pyrogen free water, etc.
  • The term "pharmaceutically acceptable salt" denotes the salt formed by the compounds of the present invention and pharmaceutically acceptable inorganic and organic acids, which is suitable for contacting the tissue of the object (e.g. human) without undue side effects. Among them, the preferred inorganic acids include (but not limited to) hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid; the preferred organic acids include (but not limited to) formic acid, acetic acid, propionic acid, succinic acid, naphthalene disulfonic acid (1,5), asiatic acid, oxalic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, valeric acid, diethylacetic acid, malonic acid, succinic acid, fumaric acid, pimelic acid, adipic acid, maleic acid, malic acid, sulfamic acid, phenylpropionic acid, gluconic acid, ascorbic acid, niacin, isoniacin, methanesulfonic acid, p-toluenesulfonic acid, citric acid, and amino acids.
  • The term "pharmaceutically acceptable solvate" denotes the solvate formed by the compounds of the present invention and pharmaceutically acceptable solvents, in which the pharmaceutically acceptable solvent includes (but not limited to) water, ethanol, methanol, isopropanol, propylene glycol, tetrahydrofuran, and dichloromethane.
  • As used herein, the term "pharmaceutically acceptable stereoisomer" means that the chiral carbon atom involved in the compounds of the present invention may be R-configuration, S-configuration, or a combination thereof.
  • The compounds of the present invention or composition thereof, as well as the use method thereof:
    The compounds of the present invention, and various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates thereof, as well as the pharmaceutical composition containing the compounds of the present invention as the main active ingredients can be used for sedation, hypnosis and/or general anesthesia.
  • The compounds of the present invention can also be used for controlling epileptic persistent state and the like.
  • The pharmaceutical composition of the present invention includes a compound of the present invention or a pharmaceutically acceptable salt thereof within a safe and effective amount, as well as a pharmaceutically acceptable excipient or carrier thereof. The administration ways for the compound or pharmaceutical composition of the present invention include (but not limited to) intragastric, intraintestinal, extragastrointestinal (intravenous, intramuscular or subcutaneous), oral and various local administration.
  • The composition for extragastrointestinal injection (intravenous, intramuscular, subcutaneous) may contain physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powder used for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and their suitable mixtures.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or mixed with following ingredients: (a) bulking agent or compatibilizer, such as starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binding agent, such as hydroxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and gum arabic; (c) moisturing agent, such as glycerin; (d) disintegrating agent, such as agar, calcium carbonate, potato starch or cassava starch, alginate, some complex silicates, and sodium carbonate; (e) solvents, such as paraffin; (f) absorption accelerators, such as quaternary amine compounds; (g) wetting agents, such as cetyl alcohol and glycerin monostearate; (h) adsorbents, such as kaolin; and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium dodecyl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage form may also include buffers. The liquid dosage forms used for oral administration include pharmaceutically acceptable emulsion, solution, suspension, syrup or tincture. In addition to the active compounds, the liquid dosage form may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide and oil, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or the mixture thereof, etc.
  • Solid dosage forms such as tablets, sugar pills, capsules, pills and granules can be prepared by coating and shell materials, such as casing and other materials known in the art. They may comprise an opaque agent, and the release of the active compound or compound in the composition may be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymers and waxes. If necessary, the active compound may also form a microcapsule form with one or more of above excipients.
  • The dosage form of the compound of the present invention for local administration includes ointment, powder, patch, spray and inhalant. The active ingredient is mixed in sterile conditions with a biologically acceptable carrier and any preservatives, buffers, or propellants that may be required if necessary.
  • Except for these inert diluents, the composition may also include auxiliaries such as wetting agents, emulsifiers and suspensions, sweeteners, flavoring agents and perfumes. Except for the active compounds, the suspension may contain a suspending agent, such as ethoxylated isooctadecanol, polyoxyethylene sorbitol and dehydrated sorbitol ester, microcrystalline cellulose, aluminum methoxide and agar or the mixture thereof, etc. The compound of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds.
  • When the pharmaceutical composition is used, the safe and effective amount of the compound of the present invention is administrated to the mammal (such as human) in need thereof, in which the dosage is the pharmaceutically acceptable safe and effective dosage.
  • When the pharmaceutical composition is used, the safe and effective amount of the compound of the present invention is administrated to the mammal (such as human) that need to be treated, in which the pharmaceutically effective dosage is given. For the person with 60 kg body weight, the daily dosage is usually 1-2000 mg, preferably 5-500 mg. Of course, the specific dose should be adjusted dependent on the route of administration, the health status of patients and other factors, that are all within the scope of technical skill of practical physicians.
  • Said "room temperature" of the present invention is 25 ± 5°C.
  • Said "overnight" of the present invention is 12 ± 1 hours.
  • Said " 1N HCl" of the invention is 1 mol/L HCl.
  • The experimental results show that the present invention of substituted nitrogen heterocyclic compounds have better depressant effects on the central nervous system and produce sedative, hypnotic and/or anesthetic action as well as control of epilepsy persistence; The substituted nitrogen heterocyclic compounds not only maintain excellent anesthetic activity, but also has the characteristics of rapid onset and rapid recovery; At the same time, the substituted nitrogen heterocyclic compounds have almost no inhibitory effect on the function of adrenal cortex and has little side effects, which solves the technical problems in the field. The present invention provides a new choice for clinically screening and /or preparing sedative, hypnotic and/or general anesthesia drugs and drugs for controlling status epilepticus.
  • Obviously, based on above content of the present invention, according to the common technical knowledge and the conventional means in the field, without department from above basic technical spirits, other various modifications, alternations or changes can further be made.
  • By following specific examples of said embodiments, above content of the present invention is further illustrated. But it should not be construed that the scope of above subject of the present invention is limited to following examples. The techniques realized based on above content of the present invention are all within the scope of the present invention.
    • BRIEF DESCRIPTION OF THE DRAWINGS
    • Figure 1: Effect of the compound of the invention on the function of adrenal cortex; "∗" means that it is statistically significant compared with 0.9% NaCl group.
    • Figure 2: Effects of the compounds of the present invention on the mean arterial pressure (MAP) (actually measured values); Notes: (1) All the test animals' righting reflex disappeared within 1 min after the administration; (2) The 0 min on the abscissa in the figure represents the end of administration;(3) The recovery time of the test animals' righting reflex for compounds or drugs were PRO: 645 s (10.75 min); ETO: 440 s (7.33 min); Compound A3: 133s (2.22min); Compound A4: 174s(2.90min); Compound A8: 139s (2.32min); Compound A12: 80s (1.34min); CompoundA24: 126s (2.10min); CompoundA30: 93s (1.55min); CompoundA34: 94.2s (1.57min); CompoundA54: 72s(1.20min); CompoundA76: 203s(3.39min); Compound A83: 187s(3.12min); Compound A90: 278s(4.63min); Compound A92: 116s(1.93min)∘
    • Figure 3: Effects (rate of change) of the compounds of the present invention on the mean arterial pressure (MAP); Notes:(1) All the test animals' righting reflex disappeared within 1 min after the administration; (2) The 0 min on the abscissa in the figure represents the end of administration; (3) The recovery time of the test animals' righting reflex for compounds or drugs were PRO: 645s (10.75min); ETO: 440S (7.33 min); Compound A3: 133s(2.22min); Compound A4: 174s(2.90min) ; Compound A8: 139s (2.32min); Compound A12: 80s (1.34min); Compound A24: 126s (2.10min); Compound A30: 93s(1.55min); CompoundA34: 94.2s (1.57min); Compound A54: 72s(1.20min); Compound A76: 203s(3.39min); Compound A83: 187s(3.12min); Compound A90: 278s(4.63min); Compound A92: 116s(1.93min).
    • Figure 4: Effects of the compounds of the present invention on heart rate (HR) (actually measured values); Notes: (1) All the test animals' righting reflex disappeared within 1 min after the administration; (2) The 0 min on the abscissa in the figure represents the end of administration; (3) The recovery time of the test animals' righting reflex for compounds or drugs were PRO: 645 s (10.75 min); ETO: 440 s (7.33 min); CompoundA3: 133s (2.22min); Compound A4: 174s(2.90min) ; Compound A8: 139s (2.32min); Compound A12: 80s (1.34min); Compound A24: 126s (2.10min); Compound A30: 93s (1.55min); CompoundA34: 94.2s (1.57min); Compound A54: 72s(1.20min); Compound A76: 203s(3.39min); Compound A83: 187s(3.12min); Compound A90: 278s(4.63min); Compound A92: 116s(1.93min).
    • Figure 5: Effects (rate of change) of the compounds of the present invention on heart rate (HR). Notes: (1)All the test animals' righting reflex disappeared within 1 min after the administration; (2) The 0 min on the abscissa in the figure represents the end of administration; (3) The recovery time of the test animals' righting reflex for compounds or drugs were PRO: 645 s (10.75 min); ETO: 440 s (7.33 min); Compound A3: 133s (2.22min); Compound A4: 174s(2.90min) ; Compound A8: 139s (2.32min); CompoundA12: 80s(1.34min); CompoundA24: 126s(2.10min); CompoundA30: 93s (1.55min); Compound A34: 94.2s (1.57min); Compound A54: 72s(1.20min); Compound A76: 203s(3.39min); Compound A83: 187s(3.12min); Compound A90: 278s(4.63min); Compoun dA92: 116s(1.93min).
    • Figure 6: Effect of the compound of the invention on the function of adrenal cortex; "∗" means that it is statistically significant compared with 0.9% NaCl group.
    • Figures 7: Effects of the compounds of the present invention on the mean arterial pressure (MAP) (actually measured values); Notes: (1) All the test animals' righting reflex disappeared within 1 min after the administration; (2) The 0 min on the abscissa in the figure represents the end of administration;(3) The recovery time of the test animals' righting reflex for compounds or drugs were PRO: 645 s (10.75 min); ETO: 440 s (7.33 min); CompoundB1: 120.6s (2.01min); CompoundB6: 133s(2.22min) ; CompoundB8: 139s (2.32min); CompoundB10: 80s (1.34min); CompoundB18: 186s (3.10min); CompoundB21: 251s (4.19min); CompoundB36: 214s (3.57min); CompoundB51: 132s(2.20min); CompoundB80: 203s(3.39min); CompoundB99: 127s(2.12min); CompoundB108: 100s(1.63min); CompoundB127: 116s(1.93min)∘ Figure 8: Effects (rate of change) of the compounds of the present invention on the mean arterial pressure (MAP); Notes: (1) All the test animals' righting reflex disappeared within 1 min after the administration; (2) The 0 min on the abscissa in the figure represents the end of administration; (3) The recovery time of the test animals' righting reflex for compounds or drugs were PRO: 645s (10.75min); ETO: 440S (7.33 min); CompoundB1: 120.6s (2.01min); CompoundB6: 133s(2.22min) ; CompoundB8: 139s (2.32min); CompoundB10: 80s (1.34min); CompoundB18: 186s (3.10min); CompoundB21: 251s(4.19min); CompoundB36: 214s (3.57min); CompoundB51: 132s(2.20min); CompoundB80: 203s(3.39min); CompoundB99: 127s(2.12min); CompoundB108: 100s(1.63min); CompoundB127: 116s(1.93min).
    • Figure 9: Effects of the compounds of the present invention on heart rate (HR) (actually measured values); Notes: (1) All the test animals' righting reflex disappeared within 1 min after the administration; (2) The 0 min on the abscissa in the figure represents the end of administration; (3) The recovery time of the test animals' righting reflex for compounds or drugs were PRO: 645 s (10.75 min); ETO: 440 s (7.33 min); CompoundB1: 120.6s (2.01min); CompoundB6: 133s(2.22min) ; CompoundB8: 139s (2.32min); CompoundB10: 80s (1.34min); CompoundB18: 186s (3.10min); CompoundB21: 251s(4.19min); CompoundB36: 214s (3.57min); CompoundB51: 132s(2.20min); CompoundB80: 203s(3.39min); CompoundB99: 127s(2.12min); CompoundB108: 100s(1.63min); CompoundB127: 116s(1.93min).
    • Figure 10: Effects (rate of change) of the compounds of the present invention on heart rate (HR). Notes: (1)All the test animals' righting reflex disappeared within 1 min after the administration; (2) The 0 min on the abscissa in the figure represents the end of administration; (3) The recovery time of the test animals' righting reflex for compounds or drugs were PRO: 645 s (10.75 min); ETO: 440 s (7.33 min); CompoundB1: 120.6s (2.01min) ; CompoundB6 : 133s(2.22min) ; CompoundB8 : 139s (2.32min) ; CompoundB10: 80s (1.34min); CompoundB18: 186s (3.10min); CompoundB21: 251s (4.19min); CompoundB36: 214s (3.57min); CompoundB51: 132s(2.20min); CompoundB80: 203s(3.39min); CompoundB99: 127s(2.12min); CompoundB108: 100s(1.63min); CompoundB127: 116s(1.93min).
    • Figure 11 shows the compound effect the invention on the function of adrenal cortex.
    • Figure 12 shows the compound effect the invention on the function of adrenal cortex. Notes: "∗" means that it is statistically significant compared with 0.9% NaCl group.
    • Figure 13 shows the compound effect the invention on circulatory function of rats(MAP)
    • Figures 14 shows the compound effect the invention on circulatory function of rats(MAP,%)∘
    • Figure 15 shows effect of the compound of which the invention on circulatory function of rats(HR)∘
    • Figure 16 shows effect of the compound of which the invention on circulatory function of rats(HR, %)∘
    • Figure 17 shows the effect of the compound of the invention on the function of adrenal cortex in vitro.
    • Figure 18 shows Compound Effect on the function of adrenal cortex in rats; Note: ∗ indicates that it is statistically significant compared with 0.9% NaCl group.
    • Figure 19 shows the compound effect the invention on circulatory function of rats(MAP).
    • Figure 20 shows the compound effect the invention on circulatory function of rats (MAP,%).
    • Figure 21 shows effect of the compound of which the invention on circulatory function of rats (HR).
    • Figure 22 shows effect of the compound of which the invention on circulatory function of rats(HR, %).
    EXAMPLES
  • All starting materials and equipments used in the present invention were known products, acquired by purchasing commercially available products.
  • The structures of the compounds were confirmed by 1H NMR and/or MS spectra. NMR spectra were recorded on a Bruker NMR 400 Avance III spectrometer, using d6-DMSO, CDCl3 or CD3OD as deuterated solvent. NMR Chemical shift (δ) was given in part per million (ppm) relative to the internal standard of tetramethylsilane (TMS).
  • Agilent LCMS 1260-6110 (ESI) was used in the present invention. Column: Waters X-Bridge C18 (50 mm × 4.6 mm × 3.5 µm). Column temperature: 40°C; Flow rate: 2.0 mL/min; Chromatographic analysis was performed in gradient mode. The mobile phases were composed of 0.05% TFA in water (A) and 0.05% TFA in Acetonitrile (B). A gradient elution was applied from 95% A and 5% B to 0% A and 100% B within 3 mins, then extended for another 1 min, and at end changed back to 95% A and 5% B within 0.05 mins and kept eluting for another 0.7 mins.
    • 1) Materials and Reagents
  • The silica gel plate (HSGF254) for thin layer chromatography was bought from Yantai Xinnuo Chemical Co., Ltd, with the thickness of 1 mm.
  • Thin layer chromatography (TLC) was bought from Yantai Jiangyou silicone Development Co., Ltd., with the thickness of 0.2±0.03 mm.
  • Silica gel used for column chromatography was mostly made by Rushan Sun Desiccant Co., Ltd. (Weihai, Shandong) with 100-200 meshes or 200-300 meshes.
    • 2) The Main Instruments
    • Electronic Balance JA2003N (manufactured by Shanghai Yoke Instrument Co., Ltd);
    • Magnetic Stirrer (model: 98-2, manufactured by Shanghai Sile Instrument Co., Ltd);
    • Contact Voltage Regulator (manufacturer: Zhejiang Tianzheng Electric Co., Ltd);
    • Temperature Controller (made by Shanghai Lulin Electric Co., Ltd);
    • Three-function Ultraviolet Analysis (model: ZF-2, manufactured by Shanghai Anting Electronic Instrument Factory);
    • Rotary Evaporator R-201 (manufactured by Shanghai Shenshun Biological Technology Co., Ltd)
    • Constant Temperature Water Bath (model: W201D, manufactured by Shanghai Shenshun Biological Technology Co., Ltd).
    • Circulating Water Vacuum Pump SHB-III (manufactured by Zhengzhou Huicheng Technology Industry and Trade Co., Ltd).
    • Mobile Water Pump SHB-B95 (manufactured by Zhengzhou Huicheng Technology Industry and Trade Co., Ltd).
    • Low-temperature Cooling Liquid Circulating Pump (manufactured by Gongyi Yuhua Instrument Co., Ltd).
    • Rotary Vane Vacuum Pump (manufactured by Linhai Yonghao Vacuum Equipment Co., Ltd).
    • Ultraviolet High-pressure Mercury Lamp (manufactured by Beijing Tianmai Henghui Lamp-house Electric Appliances Co., Ltd).
    • General Procedure A:
      At room temperature, R-1-(1-phenethyl)-1H-pyrazole-5-carboxylic acid/R-1-(1-phenethyl)-1H-triazole-5-carboxylic acid or its derivatized acids (1 eq), DCC (1.5 eq) and DMAP (1.5 eq) were dissolved in dichloromethane. After stirring 5 min, Alcohol or Thiol was added dropwise into above mixture using a syringe and the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion, then it was concentrated under reduced pressure. Methyl tert-butyl ether was added into the residue and stirred, filtered, the filter cake was washed with methyl tert-butyl ether, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography or Prep-TLC to give the desired product. The following are the specific preparation methods for the four groups (A, B, C, D) target compounds of the present invention.
  • Examples of Group A compounds are as follows:
    • Example 1 Preparation of Compounds A1 and A2
  • Figure imgb0230
  • In an ice-water bath, DEAD (3.7 g, 21.2 mmol) in THF (10 mL) was added dropwise into a solution of S-1-phenylethan-1-ol (2.3 g, 18.8 mmol), ethyl 1H-pyrazole-5-carboxylate (6.78 g, 25.5 mmol) and PPh3 (5.6 g, 21.4 mmol) in the THF (50 mL) at 0°C at the rate of 1 mmol/min, then the mixture was warmed slowly to room temperature and stirred at this temperature overnight. The reaction was monitored by TLC until completion, then it was quenched with the saturated brine (50 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give crude product. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) =1/20 ~ 1/10) and the eluate was monitored by TLC (ethyl acetate/petroleum ether (v/v) = 1/2). The fraction with Rf = 0.5 ~ 0.6 was collected and dried to give products A1 (610 mg, yield 18%) and A2 (91 mg, yield 3%).
  • The compound A1: ESI[M + H]+= 245.1
  • 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 1.9 Hz, 1H), 7.33 - 7.27 (m, 4H), 7.25 - 7.18 (m, 1H), 6.86 (d, J = 2.0 Hz, 1H), 6.59 (q, J = 7.1 Hz, 1H), 4.42 - 4.16 (m, 2H), 1.92 (d, J = 7.1 Hz, 3H), 1.33 (t, J = 7.1 Hz, 3H).
  • The compound A2: ESI[M + H]+= 245.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.28 (m, 4H), 7.25 - 7.20 (m, 2H), 6.81 (d, J = 2.4 Hz, 1H), 5.68 (q, J = 7.1 Hz, 1H), 4.41 (q, J = 7.1 Hz, 2H), 1.92 (d, J = 7.1 Hz, 3H), 1.40 (t, J = 7.1 Hz, 3H).
    • Example 2 Preparation of Compounds A3 ~ A48
  • Figure imgb0231
    • 1. Preparation of (R)-1-(1-phenylethyl)-1H-pyrazole-5-carboxylic acid (A)
  • Figure imgb0232
  • At room temperature, NaOH (3.1 g, 77.5 mmol) and A1 (9.5 g, 38.9 mmol) were dissolved in EtOH/H2O (25 mL, 1/1), and then it was stirred at 60°C for 1 hour. The reaction was monitored by TLC until completion, the mixture was concentrated under reduced pressure, cooled and adjusted pH to 4 ~ 5 with 1 N HCl solution, then it was extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound A (6.7 g, yield 80%). ESI[M + H]+= 217.1
  • 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 2.0 Hz, 1H), 7.39 - 7.16 (m, 5H), 7.00 (d, J = 2.0 Hz, 1H), 6.56 (q, J = 7.0 Hz, 1H), 1.93 (d, J = 7.1 Hz, 3H).
    • 2. Preparation of compounds A3 ~ A48
  • Figure imgb0233
  • The target compounds A3 ~ A48 were prepared according to the general procedure A, using A (100 mg, 0.41 mmol) and corresponding alcohol (0.61 mmol) as starting materials. The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether (v/ v) = 1/5) and the fraction with Rf = 0.4 ~ 0.6 was collected and dried to give target compounds as colorless oil.
  • The compound A3: 104 mg, ESI[M + H]+= 271.1
  • 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 1.8 Hz, 1H), 7.33 - 7.27 (m, 4H), 7.25 - 7.19 (m, 1H), 6.90 (d, J = 1.9 Hz, 1H), 6.59 (q, J = 7.0 Hz, 1H), 4.18 - 3.94 (m, 2H), 1.92 (d, J = 7.1 Hz, 3H), 1.26 - 1.09 (m, 1H), 0.66 - 0.48 (m, 2H), 0.40 - 0.21 (m, 2H). The compound A4: 28 mg, ESI[M + H]+ = 271.1
  • 1H NMR (400 MHz, CDCl3) δ 7.56 (s, 1H), 7.31 - 7.27 (m, 4H), 7.25 - 7.20 (m, 1H), 6.87 (s, 1H), 6.67 - 6.51 (m, 1H), 5.20 - 5.05 (m, 1H), 2.49 - 2.31 (m, 2H), 2.22 - 2.02 (m, 2H), 1.91 (d, J = 7.0 Hz, 3H), 1.88 - 1.78 (m, 1H), 1.75 - 1.59 (m, 1H).
  • The compound A5: 65 mg, ESI[M + H]+ = 273.1
  • 1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 1.9 Hz, 1H), 7.33 - 7.20 (m, 5H), 6.95 (d, J = 1.9 Hz, 1H), 6.50 (q, J = 7.1 Hz, 1H), 5.64 - 5.52 (m, 1H), 4.99 - 4.87 (m, 2H), 4.76 - 4.62 (m, 2H), 1.92 (d, J = 7.1 Hz, 3H).
  • The compound A6: 46 mg, ESI[M + H]+ = 289.0
  • 1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 1.9 Hz, 1H), 7.36 - 7.16 (m, 5H), 6.88 (d, J = 1.9 Hz, 1H), 6.51 (q, J = 7.0 Hz, 1H), 5.77 (p, J = 8.0 Hz, 1H), 3.65 - 3.45 (m, 2H), 3.43 - 3.22 (m, 2H), 1.91 (d, J = 7.1 Hz, 3H).
  • The compound A7: 83 mg, ESI[M + H]+ = 273.1
  • 1H NMR (400 MHz, CDCl3) δ 7.54 (s, 1H), 7.33 - 7.27 (m, 4H), 7.25 - 7.19 (m, 1H), 6.77 (s, 1H), 6.59 (q, J = 7.1 Hz, 1H), 1.92 (d, J = 7.0 Hz, 3H), 1.52 (s, 9H).
  • The compound A8: 36 mg, ESI[M + H]+ = 315.1
  • 1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 1.8 Hz, 1H), 7.32 - 7.16 (m, 5H), 7.01 (d, J = 1.8 Hz, 1H), 6.41 (q, J = 7.0 Hz, 1H), 4.96 (dd, J = 24.8, 7.7 Hz, 2H), 4.77 (dd, J = 21.8, 7.7 Hz, 2H), 2.19 (s, 3H), 1.92 (d, J = 7.0 Hz, 3H).
  • The compound A9: 27 mg, ESI[M + H]+ = 299.1
  • 1H NMR (400 MHz, CDCl3) δ 7.60 (s, 1H), 7.35 - 7.14 (m, 5H), 7.00 (d, J = 1.6 Hz, 1H), 6.54 (q, J = 7.0 Hz, 1H), 1.91 (d, J = 7.1 Hz, 3H), 1.89 (s, 3H), 1.60 - 1.45 (m, 2H), 1.38 - 1.10 (m, 2H).
  • The compound A10: 113 mg, ESI[M + H]+ = 311.0
  • 1H NMR (400 MHz, CDCl3) δ 7.59 (s, 1H), 7.34 - 7.17 (m, 5H), 6.91 (d, J = 1.4 Hz, 1H), 6.53 (q, J = 7.0 Hz, 1H), 5.16 - 4.43 (m, 4H), 1.93 (d, J = 7.0 Hz, 3H), 1.89 (s, 3H).
  • The compound A11: 69 mg, ESI[M + H]+ = 283.0
  • 1H NMR (400 MHz, CDCl3) δ 7.57 (s, 1H), 7.36 - 7.17 (m, 5H), 6.95 - 6.83 (m, 1H), 6.68 - 6.50 (m, 1H), 5.67 - 5.42 (m, 1H), 1.92 (d, J = 7.0 Hz, 3H), 1.84 (dd, J = 12.9, 2.1 Hz, 3H), 1.52 (t, J = 6.6 Hz, 3H).
  • The compound A12: 52 mg, ESI[M + H]+ = 297.1
  • 1H NMR (400 MHz, CDCl3) δ 7.54 (s, 1H), 7.37 - 7.14 (m, 5H), 6.79 (s, 1H), 6.63 (q, J = 6.9 Hz, 1H), 1.92 (d, J = 7.0 Hz, 3H), 1.84 (s, 3H), 1.71 (s, 3H), 1.69 (s, 3H).
  • The compound A13: 86 mg, ESI[M + H]+ = 283.1
  • 1H NMR (400 MHz, CDCl3) δ 7.57 (s, 1H), 7.33 - 7.19 (m, 5H), 6.87 (t, 1H), 6.66 - 6.50 (m, 1H), 5.60 - 5.47 (m, 1H), 5.39 - 5.25 (m, 1H), 4.97 - 4.72 (m, 2H), 1.92 (d, J = 7.1 Hz, 3H), 1.45 - 1.38 (m, 3H).
  • The compound A14: 21 mg, ESI[M + H]+ = 297.1
  • 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 1.7 Hz, 1H), 7.37 - 7.16 (m, 5H), 6.98 - 6.87 (m, 1H), 6.62 - 6.49 (m, 1H), 6.17 - 5.55 (m, 1H), 5.45 - 4.69 (m, 2H), 2.06 - 1.85 (m, 6H), 1.82 - 1.59 (m, 3H).
  • The compound A15: 79 mg, ESI[M + H]+ = 295.1
  • 1H NMR (400 MHz, CDCl3) δ 7.57 (t, J = 1.7 Hz, 1H), 7.35 - 7.18 (m, 5H), 6.97 - 6.84 (m, 1H), 6.66 - 6.48 (m, 1H), 5.89 - 5.60 (m, 3H), 5.59 - 5.34 (m, 1H), 1.92 (d, J = 7.1 Hz, 3H), 1.57 (t, J = 6.5 Hz, 3H).
  • The compound A16: 66 mg, ESI[M + H]+ = 309.1
  • 1H NMR (400 MHz, CDCl3) δ 7.54 (s, 1H), 7.36 - 7.18 (m, 5H), 6.80 (s, 1H), 6.62 (q, J = 7.0 Hz, 1H), 5.91 - 5.75 (m, 1H), 5.68 - 5.58 (m, 1H), 5.53 - 5.44 (m, 1H), 1.92 (d, J = 7.0 Hz, 3H), 1.76 (s, 3H), 1.73 (s, 3H).
  • The compound A17: 90 mg, ESI[M + H]+ = 339.1
  • 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 1.5 Hz, 1H), 7.32 - 7.18 (m, 5H), 6.95 (d, J = 1.3 Hz, 1H), 6.51 (q, J = 6.9 Hz, 1H), 2.43 - 2.22 (m, 4H), 2.07 (s, 3H), 1.94 (d, J = 7.1 Hz, 3H), 1.81 - 1.71 (m, 2H), 1.72 - 1.63 (m, 2H).
  • The compound A18: 56 mg, ESI[M + H]+ = 325.0
  • 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 1.3 Hz, 1H), 7.34 - 7.20 (m, 5H), 6.95 (d, J = 1.2 Hz, 1H), 6.48 (q, J = 7.0 Hz, 1H), 2.51 - 2.31 (m, 7H), 1.94 (d, J = 7.0 Hz, 3H), 1.88 - 1.76 (m, 2H).
  • The compound A19: 8 mg, ESI[M + H]+ = 325.0
  • 1H NMR (400 MHz, CDCl3) δ 7.67 - 7.58 (m, 1H), 7.36 - 7.27 (m, 4H), 7.25 - 7.20 (m, 1H), 7.02 - 6.92 (m, 1H), 6.55 - 6.45 (m, 1H), 2.89 - 2.69 (m, 2H), 2.67 - 2.57 (m, 1H), 2.42 - 2.29 (m, 2H), 2.19 (s, 1H), 2.05 - 1.90 (m, 6H).
  • The compound A20: 61 mg, ESI[M + H]+ = 341.0
  • 1H NMR (400 MHz, CDCl3) δ 7.62 (s, 1H), 7.34 - 7.19 (m, 5H), 7.02 (s, 1H), 6.57 - 6.47 (m, 1H), 3.55 (s, 3H), 2.76 - 2.63 (m, 4H), 2.07 - 1.95 (m, 2H), 1.94 (d, J = 7.0 Hz, 3H).
  • The compound A21: 94 mg, ESI[M + H]+ = 287.1
  • 1H NMR (400 MHz, CDCl3) δ 7.56 (s, 1H), 7.34 - 7.27 (m, 4H), 7.25 - 7.18 (m, 1H), 6.85 (s, 1H), 6.60 (q, J = 6.5 Hz, 1H), 5.01 - 4.76 (m, 1H), 1.93 (d, J = 6.9 Hz, 3H), 1.69 - 1.55 (m, 4H), 0.90 (t, J = 7.4 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H).
  • The compound A22: 102 mg, ESI[M + H]+ = 297.1
  • 1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 2.0 Hz, 1H), 7.34 - 7.19 (m, 5H), 6.92 (d, J = 2.0 Hz, 1H), 6.52 (q, J = 7.0 Hz, 1H), 5.03 - 4.70 (m, 4H), 2.79 (s, 1H), 1.93 (d, J =
  • 7.1 Hz, 3H).
  • The compound A23: 105.3 mg, ESI[M + H]+ = 269.1
  • 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 1.9 Hz, 1H), 7.35 - 7.19 (m, 5H), 6.92 (d, J = 1.9 Hz, 1H), 6.57 (q, J = 7.1 Hz, 1H), 4.96 - 4.63 (m, 2H), 1.92 (d, J = 7.1 Hz, 3H), 1.86 (t, J = 2.4 Hz, 3H).
  • The compound A24: 95.6 mg, ESI[M + H]+ = 311.0
  • 1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 2.0 Hz, 1H), 7.35 - 7.20 (m, 5H), 6.89 (d, J = 2.0 Hz, 1H), 6.49 (q, J = 7.1 Hz, 1H), 5.65 (t, J = 6.6 Hz, 1H), 5.05 - 4.70 (m, 6H), 1.92 (d, J = 7.1 Hz, 3H).
  • The compound A25: 79 mg, ESI[M + H]+ = 301.0
  • 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 1.4 Hz, 1H), 7.35 - 7.17 (m, 5H), 6.94 (d, J = 1.3 Hz, 1H), 6.52 (q, J = 7.1 Hz, 1H),4.80 - 4.74 (m, 1H), 3.65 - 3.55 (m, 1H), 3.24 (s, 3H), 2.88 - 2.74 (m, 2H), 2.15 - 2.03 (m, 2H), 1.92 (d, J = 7.1 Hz, 3H).
  • The compound A26: 23 mg, ESI[M + H ]+ = 297.1
  • 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 1.8 Hz, 1H), 7.35 - 7.18 (m, 5H), 6.91 (d, J = 1.6 Hz, 1H), 6.51 (q, J = 7.0 Hz, 1H), 4.88 - 4.70 (m, 2H), 4.36 - 4.15 (m, 2H), 2.89 - 2.74 (m, 2H), 2.75 - 2.39 (m, 3H), 1.92 (d, J = 7.1 Hz, 3H).
  • The compound A27: 85 mg, ESI[M + H]+ = 257.0
  • 1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 2.0 Hz, 1H), 7.39 - 7.16 (m, 5H), 6.89 (d, J = 2.0 Hz, 1H), 6.50 (q, J = 7.0 Hz, 1H), 6.08 - 5.80 (m, 1H), 5.52 - 5.19 (m, 1H), 4.98 - 4.58 (m, 1H), 1.92 (d, J = 7.0 Hz, 3H).
  • The compound A28: 27 mg, ESI[M + H]+ = 337.1
  • 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 1.8 Hz, 1H), 7.38 - 7.19 (m, 5H), 6.90 (d, J = 1.8 Hz, 1H), 6.51 (q, J = 7.1 Hz, 1H), 5.61 (s, 1H), 4.98 - 4.86 (m, 2H), 2.38 - 2.25 (m, 2H), 2.13 (t, J = 5.7 Hz, 2H), 1.93 (d, J = 7.1 Hz, 3H), 1.65 - 1.48 (m, 6H).
  • The compound A29: 112 mg, ESI[M + H]+ = 285.0
  • 1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 2.0 Hz, 1H), 7.35 - 7.18 (m, 5H), 6.91 (d, J = 2.0 Hz, 1H), 6.52 (q, J = 7.0 Hz, 1H), 5.88 - 5.72 (m, 1H), 5.45 - 5.17 (m, 3H) , 1.92 (d, J = 7.1 Hz, 3H), 1.80 - 1.71 (m, 2H), 1.05 - 0.82 (m, 3H).
  • The compound A30: 75 mg, ESI[M + H]+ = 287.0
  • 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 1.8 Hz, 1H), 7.37 - 7.15 (m, 5H), 6.90 (d, J = 1.8 Hz, 1H), 6.51 (q, J = 7.1 Hz, 1H), 4.86 - 4.77 (m, 2H), 4.60 - 4.49 (m, 2H), 1.91 (d, J = 7.1 Hz, 3H), 1.75 (s, 3H).
  • The compound A31: 84 mg, ESI[M + H]+ = 287.0
  • 1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 2.0 Hz, 1H), 7.38 - 7.15 (m, 5H), 6.92 (d, J = 2.0 Hz, 1H), 6.52 (q, J = 7.0 Hz, 1H), 4.29 - 4.20 (m, 1H), 2.59 - 2.42 (m, 2H), 2.27 - 2.00 (m, 4H), 2.06 (d, J = 7.1 Hz, 3H), 1.90 (d, J = 7.0 Hz, 3H).
  • The compound A32: 103 mg, ESI[M + H]+ = 259.0
  • 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 1.6 Hz, 1H), 7.39 - 7.14 (m, 5H), 6.90 (d, J = 2.1 Hz, 1H), 6.50 (q, J = 7.1 Hz, 1H), 5.27 - 5.17 (m, 1H), 1.91 (d, J = 7.1 Hz, 3H), 1.36 (d, J = 6.2 Hz, 3H), 1.32 (d, J = 6.3 Hz, 3H).
  • The compound A33: 83 mg, ESI[M + H]+ = 257.0
  • 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 2.0 Hz, 1H), 7.38 - 7.14 (m, 5H), 6.89 (d, J = 2.0 Hz, 1H), 6.52 (q, J = 7.0 Hz, 1H), 4.35 - 4.25 (m, 1H), 1.90 (d, J = 7.1 Hz, 3H), 0.90 - 0.70 (m, 4H).
  • The compound A34: 31 mg, ESI[M + H]+ = 299.0
  • 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 2.0 Hz, 1H), 7.38 - 7.15 (m, 5H), 6.89 (d, J = 2.1 Hz, 1H), 6.51 (q, J = 7.1 Hz, 1H), 6.27 - 6.23 (m, 1H), 5.36 - 5.30 (m, 2H), 4.94 - 4.77 (m, 4H), 1.92 (d, J = 6.9 Hz, 3H).
  • The compound A35: 84 mg, ESI[M + H]+ = 337.1
  • 1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 1.6 Hz, 1H), 7.37 - 7.14 (m, 5H), 6.90 (d, J = 1.8 Hz, 1H), 6.52 (q, J = 7.0 Hz, 1H), 2.18 - 1.92 (m, 4H), 1.91 (d, J = 7.0 Hz, 3H), 1.86 (s, 3H), 1.69 - 1.24 (m, 6H).
  • The compound A36: 51 mg, ESI[M + H]+ = 313.1
  • 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 1.8 Hz, 1H), 7.34 - 7.15 (m, 5H), 6.92 (d, J = 2.0 Hz, 1H), 6.51 (q, J = 7.1 Hz, 1H), 5.95 - 5.64 (m, 2H), 5.02 - 4.77 (m, 3H), 4.72 (d, J = 8.0 Hz, 1H), 1.90 - 1.82 (m, 3H), 1.75 - 1.57 (m, 3H).
  • The compound A37: 76 mg, ESI[M + H]+ = 317.0
  • 1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 1.8 Hz, 1H), 7.35 - 7.16 (m, 5H), 6.90 (d, J = 1.8 Hz, 1H), 6.50 (q, J = 7.0 Hz, 1H), 4.45 - 4.39 (m, 2H), 4.35 - 4.30 (m, 2H), 3.34 (s, 2H), 1.90 (d, J = 7.1 Hz, 3H), 1.33 (s, 3H).
  • The compound A38: 99 mg, ESI[M + H]+ = 301.0
  • 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 2.0 Hz, 1H), 7.38 - 7.15 (m, 5H), 6.91 (d, J = 2.0 Hz, 1H), 6.50 (q, J = 7.1 Hz, 1H), 4.51 (dd, J = 6.1, 2.0 Hz, 2H), 4.42 (dd, J = 6.1, 1.5 Hz, 2H), 4.39 - 4.30 (m, 2H), 1.91 (d, J = 7.1 Hz, 3H), 1.35 (s, 3H).
  • The compound A39: 101 mg, ESI[M + H]+ = 317.0
  • 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 1.6 Hz, 1H), 7.35 - 7.15 (m, 5H), 6.89 (d, J = 2.0 Hz, 1H), 6.49 (q, J = 7.1 Hz, 1H), 4.25 (q, J = 10.9 Hz, 2H), 3.07 (d, J = 9.4 Hz, 2H), 2.94 (dd, J = 9.4, 1.1 Hz, 2H), 1.89 (d, J = 7.1 Hz, 3H), 1.33 (s, 3H).
  • The compound A40: 82 mg, ESI[M + H]+ = 301.0
  • 1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 2.0 Hz, 1H), 7.37 - 7.15 (m, 5H), 6.90 (d, J = 2.0 Hz, 1H), 6.50 (q, J = 7.1 Hz, 1H),1.91 (s, 3H), 1.88 (d, J = 7.1 Hz, 3H), 1.53 (s, 3H), 1.46 (s, 3H).
  • The compound A41: 38 mg, ESI[M + H]+ = 317.1
  • 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 2.0 Hz, 1H), 7.38 - 7.13 (m, 5H), 6.92 (d, J = 2.0 Hz, 1H), 6.51 (q, J = 7.1 Hz, 1H), 2.13 (s, 3H), 1.89 (d, J = 7.1 Hz, 3H), 1.55 (s, 3H), 1.46 (s, 3H).
  • The compound A42: 70 mg, ESI[M + H]+ = 329.1
  • 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 2.0 Hz, 1H), 7.37 - 7.14 (m, 5H), 6.90 (d, J = 2.0 Hz, 1H), 6.52 (q, J = 7.1 Hz, 1H), 4.82 - 4.71 (m, 1H), 3.80 - 3.69 (m, 1H), 3.65 - 3.54 (m, 1H), 2.89 - 2.74 (m, 2H), 2.20 - 2.07 (m, 2H), 1.86 (d, J = 7.1 Hz, 3H), 1.15 (d, J = 6.1 Hz, 6H).
  • The compound A43: 15mg, ESI[M + H]+ = 425.2
  • 1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 2.0 Hz, 1H), 7.35 - 7.15 (m, 5H), 6.91 (d, J = 2.0 Hz, 1H), 6.52 (q, J = 7.1 Hz, 1H), 6.15 - 5.80 (m, 1H), 3.87 - 3.13 (m, 4H), 2.58 - 2.35 (m, 1H), 2.18 - 1.11 (m, 18H).
  • The compound A44: 22 mg, ESI[M + H]+ = 359.2
  • 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 2.0 Hz, 1H), 7.38 - 7.13 (m, 5H), 6.91 (d, J = 1.8 Hz, 1H), 6.51 (q, J = 7.1 Hz, 1H),5.09 - 4.94 (m, 1H), 3.50 - 3.36 (m, 4H), 2.82 - 2.65 (m, 2H), 2.35 - 2.20 (m, 2H), 1.90 (d, J = 7.1 Hz, 3H), 1.19 (q, J = 7.0 Hz, 6H).
  • The compound A45: 54 mg, ESI[M + H]+ = 327.1
  • 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 1.6 Hz, 1H), 7.35 - 7.18 (m, 5H), 6.94 (d, J = 1.6 Hz, 1H), 6.51 (q, J = 7.0 Hz, 1H), 4.65 - 4.49 (m, 1H), 4.34 - 4.15 (m, 1H), 2.82 - 2.64 (m, 1H), 2.50 - 1.93 (m, 5H), 1.90 (d, J = 7.1 Hz, 3H), 1.78 - 1.35 (m, 3H).
  • The compound A46: 95 mg, ESI[M + H]+ = 355.1
  • 1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 1.8 Hz, 1H), 7.38 - 7.15 (m, 5H), 6.92 (d, J = 1.8 Hz, 1H), 6.51 (q, J = 7.1 Hz, 1H), 3.51 (s, 3H), 2.48 - 2.35 (m, 2H), 2.35 - 2.20 (m, 2H), 1.90 (d, J = 7.1 Hz, 3H), 1.81 - 1.75 (m, 2H), 1.73 - 1.65 (m, 2H).
  • The compound A47: 76 mg, ESI[M + H]+ = 325.0
  • 1H NMR (400 MHz, CDCl3) δ 8.09 (s, 1H), 7.61 (d, J = 1.9 Hz, 1H), 7.36 - 7.15 (m, 5H), 6.91 (d, J = 1.8 Hz, 1H), 6.51 (q, J = 7.1 Hz, 1H), 2.67 - 2.63 (m, 2H), 2.46 (t, J = 6.6 Hz, 2H), 1.91 (d, J = 7.1 Hz, 3H), 1.88-1.84 (m, 2H), 1.80 - 1.72 (m, 2H).
  • The compound A48: 85 mg, ESI[M + H]+ = 357.1
  • 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 1.6 Hz, 1H), 7.37 - 7.15 (m, 5H), 6.90 (d, J = 2.0 Hz, 1H), 6.50 (q, J = 7.1 Hz, 1H), 3.55 (s, 3H), 2.28 - 2.05 (m, 2H), 1.94 - 1.76 (m, 5H), 1.74 - 1.20 (m, 6H).
    • Example 3 Preparation of Compounds A49 and A50
  • Figure imgb0234
    • 1.Preparation of ethyl 3-nitro-1H-pyrazole-5-carboxylate (49-2)
  • Figure imgb0235
  • At room temperature, 49-1 (50 g, 318.3 mmol) was dissolved in ethanol (300 mL), and the mixture was cooled to 0°C by an ice-salt bath. SOCl2 (49 g, 412 mmol) was added dropwise into the mixture, then it was stirred at 85°C for 10 hrs. The reaction was monitored by TLC until completion and concentrated under reduced pressure. The residue was dissolved in dichloromethane (3 mL) and adjusted pH to 8 with sat NaHCO3 solution. The mixture was extracted with dichloromethane (3 × 30 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound 49-2 (58.7 g, yield 99.6%) as a white solid. ESI[M + H]+ = 186.1
    • 2. Preparation of ethyl 3-amino-1H-pyrazole-5-carboxylate (49-3)
  • Figure imgb0236
  • At room temperature, 49-2 (58.7 g, 317 mmol) and 10% wet palladium on carbon (6 g) were dissolved in EtOH (200 mL), the system was replaced with hydrogen three times and stirred under hydrogen for 18 hrs. The reaction was monitored by TLC until completion, filtered and the filter cake was washed with ethanol (3 × 30 mL). The filtrate was concentrated under reduced pressure to give a crude product. The crude product was purified by silica gel column chromatography with ethyl acetate/petroleum ether (v/v =1/5) and the eluate was monitored by TLC (ethyl acetate/petroleum ether (v/v) = 1/1). The fraction with Rf = 0.4 ~ 0.5 was collected to give 49-3 (43.5 g, yield 88%) as a gray solid. ESI[M + H]+ = 156.1
    • 3. Preparation of ethyl 3-fluoro-1H-pyrazole-5-carboxylate (49-4)
  • Figure imgb0237
  • In an ice-salt bath, 49-3 (43.5 g, 280 mmol) was dissolved in the HBF4 (40%), and then NaNO2 (20.3 g, 294 mmol) in the water (30 mL) was added dropwise into solution at - 10°C. The mixture was allowed to react under the irradiation of a mercury lamp (254 nm) for 12 hrs. The reaction was monitored by TLC until completion, and then the reaction solution was adjusted pH to 7 with IN NaOH solution in an ice-water bath. The mixture was extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography with ethyl acetate/petroleum ether (v/v =1/1) and the eluate was monitored by TLC (ethyl acetate/petroleum ether (v/v) = 1/1). The fraction with Rf = 0.4 ~ 0.5 was collected to give 49-4 (3.4 g, yield 8%) as a gray solid.
    • 4. Preparation of compounds A49 and A50
  • Figure imgb0238
  • In an ice-water bath, S-1-phenylethan-1-ol (3.4 g, 27.8 mmol), 49-4 (3.4 g, 21.5 mmol) and PPh3 (8.4 g, 32.0 mmol) were dissolved in THF (50 mL) at 0°C, then DEAD (5.6 g, 32.2 mmol) was added into mixture at the rate of 0.5 mmol/min. The mixture was warmed slowly to room temperature and stirred at this temperature overnight. The reaction was monitored by TLC until completion, then it was quenched with saturated brine (30 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give crude product. The crude product was purified by silica gel column chromatography with ethyl acetate/petroleum ether (v/v =1/20 ~ 1/10) and the eluate was monitored by TLC (ethyl acetate/petroleum ether (v/v) = 1/2). The fraction with Rf = 0.5 ~ 0.6 was collected to give the products A49 (4.2 g, yield 74%) and A50 (400 mg, yield 7%).
  • The compound A49: ESI[M + H]+ = 263.1
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.21 (m, 5H), 6.56 - 6.47 (m, 1H), 6.33 (d, J = 6.3 Hz, 1H), 4.41 - 4.17 (m, 2H), 1.85 (d, J = 7.1 Hz, 3H), 1.33 (t, J = 7.1 Hz, 3H). The compound A50: ESI[M + H]+ = 263.0
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.27 (m, 5H), 6.26 (d, J= 5.6 Hz, 1H), 5.58 (q, J = 7.2 Hz, 1H), 4.40 (q, J = 7.1 Hz, 2H), 1.95 (d, J = 7.2 Hz, 3H), 1.39 (t, J = 7.1 Hz, 3H).
    • Example 4 Preparation of Compounds A51 ~ A69
  • Figure imgb0239
    • 1. Preparation of (R)-3-fluoro-1-(1-phenylethyl)-1H-pyrazole-5-carboxylic acid (B)
  • Figure imgb0240
  • At room temperature, NaOH (1.3 g, 32.5 mmol) and A49 (4.2 g, 16.0 mmol) were dissolved in ethanol/water (20 mL, v/v = 1/1), and then it was reacted at 60°C for 1 hour. The reaction was monitored by TLC until completion, then it was concentrated under reduced pressure. The residue was dissolved in H2O (20 mL) and adjusted pH to 4-5 with 1 N HCl solution. The mixture was extracted with dichloromethane (3 × 15 mL). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound B (2.8 g, yield 75%) as a white solid. ESI[M + H]+ = 234.9
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.14 (m, 6H), 6.55 - 6.36 (m, 2H), 1.87 (d, J = 7.0 Hz, 3H).
    • 2. Preparation of compounds A51 ~ A69
  • Figure imgb0241
  • The target compounds A51 ~ A69 were prepared according to the general procedure A, using B (100 mg, 0.43 mmol) and corresponding alcohol (0.64 mmol) as starting materials. The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether (v/ v) = 1/5) and the fraction with Rf = 0.4 ~ 0.6 was collected and dried to give target compounds as colorless oil.
  • The compound A51: 84 mg, ESI[M + H]+ = 287.0
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.21 (m, 5H), 6.54 - 6.44 (m, 1H), 6.39 (d, J = 6.3 Hz, 1H), 4.91 - 4.71 (m, 2H), 1.87 (d, J = 2.4 Hz, 3H), 1.85 (d, J = 7.2 Hz, 3H).
  • The compound A52: 89 mg, ESI[M + H]+ = 329.0
  • 1H NMR (400 MHz, CDCl3) δ 7.58 - 7.14 (m, 5H), 6.49 - 6.39 (m, 1H), 6.37 (d, J= 6.3 Hz, 1H), 5.64 (t, J = 6.6 Hz, 1H), 5.08 - 4.70 (m, 6H), 1.85 (d, J= 7.0 Hz, 3H).
  • The compound A53: 32 mg, ESI[M + H]+ = 315.0
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.19 (m, 6H), 6.48 - 6.41 (m, 1H), 6.40 (d, J = 6.3 Hz, 1H), 5.09 - 4.59 (m, 4H), 2.81 (s, 1H), 1.86 (d, J = 7.0 Hz, 3H).
  • The compound A54: 84 mg, ESI[M + H]+ = 373.0
  • 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.18 (m, 5H), 6.52 - 6.43 (m, 1H), 6.41 (d, J = 6.3 Hz, 1H), 3.46 (s, 3H), 2.51 - 2.37 (m, 2H), 2.34 - 2.21 (m, 2H), 1.87 (d, J= 7.0 Hz, 3H), 1.82 - 1.73 (m, 2H), 1.73 - 1.64 (m, 2H).
  • The compound A55: 88 mg, ESI[M + H]+ = 319.0
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.21 (m, 5H), 6.52 - 6.42 (m, 1H), 6.34 (d, J = 6.3 Hz, 1H), 4.80 (p, J = 7.3 Hz, 1H), 3.63 (p, J = 6.9 Hz, 1H), 3.26 (s, 3H), 2.95 - 2.73 (m, 2H), 2.17 - 2.02 (m, 2H), 1.84 (d, J= 7.0 Hz, 3H).
  • The compound A56: 39 mg, ESI[M + H]+ = 305.0
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.21 (m, 5H), 6.48 - 6.38 (m, 1H), 6.33 (d, J = 6.3 Hz, 1H), 4.80 (dd, J= 24.7, 7.3 Hz, 2H), 4.55 (t, J= 6.7 Hz, 2H), 1.85 (d, J= 7.0 Hz, 3H), 1.75 (s, 3H).
  • The compound A57: 70 mg, ESI[M + H]+ = 291.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.20 (m, 5H), 6.58 - 6.45 (m, 1H), 6.23 (d, J = 6.3 Hz, 1H), 1.84 (d, J= 7.1 Hz, 3H), 1.52 (s, 9H).
  • The compound A58: 99 mg, ESI[M + H]+ = 289.0
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.18 (m, 5H), 6.50 - 6.41 (m, 1H), 6.35 (d, J = 6.3 Hz, 1H), 4.20 - 3.95 (m, 2H), 1.85 (d, J= 7.1 Hz, 3H), 1.27 - 1.00 (m, 1H), 0.68 - 0.48 (m, 2H), 0.45 - 0.20 (m, 2H).
  • The compound A59: 86 mg, ESI[M + H]+ = 289.0
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.19 (m, 5H), 6.50 - 6.40 (m, 1H), 6.32 (d, J = 6.3 Hz, 1H), 5.19 - 5.04 (m, 1H), 2.47 - 2.30 (m, 2H), 2.25 - 2.01 (m, 2H), 1.86 (d, J = 7.1 Hz, 3H), 1.86 - 1.59 (m, 2H).
  • The compound A60: 62 mg, ESI[M + H]+ = 307.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.18 (m, 5H), 6.48 - 6.37 (m, 1H), 6.28 (d, J = 6.3 Hz, 1H), 5.75 (p, J = 8.0 Hz, 1H), 3.61 - 3.20 (m, 4H), 1.87 (d, J= 7.1 Hz, 3H). The compound A61: 51 mg, ESI[M + H]+ = 327.1
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.16 (m, 5H), 6.50 - 6.37 (m, 1H), 6.30 (d, J = 6.3 Hz, 1H), 5.92 - 5.74 (m, 1H), 5.70 - 5.59 (m, 1H), 5.55 - 5.40 (m, 1H), 1.88 (d, J = 7.0 Hz, 3H), 1.77 (s, 3H), 1.74 (s, 3H).
  • The compound A62: 47 mg, ESI[M + H]+ = 315.0
  • 1H NMR (400 MHz, CDCl3) δ 7.45 - 7.16 (m, 5H), 6.49 - 6.38 (m, 1H), 6.29 (d, J = 6.3 Hz, 1H), 1.89 (d, J= 7.1 Hz, 3H), 1.85 (s, 3H), 1.72 (s, 3H), 1.68 (s, 3H).
  • The compound A63: 39 mg, ESI[M + H]+ = 315.0
  • 1H NMR (400 MHz, CDCl3) δ 7.48 - 7.16 (m, 5H), 6.50 - 6.38 (m, 1H), 6.32 (d, J = 6.3 Hz, 1H), 5.87 - 5.51 (m, 1H), 5.23 - 4.68 (m, 2H), 2.12 - 1.85 (m, 6H), 1.80 - 1.59 (m, 3H).
  • The compound A64: 50 mg, ESI[M + H]+ = 333.0
  • 1H NMR (400 MHz, CDCl3) δ 7.47 - 7.16 (m, 5H), 6.48 - 6.38 (m, 1H), 6.29 (d, J= 6.3 Hz, 1H), 5.05 - 4.90 (m, 2H), 4.81 - 4.70 (m, 2H), 2.21 (s, 3H), 1.88 (d, J = 7.1 Hz, 3H).
  • The compound A65: 27 mg, ESI[M + H]+ = 317.0
  • 1H NMR (400 MHz, CDCl3) δ 7.50 - 7.15 (m, 5H), 6.55 - 6.41 (m, 1H), 6.30 (d, J = 6.3 Hz, 1H), 6.26 - 6.18 (m, 1H), 5.35 - 5.21 (m, 2H), 4.97 - 4.71 (m, 4H), 1.88 (d, J = 7.0 Hz, 3H).
  • The compound A66: 49 mg, ESI[M + H]+ = 355.1
  • 1H NMR (400 MHz, CDCl3) δ 7.49 - 7.18 (m, 5H), 6.50 - 6.41 (m, 1H), 6.33 (d, J = 6.3 Hz, 1H), 2.21 - 1.90 (m, 4H), 1.89 (d, J = 7.0 Hz, 3H), 1.85 (s, 3H), 1.70 - 1.29 (m, 6H).
  • The compound A67: 93 mg, ESI[M + H]+ = 375.1
  • 1H NMR (400 MHz, CDCl3) δ 7.50 - 7.17 (m, 5H), 6.48 - 6.45 (m, 1H), 6.28 (d, J= 6.3 Hz, 1H), 3.54 (s, 3H), 2.30 - 2.05 (m, 2H), 1.96 - 1.20 (m, 11H).
  • The compound A68: 58 mg, ESI[M + H]+ = 357.0
  • 1H NMR (400 MHz, CDCl3) δ 7.47 - 7.15 (m, 5H), 6.50 - 6.42 (m, 1H), 6.31 (d, J = 6.3 Hz, 1H), 2.45 - 2.21 (m, 4H), 2.09 (s, 3H), 1.89 (d, J = 7.1 Hz, 3H), 1.80 - 1.561 (m, 4H).
  • The compound A69: 32 mg, ESI[M + H]+ = 343.0
  • 1H NMR (400 MHz, CDCl3) δ 7.50 - 7.17 (m, 5H), 6.49 - 6.44 (m, 1H), 6.27 (d, J= 6.3 Hz, 1H), 2.50 - 2.31 (m, 7H), 1.89 (d, J = 7.1 Hz, 3H), 1.88 - 1.74 (m, 2H).
    • Example 5 Preparation of Compounds A70 and A71
  • Figure imgb0242
    • 1. Preparation of Ethyl 4-nitro-1H-pyrazole-5-carboxylate (70-2)
  • Figure imgb0243
  • At room temperature, 70-1 (50 g, 318.3 mmol) was dissolved in ethanol (300 mL), the mixture was cooled to 0°C by an ice-salt bath. SOCl2 (49 g, 412 mmol) was added dropwise into the mixture, then it was stirred at 85°C for 10 hrs. The reaction was monitored by TLC until completion and concentrated under reduced pressure. The residue was dissolved in dichloromethane (30 mL) and adjusted pH to 8 with sat NaHCO3. The mixture was extracted with dichloromethane (3 × 30 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound 70-2 (54.8 g, yield 93%) as a white solid. ESI[M + H]+ = 186.1
    • 2. Preparation of Ethyl 4-amino-1H-pyrazole-5-carboxylate (70-3)
  • Figure imgb0244
  • At room temperature, 70-2 (54.8 g, 296 mmol) and 10% wet palladium on carbon (5 g) were dissolved in EtOH (200 mL), the system was replaced with hydrogen three times and stirred under hydrogen for 18 hrs. The reaction was monitored by TLC until completion, filtered and the filter cake was washed with ethanol (3 × 30 mL). The filtrate was concentrated under reduced pressure to give a crude product. The crude product was purified by silica gel column chromatography with ethyl acetate/petroleum ether (v/v =1/5) and the eluate was monitored by TLC (ethyl acetate/petroleum ether (v/v) = 1/1). The fraction with Rf = 0.4 ~ 0.5 was collected to give 70-3 (41.1 g, yield 89%) as a gray solid. ESI[M + H]+ = 156.1
    • 3. Preparation of Ethyl 4-fluoro-1H-pyrazole-5-carboxylate (70-4)
  • Figure imgb0245
  • In an ice-salt bath, 70-3 (35 g, 226 mmol) was dissolved in the HBF4 (40%), and then NaNO2 (16.4 g, 238 mmol) in the water (30 mL) was added dropwise into solution at - 10°C. The mixture was allowed to react under the irradiation of a mercury lamp (302 nm) for 12 hrs. The reaction was monitored by TLC until completion, and then the reaction solution was adjusted pH to 7 with IN NaOH solution in an ice-water bath. The mixture was extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with saturated brine, dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography with ethyl acetate/petroleum ether (v/v =1/1) and the eluate was monitored by TLC (ethyl acetate/petroleum ether (v/v) = 1/1). The fraction with Rf = 0.4 ~ 0.5 was collected to give 70-4 (6 g, yield 17%) as a gray solid.
    • 4. Preparation of compounds A70 and A71
  • Figure imgb0246
  • In an ice-water bath, S-1-phenylethan-1-ol (3.4 g, 27.8 mmol), 70-4 (6 g, 37.9 mmol), and PPh3 (14.9 g, 56.8 mmol) were dissolved in THF (50 mL) at 0°C, then DEAD (9.9 g, 56.8 mmol) in THF (15 mL) was added in to mixture at the rate of 0.5 mmol/min, then the mixture was warmed slowly to room temperature and stirred at this temperature overnight. The reaction was monitored by TLC until completion, then it was quenched with the saturated brine (30 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give crude product. The crude product was purified by silica gel column chromatography with ethyl acetate/petroleum ether (v/v =1/20 ~ 1/10) and the eluate was monitored by TLC (ethyl acetate/petroleum ether (v/v) = 1/2). The fraction with Rf = 0.5 ~ 0.6 was collected to give the products A70 (5.9 g, yield 59%) and A71 (1.5 g, yield 15%).
  • The compound A70: ESI[M + H]+ = 263.1
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J= 4.5 Hz, 1H), 7.35 - 7.20 (m, 5H), 6.46 (q, J = 7.1 Hz, 1H), 4.53 - 4.09 (m, 2H), 1.88 (d, J = 7.1 Hz, 3H), 1.34 (t, J = 7.1 Hz, 3H). The compound A71: ESI[M + H]+ = 263.0
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.29 (m, 3H), 7.27 - 7.23 (m, 2H), 7.21 (d, J = 4.8 Hz, 1H), 5.55 (q, J = 7.1 Hz, 1H), 4.43 (q, J = 7.1 Hz, 2H), 1.89 (d, J = 7.1 Hz, 3H), 1.40 (t, J = 7.1 Hz, 3H).
    • Example 6 Preparation of Compounds A72 ~ A90
  • Figure imgb0247
    • 1.Preparation of (R)-4-fluoro-1-(1-phenylethyl)-1H-pyrazole-5-carboxylic acid (C)
  • Figure imgb0248
  • At room temperature, NaOH (1.8 g, 45.0 mmol) and A70 (5.9 g, 22.5 mmol) were dissolved in EtOH/H2O (20 mL, 1/1), and then it was stirred at 60°C for 1 hour. The reaction was monitored by TLC until completion, the mixture was concentrated under reduced pressure, cooled and adjusted pH to 4 ~ 5 with 1 N HCl solution. The mixture was extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound C (3.8 g, yield 72%). ESI[M + H]+ = 235.2
  • 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 4.5 Hz, 1H), 7.36 - 7.20 (m, 5H), 6.43 (q, J = 7.0 Hz, 1H), 1.89 (d, J = 7.1 Hz, 3H).
    • 2.Preparation of compounds A72 ~ A90
  • Figure imgb0249
  • The target compounds A72 ~ A90 were prepared according to the general procedure A, using C (100 mg, 0.43 mmol) and corresponding alcohol (0.64 mmol) as starting materials. The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether (v/ v) = 1/5) and the fraction with Rf = 0.4 ~ 0.6 was collected and dried to give target compounds as colorless oil.
  • The compound A72: 40 mg, ESI[M + H]+ = 287.2
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 4.5 Hz, 1H), 7.33 - 7.20 (m, 5H), 6.44 (q, J = 6.9 Hz, 1H), 4.92 - 4.71 (m, 2H), 1.90 - 1.85 (m, 6H).
  • The compound A73: 52 mg, ESI[M + H]+ = 329.2
  • 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 4.5 Hz, 1H), 7.35 - 7.18 (m, 5H), 6.37 (q, J = 7.1 Hz, 1H), 5.63 (t, J = 6.6 Hz, 1H), 5.03 - 4.95 (m, 1H), 4.95 - 4.87 (m, 2H), 4.85 - 4.74 (m, 3H), 1.88 (d, J = 7.1 Hz, 3H).
  • The compound A74: 76 mg, ESI[M + H]+ = 315.2
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 4.5 Hz, 1H), 7.34 - 7.18 (m, 5H), 6.43 (q, J = 7.1 Hz, 1H), 5.05 - 4.72 (m, 4H), 2.80 (s, 1H), 1.89 (d, J = 7.1 Hz, 3H).
  • The compound A75: 109 mg, ESI[M + H]+ = 373.2
  • 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 4.5 Hz, 1H), 7.35 - 7.16 (m, 5H), 6.41 (q, J = 7.0 Hz, 1H), 3.50 (s, 3H), 2.48 - 2.19 (m, 4H), 1.88 (d, J = 7.1 Hz, 3H), 1.82 - 1.63 (m, 4H).
  • The compound A76: 57 mg, ESI[M + H]+ = 319.1
  • 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 4.5 Hz, 1H), 7.35 - 7.16 (m, 5H), 6.41 (q, J = 7.0 Hz, 1H), 4.84 - 4.72 (m, 1H), 3.68 - 3.54 (m, 1H), 3.24 (s, 3H), 2.93 - 2.70 (m, 2H), 2.19 - 2.01 (m, 2H), 1.87 (d, J = 7.1 Hz, 3H).
  • The compound A77: 76 mg, ESI[M + H]+ = 347.2
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 4.5 Hz, 1H), 7.38 - 7.14 (m, 5H), 6.36 (q, J = 7.1 Hz, 1H), 4.84 - 4.68 (m, 1H), 3.78 - 3.52 (m, 2H), 2.84 - 2.71 (m, 2H), 2.24 - 2.00 (m, 2H), 1.87 (d, J = 7.1 Hz, 3H), 1.17 (d, J = 6.1 Hz, 6H ).
  • The compound A78: 31 mg, ESI[M + H]+ = 291.1
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 4.5 Hz, 1H), 7.35 - 7.14 (m, 5H), 6.41 (q, J = 7.1 Hz, 1H), 1.89 (d, J = 7.1 Hz, 3H), 1.53 (s, 9H).
  • The compound A79: 105 mg, ESI[M + H]+ = 289.2
  • 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 4.5 Hz, 1H), 7.37 - 7.16 (m, 5H), 6.45 (q, J = 7.0 Hz, 1H), 4.20 - 3.94 (m, 2H), 1.90 (d, J = 7.1 Hz, 3H), 1.24 - 1.01 (m, 1H), 0.64 - 0.20 (m, 4H).
  • The compound A80: 92 mg, ESI[M + H]+ = 289.1
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 4.5 Hz, 1H), 7.36 - 7.12 (m, 5H), 6.39 (q, J = 7.1 Hz, 1H), 5.18 - 5.07 (m, 1H), 2.45 - 2.05 (m, 4H), 1.87 (d, J = 7.1 Hz, 3H), 1.86 - 1.58 (m, 2H).
  • The compound A81: 67 mg, ESI[M + H]+ = 307.0
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 4.5 Hz, 1H), 7.39 - 7.15 (m, 5H), 6.42 (q, J = 7.1 Hz, 1H), 5.80 - 5.73 (m, 1H), 3.69 - 3.19 (m, 4H), 1.88 (d, J = 7.1 Hz, 3H).
  • The compound A82: 25 mg, ESI[M + H]+ = 327.2
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 4.5 Hz, 1H), 7.37 - 7.18 (m, 5H), 6.45 (q, J = 7.1 Hz, 1H), 5.90 - 5.40 (m, 3H), 1.88 (d, J = 7.1 Hz, 3H), 1.78 (s, 3H), 1.75 (s, 3H).
  • The compound A83: 61 mg, ESI[M + H]+ = 315.0
  • 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 4.5 Hz, 1H), 7.38 - 7.16 (m, 5H), 6.40 (q, J = 7.1 Hz, 1H), 1.89 (d, J = 7.1 Hz, 3H), 1.86 (s, 3H), 1.74 (s, 3H), 1.69 (s, 3H).
  • The compound A84: 16 mg, ESI[M + H]+ = 315.2
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 4.5 Hz, 1H), 7.35 - 7.15 (m, 5H), 6.41 (q, J = 7.1 Hz, 1H), 5.77 - 5.50 (m, 1H), 5.34 - 4.64 (m, 2H), 2.08 - 1.84 (m, 6H), 1.78 - 1.55 (m, 3H).
  • The compound A85: 82 mg, ESI[M + H]+ = 305.2
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 4.5 Hz, 1H), 7.38 - 7.15 (m, 5H), 6.38 (q, J = 7.1 Hz, 1H), 4.89 - 4.74 (m, 2H), 4.61 - 4.44 (m, 2H), 1.86 (d, J = 7.1 Hz, 3H), 1.74 (s, 3H).
  • The compound A86: 59 mg, ESI[M + H]+ = 333.1
  • 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 4.5 Hz, 1H), 7.36 - 7.15 (m, 5H), 6.42 (q, J = 7.1 Hz, 1H), 5.01 - 4.91 (m, 2H), 4.85 - 4.66 (m, 2H), 2.24 (s, 3H), 1.89 (d, J = 7.1 Hz, 3H).
  • The compound A87: 33 mg, ESI[M + H]+ = 317.2
  • 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 4.5 Hz, 1H), 7.39 - 7.15 (m, 5H), 6.38 (q, J = 7.1 Hz, 1H), 6.29 - 6.17 (m, 1H), 5.36 - 5.20 (m, 2H), 4.94 - 4.56 (m, 4H), 1.88 (d, J = 7.0 Hz, 3H).
  • The compound A88: 79 mg, ESI[M + H]+ = 355.2 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J= 4.5 Hz, 1H), 7.40 - 7.16 (m, 5H), 6.41 (q, J = 7.1 Hz, 1H), 2.21 - 1.92 (m, 4H), 1.88 (d, J= 7.1 Hz, 3H), 1.86 (s, 3H), 1.72 - 1.24 (m, 6H).
  • The compound A89: 101 mg, ESI[M + H]+ = 375.2
  • 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 4.5 Hz, 1H), 7.36 - 7.15 (m, 5H), 6.37 (q, J = 7.1 Hz, 1H), 3.52 (s, 3H), 2.33 - 2.01 (m, 2H), 1.94 - 1.22 (m, 11H).
  • The compound A90: 49 mg, ESI[M + H]+ = 343.2
  • 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J= 4.5 Hz, 1H), 7.35 - 7.12 (m, 5H), 6.39 (q, J = 7.1 Hz, 1H), 2.51 - 2.28 (m, 7H), 1.88 (d, J= 7.1 Hz, 3H), 1.84 - 1.70 (m, 2H). The preparation method of the target compounds A91 ~ A114 was the similar as the compounds A1, A49 and A70. 3,4-Difluoro-1H-pyrazole-5 carboxylic acid ethyl ester, 4-chloro-1H-pyrazole-5-carboxylate ethyl ester or 4-trifluoromethyl-1H-pyrazole-5 carboxylic acid ethyl ester reacted with S-1-phenylethan-1-ol under PPh3 and DEAD to give corresponding intermediates, which were hydrolyzed by NaOH to give the corresponding carboxylic acid. The carboxylic acid reacted with a series of alcohols by DCC condensation according to general procedure A to give the target compounds.
  • The compound A91: 89 mg, ESI[M + H]+ = 305.1
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.18 (m, 5H), 6.52 - 6.44 (m, 1H), 4.90 - 4.69 (m, 2H), 1.88 (d, J= 2.2 Hz, 3H), 1.88 (d, J= 7.1 Hz, 3H).
  • The compound A92: 20 mg, ESI[M + H]+ = 347.2
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.20 (m, 5H), 6.53 - 6.41 (m, 1H), 5.67 (t, J= 6.5 Hz, 1H), 5.05 - 4.64 (m, 6H), 1.86 (d, J = 7.1 Hz, 3H).
  • The compound A93: 77 mg, ESI[M + H]+ = 391.1
  • 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.21 (m, 5H), 6.51 - 6.40 (m, 1H), 3.55 (s, 3H), 2.50 - 2.17 (m, 4H), 1.85 (d, J= 7.0 Hz, 3H), 1.81 - 1.60 (m, 4H).
  • The compound A94: 60 mg, ESI[M + H]+ = 337.2
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.21 (m, 5H), 6.54 - 6.38 (m, 1H), 4.87 - 4.76 (m, 1H), 3.70 - 3.55 (m, 1H), 3.27 (s, 3H), 2.97 - 2.73 (m, 2H), 2.20 - 2.03 (m, 2H), 1.84 (d, J = 7.1 Hz, 3H).
  • The compound A95: 26 mg, ESI[M + H]+ = 345.2
  • 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.20 (m, 5H), 6.51 - 6.34 (m, 1H), 6.00 - 5.77 (m, 1H), 5.68 - 5.41 (m, 2H), 1.88 (d, J= 7.0 Hz, 3H), 1.78 (s, 3H), 1.74 (s, 3H).
  • The compound A96: 20 mg, ESI[M + H]+ = 333.1
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.23 (m, 5H), 6.50 - 6.33 (m, 1H), 1.87 (d, J = 7.1 Hz, 3H), 1.84 (s, 3H), 1.74 (s, 3H), 1.65 (s, 3H).
  • The compound A97: 76 mg, ESI[M + H]+ = 373.2
  • 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.21 (m, 5H), 6.51 - 6.32 (m, 1H), 2.25 - 1.92 (m, 4H), 1.86 (d, J = 7.1 Hz, 3H), 1.84 (s, 3H), 1.72 - 1.24 (m, 6H).
  • The compound A98: 64 mg, ESI[M + H]+ = 361.2
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.20 (m, 5H), 6.49 - 6.37 (m, 1H), 2.53 - 2.30 (m, 7H), 1.86 (d, J = 7.1 Hz, 3H), 1.86 - 1.74 (m, 2H).
  • The compound A99: 20 mg, ESI[M + H]+ = 337.2
  • 1H NMR (400 MHz, CDCl3) δ 7.62 (s, 1H), 7.35 - 7.20 (m, 5H), 6.48 (q, J = 7.1 Hz, 1H), 4.97 - 4.69 (m, 2H), 1.92 - 1.81 (m, 6H).
  • The compound A100: 35 mg, ESI[M + H]+ = 379.2
  • 1H NMR (400 MHz, CDCl3) δ 7.64 (s, 1H), 7.3 7 - 7.23 (m, 5H), 6.51 (q, J = 7.1 Hz, 1H), 5.64 (t, J = 6.7 Hz, 1H), 5.05 - 4.72 (m, 6H), 1.87 (d, J= 7.1 Hz, 3H).
  • The compound A101: 35 mg, ESI[M + H]+ = 423.3
  • 1H NMR (400 MHz, CDCl3) δ 7.66 (s, 1H), 7.35 - 7.21 (m, 5H), 6.47 (q, J = 7.1 Hz, 1H), 3.52 (s, 3H), 2.50 - 2.16 (m, 4H), 1.84 (d, J = 7.1 Hz, 3H), 1.80 - 1.58 (m, 4H). The compound A102: 72 mg, ESI[M + H]+ = 369.2
  • 1H NMR (400 MHz, CDCl3) δ 7.60 (s, 1H), 7.34 - 7.20 (m, 5H), 6.51 (q, J = 7.1 Hz, 1H), 4.85 - 4.70 (m, 1H), 3.70 - 3.52 (m, 1H), 3.22 (s, 3H), 2.91 - 2.68 (m, 2H), 2.22 - 2.01 (m, 2H), 1.85 (d, J= 7.1 Hz, 3H).
  • The compound A103: 28 mg, ESI[M + H]+ = 377.2
  • 1H NMR (400 MHz, CDCl3) δ 7.64 (s, 1H), 7.35 - 7.19 (m, 5H), 6.47 (q, J = 7.1 Hz, 1H), 5.88 - 5.40 (m, 3H), 1.86 (d, J = 7.1 Hz, 3H), 1.77 (s, 3H), 1.75 (s, 3H).
  • The compound A104: 62 mg, ESI[M + H]+ = 365.2
  • 1H NMR (400 MHz, CDCl3) δ 7.62 (s, 1H), 7.36 - 7.23 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 1.87 (d, J= 7.1 Hz, 3H), 1.85 (s, 3H), 1.73 (s, 3H), 1.68 (s, 3H).
  • The compound A105: 35 mg, ESI[M + H]+ = 405.2
  • 1H NMR (400 MHz, CDCl3) δ 7.63 (s, 1H), 7.36 - 7.20 (m, 5H), 6.50 (q, J= 7.1 Hz, 1H), 2.20 - 1.89 (m, 4H), 1.86 (d, J = 7.1 Hz, 3H), 1.85 (s, 3H), 1.70 - 1.21 (m, 6H).
  • The compound A106: 43 mg, ESI[M + H]+ = 393.2
  • 1H NMR (400 MHz, CDCl3) δ 7.66 (s, 1H), 7.38 - 7.19 (m, 5H), 6.48 (q, J = 7.1 Hz, 1H), 2.50 - 2.20 (m, 7H), 1.87 (d, J = 7.1 Hz, 3H), 1.85 - 1.66 (m, 2H).
  • The compound A107: 109 mg, ESI[M + H]+ = 303.0
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (s, 1H), 7.35 - 7.20 (m, 5H), 6.46 (q, J = 6.9 Hz, 1H), 4.88 - 4.70 (m, 2H), 1.89 - 1.83 (m, 6H).
  • The compound A108: 19 mg, ESI[M + H]+ = 345.2
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (s, 1H), 7.36 - 7.17 (m, 5H), 6.40 (q, J = 7.1 Hz, 1H), 5.64 (t, J = 6.5 Hz, 1H), 5.00 - 4.70 (m, 6H), 1.86 (d, J = 7.1 Hz, 3H).
  • The compound A109: 77 mg, ESI[M + H]+ = 389.2
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (s, 1H), 7.34 - 7.15 (m, 5H), 6.45 (q, J = 7.1 Hz, 1H), 3.52 (s, 3H), 2.45 - 2.15 (m, 4H), 1.84 (d, J = 7.1 Hz, 3H), 1.80 - 1.52 (m, 4H).
  • The compound A110: 109 mg, ESI[M + H]+ = 335.1
  • 1H NMR (400 MHz, CDCl3) δ 7.43 (s, 1H), 7.35 - 7.11 (m, 5H), 6.46 (q, J = 7.1 Hz, 1H), 4.85 - 4.70 (m, 1H), 3.69 - 3.51 (m, 1H), 3.22 (s, 3H), 2.91 - 2.65 (m, 2H), 2.20 - 2.01 (m, 2H), 1.85 (d, J = 7.1 Hz, 3H).
  • The compound A111: 26 mg, ESI[M + H]+ = 343.2
  • 1H NMR (400 MHz, CDCl3) δ 7.46 (s, 1H), 7.37 - 7.15 (m, 5H), 6.48 (q, J = 7.1 Hz, 1H), 5.91 - 5.45 (m, 3H), 1.86 (d, J = 7.1 Hz, 3H), 1.77 (s, 3H), 1.75 (s, 3H).
  • The compound A112: 53 mg, ESI[M + H]+ = 331.1
  • 1 H NMR (400 MHz, CDCl3) δ 7.45 (s, 1H), 7.35 - 7.16 (m, 5H), 6.46 (q, J = 7.1 Hz, 1H), 1.88 (d, J = 7.1 Hz, 3H), 1.85 (s, 3H), 1.74 (s, 3H), 1.67 (s, 3H).
  • The compound A113: 29 mg, ESI[M + H]+ = 371.2
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (s, 1H), 7.38 - 7.15 (m, 5H), 6.48 (q, J = 7.1 Hz, 1H), 2.25 - 1.91 (m, 4H), 1.87 (d, J = 7.1 Hz, 3H), 1.85 (s, 3H), 1.78 - 1.21 (m, 6H).
  • The compound A114: 45 mg, ESI[M + H]+ = 359.1
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (s, 1H), 7.37 - 7.12 (m, 5H), 6.50 (q, J = 7.1 Hz, 1H), 2.55 - 2.24 (m, 7H), 1.86 (d, J = 7.1 Hz, 3H), 1.83 - 1.65 (m, 2H).
  • Examples of Group B compounds are as follows:
    • Example 1 Preparation of Compounds B1 and B2
  • Figure imgb0250
    • 1. Preparation of (R)-(1-Azidoethyl)benzene (1-2)
  • Figure imgb0251
  • In an ice bath, (S)-1-phenylethan-1-ol (1-1) (20 g, 164 mmol) and PPh3 (85.9 g, 328 mmol) were dissolved in THF (300 mL) at 0°C. DEAD (57.1 g, 328 mmol) in THF (50 mL) was added dropwise into the mixture at the rate of 10 mmol/min, then DPPA (54.1 g, 197 mmol) was added dropwise into the mixture at the rate of 6 mmol/min. The mixture was warmed to room temperature slowly and allowed to react for overnight. The reaction was monitored by TLC until completion, then it was quenched with brine (150 mL) and extracted with hexane (3 × 50 mL). The mixture was divided into three layers, collected the top layer. The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/100 ~ 1/50) and the eluate was monitored by TLC (ethyl acetate/petroleum ether (v/v) = 1/10). The fraction with Rf = 0.5 ~ 0.6 was collected and dried to give compound 1-2 (20.0 g, yield 83%).
    • 2. Preparation of Compounds B1 and B2
  • Figure imgb0252
  • At room temperature, (R)-(1-azidoethyl)benzene 1-2 (4.8 g, 32.6 mmol) and ethyl propiolate (6.4 g, 65.2 mmol) were dissolved in toluene (100 mL), then the mixture was refluxed for 2 hrs. The reaction was monitored by TLC until completion, then it was quenched with the saturated brine (30 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/1) and the eluate was monitored by TLC (ethyl acetate/petroleum ether (v/v) = 1/5). The fraction with Rf = 0.5 ~ 0.6 was collected and dried to give the products B1 (1.3 g, yield 16%) and B2 (4.0 g, yield 50%).
  • The compound B1: ESI[M + H]+ = 246.3
  • 1H NMR (400 MHz, CDCl3) δ 8.17 (s, 1H), 7.42 - 7.29 (m, 5H), 6.58 (q, J = 7.1 Hz, 1H), 4.45 - 4.26 (m, 2H), 2.08 (d, J = 7.1 Hz, 3H), 1.37 (t, J = 7.1 Hz, 3H).
  • The compound B2: ESI[M + H]+ = 246.3
  • 1H NMR (400 MHz, CDCl3) δ 7.97 (s, 1H), 7.46 - 7.36 (m, 3H), 7.35 - 7.29 (m, 2H), 5.91 (q, 7 = 7.1 Hz, 1H), 4.42 (q, J = 7.1 Hz, 2H), 2.03 (d, J = 7.1 Hz, 3H), 1.41 (t, J = 7.1 Hz, 3H).
    • Example 2 Preparation of Compounds B3 ~ B32
  • Figure imgb0253
    • 1.Preparation of (R)-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylic acid (A)
  • Figure imgb0254
  • At room temperature, LiOH.H2O (220 mg, 5.24 mmol) was added into the mixture of B1 (643 mg, 2.62 mmol) in MeOH/THF/H2O (3 mL, 1/1/1), then it was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was concentrated under reduced pressure and H2O (10 mL) was added. The mixture was adjusted to PH = 4 ∼ 5 with 1 N hydrochloric acid and extracted with dichloromethane (3 × 15 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound A (545 mg, yield 96%) as a white solid. ESI[M + H]+ = 218.2
  • 1H NMR (400 MHz, CDCl3) δ 8.25 (s, 1H), 7.38 - 7.30 (m, 5H), 6.58 - 6.52 (m, 1H), 2.10 (d, J = 7.0 Hz, 3H).
    • 2.The preparation of Compounds B3 ~ B32
  • Figure imgb0255
  • The target compounds B3 ~ B32 were prepared according to the general procedure A, using (R)-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylic acid A (100 mg, 0.46 mmol) and corresponding alcohols (0.69 mmol) as starting materials. The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether (v/ v) = 1/5) and the fraction with Rf = 0.4 ~ 0.6 was collected and dried to give target compounds as colorless oil.
  • The compound B3: 21 mg, ESI[M + H]+ = 312.3
  • 1H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H), 7.39 - 7.29 (m, 5H), 6.48 (q, J = 7.0 Hz, 1H), 5.64 (t, J = 6.6 Hz, 1H), 5.04 - 4.75 (m, 6H), 2.09 (d, J = 7.1 Hz, 3H).
  • The compound B4: 82 mg, ESI[M + H]+ = 342.1 1H NMR (400 MHz, CDCl3) δ 8.18 (s, 1H), 7.38 - 7.29 (m, 5H), 6.46 (q, J = 7.0 Hz, 1H), 3.57 (s, 3H), 2.82 - 2.55 (m, 4H), 2.05 - 1.88 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H).
  • The compound B5: 77 mg, ESI[M + H]+ = 296.1
  • 1H NMR (400 MHz, CDCl3) δ 8.16 (s, 1H), 7.39 - 7.28 (m, 5H), 6.47 (q, J = 7.0 Hz, 1H), 5.87 - 5.60 (m, 3H), 5.59 - 5.23 (m, 1H), 2.07 (d, J = 7.1 Hz, 3H), 1.66 (t, J = 6.0 Hz, 3H).
  • The compound B6: 105 mg, ESI[M + H]+ = 272.2
  • 1H NMR (400 MHz, CDCl3) δ 8.16 (s, 1H), 7.41 - 7.29 (m, 5H), 6.56 (q, J = 7.1 Hz, 1H), 5.17 (p, J = 7.5 Hz, 1H), 2.51 - 2.34 (m, 2H), 2.25 - 2.11 (m, 2H), 2.08 (d, J = 7.1 Hz, 3H), 1.94 - 1.82 (m, 1H), 1.77 - 1.63 (m, 1H).
  • The compound B7: 96 mg, ESI[M + H]+ = 272.2
  • 1H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H), 7.39 - 7.29 (m, 5H), 6.58 (q, J = 7.0 Hz, 1H), 4.21 - 4.04 (m, 2H), 2.09 (d, J = 7.1 Hz, 3H), 1.26 - 1.14 (m, 1H), 0.69 - 0.58 (m, 2H), 0.42 - 0.28 (m, 2H).
  • The compound B8: 46 mg, ESI[M + H]+ = 302.2
  • 1H NMR (400 MHz, CDCl3) δ 8.17 (s, 1H), 7.40 - 7.30 (m, 5H), 6.54 (q, J = 7.0 Hz, 1H), 4.89 - 4.80 (m, 1H), 3.70 - 3.61 (m, 1H), 3.28 (s, 3H), 2.95 - 2.78 (m, 2H), 2.18 - 2.10 (m, 2H), 2.08 (d, J = 7.1 Hz, 3H).
  • The compound B9: 33 mg, ESI[M + H]+ = 298.0
  • 1H NMR (400 MHz, CDCl3) δ 7.97 (s, 1H), 7.46 - 7.36 (m, 3H), 7.35 - 7.29 (m, 2H), 5.91 (q, J = 7.1 Hz, 1H), 4.85 - 4.73 (m, 2H), 4.35 - 4.18 (m, 2H), 2.89 - 2.71 (m, 2H), 2.74 - 2.29 (m, 3H), 2.03 (d, J = 7.1 Hz, 3H).
  • The compound B10: 85 mg, ESI[M + H]+ = 258.3
  • 1H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H), 7.40 - 7.29 (m, 5H), 6.57 (q, J = 7.3 Hz, 1H), 6.05 - 5.90 (m, 1H), 5.44 - 5.28 (m, 2H), 4.87 - 4.71 (m, 2H), 2.09 (d, J = 7.1 Hz, 3H).
  • The compound B11: 20 mg, ESI[M + H]+ = 338.2
  • 1H NMR (400 MHz, CDCl3) δ 8.24 (s, 1H), 7.41 - 7.29 (m, 5H), 6.55 (q, J = 7.1 Hz, 1H), 5.60 (s, 1H), 4.93 (d, J = 3.8 Hz, 2H), 2.35 - 2.18 (m, 2H), 2.17 - 2.03 (m, 5H), 1.62 - 1.49 (m, 4H), 1.46 - 1.33 (m, 2H).
  • The compound B12: 39 mg, ESI[M + H]+ = 274.3
  • 1H NMR (400 MHz, CDCl3) δ 8.08 (s, 1H), 7.40 - 7.30 (m, 5H), 6.59 (q, J = 6.7 Hz, 1H), 2.08 (d, J = 7.0 Hz, 3H), 1.55 (s, 9H).
  • The compound B13: 94 mg, ESI[M + H]+ = 286.3
  • 1H NMR (400 MHz, CDCl3) δ 8.17 (s, 1H), 7.42 - 7.28 (m, 5H), 6.58 (q, J = 7.5 Hz, 1H), 5.89 - 5.74 (m, 1H), 5.41 - 5.17 (m, 3H), 2.13 - 2.03 (m, 3H), 1.77 - 1.67 (m, 2H), 1.00 - 0.87 (m, 3H).
  • The compound B14: 55 mg, ESI[M + H]+ = 288.3
  • 1H NMR (400 MHz, CDCl3) δ 8.16 (s, 1H), 7.41 - 7.29 (m, 5H), 6.48 (q, J = 7.1 Hz, 1H), 4.81 (dd, J = 27.0, 7.3 Hz, 2H), 4.57 (t, J = 6.6 Hz, 2H), 2.09 (d, J = 7.1 Hz, 3H), 1.77 (s, 3H).
  • The compound B15: 15 mg, ESI[M + H]+ = 340.3
  • 1H NMR (400 MHz, CDCl3) δ 8.24 (s, 1H), 7.37 - 7.30 (m, 5H), 6.50 (q, J = 7.2 Hz, 1H), 2.45 - 2.38 (m, 2H), 2.36 - 2.28 (m, 2H), 2.12 (d, J = 7.0 Hz, 3H), 2.06 (s, 3H), 1.83 - 1.76 (m, 2H), 1.75 - 1.68 (m, 2H).
  • The compound B16: 15 mg, ESI[M + H]+ = 288.2
  • 1H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H), 7.38 - 7.29 (m, 5H), 6.42 (q, J = 7.2 Hz, 1H), 4.29 - 4.21 (m, 1H), 2.59 - 2.44 (m, 2H), 2.25 - 2.07 (m, 4H), 2.06 (d, J = 7.1 Hz, 3H).
  • The compound B17: 86 mg, ESI[M + H]+ = 260.2
  • 1H NMR (400 MHz, CDCl3) δ 8.14 (s, 1H), 7.43 - 7.29 (m, 5H), 6.58 (q, J = 7.1 Hz, 1H), 5.29 - 5.13 (m, 1H), 2.08 (d, J = 7.1 Hz, 3H), 1.35 (d, J = 6.2 Hz, 3H), 1.32 (d, J = 6.3 Hz, 3H).
  • The compound B18: 98 mg, ESI[M + H]+ = 258.3
  • 1H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H), 7.42 - 7.28 (m, 5H), 6.55 (q, J = 7.1 Hz, 1H), 4.36 - 4.25 (m, 1H), 2.08 (d, J = 7.1 Hz, 3H), 0.92 - 0.70 (m, 4H).
  • The compound B19: 102 mg, ESI[M + H]+ = 300.2
  • 1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.43 - 7.28 (m, 5H), 6.54 (q, J = 7.1 Hz, 1H), 6.24 - 6.13 (m, 1H), 5.37 - 5.14 (m, 2H), 4.97 - 4.61 (m, 4H), 2.08 (d, J = 7.1 Hz, 3H).
  • The compound B20: 56 mg, ESI[M + H]+ = 338.3
  • 1H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 7.41 - 7.25 (m, 5H), 6.56 (q, J = 7.1 Hz, 1H), 2.17 - 2.02 (m, 5H), 2.01 - 1.90 (m, 2H), 1.87 (s, 3H), 1.69 - 1.25 (m, 6H).
  • The compound B21: 49 mg, ESI[M + H]+ = 314.2
  • 1H NMR (400 MHz, CDCl3) δ 8.13 (s, 1H), 7.44 - 7.28 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 5.97 - 5.61 (m, 2H), 5.03 - 4.71 (m, 3H), 4.71 (d, J = 8.0 Hz, 1H), 2.08 (d, J = 7.1 Hz, 3H), 1.73 - 1.60 (m, 3H).
  • The compound B22: 34 mg, ESI[M + H]+ = 318.2
  • 1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.43 - 7.28 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H), 4.41 - 4.33 (m, 4H), 3.33 (s, 2H), 2.08 (d, J = 7.1 Hz, 3H), 1.31 (s, 3H).
  • The compound B23: 75 mg, ESI[M + H]+ = 302.2
  • 1H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 7.42 - 7.29 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H), 4.52 - 4.32 (m, 6H), 2.08 (d, J = 7.1 Hz, 3H), 1.31 (s, 3H).
  • The compound B24: 29 mg, ESI[M + H]+ = 302.2
  • 1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.43 - 7.28 (m, 5H), 6.55 (q, J = 7.1 Hz, 1H), 2.08 (d, J = 7.1 Hz, 3H), 2.03 (s, 3H), 1.49 (s, 3H), 1.45 (s, 3H).
  • The compound B25: 54 mg, ESI[M + H]+ = 318.2
  • 1H NMR (400 MHz, CDCl3) δ 8.13 (s, 1H), 7.45 - 7.29 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H), 2.12 (s, 3H), 2.05 (d, J = 7.1 Hz, 3H), 1.55 (s, 3H), 1.44 (s, 3H).
  • The compound B26: 45 mg, ESI[M + H]+ = 330.3
  • 1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.43 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 4.76 (t, J = 7.4 Hz, 1H), 3.74 (t, J = 7.0 Hz, 1H), 3.64 - 3.58 (m, 1H), 2.89 - 2.72 (m, 2H), 2.21 - 2.07 (m, 2H), 2.10 (d, J = 7.1 Hz, 3H), 1.15 (d, J = 8.0 Hz, 6H).
  • The compound B27: 34 mg, ESI[M + H]+ = 360.3
  • 1H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 7.41 - 7.27 (m, 5H), 6.54 (q, J = 7.1 Hz, 1H), 5.07 - 4.95 (m, 1H), 3.49 - 3.36 (m, 4H), 2.81 - 2.66 (m, 2H), 2.32 - 2.22 (m, 2H), 2.08 (d, J = 7.1 Hz, 3H), 1.20 (q, J = 7.0 Hz, 6H).
  • The compound B28: 17 mg, ESI[M + H]+ = 426.3
  • 1H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H), 7.42 - 7.28 (m, 5H), 6.55 (q, J = 7.1 Hz, 1H), 6.14 - 5.81 (m, 1H), 3.85 - 3.62 (m, 1H), 3.59 - 3.13 (m, 3H), 2.55 - 2.39 (m, 1H), 2.18 - 1.92 (m, 7H), 1.91 - 1.83 (m, 3H), 1.82 - 1.41 (m, 2H), 1.28 - 1.14 (m, 4H), 1.08 - 0.88 (m, 2H).
  • The compound B29: 38 mg, ESI[M + H]+ = 328.3
  • 1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.44 - 7.29 (m, 5H), 6.55 (q, J = 7.1 Hz, 1H), 4.63 - 4.49 (m, 1H), 4.32 - 4.16 (m, 1H), 2.80 - 2.61 (m, 1H), 2.50 - 2.01 (m, 7H), 1.98 - 1.91 (m, 1H), 1.77 - 1.31 (m, 3H).
  • The compound B30: 78 mg, ESI[M + H]+ = 356.3
  • 1H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 7.43 - 7.29 (m, 5H), 6.55 (q, J = 7.1 Hz, 1H), 3.50 (s, 3H), 2.48 - 2.23 (m, 4H), 2.08 (d, J = 7.1 Hz, 3H), 1.81 - 1.63 (m, 4H). The compound B31: 46 mg, ESI[M + H]+ = 326.2
  • 1H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H), 7.42 - 7.28 (m, 5H), 6.55 (q, J = 7.1 Hz, 1H), 2.67 - 2.64 (m, 2H), 2.46 - 2.44 (m, 2H), 2.08 (d, J = 7.1 Hz, 3H), 1.88-1.71 (m, 4H), 1.81 - 1.72 (m, 2H).
  • The compound B32: 47 mg, ESI[M + H]+ = 318.2
  • 1H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H), 7.42 - 7.28 (m, 5H), 6.55 (q, J = 7.1 Hz, 1H), 4.23 - 4.20 (m, 2H), 3.09 - 3.07 (m, 2H), 2.94 - 2.91 (m, 2H), 2.08 (d, J = 7.1 Hz, 3H), 1.33 (s, 3H).
    • Example 3 Preparation of Compounds B33 and B34
  • Figure imgb0256
  • At room temperature, (R)-(1-azidoethyl)benzene 1-2 (5.1 g, 34.7 mmol) and ethyl 3-fluoropropiolate (8.1 g, 69.8 mmol) were dissolved in toluene (50 mL), then the mixture was refluxed for 14 hrs. The reaction was monitored by TLC until completion and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) =1/10 ~ 1/1) and the eluate was monitored by TLC (ethyl acetate/petroleum ether (v/v) = 1/5). The fraction with Rf = 0.5 ~ 0.6 was collected and dried to give the products B33 (890 mg, yield 10%) and the B34 (1.2 g, yield 13%).
  • The compound B33: ESI[M + H]+ = 264.3
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.21 (m, 5H), 6.57 - 6.53 (m, 1H), 4.45 - 4.26 (m, 2H), 2.02 (d, J = 7.1 Hz, 3H), 1.37 (t, J = 7.1 Hz, 3H).
  • The compound B34: ESI[M + H]+ = 264.3
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.23 (m, 5H), 6.54 - 6.51 (m, 1H), 4.41 - 4.21 (m, 2H), 2.03 (d, J = 7.1 Hz, 3H), 1.33 (t, J = 7.1 Hz, 3H).
    • Example 4 Preparation of Compounds B35 ~ B64
  • Figure imgb0257
    • 1.Preparation of (R)-4-fluoro-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylic acid (B)
  • Figure imgb0258
  • At room temperature, LiOH.H2O (223 mg, 5.32 mmol) was added into the mixture of B33 (700 mg, 2.66 mmol) in MeOH/THF/H2O (3 mL, 1/1/1), then it was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was concentrated under reduced pressure and H2O (10 mL) was added. The mixture was adjusted to PH = 4 ∼ 5 with 1 N hydrochloric acid and extracted with dichloromethane (3 × 15 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound A (586 mg, yield 94%) as a white solid. ESI[M + H]+ = 236.1
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.14 (m, 5H), 6.55 - 6.49 (m, 1H), 2.03 (d, J = 7.1 Hz, 3H).
    • 2.The preparation of compounds B35 ~ B64
  • Figure imgb0259
  • The target compounds B35 ~ B64 were prepared according to the general procedure A, using (R)-4-fluoro-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylic acid B (100 mg, 0.46 mmol) and corresponding alcohols (0.69 mmol) as starting materials. The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether (v/ v) = 1/5) and the fraction with Rf = 0.4 ~ 0.6 was collected and dried to give target compounds as colorless oil.
  • The compound B35: 36 mg, ESI[M + H]+ = 330.3
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.28 (m, 5H), 6.57 - 6.53 (m, 1H), 5.63 (t, J = 6.4 Hz, 1H), 5.03 - 4.75 (m, 6H), 2.02 (d, J = 7.1 Hz, 3H).
  • The compound B36: 52 mg, ESI[M + H]+ = 360.2
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.28 (m, 5H), 6.55 - 6.52 (m, 1H), 3.58 (s, 3H), 2.82 - 2.55 (m, 4H), 2.05 - 1.88 (m, 5H).
  • The compound B37: 48 mg, ESI[M + H]+ = 314.2
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.28 (m, 5H), 6.57 - 6.51 (m, 1H), 5.87 - 5.69 (m, 3H), 5.61 - 5.54 (m, 1H), 2.04 (d, J = 7.1 Hz, 3H), 1.65 (t, J = 5.9 Hz, 3H).
  • The compound B38: 66 mg, ESI[M + H]+ = 290.3
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.27 (m, 5H), 6.57 - 6.53 (m, 1H), 5.20 - 5.01 (m, 1H), 2.51 - 2.34 (m, 2H), 2.24 - 2.08 (m, 2H), 2.02 (d, J = 7.1 Hz, 3H), 1.93 - 1.62 (m, 2H), 1.77 - 1.63 (m, 1H).
  • The compound B39: 67 mg, ESI[M + H]+ = 290.3
  • 1H NMR (400 MHz, CDCl3) δ 7.43 - 7.28 (m, 5H), 6.58 - 6.53 (m, 1H), 4.21 - 4.04 (m, 2H), 2.01 (d, J = 7.1 Hz, 3H), 1.26 - 1.14 (m, 1H), 0.68 - 0.28 (m, 4H).
  • The compound B40: 88 mg, ESI[M + H]+ = 320.2
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.27 (m, 5H), 6.56 - 6.52 (m, 1H), 4.88 - 4.80 (m, 1H), 3.70 - 3.60 (m, 1H), 3.29 (s, 3H), 2.94 - 2.78 (m, 2H), 2.17 - 2.10 (m, 2H), 2.03 (d, J = 7.1 Hz, 3H).
  • The compound B41: 38 mg, ESI[M + H]+ = 316.2
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.26 (m, 5H), 6.57 - 6.53 (m, 1H),4.85 - 4.74 (m, 2H), 4.35 - 4.17 (m, 2H), 2.85 - 2.75 (m, 2H), 2.74 - 2.59 (m, 1H), 2.53 - 2.39 (m, 2H), 2.01 (d, J = 7.1 Hz, 3H).
  • The compound B42: 45 mg, ESI[M + H]+ = 276.2
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.28 (m, 5H), 6.57 - 6.53 (m, 1H), 6.05 - 5.90 (m, 1H), 5.44 - 5.28 (m, 2H), 4.87 - 4.71 (m, 2H), 2.04 (d, J = 7.1 Hz, 3H).
  • The compound B43: 25 mg, ESI[M + H]+ = 356.3
  • 1H NMR (400 MHz, CDCl3) δ 7.44 - 7.29 (m, 5H), 6.56 - 6.52 (m, 1H), 5.61 (s, 1H), 4.91 (d, J = 3.8 Hz, 2H), 2.35 - 2.18 (m, 2H), 2.17 - 2.02 (m, 5H), 1.62 - 1.33 (m, 6H). The compound B44: 47 mg, ESI[M + H]+ = 292.2
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.28 (m, 5H), 6.55 - 6.51 (m, 1H), 2.02 (d, J = 7.1 Hz, 3H), 1.55 (s, 9H).
  • The compound B45: 39 mg, ESI[M + H]+ = 304.3
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.28 (m, 5H), 6.55 - 6.53 (m, 1H), 5.88 - 5.73 (m, 1H), 5.40 - 5.17 (m, 3H), 2.01 (d, J = 7.1 Hz, 3H), 1.77 - 1.67 (m, 2H), 1.03 - 0.81 (m, 3H).
  • The compound B46: 67 mg, ESI[M + H]+ = 306.2
  • 1H NMR (400 MHz, CDCl3) δ 7.43 - 7.28 (m, 5H), 6.57 - 6.53 (m, 1H), 4.87 - 4.70 (m, 2H), 4.60 - 4.41 (m, 2H), 2.02 (d, J = 7.1 Hz, 3H), 1.77 (s, 3H).
  • The compound B47: 74 mg, ESI[M + H]+ = 358.2
  • 1H NMR (400 MHz, CDCl3) δ 7.44 - 7.29 (m, 5H), 6.58 - 6.54 (m, 1H), 2.45 - 2.38 (m, 2H), 2.36 - 2.28 (m, 2H), 2.06 (s, 3H), 2.01 (d, J = 7.1 Hz, 3H), 1.83 - 1.63 (m, 4H).
  • The compound B48: 46 mg, ESI[M + H]+ = 306.2
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.27 (m, 5H), 6.56 - 6.53 (m, 1H), 4.28 - 4.21 (m, 1H), 2.56 - 2.44 (m, 2H), 2.25 - 2.08 (m, 4H), 2.01 (d, J = 7.0 Hz, 3H).
  • The compound B49: 75 mg, ESI[M + H]+ = 278.3
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.28 (m, 5H), 6.57 - 6.53 (m, 1H), 5.29 - 5.13 (m, 1H), 2.02 (d, J = 7.1 Hz, 3H), 1.36 (d, J = 6.3 Hz, 3H), 1.33 (d, J = 6.3 Hz, 3H). The compound B50: 42 mg, ESI[M + H]+ = 276.2
  • 1H NMR (400 MHz, CDCl3) δ 7.43 - 7.26 (m, 5H), 6.58 - 6.54 (m, 1H), 4.36 - 4.25 (m, 1H), 2.02 (d, J = 7.1 Hz, 3H), 0.92 - 0.70 (m, 4H).
  • The compound B51: 28 mg, ESI[M + H]+ = 318.3
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.28 (m, 5H), 6.57 - 6.53 (m, 1H), 6.24 - 6.13 (m, 1H), 5.22 - 5.14 (m, 2H), 4.79 - 4.63 (m, 4H), 2.03 (d, J = 7.1 Hz, 3H).
  • The compound B52: 92 mg, ESI[M + H]+ = 356.3
  • 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.28 (m, 5H), 6.56 - 6.53 (m, 1H), 2.16 - 2.02 (m, 5H), 2.01 - 1.90 (m, 2H), 1.86 (s, 3H), 1.69 - 1.25 (m, 6H).
  • The compound B53: 46 mg, ESI[M + H]+ = 332.3
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.28 (m, 5H), 6.57 - 6.53 (m, 1H), 5.95 - 5.64 (m, 2H), 5.02 - 4.72 (m, 4H), 2.02 (d, J = 7.1 Hz, 3H), 1.73 - 1.60 (m, 3H).
  • The compound B54: 47 mg, ESI[M + H]+ = 336.2
  • 1H NMR (400 MHz, CDCl3) δ 7.43 - 7.25 (m, 5H), 6.55 - 6.51 (m, 1H), 4.41 - 4.30 (m, 4H), 3.33 (s, 2H), 2.02 (d, J = 7.1 Hz, 3H), 1.31 (s, 3H).
  • The compound B55: 56 mg, ESI[M + H]+ = 320.3
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.28 (m, 5H), 6.57 - 6.53 (m, 1H), 4.52 - 4.31 (m, 6H), 2.02 (d, J = 7.1 Hz, 3H), 1.36 (s, 3H),
  • The compound B56: 24 mg, ESI[M + H]+ = 320.3
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.28 (m, 5H), 6.58 - 6.53 (m, 1H), 2.04 (d, J = 7.1 Hz, 3H), 1.98 (s, 3H), 1.54 (s, 3H), 1.47 (s, 3H).
  • The compound B57: 16 mg, ESI[M + H]+ = 336.2
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.27 (m, 5H), 6.57 - 6.52 (m, 1H), 2.15 (s, 3H), 2.01 (d, J = 7.0 Hz, 3H), 1.57 (s, 3H), 1.48 (s, 3H).
  • The compound B58: 60 mg, ESI[M + H]+ = 348.3
  • 1H NMR (400 MHz, CDCl3) δ 7.43 - 7.29 (m, 5H), 6.56 - 6.52 (m, 1H), 4.85 - 4.69 (m, 1H), 3.82 - 3.521 (m, 2H), 2.90 - 2.76 (m, 2H), 2.22 - 2.08 (m, 2H), 2.10 (d, J = 7.1 Hz, 3H), 1.18 (d, J = 6.1 Hz, 6H).
  • The compound B59: 31 mg, ESI[M + H]+ = 378.3
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.26 (m, 5H), 6.57 - 6.51 (m, 1H), 5.08 - 4.95 (m, 1H), 3.48 - 3.34 (m, 4H), 2.81 - 2.62 (m, 2H), 2.32 - 2.22 (m, 2H), 2.01 (d, J = 7.1 Hz, 3H), 1.20 (q, J = 7.0 Hz, 6H).
  • The compound B60: 35 mg, ESI[M + H]+ = 444.3
  • 1H NMR (400 MHz, CDCl3) δ 7.43 - 7.27 (m, 5H), 6.59 - 6.54 (m, 1H), 6.15 - 5.80 (m, 1H), 3.87 - 3.13 (m, 4H), 2.58 - 2.35 (m, 1H), 2.18 - 0.88 (m, 18H).
  • The compound B61: 42 mg, ESI[M + H]+ = 346.2
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.28 (m, 5H), 6.57 - 6.53 (m, 1H), 4.65 - 4.11 (m, 2H), 2.82 - 2.64 (m, 1H), 2.50 - 1.90 (m, 8H), 1.78 - 1.31 (m, 3H).
  • The compound B62: 86 mg, ESI[M + H]+ = 374.2
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.27 (m, 5H), 6.57 - 6.53 (m, 1H), 3.55 (s, 3H), 2.49 - 2.19 (m, 4H), 2.01 (d, J = 7.1 Hz, 3H), 1.82 - 1.61 (m, 4H).
  • The compound B63: 88 mg, ESI[M + H]+ = 344.3
  • 1H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 7.43 - 7.29 (m, 5H), 6.58 - 6.53 (m, 1H), 2.67 - 2.61 (m, 2H), 2.46 - 2.40 (m, 2H), 2.01 (d, J = 7.1 Hz, 3H), 1.89-1.85 (m, 2H), 1.81 - 1.70 (m, 2H).
  • The compound B64: 88 mg, ESI[M + H]+ = 336.2
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.28 (m, 5H), 6.58 - 6.53 (m, 1H), 4.23 - 4.20 (m, 2H), 3.09 - 3.05 (m, 2H), 2.99 - 2.85 (m, 2H), 2.01 (d, J = 7.1 Hz, 3H), 1.33 (s, 3H).
    • Example 5 Preparation of Compounds B65 and B66
  • Figure imgb0260
    • 1.Preparation of ethyl 3-chloropropiolate (65-1)
  • Figure imgb0261
  • At room temperature, ethyl propiolate (9.0 g, 91.7 mmol) and tert-butyl hypochlorite (10 g, 92.1 mmol) were dissolved in t-BuOH (100 mL). t-BuOK (2.0 g, 17.8 mmol) was added into the mixture twice within 5 minutes, then it was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was filtered and concentrated under reduced pressure to give crude product 65-1, which was used for next step directly without further purification.
    • 2. Preparation of Compounds B65 and B66
  • Figure imgb0262
  • At room temperature, Ethyl 3-chloropropiolate (65-1) and (R)-(1-azidoethyl)benzene 1-2 (3.2 g, 21.7 mmol) were dissolved in toluene (100 mL), then the mixture was refluxed for 14 hrs. The reaction was monitored by TLC until completion. The mixture was quenched with the saturated brine (30 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/1), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the products B65 (620 mg, yield 10%) and B66 (3.2 g, yield 53%).
  • The compound B65: ESI[M + H]+ = 280.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 4.43 - 4.33 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H), 1.38 (t, J = 7.1 Hz, 3H).
  • The compound B66: ESI[M + H]+ = 280.1
  • 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.29 (m, 5H), 5.76 (q, J = 7.1 Hz, 1H), 4.45 (q, J = 7.1 Hz, 2H), 2.11 (d, J = 7.1 Hz, 3H), 1.43 (t, J = 7.1 Hz, 3H).
    • Example 6 Preparation of Compounds B67 ~ 98
  • Figure imgb0263
    • 1.Preparation of (R)-4-chloro-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylic acid
  • Figure imgb0264
  • At room temperature, LiOH.H2O (156 mg, 3.72 mmol) was added into the mixture of B65 (520 mg, 1.86 mmol) in MeOH/THF/H2O (3 mL, 1/1/1), then it was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was concentrated under reduced pressure and H2O (10 mL) was added. The mixture was adjusted to PH = 4 ∼ 5 with 1 N hydrochloric acid and extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound C (445 mg, yield 95%) as a white solid. ESI[M + Na]+ = 274.1, [M + H - 105]+ = 148.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 2.08 (d, J = 7.0 Hz, 3H).
    • 2.Preparation of Compounds B67 ~ B98
  • Figure imgb0265
  • The target compounds B67 ~ B98 were prepared according to the general procedure A, using (R)-4-chloro-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylic acid C (80 mg, 0.32 mmol) and corresponding alcohols (0.48 mmol) as starting materials. The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether (v/ v) = 1/5) and the fraction with Rf = 0.4 ~ 0.6 was collected and dried to give target compounds as colorless oil.
  • The compound B67: 47 mg, ESI[M + H]+ = 346.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.29 (m, 5H), 6.51 (q, J = 7.1 Hz, 1H), 5.64 (t, J = 6.6 Hz, 1H), 5.04 - 4.75 (m, 6H), 2.09 (d, J = 7.1 Hz, 3H).
  • The compound B68: 82 mg, ESI[M + H]+ = 376.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H),3.56 (s, 3H), 2.82 - 2.55 (m, 4H), 2.07 (d, J = 7.1 Hz, 3H), 2.05 - 1.88 (m, 2H).
  • The compound B69: 28 mg, ESI[M + H]+ = 330.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.28 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H),5.86 - 5.68 (m, 3H), 5.61 - 5.54 (m, 1H), 2.08 (d, J = 7.1 Hz, 3H), 1.66 (t, J = 5.9 Hz, 3H).
  • The compound B70: 28 mg, ESI[M + H]+ = 306.2
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.26 (m, 5H), 6.50 (q, J = 7.1 Hz, 1H), 5.23 - 5.14 (m, 1H), 2.51 - 2.37 (m, 2H), 2.26 - 2.13 (m, 2H), 2.06 (d, J = 7.1 Hz, 3H), 1.95 - 1.85 (m, 1H), 1.77 - 1.66 (m, 1H).
  • The compound B71: 80 mg, ESI[M + H]+ = 306.1
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.25 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 4.20 - 4.03 (m, 2H), 2.08 (d, J = 7.1 Hz, 3H), 1.27 - 1.14 (m, 1H), 0.69 - 0.25 (m, 4H).
  • The compound B72: 54 mg, ESI[M + H]+ = 336.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.30 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 4.88 - 4.80 (m, 1H), 3.71 - 3.61 (m, 1H), 3.27 (s, 3H), 2.96 - 2.78 (m, 2H), 2.18 - 2.10 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H).
  • The compound B73: 29 mg, ESI[M + H]+ = 332.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.29 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H), 4.85 - 4.73 (m, 2H), 4.35 - 4.18 (m, 2H), 2.89 - 2.75 (m, 2H), 2.74 - 2.59 (m, 1H), 2.53 - 2.39 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H).
  • The compound B74: 22 mg, ESI[M + H]+ = 292.2
  • 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.29 (m, 5H), 6.50 (q, J = 7.1 Hz, 1H), 6.03 - 5.91 (m, 1H), 5.48 - 5.30 (m, 2H), 4.88 - 4.75 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H).
  • The compound B75: 66 mg, ESI[M + H]+ = 372.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.27 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 5.63 (s, 1H), 4.99 - 4.86 (m, 2H), 2.36 - 2.18 (m, 2H), 2.15 - 2.03 (m, 5H), 1.61 - 1.431 (m, 6H).
  • The compound B76: 23 mg, ESI[M + H]+ = 308.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.26 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H), 2.07 (d, J = 7.1 Hz, 3H), 1.56 (s, 9H).
  • The compound B77: 33 mg, ESI[M + H]+ = 320.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.28 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 5.89 - 5.75 (m, 1H), 5.42 - 5.17 (m, 3H), 2.14 - 2.03 (m, 3H), 1.78 - 1.67 (m, 2H), 1.01 - 0.87 (m, 3H).
  • The compound B78: 46 mg, ESI[M + H]+ = 322.1
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.26 (m, 5H), 6.50 (q, J = 7.1 Hz, 1H), 4.82 - 4.80 (m, 2H), 4.59 - 4.56 (m, 2H), 2.08 (d, J = 7.1 Hz, 3H), 1.77 (s, 3H).
  • The compound B79: 89 mg, ESI[M + H]+ = 374.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H),2.46 - 2.21 (m, 4H), 2.07 (d, J = 7.0 Hz, 3H), 2.05 (s, 3H), 1.84 - 1.61 (m, 4H).
  • The compound B80: 35 mg, ESI[M + H]+ = 322.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.29 (m, 5H), 6.38 (q, J = 7.2 Hz, 1H), 4.27 - 4.20 (m, 1H), 2.59 - 2.44 (m, 2H), 2.23 - 2.06 (m, 4H), 2.04 (d, J = 7.1 Hz, 3H).
  • The compound B81: 27 mg, ESI[M + H]+ = 294.3
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.30 (m, 5H), 6.50 (q, J = 7.2 Hz, 1H), 5.27 - 5.17 (m, 1H), 2.07 (d, J = 7.1 Hz, 3H), 1.36 (d, J = 6.2 Hz, 3H), 1.32 (d, J = 6.3 Hz, 3H).
  • The compound B82: 55 mg, ESI[M + H]+ = 292.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 4.36 - 4.25 (m, 1H), 2.08 (d, J = 7.1 Hz, 3H), 0.94 - 0.58 (m, 4H).
  • The compound B83: 24 mg, ESI[M + H]+ = 294.2
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.30 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H), 4.34 - 4.23 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H), 1.82 - 1.72 (m, 2H), 1.02 (t, J = 7.4 Hz, 3H). The compound B84: 39 mg, ESI[M + H]+ = 296.1
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.30 (m, 5H), 6.40 (q, J = 7.1 Hz, 1H), 3.06 (q, J = 7.4 Hz, 2H), 2.05 (d, J = 7.1 Hz, 3H), 1.31 (t, J = 7.4 Hz, 3H).
  • The compound B85: 54 mg, ESI[M + H]+ = 334.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 6.25 - 6.13 (m, 1H), 5.22 - 5.14 (m, 2H), 4.79 - 4.63 (m, 4H), 2.07 (d, J = 7.1 Hz, 3H).
  • The compound B86: 67 mg, ESI[M + H]+ = 372.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 2.17 - 1.90 (m, 7H), 1.88 (s, 3H), 1.69 - 1.21 (m, 6H).
  • The compound B87: 77 mg, ESI[M + H]+ = 348.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.28 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H), 5.96 - 5.64 (m, 2H), 5.05 - 4.77 (m, 3H), 4.74 (d, J = 8.0 Hz, 1H), 2.08 (d, J = 7.1 Hz, 3H), 1.73 - 1.60 (m, 3H).
  • The compound B88: 42 mg, ESI[M + H]+ = 352.1
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.29 (m, 5H), 6.51 (q, J = 7.1 Hz, 1H), 4.41 - 4.33 (m, 4H), 3.33 (s, 2H), 2.06 (d, J = 7.1 Hz, 3H), 1.32 (s, 3H).
  • The compound B89: 68 mg, ESI[M + H]+ = 336.1 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 4.52 - 4.32 (m, 6H), 2.08 (d, J = 7.1 Hz, 3H), 1.32 (s, 3H).
  • The compound B90: 24 mg, ESI[M + H]+ = 336.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.27 (m, 5H), 6.50 (q, J = 7.1 Hz, 1H), 2.04 (d, J = 7.1 Hz, 3H).2.00 (s, 3H), 1.49 (s, 3H), 1.45 (s, 3H).
  • The compound B91: 16 mg, ESI[M + H]+ = 352.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.28 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 2.12 (s, 3H), 2.07 (d, J = 7.1 Hz, 3H), 1.56 (s, 3H), 1.47 (s, 3H).
  • The compound B92: 35 mg, ESI[M + H]+ = 364.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.27 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H), 4.76 (t, J = 7.4 Hz, 1H), 3.75 (t, J = 7.0 Hz, 1H), 3.64 - 3.58 (m, 1H), 2.88 - 2.72 (m, 2H), 2.21 - 2.07 (m, 2H), 2.08 (d, J = 7.1 Hz, 3H), 1.15 (d, J = 8.0 Hz, 6H).
  • The compound B93: 28 mg, ESI[M + H]+ = 394.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.28 (m, 5H), 6.55 (q, J = 7.1 Hz, 1H), 5.07 - 4.95 (m, 1H), 3.48 - 3.36 (m, 4H), 2.83 - 2.66 (m, 2H), 2.33 - 2.22 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H), 1.20 (q, J = 7.0 Hz, 6H).
  • The compound B94: 26 mg, ESI[M + H]+ = 460.2
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.29 (m, 5H), 6.51 (q, J = 7.1 Hz, 1H),6.15 - 5.81 (m, 1H), 3.86 - 3.62 (m, 1H), 3.58 - 3.13 (m, 3H), 2.55 - 2.39 (m, 1H), 2.19 - 1.92 (m, 7H), 1.90 - 1.83 (m, 3H), 1.82 - 1.42 (m, 2H), 1.28 - 1.14 (m, 4H), 1.09 - 0.88 (m, 2H).
  • The compound B95: 29 mg, ESI[M + H]+ = 362.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.29 (m, 5H), 6.54 (q, J = 7.1 Hz, 1H), 4.64 - 4.49 (m, 1H), 4.33 - 4.16 (m, 1H), 2.80 - 2.64 (m, 1H), 2.51 - 2.26 (m, 2H), 2.24 - 2.03 (m, 5H), 1.99 - 1.91 (m, 1H), 1.76 - 1.25 (m, 3H).
  • The compound B96: 88 mg, ESI[M + H]+ = 390.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.28 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 3.51 (s, 3H), 2.48 - 2.21 (m, 4H), 2.07 (d, J = 7.1 Hz, 3H), 1.82 - 1.63 (m, 4H).
  • The compound B97: 48 mg, ESI[M + H]+ = 360.1
  • 1H NMR (400 MHz, CDCl3) δ 8.18 (t, J = 2.0 Hz, 1H), 7.39 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 2.68 - 2.64 (m, 2H), 2.47 - 2.44 (m, 2H), 2.06 (d, J = 7.1 Hz, 3H), 1.89-1.85 (m, 2H), 1.81 - 1.72 (m, 2H).
  • The compound B98: 28 mg, ESI[M + H]+ = 352.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 4.23 - 4.20 (m, 2H), 3.09 - 3.07 (m, 2H), 2.96 - 2.90 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H), 1.35 (s, 3H).
    • Example 7 Preparation of Compounds B99 and B100
  • Figure imgb0266
    • 1.Preparation of ethyl 3-bromopropiolate (99-1)
  • Figure imgb0267
  • At room temperature, ethyl propiolate (12.0 g, 122 mmol), NBS (26.2 g, 147 mmo) and AgNO3 (10.4 g, 61 mmol) were dissolved in acetone (400 mL). Then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was filtered and concentrated under reduced pressure to give the crude product 99-1, which was used for next step directly without further purification.
    • 2. Preparation of Compounds B99 and B100
  • Figure imgb0268
  • At room temperature, ethyl 3-bromopropiolate (99-1) and (R)-(1-azidoethyl)benzene 1-2 (7.1 g, 48.2 mmol) were dissolved in toluene (100 mL), then the mixture was refluxed for 14 hrs. The reaction was monitored by TLC until completion. The mixture was quenched with the saturated brine (30 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/1), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the products B99 (2.3 g, yield 15%) and B100 (6.0 g, yield 38%).
  • The compound B99: ESI[M + H]+ = 324.1
  • 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.29 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H), 4.45 - 4.31 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H), 1.39 (t, J = 7.1 Hz, 3H).
  • The compound B100: ESI[M + H]+ = 324.1
  • 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.29 (m, 5H), 5.80 (q, J = 7.1 Hz, 1H), 4.45 (q, J = 7.1 Hz, 2H), 2.12 (d, J = 7.1 Hz, 3H), 1.44 (t, J = 7.1 Hz, 3H).
    • Example 8 Preparation of Compounds B101 ~ B126
  • Figure imgb0269
    • 1.Preparation of (R)-4-bromo-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylic acid
  • Figure imgb0270
  • At room temperature, LiOH.H2O (337 mg, 8.0 mmol) was added into the mixture of B100 (1.3 g, 4.0 mmol) in MeOH/THF/H2O (15 mL, 1/1/1), then it was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was concentrated under reduced pressure and H2O (10 mL) was added. The mixture was adjusted to PH = 4 ∼ 5 with 1 N hydrochloric acid and extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound D (445 mg, yield 95%) as a white solid.
  • 1H NMR (400 MHz, CD3OD) δ 7.48 - 7.13 (m, 5H), 6.76 - 6.65 (m, 1H), 2.00 (d, J = 5.5 Hz, 3H).
    • 2.Preparation of compounds B101 ~ B126
  • Figure imgb0271
  • The target compounds B101 ~ B126 were prepared according to the general procedure A, using (R)-4-bromo-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylic acid (D) (100 mg, 0.34 mmol) and corresponding alcohols (0.51 mmol) as starting materials. The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether (v/ v) = 1/5) and the fraction with Rf = 0.4 ~ 0.6 was collected and dried to give target compounds as colorless oil.
  • The compound B101: 16.8 mg, ESI[M + H]+ = 390.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.24 (m, 5H), 6.44 (q, J = 7.1 Hz, 1H), 5.60 (t, J = 6.6 Hz, 1H), 5.09 - 4.76 (m, 6H), 2.07 (d, J = 7.1 Hz, 3H).
  • The compound B102: 80 mg, ESI[M + H]+ = 420.1
  • 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.28 (m, 5H), 6.41 (q, J = 7.1 Hz, 1H), 3.57 (s, 3H), 2.82 - 2.55 (m, 4H), 2.12 (d, J = 7.1 Hz, 3H), 2.05 - 1.88 (m, 2H).
  • The compound B103: 66 mg, ESI[M + H]+ = 374.1
  • 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.29 (m, 5H), 6.42 (q, J = 7.1 Hz, 1H), 5.88 - 5.69 (m, 3H), 5.60 - 5.54 (m, 1H), 2.11 (d, J = 7.1 Hz, 3H), 1.65 (t, J = 5.9 Hz, 3H). The compound B104: 62 mg, ESI[M + H]+ = 246.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.51 (q, J = 7.1 Hz, 1H), 5.24 - 5.14 (m, 1H), 2.54 - 2.37 (m, 2H), 2.27 - 2.14 (m, 2H), 2.06 (d, J = 7.1 Hz, 3H), 1.96 - 1.85 (m, 1H), 1.78 - 1.66 (m,1H).
  • The compound B105: 55 mg, ESI[M + H]+ = 350.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.29 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H), 4.23 - 4.10 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H), 1.27 - 1.17 (m, 1H), 0.69 - 0.59 (m, 2H), 0.41 - 0.32 (m, 2H).
  • The compound B106: 56 mg, ESI[M + H]+ = 380.2
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.28 (m, 5H), 6.51 (q, J = 7.1 Hz, 1H), 4.89 - 4.80 (m, 1H), 3.71 - 3.61 (m, 1H), 3.28 (s, 3H), 2.96 - 2.78 (m, 2H), 2.18 - 2.02 (m, 5H).
  • The compound B107: 33 mg, ESI[M + H]+ = 376.2
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.29 (m, 5H), 6.49 (q, J = 7.1 Hz, 1H), 4.86 - 4.73 (m, 2H), 4.36 - 4.18 (m, 2H), 2.89 - 2.76 (m, 2H), 2.74 - 2.59 (m, 1H), 2.54 - 2.39 (m, 2H), 2.06 (d, J = 7.1 Hz, 3H).
  • The compound B108: 63 mg, ESI[M + H]+ = 336.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 6.04 - 5.91 (m, 1H), 5.50 -5.30 (m, 2H), 4.89 - 4.74 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H).
  • The compound B109: 51 mg, ESI[M + H]+ = 416.2
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.29 (m, 5H), 6.48 (q, J = 7.1 Hz, 1H),5.61 (s, 1H), 4.92 (d, J = 3.8 Hz, 2H), 2.34 - 2.18 (m, 2H), 2.17 - 2.02 (m, 5H), 1.63 - 1.49 (m, 4H), 1.46 - 1.33 (m, 2H).
  • The compound B110: 66 mg, ESI[M + H]+ = 352.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.30 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 2.06 (d, J = 7.1 Hz, 3H), 1.56 (s, 9H).
  • The compound B111: 56 mg, ESI[M + H]+ = 364.1
  • 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.28 (m, 5H), 6.51 (q, J = 7.1 Hz, 1H), 5.89 - 5.72 (m, 1H), 5.41 - 5.16 (m, 3H), 2.15 - 2.02 (m, 3H), 1.77 - 1.68 (m, 2H), 1.00 - 0.66 (m, 3H).
  • The compound B112: 46 mg, ESI[M + H]+ = 366.1
  • 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.29 (m, 5H), 6.49 (q, J = 7.1 Hz, 1H), 4.82 - 4.79 (m, 2H), 4.59 - 4.56 (m, 2H), 2.10 (d, J = 7.1 Hz, 3H), 1.77 (s, 3H).
  • The compound B113: 79 mg, ESI[M + H]+ = 418.2
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.29 (m, 5H), 6.50 (q, J = 7.1 Hz, 1H), 2.46 - 2.38 (m, 2H), 2.35 - 2.27 (m, 2H), 2.06 (d, J = 7.0 Hz, 3H), 2.07 (s, 3H), 1.84 - 1.76 (m, 2H), 1.75 - 1.68 (m, 2H).
  • The compound B114: 35 mg, ESI[M + H]+ = 366.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.25 (m, 5H), 6.35 (q, J = 7.1 Hz, 1H), 4.29 - 4.20 (m, 1H), 2.59 - 2.42 (m, 2H), 2.23 - 2.05 (m, 4H), 2.04 (d, J = 7.1 Hz, 3H).
  • The compound B115: 57 mg, ESI[M + H]+ = 338.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.29 (m, 5H), 6.52 (q, J = 7.2 Hz, 1H), 5.25 - 5.19 (m, 1H), 2.07 (d, J = 7.1 Hz, 3H), 1.37 (d, J = 6.2 Hz, 3H), 1.33 (d, J = 6.3 Hz, 3H).
  • The compound B116: 67 mg, ESI[M + H]+ = 336.0
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.29 (m, 5H), 6.51 (q, J = 7.1 Hz, 1H), 4.41 - 4.29 (m, 1H), 2.07 (d, J = 7.1 Hz, 3H), 0.89 - 0.80 (m, 4H).
  • The compound B117: 39 mg, ESI[M + H]+ = 310.1
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 3.92 (s, 3H), 2.07 (d, J = 7.1 Hz, 3H).
  • The compound B118: 238 mg, ESI[M + H]+ = 324.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H), 4.45 - 4.31 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H), 1.39 (t, J = 7.1 Hz, 3H).
  • The compound B119: 63 mg, ESI[M + H]+ = 338.1
  • 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.30 (m, 5H), 6.55 (q, J = 7.2 Hz, 1H), 4.35 - 4.22 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H), 1.84 - 1.72 (m, 2H), 1.03 (t, J = 7.4 Hz, 3H). The compound B120: 82 mg, ESI[M + H]+ = 340.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.29 (m, 5H), 6.37 (q, J = 7.0 Hz, 1H), 3.09 - 3.01 (m, 2H), 2.05 (d, J = 7.1 Hz, 3H), 1.30 (t, J = 7.4 Hz, 3H).
  • The compound B121: 99 mg, ESI[M + H]+ = 394.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.29 (m, 5H), 6.47 (q, J = 7.1 Hz, 1H), 3.70 (s, 3H), 2.08 (d, J = 7.1 Hz, 3H), 1.71 - 1.60 (m, 2H), 1.35 - 1.21 (m, 2H).
  • The compound B122: 194 mg, ESI[M + H]+ = 558.0
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.30 (m, 5H), 6.56 (q, J = 7.2 Hz, 0H), 5.16 (s, 0H), 2.10 (d, J = 7.1 Hz, 1H).
  • The compound B123: 32 mg, ESI[M + H]+ = 322.1
  • 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.31 (m, 5H), 6.51 (q, J = 7.2 Hz, 1H), 5.16 (dd, J = 13.8, 2.1 Hz, 1H), 4.82 (dd, J = 6.1, 2.1 Hz, 1H), 2.08 (d, J = 7.1 Hz, 3H).
  • The compound B124: 26 mg, ESI[M + H]+ = 320.1
  • 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 2.55 (s, 1H), 2.12 (d, J = 7.1 Hz, 3H).
  • The compound B125: 48 mg, ESI[M + H]+ = 370.1
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.29 (m, 5H), 6.48 (q, J = 7.1 Hz, 1H), 4.51 - 4.34 (m, 2H), 2.80 (t, J = 6.9 Hz, 2H), 2.18 (s, 3H), 2.10 (d, J = 7.1 Hz, 3H).
  • The compound B126: 37 mg, ESI[M + H]+ = 386.1
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.29 (m, 5H), 6.51 (q, J = 7.1 Hz, 1H), 3.38 - 2.95 (m, 2H), 2.78 - 2.59 (m, 2H), 2.18 (s, 3H), 2.11 (d, J = 7.1 Hz, 3H).
    • Example 9 Preparation of Compound B127 and Compound B128
  • Figure imgb0272
    • 1. Preparation of ethyl 3-iodopropiolate (127-1)
  • Figure imgb0273
  • At room temperature, ethyl propiolate (12.0 g, 122 mmol), NIS (33.1 g, 147 mmol) and AgNO3 (10.4 g, 61 mmol) were dissolved in acetone (400 mL). Then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was filtered and concentrated under reduced pressure to give the crude product 127-1, which was used for next step directly without further purification.
    • 2.Preparation of compounds B12 and B128
  • Figure imgb0274
  • At room temperature, ethyl 3-iodopropiolate (127-1) and (R)-(1-azidoethyl)benzene 1-2 (4.5 g, 30.6 mmol) were dissolved in toluene (100 mL), then the mixture was refluxed for 14 hrs. The reaction was monitored by TLC until completion. The mixture was quenched with the saturated brine (30 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/1), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the products B127 (4.5 g, yield 40%) and B128 (4.9 g, yield 43%).
  • The compound B127: ESI[M + H]+ = 372.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.29 (m, 5H), 6.55 (q, J = 7.1 Hz, 1H), 4.46 - 4.30 (m, 2H), 2.06 (d, J = 7.1 Hz, 3H), 1.41 (t, J = 7.1 Hz, 3H).
  • The compound B128: ESI[M + H]+ = 372.1
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.29 (m, 5H), 5.83 (q, J = 7.0 Hz, 1H), 4.46 (q, J = 7.1 Hz, 2H), 2.13 (d, J = 7.1 Hz, 3H), 1.45 (t, J = 7.1 Hz, 3H).
    • Example 10 Preparation of Compounds B129 ~ B144
  • Figure imgb0275
    • 1.Preparation of (R)-4-iodo-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylic acid (E)
  • Figure imgb0276
  • At room temperature, LiOH.H2O (906 mg, 21.6 mmol) was added into the mixture of B127 (4.0 g, 10.8 mmol) in MeOH/THF/H2O (30 mL, 1/1/1), then it was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was concentrated under reduced pressure and H2O (10 mL) was added. The mixture was adjusted to PH = 4 ∼ 5 with 1 N hydrochloric acid and extracted with dichloromethane (3 × 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound E (3.0 g, yield 81%) as a white solid. ESI[M + H]+ = 344.0, [M + H - 105]+ = 240.1
  • 1H NMR (400 MHz, CD3OD) δ 7.39 - 7.22 (m, 5H), 6.74 - 6.64 (m, 1H), 1.99 (d, J = 6.0 Hz, 3H).
    • 2.Preparation of compounds B129 ~ B144
  • Figure imgb0277
  • The target compounds B129 ~ B144 were prepared according to the general procedure A, using (R)-4-iodo-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylic acid (E) (100 mg, 0.29 mmol) and corresponding alcohols (0.44 mmol) as starting materials. The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether (v/ v) = 1/5) and the fraction with Rf= 0.4 ~ 0.6 was collected and dried to give target compounds as colorless oil.
  • The compound B129: 37 mg, ESI[M + H]+ = 438.1
  • 1H NMR (400 MHz, CDCl3) δ 7.46 - 7.29 (m, 5H), 6.46 (q, J = 7.3 Hz, 1H), 5.61 (t, J = 6.9 Hz, 1H), 5.10 - 4.69 (m, 6H), 2.07 (d, J = 7.6 Hz, 3H).
  • The compound B130: 82 mg, ESI[M + H]+ = 468.1
  • 1H NMR (400 MHz, CDCl3) δ 7.46 - 7.29 (m, 5H), 6.46 (q, J = 7.1 Hz, 1H), 3.57 (s, 3H), 2.82 - 2.55 (m, 4H), 2.07 (d, J = 7.1 Hz, 3H), 2.05 - 1.88 (m, 2H).
  • The compound B131: 49 mg, ESI[M + H]+ = 422.0
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.30 (m, 5H), 6.59 - 6.49 (m, 1H), 5.87 - 5.69 (m, 3H), 5.61 - 5.54 (m, 1H), 2.07 (d, J = 6.9 Hz, 3H), 1.65 (t, J = 5.9 Hz, 3H).
  • The compound B132: 68 mg, ESI[M + H]+ = 398.0
  • 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.29 (m, 5H), 6.53 (q, J = 7.2 Hz, 1H), 5.26 - 5.15 (m, 1H), 2.53 - 2.37 (m, 2H), 2.31 - 2.18 (m, 2H), 2.05 (d, J = 7.1 Hz, 3H), 1.98 - 1.85 (m, 1H), 1.80 - 1.65 (m, 1H).
  • The compound B133: 72 mg, ESI[M + H]+ = 398.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.62 - 6.50 (m, 1H), 4.25 - 4.09 (m, 2H), 2.07 (d, J = 6.2 Hz, 3H), 1.28 - 1.19 (m, 1H), 0.72 - 0.60 (m, 2H), 0.44 - 0.33 (m, 2H).
  • The compound B134: 33 mg, ESI[M + H]+ = 428.0
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 4.92 - 4.82 (m, 1H), 3.71 - 3.62 (m, 1H), 3.29 (s, 3H), 2.95 - 2.79 (m, 2H), 2.26 - 2.15 (m, 2H), 2.06 (d, J = 7.1 Hz, 3H).
  • The compound B135: 72 mg, ESI[M + H]+ = 424.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.28 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H),4.86 - 4.73 (m, 2H), 4.36 - 4.18 (m, 2H), 2.90 - 2.77 (m, 2H), 2.74 - 2.56 (m, 1H), 2.53 - 2.39 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H).
  • The compound B136: 66 mg, ESI[M + H]+ = 384.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.54 (q, J = 7.0 Hz, 1H), 6.06 - 5.94 (m, 1H), 5.49 - 5.41 (m, 1H), 5.38 - 5.31 (m, 1H), 4.89 - 4.75 (m, 2H), 2.06 (d, J = 7.1 Hz, 3H).
  • The compound B137: 21 mg, ESI[M + H]+ = 464.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.30 (m, 5H), 6.53 (q, J = 7.0 Hz, 1H), 5.57 (s, 1H), 4.96-4.90 (m, 2H), 2.35 - 2.21 (m, 2H), 2.16-2.10 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H), 1.56 - 1.49 (m, 2H), 1.49 - 1.37 (m, 2H).
  • The compound B138: 17 mg, ESI[M + H]+ = 400.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.29 (m, 5H), 6.53 (q, J = 6.9 Hz, 1H), 2.05 (d, J = 7.1 Hz, 3H), 1.57 (s, 9H).
  • The compound B139: 80 mg, ESI[M + H]+ = 412.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.30 (m, 5H), 6.61 - 6.52 (m, 1H), 5.91 - 5.75 (m, 1H), 5.45 - 5.17 (m, 3H), 2.11 - 1.99 (m, 3H), 1.88 - 1.70 (m, 2H), 1.03 - 0.90 (m, 3H).
  • The compound B140: 28 mg, ESI[M + H]+ = 414.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.23 (m, 5H), 6.45 (q, J = 7.1 Hz, 1H), 4.93 - 4.79 (m, 2H), 4.63 - 4.52 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H), 1.75 (s, 3H).
  • The compound B141: 51 mg, ESI[M + H]+ = 466.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.22 (m, 5H), 6.50 (q, J = 7.1 Hz, 1H), 2.55 - 2.15 (m, 4H), 2.09 (d, J = 7.1 Hz, 3H), 2.00 (s, 3H), 1.87 - 1.67 (m, 4H).
  • The compound B142: 72 mg, ESI[M + H]+ = 414.1
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.24 (m, 5H), 6.29 (q, J = 7.1 Hz, 1H), 4.31 - 4.17 (m, 1H), 2.59 - 2.42 (m, 2H), 2.23 - 2.05 (m, 4H), 2.04 (d, J = 7.1 Hz, 3H).
  • The compound B143: 76 mg, ESI[M + H]+ = 386.0
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.29 (m, 5H), 6.54 (q, J = 7.2 Hz, 1H), 5.29 - 5.18 (m, 1H), 2.06 (d, J = 7.1 Hz, 3H), 1.39 (d, J = 6.3 Hz, 3H), 1.35 (d, J = 6.3 Hz, 3H).
  • The compound B144: 102 mg, ESI[M + H]+ = 384.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.29 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H), 4.42 - 4.34 (m, 1H), 2.06 (d, J = 7.1 Hz, 3H), 0.94 - 0.78 (m, 4H).
    • Example 11 Preparation of Compounds B145 and B146
  • Figure imgb0278
  • At room temperature, (R)-(1-azidoethyl)benzene 1-2 (200 mg, 1.36 mmol) and ethyl 4,4,4-trifluorobut-2-ynoate 145-1 (452 mg, 2.72 mmol) were dissolved in toluene (100 mL), then the mixture was refluxed for 14 hrs. The reaction was monitored by TLC until completion. The mixture concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) ~ 1/5), collecting the fraction with Rf = 0.4 ~ 0.6 to give the product B145 (230 mg, yield 54%) and the product B146 (192 mg, yield 45%) as colorless oil.
  • The compound B145: ESI[M + H]+ = 314.1
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.31 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 4.47 - 4.31 (m, 2H), 2.11 (d, J = 7.1 Hz, 3H), 1.36 (t, J = 7.2 Hz, 3H).
  • The compound B146: ESI[M + Na]+ = 336.1
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.29 (m, 5H), 5.90 (q, J = 7.0 Hz, 1H), 4.46 (q, J = 7.1 Hz, 2H), 2.13 (d, J = 7.0 Hz, 3H), 1.42 (t, J = 7.1 Hz, 3H).
    • Example 12 Preparation of Compound B147
  • Figure imgb0279
  • At room temperature, compound B128 (200 mg, 0.54 mmol), 18-crown-6 (29 mg, 0.11 mmol) and AgF (69 mg, 0.54 mmol) were dissolved in DMF (2 mL), then the mixture was stirred at 160°C for 1 hour. The reaction was monitored by TLC until completion. The mixture concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/ v) = 1/1) and the fraction with Rf = 0.4 ~ 0.6 was collected and dried to give target compound B147 (20 mg, yield 13%) as colorless oil. ESI[M + H]+ = 289.3
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 5.79 (q, J = 7.2 Hz, 1H), 4.44 (q, J = 7.1 Hz, 2H), 2.66 (s, 6H), 2.02 (d, J = 7.2 Hz, 3H), 1.45 (t, J = 7.1 Hz, 3H).
  • Examples of Group C compounds are as follows:
    • Example 1 Preparation of Compounds C1 ~ C7
  • Figure imgb0280
    • 1. Preparation of ethyl (R)-1-(1-phenylethyl)-1H-pyrazole-5-carboxylate (A-1)
  • Figure imgb0281
  • In an ice-water bath, S-1-phenylethan-1-ol (8.38 g, 68.6 mmol), ethyl 1H-pyrazole-5-carboxylate (7.4 g, 52.8 mmol) and PPh3 (20.8 g, 79.3 mmol) were dissolved in THF (15 mL) at 0°C, then DEAD (5.6 g, 32.2 mmol) in THF (15 mL) was added into mixture at the rate of 2.0 mmol/min. The mixture was warmed slowly to room temperature and stirred at this temperature overnight. The reaction was monitored by TLC until completion. The mixture was quenched with the saturated brine (100 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound A-1 (9.5 g, yield 73.7%). ESI[M + H]+ = 245.1
  • 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 1.9 Hz, 1H), 7.33 - 7.27 (m, 4H), 7.25 - 7.18 (m, 1H), 6.86 (d, J = 2.0 Hz, 1H), 6.59 (q, J = 7.1 Hz, 1H), 4.42 - 4.16 (m, 2H), 1.92 (d, J = 7.1 Hz, 3H), 1.33 (t, J = 7.1 Hz, 3H).
    • 2. Preparation of (R)-1-(1-phenylethyl)-1H-pyrazole-5-carboxylic acid (A-2)
  • Figure imgb0282
  • At room temperature, NaOH (3.1 g, 77.5 mmol) was added into the mixture ethyl (R)-1-(1-phenylethyl)-1H-pyrazole-5-carboxylate A-1 (9.5 g, 38.9 mmol) in EtOH/H2O (25 mL,1/1), then it was stirred at 60°C for 1 hour. The reaction was monitored by TLC until completion. The mixture was concentrated under reduced pressure and H2O (20 mL) was added. The mixture was adjusted to PH = 4 ∼ 5 with 1 N hydrochloric acid and extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound A-2 (6.7 mg, yield 80%) as a white solid. ESI[M + H]+ = 217.1 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J= 2.0 Hz, 1H), 7.39 - 7.16 (m, 5H), 7.00 (d, J = 2.0 Hz, 1H), 6.56 (q, J = 7.0 Hz, 1H), 1.93 (d, J = 7.1 Hz, 3H).
    • 3. Preparation of (R)-N-methoxy-N-methyl-1-(1-phenylethyl)-1H-pyrazole-5-carbox amide (A-3)
  • Figure imgb0283
  • At room temperature, (R)-1-(1-phenylethyl)-1H-pyrazole-5-carboxylic acid A-2 (3.5 g, 16.2 mmol), N, O-dimethylhydroxylamine hydrochloride (2.4 g, 24.6 mmol), DIEA (3.2 g, 24.8 mmol) and HATU (9.2 g, 24.2 mmol) were dissolved in DMF (100 mL).
  • Then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion, H2O (100 mL) was added, and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) =1/10 ~ 1/3) and the eluate was monitored by TLC (ethyl acetate/petroleum ether (v/v) = 1/1). The fraction with Rf = 0.5 ~ 0.6 was collected and dried to give the product A-3 (4.1 g, yield 64%) as a white solid. ESI[M + H]+ = 260.2
    • 4. Preparation of (R)-1-(1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-one (A-4)
  • Figure imgb0284
  • At room temperature, (R)-N-methoxy-N-methyl-1-(1-phenylethyl)-1H-pyrazole-5-carboxamide A-3 (4.1 g, 15.8 mmol) was dissolved in anhydrous THF (20 mL). The mixture was cooled to 0°C with an ice-water bath. MeMgBr (23.7 mL, 1 mol/L in THF, 23.7 mmol) was added dropwise into the mixture at the rate of 2 mmol/min. Then the mixture was warmed to room temperature slowly and allowed to react for 2 hrs. The reaction was monitored by TLC until completion, then it was cooled to 0°C with an ice-water bath. The mixture was quenched with the saturated ammonium chloride solution (50 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) =1/20 ~ 1/10) and the eluate was monitored by TLC (ethyl acetate/petroleum ether (v/v) = 1/5). The fraction with Rf = 0.5 ~ 0.6 was collected and dried to give compound A-4 (3.1 g, yield 92%) as a white solid. ESI[M + H]+ = 215.1
    • 5. Preparation of (R)-2,2-dimethoxy-2-(1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-ol (A)
  • Figure imgb0285
  • At room temperature, (R)-1-(1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-one A-4 (3.1 g, 14.5 mmol) and PhI(OAc)2 (7.0 g, 21.7 mmol) were dissolved in MeOH (50 mL). The mixture was cooled to -10°C with an ice-brine bath. KOH (9.8 g, 175 mol) was added in portions into the mixture within 30 minutes. Then the mixture was stirred at - 10°C for 3 hrs. The reaction was monitored by TLC until completion, the saturated brine (100 mL) was added slowly into the mixture and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound A-4 (3.6 g, yield 90%) as a white solid. ESI[M + H]+ = 277.1
    • 6. Preparation of Compound C1
  • Figure imgb0286
  • In an ice bath, NaH (26.0 mg, 60% in mineral oil, 0.65 mmol) was added into the solution of compound A (150 mg, 0.54 mmol) in anhydrous DMF (25 mL), the mixture was stirred at 0°C for 30 minutes. 1-bromobut-2-yne (108 mg, 0.81 mmol) was added slowly into the mixture using a syringe, then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion, ice-water (10 mL) was added slowly into the mixture and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product 1-1 (171 mg), which was used for next step directly without further purification. ESI[M + H]+ = 329.1
  • At room temperature, PTSA.H2O (99 mg, 0.52 mmol) was added into the solution of the crude product 1-1 (171 mg) in acetone (5 mL). Then the mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC until completion, the ice-water (10 mL) was added slowly into the mixture and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether (v/ v) = 1/5) and the fraction with Rf = 0.4 ~ 0.6 was collected and dried to give the product C1 (88 mg, two steps yield 58%) as colorless oil. ESI[M + H]+ = 283.0
  • 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 2.0 Hz, 1H), 7.35 - 7.27 (m, 3H), 7.26 - 7.19 (m, 2H), 6.91 (d, J = 2.0 Hz, 1H), 6.60 (q, J = 7.1 Hz, 1H), 4.59 (q, J = 16.6 Hz, 2H), 4.25 (q, J = 2.3 Hz, 2H), 1.91 (d, J = 7.1 Hz, 3H), 1.83 (t, J = 2.3 Hz, 3H).
    • 7.Preparation of compounds C2 ∼ C7
  • Figure imgb0287
  • The target compounds C2 ~ C7 were prepared according to the operation method of preparing compound C1. Compound A reacted with corresponding halides under NaH condition to give intermediate compounds 2-1 ~ 7-1, which were deprotected with PTSA.H2O to give target compounds C2 ~ C7.
  • The compound C2: 91 mg, ESI[M + H]+ = 259.1
  • 1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 2.1 Hz, 1H), 7.35 - 7.18 (m, 5H), 6.89 (d, J = 2.1 Hz, 1H), 6.61 (q, J = 7.1 Hz, 1H), 4.59 - 4.33 (m, 2H), 3.65 - 3.42 (m, 2H), 1.91 (d, J = 7.1 Hz, 3H), 1.25 (t, J = 7.0 Hz, 3H).
  • The compound C3: 39 mg, ESI[M + H]+ = 299.1
  • 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 2.1 Hz, 1H), 7.37 - 7.19 (m, 5H), 6.89 (d, J = 2.1 Hz, 1H), 6.62 (q, J = 7.1 Hz, 1H), 4.59 - 4.33 (m, 2H), 3.48 (d, J = 6.9 Hz, 2H), 2.71 - 2.56 (m, 1H), 2.12 - 2.01 (m, 2H), 1.98 - 1.84 (m, 5H), 1.79- 1.69 (m, 2H).
  • The compound C4: 37 mg, ESI[M + H]+ = 335.0
  • 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 2.1 Hz, 1H), 7.35 - 7.18 (m, 5H), 6.87 (d, J = 2.1 Hz, 1H), 6.63 (q, J= 7.1 Hz, 1H), 4.59-4.33 (m, 2H), 4.28-4.14 (m, 2H), 2.75 - 2.58 (m, 2H), 2.58 - 2.29 (m, 3H), 1.92 (d, J = 7.1 Hz, 3H).
  • The compound C5: 23 mg, ESI[M + H]+ = 297.0
  • 1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 2.1 Hz, 1H), 7.35 - 7.18 (m, 5H), 6.89 (d, J = 2.1 Hz, 1H), 6.61 (q, J = 7.1 Hz, 1H), 4.60 - 4.41 (m, 3H), 1.88 (d, J = 7.1 Hz, 3H), 1.86- 1.84 (m, 6H).
  • The compound C6: 48 mg, ESI[M + H]+ = 313.1
  • 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 2.1 Hz, 1H), 7.37 - 7.18 (m, 5H), 6.88 (d, J = 2.1 Hz, 1H), 6.62 (q, J = 7.1 Hz, 1H), 4.58 - 4.33 (m, 2H), 3.42 (t, J = 6.9 Hz, 2H), 2.43 - 2.29 (m, 1H), 2.11 - 1.96 (m, 2H), 1.91 (d, J = 7.1 Hz, 3H), 1.90- 1.85 (m, 1H), 1.81 - 1.77 (m, 1H), 1.76 - 1.69 (m, 2H), 1.68 - 1.58 (m, 2H).
  • The compound C7: 46 mg, ESI[M + H]+ = 269.0
  • 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 2.1 Hz, 1H), 7.36 - 7.18 (m, 5H), 6.85 (d, J = 2.1 Hz, 1H), 6.64 (q, J = 7.1 Hz, 1H), 4.56 - 4.31 (m, 2H), 4.28 (d, J = 2.4 Hz, 2H), 2.45 (t, J = 2.4 Hz, 1H), 1.92 (d, J = 7.1 Hz, 3H).
    • Example 2 Preparation of Compound C8
  • Figure imgb0288
  • At room temperature, the compound C7 (100 mg, 0.37 mmol) and Hg2SO4/H2SO4/silica gel (200 mg) was dissolved in CH2Cl2 (5 mL). Then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion, the saturated NaHCO3 solution was added into the mixture and extracted with CH2Cl2 (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) ~ 1/3) and the fraction with Rf = 0.4 ~ 0.5 was collected and dried to give the product C8 (69 mg, yield 65%) as colorless oil. ESI[M + H]+ = 287.0
  • 1H NMR (400 MHz, CDCl3) δ 7.55 (d, J= 2.1 Hz, 1H), 7.35 - 7.18 (m, 5H), 6.86 (d, J = 2.1 Hz, 1H), 6.60 (q, J= 7.1 Hz, 1H), 4.57 - 4.33 (m, 2H), 4.21 (s, 2H), 2.15 (s, 3H), 1.91 (d, J = 7.1 Hz, 3H).
    • Example 3 Preparation of Compounds C9~C10
  • Figure imgb0289
    • 1 .Preparation of (R)-2-bromo-1-(1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-one (9-1)
  • Figure imgb0290
  • At room temperature, CuBr2(4.17 g, 18.7 mmol) was added into the solution of (R)-1-(1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-one A-4 (2.0 g, 9.3 mmol) in EtOH (50 mL). Then the mixture was stirred at 60°C for 1 hour. The reaction was monitored by TLC until completion, then it was cooled to room temperature, quenched with H2O (50 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the compound 9-1 (2.2 g, yield 81%) as colorless oil. ESI[M + H]+ = 293.0
    • 2. Preparation of compounds C9 ~ C10
  • Figure imgb0291
  • At an ice bath, NaSEt (631 mg, 7.5 mmol) was added into the solution of (R)-2-bromo-1-(1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-one 9-1 (2.2 g, 7.5 mmol) in DMF (30 mL). Then the mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC until completion. The mixture was quenched with the ice-water (10 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.4 ~ 0.6 to give the compound C9 (1.26 g, yield 61%). ESI[M + H]+ = 275.2
  • 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J= 1.9 Hz, 1H), 7.34 - 7.20 (m, 5H), 6.88 (d, J = 2.0 Hz, 1H), 6.59 (q, J = 7.0 Hz, 1H), 3.60 (s, 2H), 2.49 - 2.35 (m, 2H), 1.94 (d, J= 7.1 Hz, 3H), 1.18 (t, J = 7.4 Hz, 3H).
  • The target compound C10 were prepared according to the operation method of preparing compound C9. compound 9-1 reacted with sodium cyclobutyl methanethiolate to give the compound C10 (87 mg, yield 43%). ESI[M + H]+ = 315.2 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J= 1.9 Hz, 1H), 7.37 - 7.25 (m, 5H), 6.88 (d, J = 2.0 Hz, 1H), 6.58 (q, J = 7.0 Hz, 1H), 3.61 (s, 2H), 2.71 - 2.56 (m, 1H), 2.48 - 2.36 (m, 2H), 2.12 - 2.01 (m, 2H), 1.98- 1.84 (m, 5H), 1.79- 1.69 (m, 2H).
    • Example 4 Preparation of Compounds C11 ~ C13
  • Figure imgb0292
    • 1 .Preparation of (R)-(1-(1-phenylethyl)-1H-pyrazol-5-yl)methanol (11-1)
  • Figure imgb0293
  • In an ice-water bath, LAH (133 mg, 3.5 mmol) was added in two portions into the mixture of ethyl (R)-1-(1-phenylethyl)-1H-pyrazole-5-carboxylate A-1 (854 mg, 3.5 mmol) in THF (20 mL) within 10 min. The mixture was allowed to react at 0°C for 2 hrs. The reaction was monitored by TLC until completion. Na2SO4.10H2O (1.12 g, 3.5 mmol) was added slowly into the mixture at 0°C, then it was filtered and the filter cake was washed with THF (3 × 10 mL). The filtrate was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product 11-1, which was used for next step directly without further purification. ESI[M + H]+ = 203.1
    • 2. Preparation of (R)-1-(1-phenylethyl)-1H-pyrazole-5-carbaldehyde(11-2)
  • Figure imgb0294
  • At room temperature, active MnO2 (12.2 g, 140 mmol) was added into the solution of (R)-(1-(1-phenylethyl)-1H-pyrazol-5-yl)methanol 11-1 in CH2Cl2 (100 mL), then it was refluxed for 3 hrs. The reaction was monitored by TLC until completion, then it was cooled to room temperature, filtered and the filter cake was washed with CH2Cl2 (300 mL). The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/5), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the product 11-2 (451 mg, two steps yield 64%) as colorless oil. ESI[M + H]+ = 201.1
    • 3.Preparation of 1-(1-((R)-1-phenylethyl)-1H-pyrazol-5-yl)but-2-yn-1-ol(11-3)
  • Figure imgb0295
  • At room temperature, (R)-1-(1-phenylethyl)-1H-pyrazole-5-carbaldehyde 11-2 (451 mg, 2.25 mmol) was dissolved in anhydrous THF (20 mL). The mixture was replaced with nitrogen and cooled to -15°C with an ice-brine bath. Prop-1-yn-1-ylmagnesium bromide (3.4 mL, 0.5 mol/L in THF, 2.70 mmol) was added dropwise into the mixture at the rate of 0.5 mmol/min at -15°C. Then the mixture was warmed to room temperature slowly and allowed to react for 2 hrs. The reaction was monitored by TLC until completion, the mixture was quenched with the saturated ammonium chloride (50 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product 11-3 as colorless oil, which was used for next step directly without further purification.
    • 4. Preparation of compound C11
  • Figure imgb0296
  • At room temperature, active MnO2 (7.8 g, 90 mmol) was added in portions into the solution of crude 11-3 in dioxane (50 mL). The mixture was stirred at 80°C for 2 hrs. The reaction was monitored by TLC until completion. The mixture was cooled to room temperature, filtered and the filter cake was washed with CH2Cl2 (300 mL). The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/5), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the product C11 (365 mg, two steps yield 68%). ESI[M + H]+ = 239.1 1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 2.1 Hz, 1H), 7.34 - 7.18 (m, 5H), 6.88 (d, J = 2.1 Hz, 1H), 6.63 (q, J= 7.1 Hz, 1H), 2.09 (s, 3H), 1.92 (d, J= 7.1 Hz, 3H).
    • 5.Preparation of compound C12
  • Figure imgb0297
  • At room temperature, the compound C11 (300 mg, 1.26 mmol) and Lindlar catlyst (15 mg) were dissolved in THF (10 mL). The mixture was replaced three times with hydrogen, then it was allowed to react at room temperature for 2 hrs under hydrogen. The reaction was monitored by TLC until completion. The mixture was concentrated under reduced pressure and the residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) ~ 1/3) and the fraction with Rf = 0.4 ~ 0.5 was collected and dried to give the product C12 (217 mg, yield 72%). ESI[M + H]+ = 241.2
  • 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J= 2.1 Hz, 1H), 7.36 - 7.18 (m, 5H), 6.85 (d, J = 2.1 Hz, 1H), 6.68 (q, J= 7.1 Hz, 1H), 6.73 - 6.53 (m, 1H), 6.45 - 6.30 (m, 1H), 2.15 (dd, J = 7.3, 1.7 Hz, 3H), 1.89 (d, J = 7.1 Hz, 3H).
    • 6. Preparation of compound C13
  • Figure imgb0298
  • In an ice-water bath, m-CPBA (162 mg, 0.94 mmol) was added in portions into the mixture of compound C12 (150 mg, 0.62 mmol) in CH2Cl2 (5 mL) at the rate of 0.5 mmol/min. Then the mixture was warmed to room temperature and stirred for 1 hour. The reaction was monitored by TLC until completion. The mixture was quenched with H2O (10 mL) and extracted with CH2Cl2 (3 × 5 mL). The combined organic layers were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) ~ 1/3) and the fraction with Rf = 0.4 ~ 0.5 was collected and dried to give the product C13 (89 mg, yield 37%). ESI[M + H]+ = 257.2
  • 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J= 2.1 Hz, 1H), 7.35 -7.18 (m, 5H), 6.89 (d, J = 2.1 Hz, 1H), 6.63 (q, J = 7.1 Hz, 1H), 3.42 - 3.28 (m, 1H), 2.92 - 2.80 (m, 1H), 1.92 (d, J= 7.1 Hz, 3H), 1.19 - 1.15 (m, 3H).
    • Example 5 Preparation of Compound C14 ~ C15
  • Figure imgb0299
    • 1. Preparation of ethyl 3-nitro-1H-pyrazole-5-carboxylate (B-1)
  • Figure imgb0300
  • At room temperature, 3-nitro-1H-pyrazole-5-carboxylic acid (50 g, 318.3 mmol) was dissolved in EtOH (300 mL). SOCl2 (49 g, 412 mmol) was added dropwise slowly into above mixture, then the mixture was refluxed for 8 hrs. The reaction was monitored by TLC until completion. The mixture was concentrated under reduced pressure and the residue was dissolved in CH2Cl2 (30 mL). The mixture was adjusted to PH = 8 ∼ 9 with saturated sodium bicarbonate solution and extracted with dichloromethane (3 × 30 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the product B-1 (58.7 g, yield 99.6%) as a white solid. ESI[M + H]+ = 186.1
    • 2. Preparation of ethyl 3-amino-1H-pyrazole-5-carboxylate (B-2)
  • Figure imgb0301
  • At room temperature, ethyl 3-nitro-1H-pyrazole-5-carboxylate B-1 (58.7 g, 317 mmol) and 10% Pd/C (6 g) were dissolved in EtOH (200 mL), the system was replaced with hydrogen three times and stirred under hydrogen for 18 hrs. The reaction was monitored by TLC until completion, filtered and the filter cake was washed with ethanol (3 × 30 mL). The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/1), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.4 ~ 0.5 to give the product B-2 (43.5 g, yield 88%) as a gray solid. ESI[M + H]+ = 156.1
    • 3. Preparation of ethyl 3-fluoro-1H-pyrazole-5-carboxylate (B-3)
  • Figure imgb0302
  • At an ice-brine bath, ethyl 3-amino-1H-pyrazole-5-carboxylate B-2 (43.5 g, 280 mmol) was dissolved in the 40% HBF4. NaNO2 (20.3 g, 294 mmol) in H2O (30 mL) was added into above mixture. The mixture was stirred under high pressure mercury lamp (302 nm) for 12 hrs. The reaction was monitored by TLC until completion. The mixture was adjusted to PH = 8 ∼ 9 with 1 N NaOH and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. the residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/1), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.4 ~ 0.5 to give the product B-3 (3.4g, yield 8%) as a gray solid.
    • 4. Preparation of ethyl (R)-3-fluoro-1-(1-phenylethyl)-1H-pyrazole-5-carboxylate (B-4)
  • Figure imgb0303
  • In an ice-water bath, S-1-phenylethan-1-ol (3.4 g, 27.8 mmol), ethyl 3-fluoro-1H-pyrazole-5-carboxylate B-3 (3.4 g, 21.5 mmol) and PPh3 (8.4 g, 32.0 mmol) were dissolved in THF (15 mL) at 0°C, then DEAD (5.6 g, 32.2 mmol) in THF (15 mL) was added into mixture at the rate of 0.5 mmol/min. The mixture was warmed slowly to room temperature and stirred at this temperature overnight. The reaction was monitored by TLC until completion. The mixture was quenched with the saturated brine (30 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound B-4 (4.2 g, yield 74%). ESI[M + H]+ = 263.1
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.21 (m, 5H), 6.56 - 6.47 (m, 1H), 6.33 (d, J = 6.3 Hz, 1H), 4.41 - 4.17 (m, 2H), 1.85 (d, J = 7.1 Hz, 3H), 1.33 (t, J = 7.1 Hz, 3H).
    • 5.Preparation of (R)-3-fluoro-1-(1-phenylethyl)-1H-pyrazole-5-carboxylic acid (B-5)
  • Figure imgb0304
  • At room temperature, NaOH (1.3 g, 32.5 mmol) was added into the mixture ethyl (R)-3-fluoro-1-(1-phenylethyl)-1H-pyrazole-5-carboxylate B-4 (4.2 g, 16.0 mmol) in EtOH/H2O (25 mL, 1/1), then it was stirred at 60°C for 1 hour. The reaction was monitored by TLC until completion. The mixture was concentrated under reduced pressure and H2O (20 mL) was added. The mixture was adjusted to PH = 4 ∼ 5 with 1 N hydrochloric acid and extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound B-5 (2.8 g, yield 75%) as a white solid.
  • ESI[M + H]+ = 234.9
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.14 (m, 6H), 6.55 - 6.36 (m, 2H), 1.87 (d, J = 7.0 Hz, 3H).
    • 6. Preparation of (R)-3-fluoro-N-methoxy-N-methyl-1-(1-phenylethyl)-1H- pyrazole-5-carboxamide (B-6)
  • Figure imgb0305
  • At room temperature, (R)-3-fluoro-1-(1-phenylethyl)-1H-pyrazole-5-carboxylic acid B-5 (2.0 g, 8.5 mmol), N, O-dimethylhydroxylamine hydrochloride (1.2 g, 12.3 mmol), DIEA (1.7 g, 13.2 mmol) and HATU (4.7 g, 12.4 mmol) were dissolved in DMF (30 mL), then it was stirred at room temperature overnight. The reaction was monitored by TLC until completion, H2O (100 mL) was added, and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the product B-6 (1.8 g, yield 76%) as a white solid. ESI[M + H]+ = 278.1
    • 7.Preparation of (R)-1-(3-fluoro-1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-one (B-7)
  • Figure imgb0306
  • At room temperature, (R)-3-fluoro-N-methoxy-N-methyl-1-(1-phenylethyl)-1H-pyrazole-5-carboxamide B-6 (1.8 g, 6.5 mmol) was dissolved in anhydrous THF (20 mL). The mixture was cooled to 0°C with an ice-water bath. MeMgBr (13 mL, 1 mol/L in THF, 13.0 mmol) was added dropwise into the mixture at the rate of 2 mmol/min. Then the mixture was warmed to room temperature slowly and allowed to react for 2 hrs. The reaction was monitored by TLC until completion, then it was cooled to 0°C with an ice-water bath, quenched with saturated ammonium chloride (50 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound B-7 (1.2 g, yield 79%) as a white solid. ESI[M + H]+ = 233.1
    • 8. Preparation of (R)-2-(3-fluoro-1-(1-phenylethyl)-1H-pyrazol-5-yl)-2,2-dimethoxye than-1-ol (B)
  • Figure imgb0307
  • At room temperature, (R)-1-(3-fluoro-1-(1-phenylethyl)-1H-pyra zol-5-yl) ethan-1-one B-7 (1.2 g, 5.2 mmol) and PhI(OAc)2 (2.5 g, 7.8 mmol) were dissolved in MeOH (30 mL). The mixture was cooled to -10°C with an ice-brine bath. KOH (3.5 g, 62.4 mol) was added in portions into the mixture within 30 minutes, then it was stirred at -10°C for 3 hrs. The reaction was monitored by TLC until completion, the saturated brine (100 mL) was added slowly into the mixture and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound B (1.3 g, yield 85%) as colorless oil. ESI[M + H]+ = 295.2
    • 9.Preparation of compounds C14 ~ C15
  • Figure imgb0308
  • The target compounds C14 and C15 were prepared according to the operation method of preparing compound C1. Compound B reacted with corresponding halides under NaH condition to give intermediate compounds 14-1 and 15-1, which were deprotected with PTSA.H2O to give target compounds C14 and C15.
  • The compound C14: 85 mg, ESI[M + H]+ = 301.0
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.19 (m, 5H), 6.55 - 6.45 (m, 1H), 6.41 (d, J = 6.2 Hz, 1H), 4.51 (q, J = 16.6 Hz, 2H), 4.24 (q, J = 2.3 Hz, 2H), 1.84 (d, J = 7.0 Hz, 3H), 1.83 (d, J = 2.3 Hz, 3H).
  • The compound C15: 34 mg, ESI[M + H]+ = 287.2
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.20 (m, 5H), 6.55 - 6.44 (m, 1H), 6.40 (d, J = 6.2 Hz, 1H), 4.54 (q, J = 16.6 Hz, 2H), 4.32 - 4.25 (m, 2H), 2.43 (t, J = 2.4 Hz, 1H), 1.85 (d, J= 7.0 Hz, 3H).
    • Example 6 Preparation of Compound C16
  • Figure imgb0309
  • At room temperature, compound C15 (66 mg, 0.23 mmol) and Hg2SO4/H2SO4/silica gel (200 mg) was dissolved in CH2Cl2 (5 mL). Then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion, the saturated NaHCO3 solution was added into the mixture and extracted with CH2Cl2 (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) ~ 1/3) and the fraction with Rf = 0.4 ~ 0.5 was collected and dried to give the product C16 (33 mg, yield 47%) as colorless oil. ESI[M + H]+ = 305.0
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.18 (m, 5H), 6.52 - 6.43 (m, 1H), 6.38 (d, J = 6.2 Hz, 1H), 4.54 (q, J = 16.7 Hz, 2H), 4.23 - 4.08 (m, 2H), 2.15 (s, 3H), 1.84 (d, J= 7.0 Hz, 3H).
    • Example 7 Preparation of Compounds C17 ~ C24
  • Figure imgb0310
    • 1. Preparation of ethyl 4-nitro-1H-pyrazole-5-carboxylate (C-1)
  • Figure imgb0311
  • At room temperature, 4-nitro-1H-pyrazole-5-carboxylic acid (50 g, 318.3 mmol) was dissolved in EtOH (300 mL). SOCl2 (49 g, 412 mmol) was added dropwise into mixture at 0°C, then it was refluxed for 8 hrs. The reaction was monitored by TLC until completion. The mixture was concentrated under reduced pressure and the residue was dissolved in CH2Cl2 (30 mL). Then it was adjusted to PH = 8 ∼ 9 with saturated sodium bicarbonate solution and extracted with dichloromethane (3 × 30 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound C-1 (54.8 g, yield 93%) as a white solid. ESI[M + H]+ = 186.1
    • 2. Preparation of ethyl 4-amino-1H-pyrazole-5-carboxylate(C-2)
  • Figure imgb0312
  • At room temperature, ethyl 4-nitro-1H-pyrazole-5-carboxylate C-1 (54.8 g, 296 mmol) and 10% Pd/C (5 g) were dissolved in EtOH (200 mL), the system was replaced with hydrogen three times and stirred under hydrogen for 18 hrs. The reaction was monitored by TLC until completion, filtered and the filter cake was washed with ethanol (3 × 30 mL). The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/1), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.4 ~ 0.5 to give the product C-2 (41.1 g, yield 89%) as a gray solid. ESI[M + H]+ = 156.1
    • 3. Preparation of ethyl 4-fluoro-1H-pyrazole-5-carboxylate (C-3)
  • Figure imgb0313
  • At an ice-brine bath, ethyl 4-amino-1H-pyrazole-5-carboxylate C-2 (35 g, 226 mmol) was dissolved in the 40% HBF4. NaNO2 (16.4 g, 238 mmol) in H2O (30 mL) was added into above mixture. The mixture was stirred under high pressure mercury lamp (302 nm) for 12 hrs. The reaction was monitored by TLC until completion. The mixture was adjusted to PH = 8 ∼ 9 with 1 N NaOH and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. the residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/1), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.4 ~ 0.5 to give the product C-3 (6 g, yield 17%) as a gray solid.
    • 4. Preparation of ethyl (R)-4-fluoro-1-(1-phenylethyl)-1H-pyrazole-5-carboxylate (C-4)
  • Figure imgb0314
  • In an ice-water bath, S-1-phenylethan-1-ol (6.0 g, 49.1 mmol), ethyl 4-fluoro-1H-pyrazole-5-carboxylate C-3 (6 g, 37.9 mmol) and PPh3 (14.9 g, 56.8 mmol) were dissolved in THF (50 mL) at 0°C, then DEAD (9.9 g, 56.8 mmol) in THF (15 mL) was added into mixture at the rate of 0.5 mmol/min. The mixture was warmed slowly to room temperature and stirred at this temperature overnight. The reaction was monitored by TLC until completion. The mixture was quenched with the saturated brine (30 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound C-4 (5.9 g, yield 59%). ESI[M + H]+ = 263.1
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J= 4.5 Hz, 1H), 7.35 - 7.20 (m, 5H), 6.46 (q, J = 7.1 Hz, 1H), 4.53 - 4.09 (m, 2H), 1.88 (d, J = 7.1 Hz, 3H), 1.34 (t, J = 7.1 Hz, 3H).
    • 5.Preparation of (R)-4-fluoro-1-(1-phenylethyl)-1H-pyrazole-5-carboxylic acid (C-5)
  • Figure imgb0315
  • At room temperature, NaOH (3.1 g, 77.5 mmol) was added into the mixture ethyl (R)-4-fluoro-1-(1-phenylethyl)-1H-pyrazole-5-carboxylate C-4 (9.5 g, 38.9 mmol) in EtOH/H2O (25 mL,1/1), then it was stirred at 60°C for 1 hour. The reaction was monitored by TLC until completion. The mixture was concentrated under reduced pressure and H2O (20 mL) was added. The mixture was adjusted to PH = 4 ∼ 5 with 1 N hydrochloric acid and extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound C-5 (6.7 g, yield 80%) as a white solid. ESI[M + H]+ = 234.1
  • 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J= 2.0 Hz, 1H), 7.39 - 7.16 (m, 5H), 7.00 (d, J = 2.0 Hz, 1H), 6.56 (q, J= 7.0 Hz, 1H), 1.93 (d, J= 7.1 Hz, 3H).
    • 6.Preparation of (R)-4-fluoro-N-methoxy-N-methyl-1-(1-phenylethyl)-1H-pyrazole -5-carboxamide(C-6)
  • Figure imgb0316
  • At room temperature, (R)-4-fluoro-1-(1-phenylethyl)-1H-pyrazole-5-carboxylic acid C-5 (2.0 g, 8.5 mmol), N,O-dimethylhydroxylamine hydrochloride (1.2 g, 12.3 mmol), DIEA (1.7 g, 13.2 mmol) and HATU (4.7 g, 12.4 mmol) were dissolved in DMF (30 mL). Then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion, H2O (100 mL) was added, and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the product C-6 (1.8 g, yield 76%) as a white solid. ESI[M + H]+ = 278.1
    • 7. Preparation of (R)-1-(4-fluoro-1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-one (C-7)
  • Figure imgb0317
  • At room temperature, Preparation of (R)-4-fluoro-N-methoxy-N-methyl-1-(1-phenylethyl)-1H-pyrazole-5-carboxamide C-6 (1.8 g, 6.5 mmol) were dissolved in anhydrous THF (20 mL). The mixture was cooled to 0°C with an ice-water bath. MeMgBr (13 mL, 1 mol/L in THF, 13.0 mmol) was added dropwise into the mixture at the rate of 2 mmol/min. Then the mixture was warmed to room temperature slowly and allowed to react for 2 hrs. The reaction was monitored by TLC until completion, the mixture was cooled to 0°C with an ice-water bath. The mixture was quenched with the saturated ammonium chloride solution (50 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound C-7 (1.2 g, yield 79%) as a white solid. ESI[M + H]+ = 233.1
    • 8. Preparation of (R)-2-(4-fluoro-1-(1-phenylethyl)-1H-pyrazol-5-yl)-2,2-dimethoxye than-1-ol (C)
  • Figure imgb0318
  • At room temperature, (R)-1-(4-fluoro-1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1 -one C-7 (1.2 g, 5.2 mmol) and PhI(OAc)2 (2.5 g, 7.8 mmol) were dissolved in MeOH (30 mL). The mixture was cooled to -10°C with an ice-brine bath. KOH (3.5 g, 62.4 mol) was added in portions into the mixture within 30 minutes. Then the mixture was stirred at -10°C for 3 hrs. The reaction was monitored by TLC until completion, saturated brine (100 mL) was added slowly into the mixture and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound C (1.3 g, yield 85%) as colorless oil. ESI[M + H]+ = 295.2
    • 9.Preparation of compounds C17 ~ C24
  • Figure imgb0319
  • The target compounds C17 ~ C24 were prepared according to the operation method of preparing compound C1. Compound C reacted with corresponding halides under NaH condition to give intermediate compounds 17-1 ~ 24-1, which were deprotected with PTSA.H2O to give target compounds C17 ~ C24.
  • The compound C17: 29 mg, ESI[M + H]+ = 301.0
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J= 4.5 Hz, 1H), 7.35 - 7.20 (m, 5H), 6.46 (q, J = 7.1 Hz, 1H), 4.54 (q, J= 16.7 Hz, 2H), 4.25 (q, J= 2.3 Hz, 2H), 1.90 (d, J= 7.1 Hz, 3H), 1.83 (t, J = 2.3 Hz, 3H).
  • The compound C18: 22 mg, ESI[M + H]+ = 317.1
  • 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 4.5 Hz, 1H), 7.34 - 7.20 (m, 5H), 6.45 (q, J = 7.1 Hz, 1H), 4.54 (q, J = 16.7 Hz, 2H), 3.48 (d, J = 6.9 Hz, 2H), 2.71 - 2.56 (m, 1H), 2.12 - 2.01 (m, 2H), 1.98 - 1.84 (m, 5H), 1.79 - 1.69 (m, 2H).
  • The compound C19: 26 mg, ESI[M + H]+ = 263.0
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J= 4.5 Hz, 1H), 7.33 - 7.20 (m, 5H), 6.44 (q, J = 7.1 Hz, 1H), 4.53 (q, J= 16.7 Hz, 2H), 3.45 (s, 3H), 1.88 (d, J= 7.1 Hz, 3H).
  • The compound C20: 66 mg, ESI[M + H]+ = 277.0
  • 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J= 4.5 Hz, 1H), 7.37 - 7.22 (m, 5H), 6.46 (q, J = 7.1 Hz, 1H), 4.52 (q, J = 16.7 Hz, 2H), 3.65 - 3.42 (m, 2H), 1.89 (d, J = 7.1 Hz, 3H), 1.25 (t, J = 7.0 Hz, 3H).
  • The compound C21: 36 mg, ESI[M + H]+ = 287.2
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 4.5 Hz, 1H), 7.35 - 7.20 (m, 5H), 6.44 (q, J = 7.1 Hz, 1H), 4.53 (q, J = 16.7 Hz, 2H), 4.32 - 4.25 (m, 2H), 2.43 (t, J = 2.4 Hz, 1H), 1.85 (d, J = 7.1 Hz, 3H).
  • The compound C22: 54 mg, ESI[M + H]+ = 319.1
  • 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 4.5 Hz, 1H), 7.32 - 7.20 (m, 5H), 6.43 (q, J = 7.1 Hz, 1H), 5.01 - 4.76 (m, 1H), 4.52 (q, J = 16.7 Hz, 2H), 3.21 (p, J = 5.8 Hz, 1H), 1.86 (d, J = 7.1 Hz, 3H), 1.60 - 1.46 (m, 4H), 0.93 - 0.78 (m, 6H).
  • The compound C23: 36 mg, ESI[M + H]+ = 331.1
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 4.5 Hz, 1H), 7.35 - 7.20 (m, 5H), 6.44 (q, J = 7.1 Hz, 1H), 4.54 (q, J = 16.7 Hz, 2H), 3.42 (t, J = 6.9 Hz, 2H), 2.43 - 2.29 (m, 1H), 2.11 - 1.96 (m, 2H), 1.90 - 1.85 (m, 4H), 1.81 - 1.78 (m, 1H), 1.76 - 1.69 (m, 2H), 1.67- 1.58 (m, 2H).
  • The compound C24: 29 mg, ESI[M + H]+ = 303.1
  • 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 4.5 Hz, 1H), 7.34 - 7.20 (m, 5H), 6.46 (q, J = 7.1 Hz, 1H), 4.53 (q, J = 16.7 Hz, 2H), 4.18 - 3.94 (m, 2H), 1.87 (d, J= 7.1 Hz, 3H), 1.26 - 1.09 (m, 1H), 0.66 - 0.48 (m, 2H), 0.40 - 0.21 (m, 2H).
    • Example 8 Preparation of Compound C25
  • Figure imgb0320
  • At room temperature, compound C21 (100 mg, 0.35 mmol) and Hg2SO4/H2SO4/silica gel (200 mg) was dissolved in CH2Cl2 (5 mL). Then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion, the saturated NaHCO3 solution was added into the mixture and extracted with CH2Cl2 (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) ~ 1/3), collecting the fraction with Rf = 0.4 ~ 0.5 to give the product C25 (65 mg, yield 61%). ESI[M + H]+ = 305.1
  • 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J= 4.5 Hz, 1H), 7.37 - 7.23 (m, 5H), 6.46 (q, J = 7.1 Hz, 1H), 4.55 (q, J = 16.7 Hz, 2H), 4.21 (s, 2H), 2.15 (s, 3H), 1.88 (d, J = 7.1 Hz, 3H).
    • Example 9 Preparation of Compounds C26 ~ C49
  • Figure imgb0321
    • 1. Preparation of (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid (D-1)
  • Figure imgb0322
  • At room temperature, LiOH.H2O (6.9 g, 164.4 mmol) was added into the mixture of (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylate (20.0 g, 81.9 mmol) in MeOH/THF/H2O (80 mL,1/1/1.5), then it was stirred at room temperature for 3 hrs. The reaction was monitored by TLC until completion. The mixture was concentrated under reduced pressure and H2O (50 mL) was added. The mixture was adjusted to PH = 4 ∼ 5 with 1 N hydrochloric acid and extracted with dichloromethane (5 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was washed with tert-Butyl methyl ether to give compound D-1 (15 mg, yield 85%) as a white solid. ESI[M + H]+ = 217.3 1H NMR (400 MHz, CDCl3) δ 9.73 (brs, 1H), 7.89 (s, 1H), 7.87 (s, 1H), 7.39 - 7.27 (m, 3H), 7.26 - 7.18 (m, 2H), 6.55 (q, J= 7.1 Hz, 1H), 1.87 (d, J= 7.1 Hz, 3H).
    • 2.Preparation of (R)-N-methoxy-N-methyl-1-(1-phenylethyl)-1H-imidazole-5-carbox amide (D-2)
  • Figure imgb0323
  • At room temperature, (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid D-1 (13 g, 60 mmol), N,O-dimethylhydroxylamine hydrochloride (11.7 g, 120 mmol), DIEA (15.5 g, 120 mmol) and HATU (45.6 g, 120 mmol) were dissolved in DMF (200 mL). Then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion, H2O (500 mL) was added, and extracted with ethyl acetate (4 × 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the product D-2 (13 g, yield 84%) as a white solid. ESI[M + H]+ = 260.1
    • 3.Preparation of (R)-1-(1-(1-phenylethyl)-1H-imidazol-5-yl)ethan-1-one (D-3)
  • Figure imgb0324
  • At room temperature, (R)-N-methoxy-N-methyl-1-(1-phenylethyl)-1H-imidazole -5-carboxamide D-2 (13 g, 50.1 mmol) were dissolved in anhydrous THF (100 mL). The mixture was cooled to 0°C with an ice-water bath. MeMgBr (100.2 mL, 1 mol/L in THF, 100.2 mmol) was added dropwise into the mixture at the rate of 5 mmol/min. Then the mixture was warmed to room temperature slowly and allowed to react for 2 hrs. The reaction was monitored by TLC until completion, the mixture was cooled to 0°C with an ice-water bath. The mixture was quenched with the saturated ammonium chloride solution (100 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound D-3 (9.1 g, yield 85%) as a white solid. ESI[M + H]+ = 215.1
    • 4.Preparation of (R)-2,2-dimethoxy-2-(1-(1-phenylethyl)-1H-imidazol-5-yl)ethan-1- ol
  • Figure imgb0325
  • At room temperature, (R)-1-(1-(1-phenylethyl)-1H-imidazol-5-yl)ethan-1-one D-3 (9 g, 42 mmol) and PhI(OAc)2 (20.3 g, 63 mmol) were dissolved in MeOH (100 mL). The mixture was cooled to -10°C with an ice-brine bath. KOH (28.3 g, 504 mol) was added in portions into the mixture within 50 minutes. Then the mixture was stirred at -10°C for 3 hrs. The reaction was monitored by TLC until completion, the saturated brine (200 mL) was added slowly into the mixture and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/5), with TLC (ethyl acetate/petroleum ether (v/v) = 1/3) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound D (7.4 g, yield 64%) as a white solid. ESI[M + H]+ = 277.2
    • 5.Preparation of compounds C26 ~ C49
  • Figure imgb0326
  • The target compounds C26 ~ C49 were prepared according to the operation method of preparing compound C1. Compound D reacted with corresponding halides under NaH condition to give intermediate compounds 26-1 ~ 49-1, which were deprotected with PTSA.H2O to give target compounds C26 ~ C49.
  • The compound C26: 37 mg, ESI[M + H]+ = 269.0
  • 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.86 (s, 1H), 7.38 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.44 (q, J = 7.1 Hz, 1H), 4.32 (s, 2H), 1.86 (d, J= 7.0 Hz, 3H), 1.80 (s, 3H).
  • The compound C27: 70 mg, ESI[M + H]+ = 283.2
  • 1H NMR (400 MHz, CDCl3) δ 7.96 (s, 1H), 7.81 (s, 1H), 7.38 - 7.27 (m, 3H), 7.24 - 7.17 (m, 2H), 6.43 (q, J= 7.1 Hz, 1H), 4.54 (q, J= 15.8 Hz, 2H), 4.23 (q, J= 2.3 Hz, 2H), 1.86- 1.84 (m, 6H).
  • The compound C28: 16 mg, ESI[M + H]+ = 285.1
  • 1H NMR (400 MHz, CDCl3) δ 8.02 (s, 1H), 7.88 (s, 1H), 7.39 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.45 (q, 6.6 Hz, 1H), 4.33 (s, 2H), 3.97 (p, J = 7.1 Hz, 1H), 2.26 - 2.12 (m, 2H), 2.05 - 1.90 (m, 2H), 1.86 (d, J = 7.0 Hz, 3H), 1.77 - 1.64 (m, 1H), 1.55 - 1.39 (m, 1H).
  • The compound C29: 23 mg, ESI[M + H]+ = 299.1
  • 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.83 (s, 1H), 7.38 - 7.27 (m, 3H), 7.24 - 7.14 (m, 2H), 6.45 (q, J = 6.5 Hz, 1H), 4.40 (s, 2H), 3.45 (p, J = 9.3 Hz, 2H), 2.68 - 2.51 (m, 1H), 2.10 - 2.01 (m, 2H), 1.98 - 1.88 (m, 2H), 1.85 (d, J = 6.9 Hz, 3H), 1.78 - 1.66 (m, 2H).
  • The compound C30: 38 mg, ESI[M + H]+ = 335.0
  • 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.85 (s, 1H), 7.38 - 7.28 (m, 3H), 7.23 - 7.15 (m, 2H), 6.45 (q, J = 7.1 Hz, 1H), 4.33 (s, 2H), 4.28 - 4.14 (m, 2H), 2.75 - 2.58 (m, 2H), 2.58 - 2.29 (m, 3H), 1.85 (d, J= 7.0 Hz, 3H).
  • The compound C31: 26 mg, ESI[M + H]+ = 297.1
  • 1H NMR (400 MHz, CDCl3) δ 7.98 (s, 1H), 7.82 (s, 1H), 7.37 - 7.26 (m, 3H), 7.23 - 7.14 (m, 2H), 6.43 (q, J= 7.1 Hz, 1H), 4.32 (s, 2H), 5.23 - 5.09 (m, 1H), 4.92 (s, 2H), 3.18 - 2.97 (m, 2H), 2.93 - 2.78 (m, 2H), 1.87 (d, J = 7.0 Hz, 3H).
  • The compound C32: 17 mg, ESI[M + H]+ = 329.1
  • 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.86 (s, 1H), 7.39 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.45 (q, J= 7.1 Hz, 1H), 4.33 (s, 2H), 3.40 (s, 2H), 3.33 (s, 3H), 1.98 - 1.86 (m, 6H), 1.85 (d, J = 7.0 Hz, 3H).
  • The compound C33: 78 mg, ESI[M + H]+ = 245.1
  • 1H NMR (400 MHz, CDCl3) δ 7.93 (s, 1H), 7.82 (s, 1H), 7.37 - 7.27 (m, 3H), 7.23 - 7.16 (m, 2H), 6.44 (q, J= 7.1 Hz, 1H), 4.51 - 4.29 (m, 2H), 3.43 (s, 3H), 1.85 (d, J = 7.1 Hz, 3H).
  • The compound C34: 73 mg, ESI[M + H]+ = 259.1
  • 1H NMR (400 MHz, CDCl3) δ 7.97 (s, 1H), 7.81 (s, 1H), 7.38 - 7.27 (m, 3H), 7.20 (d, J = 6.9 Hz, 2H), 6.44 (q, J = 7.1 Hz, 1H), 4.54 - 4.33 (m, 2H), 3.56 (qd, J = 7.0, 1.1 Hz, 2H), 1.85 (d, J = 7.1 Hz, 3H), 1.25 (t, J = 7.0 Hz, 3H).
  • The compound C35: 35 mg, ESI[M + H]+ = 269.0
  • 1H NMR (400 MHz, CDCl3) δ 7.94 (s, 1H), 7.82 (s, 1H), 7.37 - 7.27 (m, 3H), 7.24 - 7.16 (m, 2H), 6.42 (q, J = 7.2 Hz, 1H), 4.57 (q, J = 15.8 Hz, 2H), 4.28 (d, J = 2.4 Hz, 2H), 2.45 (t, J = 2.4 Hz, 1H), 1.85 (d, J = 7.1 Hz, 3H).
  • The compound C36: 55 mg, ESI[M + H]+ = 301.1
  • 1H NMR (400 MHz, CDCl3) δ 8.07 (s, 1H), 7.89 (s, 1H), 7.41 - 7.28 (m, 3H), 7.24 - 7.16 (m, 2H), 6.47 (q, J = 7.1 Hz, 1H), 4.40 (s, 2H), 3.21 (p, J = 5.8 Hz, 1H), 1.86 (d, J = 7.1 Hz, 3H), 1.60 - 1.46 (m, 4H), 0.93 - 0.78 (m, 6H).
  • The compound C37: 23 mg, ESI[M + H]+ = 283.0
  • 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.83 (s, 1H), 7.39 - 7.28 (m, 3H), 7.22 - 7.15 (m, 2H), 6.42 (q, J = 6.6 Hz, 1H), 4.46 - 4.38 (m, 1H), 4.33 (s, 2H), 2.49 (dd, J = 8.8, 2.1 Hz, 1H), 1.88 (d, J = 7.1 Hz, 3H), 1.57 (dd, J = 6.7, 3.8 Hz, 3H).
  • The compound C38: 24 mg, ESI[M + H]+ = 325.0
  • 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.85 (s, 1H), 7.38 - 7.27 (m, 3H), 7.24 - 7.15 (m, 2H), 6.45 (q, J = 6.6 Hz, 1H), 5.61 (t, J = 6.9 Hz, 1H), 5.10 - 4.69 (m, 6H), 4.33 (s, 2H), 1.86 (d, J = 7.0 Hz, 3H).
  • The compound C39: 26 mg, ESI[M + H]+ = 297.1
  • 1H NMR (400 MHz, CDCl3) δ 8.02 (s, 1H), 7.88 (s, 1H), 7.39 - 7.28 (m, 3H), 7.26 - 7.17 (m, 2H), 6.47 (q, J = 6.6 Hz, 1H), 5.39 - 5.25 (m, 1H), 4.97-4.72 (m, 3H), 4.33 (s, 2H), 1.87 (d, J = 7.0 Hz, 3H), 1.45 - 1.38 (m, 3H).
  • The compound C40: 70 mg, ESI[M + H]+ = 313.1
  • 1H NMR (400 MHz, CDCl3) δ 7.98 (s, 1H), 7.82 (s, 1H), 7.38 - 7.27 (m, 3H), 7.22 - 7.16 (m, 2H), 6.44 (q, J = 7.1 Hz, 1H), 4.39 (s, 2H), 3.40 (t, J = 6.9 Hz, 2H), 2.41 - 2.31 (m, 1H), 2.08 - 1.97 (m, 2H), 1.90 - 1.76 (m, 5H), 1.71 (q, J = 7.0 Hz, 2H), 1.66 - 1.55 (m, 2H).
  • The compound C41: 11 mg, ESI[M + H]+ = 297.1
  • 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.86 (s, 1H), 7.39 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.45 (q, J= 6.6 Hz, 1H), 4.51 - 4.42 (m, 1H), 4.33 (s, 2H), 1.86 (d, J= 7.0 Hz, 3H), 1.84 (dd, J = 12.9, 2.1 Hz, 3H), 1.52 (t, J = 6.6 Hz, 3H).
  • The compound C42: 20 mg, ESI[M + H]+ = 305.0
  • 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.87 (s, 1H), 7.40 - 7.28 (m, 3H), 7.25 - 7.15 (m, 2H), 6.45 (q, J= 7.1 Hz, 1H), 5.23 - 5.12 (m, 1H), 4.33 (s, 2H), 3.33 (s, 6H), 1.86 (d, J = 7.0 Hz, 3H).
  • The compound C43: 18 mg, ESI[M + H]+ = 341.0
  • 1H NMR (400 MHz, CDCl3) δ 8.02 (s, 1H), 7.86 (s, 1H), 7.39 - 7.27 (m, 3H), 7.24 - 7.15 (m, 2H), 6.46 (q, J= 7.1 Hz, 1H), 3.93 - 3.88 (m, 1H), 4.31 (s, 2H), 3.48 (s, 4H), 1.85 (d, J = 7.0 Hz, 3H).
  • The compound C44: 32 mg, ESI[M + H]+ = 333.1
  • 1H NMR (400 MHz, CDCl3) δ 8.03 (s, 1H), 7.88 (s, 1H), 7.41 - 7.30 (m, 3H), 7.26 - 7.17 (m, 2H), 6.47 (q, J= 7.1 Hz, 1H), 4.33 (s, 2H), 3.72- 3.68 (m, 1H), 3.51- 3.46 (m, 4H), 3.31 (s, 6H), 1.87 (d, J= 7.0 Hz, 3H).
  • The compound C45: 195 mg, ESI[M + H]+ = 287.1
  • 1H NMR (400 MHz, CDCl3) δ 8.05 (s, 1H), 7.78 (s, 1H), 7.36 - 7.24 (m, 3H), 7.23 - 7.15 (m, 2H), 6.45 (q, J = 7.1 Hz, 1H), 4.44 - 4.24 (m, 2H), 1.84 (d, J = 7.1 Hz, 3H), 1.23 (s, 9H).
  • The compound C46: 66 mg, ESI[M + H]+ = 285.1
  • 1H NMR (400 MHz, CDCl3) δ 8.03 (s, 1H), 7.87 (s, 1H), 7.40 - 7.27 (m, 3H), 7.24 - 7.15 (m, 2H), 6.45 (q, J= 7.1 Hz, 1H), 4.45 (s, 2H), 3.43 - 3.23 (m, 2H), 1.85 (d, J= 7.1 Hz, 3H), 1.13 - 1.01 (m, 1H), 0.58 - 0.48 (m, 2H), 0.24 - 0.13 (m, 2H).
  • The compound C47: 19 mg, ESI[M + H]+ = 299.1
  • 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.86 (s, 1H), 7.38 - 7.27 (m, 3H), 7.24 - 7.15 (m, 2H), 6.44 (q, J= 7.1 Hz, 1H), 4.32 (s, 2H), 3.51 - 3.46 (m, 1H), 1.86 (d, J= 7.0 Hz, 3H), 1.19 - 1.00 (m, 4H), 0.63 - 0.43 (m, 2H), 0.26 - 0.09 (m, 2H).
  • The compound C48: 35 mg, ESI[M + H]+ = 271.0
  • 1H NMR (400 MHz, CDCl3) δ 8.02 (s, 1H), 7.86 (s, 1H), 7.41 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.46 (q, J = 7.1 Hz, 1H), 4.33 (s, 2H), 3.42 - 3.34 (m, 1H), 0.67 - 0.45 (m, 4H), 1.88 (d, J= 7.0 Hz, 3H).
  • The compound C49: 35 mg, ESI[M + H]+ = 301.1
  • 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.86 (s, 1H), 7.39 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.45 (q, J= 7.1 Hz, 1H), 4.33 (s, 2H), 3.82 - 3.76 (m, 2H), 1.88 (d, J= 7.0 Hz, 3H), 1.01 (s, 9H).
    • Example 10 Preparation of Compounds C50 ~ C51
  • Figure imgb0327
    Figure imgb0328
  • The target compounds C50 ~ C51 were prepared according to the operation method of preparing compound C8 described in Example 2. Compounds C37 or C35 reacted with Hg2SO4/H2SO4/silica gel, then it was purified by Prep-TLC.
  • The compound C50: 32 mg, ESI[M + H]+ = 301.1
  • 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.86 (s, 1H), 7.39 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.45 (q, J = 7.1 Hz, 1H), 4.33 (s, 2H), 4.31 - 4.25 (m, 1H), 2.03 (s, 3H), 1.86 (d, J= 7.0 Hz, 3H), 1.33 - 1.21 (m, 3H),
  • The compound C51: 150 mg, ESI[M + H]+ = 287.0
  • 1H NMR (400 MHz, CDCl3) δ 8.17 (s, 1H), 8.05 (s, 1H), 7.42 - 7.31 (m, 3H), 7.25 - 7.20 (m, 2H), 6.51 - 6.42 (m, 1H), 4.53 (s, 2H), 4.21 (s, 2H), 2.15 (s, 3H), 1.89 (d, J= 6.4 Hz, 3H).
    • Example 11 Preparation of Compounds C52 ~ C53
  • Figure imgb0329
  • The target compounds C52 ~ C53 were prepared according to the operation method of preparing compound C9 described in Example 3. D-3 worked with CuBr2 to give 52-1, which worked with sodium 3-methylenecyclobutane-1- thiolate or sodium acetate to give target compounds C52 and C53
  • The compound C52: 35 mg, ESI[M + H]+ = 313.0
  • 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.86 (s, 1H), 7.39 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.45 (q, J = 7.1 Hz, 1H), 4.82 (s, 2H), 3.60 (s, 2H), 2.62 - 2.59 (m, 1H), 2.43 - 2.39 (m, 2H), 2.21 - 2.15 (m, 2H), 1.87 (d, J = 7.0 Hz, 3H).
  • The compound C53: 18 mg, ESI[M + H]+ = 273.1
  • 1H NMR (400 MHz, CDCl3) δ 7.88 (s, 1H), 7.78 (s, 1H), 7.42 - 7.27 (m, 3H), 7.25 - 7.16 (m, 2H), 6.39 (q, J = 7.1 Hz, 1H), 5.08 (dd, J = 69.5, 15.8 Hz, 2H), 2.20 (s, 3H), 1.84 (d, J = 7.1 Hz, 3H).
    • Example 12 Preparation of Compounds C54 ~ C56
  • Figure imgb0330
    Figure imgb0331
    Figure imgb0332
  • The target compounds C54 ~ C56 were prepared according to the operation method of preparing compounds C11 ~ C13 described in Example 4.
  • Etomidate was reduced by LAH, then oxidized by active MnO2 to give compound 54-2, which worked with prop-1-yn-1-ylmagnesium bromide followed by active MnO2 to give the compound C54. The compound C54 was reduced by Lindlar catalyst to give compound C55, which was oxidized by m-CPBA to give the compound C56.
  • The compound C54: 57 mg, ESI[M + H]+ = 239.4
  • 1H NMR (400 MHz, CDCl3) δ 7.99 (s, 1H), 7.77 (s, 1H), 7.40 - 7.27 (m, 3H), 7.25 - 7.15 (m, 2H), 6.41 (q, J = 7.0 Hz, 1H), 2.09 (s, 3H), 1.84 (d, J = 7.1 Hz, 3H).
  • The compound C55: 95 mg, ESI[M + H]+ = 241.3
  • 1H NMR (400 MHz, CDCl3) δ 7.82 (s, 1H), 7.79 (s, 1H), 7.40 - 7.30 (m, 3H), 7.26 - 7.21 (m, 2H), 6.73 - 6.53 (m, 2H), 6.44 - 6.30 (m, 1H), 2.15 (dd, J = 7.3, 1.7 Hz, 3H), 1.87 (d, J = 7.1 Hz, 3H).
  • The compound C56: 13 mg, ESI[M + H]+ = 257.2
  • 1H NMR (400 MHz, CDCl3) δ 8.13 (s, 1H), 7.85 (s, 1H), 7.38 - 7.27 (m, 3H), 7.23 - 7.13 (m, 2H), 6.51- 6.32 (m, 1H), 3.63 (d, J = 12.7 Hz, 1H), 3.23 - 3.09 (m, 1H), 1.84 (d, J= 5.3 Hz, 3H), 1.44 (d, J= 4.8 Hz, 3H).
    • Example 13 Preparation of Compounds C57 ~ C67
  • Figure imgb0333
    • 1. Preparation of (R)-1-(1-(1-phenylethyl)-1H-imidazol-5-yl)pent-3-yn-1-one (57-1)
  • Figure imgb0334
  • At room temperature, Zn (245 mg, 3.75 mmol) and I2 (190 mg, 0.75 mmol) was dissolved in anhydrous THF (15 mL). The mixture was replaced with nitrogen twice. The solution of the compound 54-2 (150 mg, 0.75 mmol) and 1-bromobut-2-yne (120 mg, 0.90 mmol) in THF (5 mL) was added dropwise into the mixture at the rate of 1 mL/min using a syringe. Then the mixture was warmed to room temperature slowly and allowed to react overnight. The reaction was monitored by TLC until completion, and then it was cooled to 0°C, quenched with the saturated ammonium chloride solution (10 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product 57-1, which was used for next step directly without further purification.
    • 2. Preparation of compound C57
  • Figure imgb0335
  • At room temperature, active MnO2 (2.6 g, 30 mmol) was added into the solution of crude 57-1 in CH2Cl2 (50 mL). The mixture was refluxed for 2 hrs. The reaction was monitored by TLC until completion. The mixture was cooled to room temperature, filtered and the filter cake was washed with CH2Cl2 (30 mL). The filtrate was concentrated under reduced pressure and the residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) ~ 1/3), collecting the fraction with Rf = 0.4 ~ 0.5 to give the product C57 (12 mg, two steps yield 6.3%). ESI[M + H]+ = 253.3
  • 1H NMR (400 MHz, CDCl3) δ 7.84 (s, 1H), 7.73 (s, 1H), 7.40 - 7.28 (m, 3H), 7.22 - 7.12 (m, 2H), 6.32 (q, J = 7.1 Hz, 1H), 5.19 - 5.05 (m, 2H), 1.91 (t, J = 3.0 Hz, 3H), 1.85 (d, J = 7.1 Hz, 3H).
    • 3. Preparation of compounds C58 ~ C67
  • Figure imgb0336
  • The target compounds C58 ~ C67 were prepared according to the operation method of preparing compound C57.
  • Compound 54-2 worked with corresponding zinc reagents or grignard reagents to give 58-1 ~ 67-1, which was oxidized by active MnO2 to give C58 ~ C67.
  • The compound C58: 15 mg, ESI[M + H]+ = 317.1
  • 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.85 (s, 1H), 7.39 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.43 (q, J = 7.1 Hz, 1H), 3.43-3.31 (m, 4H), 3.33 (s, 6H), 2.43 - 2.31 (m, 2H), 2.14 - 2.03 (m, 1H), 1.87 (d, J = 7.0 Hz, 3H).
  • The compound C59: 35 mg, ESI[M + H]+ = 313.3
  • 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.84 (s, 1H), 7.39 - 7.28 (m, 3H), 7.26 - 7.15 (m, 2H), 6.45 (q, J = 7.1 Hz, 1H), 3.37 (s, 2H), 3.33 (s, 3H), 2.31 - 2.17 (m, 2H), 1.94 - 1.83 (m, 9H).
  • The compound C60: 16 mg, ESI[M + H]+ = 327.1
  • 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.86 (s, 1H), 7.39 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.45 (q, J = 7.1 Hz, 1H), 3.37 (s, 2H), 3.33 (s, 3H), 2.31 - 2.17 (m, 2H), 1.94 - 1.83 (m, 9H), 1.65- 1.46 (m, 2H).
  • The compound C61: 15 mg, ESI[M + H]+ = 259.0
  • 1H NMR (400 MHz, CDCl3) δ 8.02 (s, 1H), 7.86 (s, 1H), 7.39 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.43 (q, J = 7.1 Hz, 1H), 3.68 - 3.57 (m, 2H), 3.33 (s, 3H), 2.58 - 2.47 (m, 2H), 1.84 (d, J = 7.0 Hz, 3H).
  • The compound C62: 14 mg, ESI[M + H]+ = 287.0
  • 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.86 (s, 1H), 7.39 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.45 (q, J= 7.1 Hz, 1H), 4.15 - 4.03 (m, 2H), 2.58 - 2.47 (m, 2H), 2.04 (s, 3H), 1.84 (d, J = 7.0 Hz, 3H).
  • The compound C63: 15 mg, ESI[M + H]+ = 267.2
  • 1H NMR (400 MHz, CDCl3) δ 7.95 (s, 1H), 7.82 (s, 1H), 7.35 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.41 (q, J= 7.1 Hz, 1H), 2.58 - 2.47 (m, 2H), 2.35 - 2.28 (m, 2H), 1.84 (d, J= 7.0 Hz, 3H), 1.82 (t, J= 3.0 Hz, 3H).
  • The compound C64: 18 mg, ESI[M + H]+ = 267.2
  • 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.86 (s, 1H), 7.39 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.45 (q, J = 7.1 Hz, 1H), 2.58 - 2.47 (m, 2H), 2.44 (t, J = 2.4 Hz, 1H), 2.43 - 2.36 (m, 2H), 1.84 (d, J= 7.0 Hz, 3H), 1.82 - 1.75 (m, 2H).
  • The compound C65: 22 mg, ESI[M + H]+ = 285.1
  • 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.87 (s, 1H), 7.39 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.46 (q, J = 7.1 Hz, 1H), 2.58 - 2.47 (m, 2H), 2.45 - 2.41 (m, 2H), 2.15 (s, 3H), 1.98 - 1.79 (m, 5H).
  • The compound C66: 23 mg, ESI[M + H]+ = 297.1
  • 1H NMR (400 MHz, CDCl3) δ 8.02 (s, 1H), 7.86 (s, 1H), 7.39 - 7.28 (m, 3H), 7.25 - 7.15 (m, 2H), 6.44 (q, J= 7.1 Hz, 1H), 3.95 - 3.90 (m, 1H), 3.35 (s, 3H), 2.56 - 2.31 (m, 2H), 1.98 - 1.79 (m, 6H).
  • The compound C67: 22 mg, ESI[M + H]+ = 257.1
  • 1H NMR (400 MHz, CDCl3) δ 8.04 (s, 1H), 7.88(s, 1H), 7.43 - 7.28 (m, 3H), 7.24 - 7.15 (m, 2H), 6.45 (q, J= 7.1 Hz, 1H), 4.89 - 4.71 (m, 1H), 3.98 - 3.84 (m, 3H), 3.59 - 3.54 (m, 1H), 1.86 (d, J= 7.0 Hz, 3H).
    • Example 14 Preparation of Compounds C68 ~ C83
  • Figure imgb0337
    • 1. Preparation of ethyl 4-amino-1H-imidazole-5-carboxylate (E-1)
  • Figure imgb0338
  • At room temperature, 4-amino-1H-imidazole-5-carboxamide (3.0 g, 23.8 mmol), MeSO3H (6 mL) and EtOH (30 mL) were added into sealed tube, then it was stirred at 120°C for 10 hrs. The reaction was monitored by TLC until completion and concentrated under reduced pressure. The residue was adjusted to PH = 8 ~ 9 with saturated NaHCO3 solution and extracted with ethyl acetate (3 × 150 mL). The combined organic layers were washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the product E-1 (3.0 g, yield 81%).
    • 2. Preparation of ethyl 4-fluoro-1H-imidazole-5-carboxlate (E-2)
  • Figure imgb0339
  • At an ice-brine bath, E-1 (250 mg, 1.61 mmol) was dissolved in the HBF4 (40%), and then NaNO2 (117 mg, 1.69 mmol) in H2O (0.15 mL) was added into solution at -10°C. The mixture was stirred under high pressure mercury lamp (302 nm) for 2 hrs. The reaction was monitored by TLC until completion. The mixture was adjusted to PH = 8 ~ 9 with 1 N NaOH and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. the residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/1), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.4 ~ 0.5 to give the product E-2 (100 mg, yield 39%) as colorless oil.
    • 3. Preparation of ethyl (R)-4-fluoro-1-(1-phenylethyl)-1H-imidazole-5-carboxylate (E-3)
  • Figure imgb0340
  • In an ice-water bath, S-1-phenylethan-1-ol (134 mg, 1.1 mmol), ethyl 4-fluoro-1H-imidazole-5-carboxylate E-2 (158 mg, 1.1 mmol) and PPh3 (346 mg, 1.32 mmol) were dissolved in THF (10 mL) at 0°C, then DEAD (230 mg, 1.32 mmol) in THF (1 mL) was added into mixture at the rate of 0.5 mmol/min. The mixture was warmed to room temperature slowly and stirred for 5 hrs. The reaction was monitored by TLC until completion. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound E-3 (70 mg, yield 27%). as colorless oil. ESI[M + H]+ = 263.0
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.28 (m, 4H), 7.23 - 7.16 (m, 2H), 6.28 (q, J= 7.1 Hz, 1H), 4.39 - 4.17 (m, 2H), 1.84 (d, J = 7.1 Hz, 3H), 1.32 (t, J = 7.1 Hz, 3H).
    • 4. Preparation of (R)-4-fluoro-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid (E-4)
  • Figure imgb0341
  • At room temperature, NaOH (21.6 mg, 0.54 mmol) was added into the mixture ethyl (R)-4-fluoro-1-(1-phenylethyl)-1H-imidazole-5-carboxylate E-3 (70 mg, 0.27mmol) in EtOH/H2O (10 mL, 1/1), then it was stirred at room temperature for 5 hrs. The reaction was monitored by TLC until completion. The mixture was concentrated under reduced pressure. The mixture was adjusted to PH = 4 ~ 5 with 1 N hydrochloric acid and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound E-4 (58 mg, yield 93%) as a gray solid. ESI[M + H]+ = 235.0
  • 1H NMR (400 MHz, CDCl3) δ 7.43 - 7.28 (m, 4H), 7.24 - 7.16 (m, 2H), 6.24 (q, J = 7.0 Hz, 1H), 1.85 (d, J= 7.1 Hz, 3H).
    • 5. Preparation of (R)-4-fluoro-N-methoxy-N-methyl-1-(1-phenylethyl)-1H-imidazole-5-carboxamide (E-5)
  • Figure imgb0342
  • At room temperature, (R)-4-fluoro-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid E-4 (4.4 g, 18.8 mmol), N, O-dimethylhydroxylamine hydrochloride (2.8 g, 28.7 mmol), DIEA (3.7 g, 28.6 mmol) and HATU (10.9 g, 28.7 mmol) were dissolved in DMF (50 mL). Then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion, H2O (100 mL) was added, and extracted with ethyl acetate (4 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the product E-5 (4.7 g, yield 90%) as a white solid. ESI[M + H]+ = 278.1
    • 6. Preparation of (R)-1-(4-fluoro-1-(1-phenylethyl)-1H-imidazol-5-yl)ethan-1-one (E-6)
  • Figure imgb0343
  • At room temperature, (R)-4-fluoro-N-methoxy-N-methyl-1-(1-phenylethyl)-1H-imidazole-5-carboxamide E-5(4.7 g, 16.9 mmol) were dissolved in anhydrous THF (20 mL). The mixture was cooled to 0°C with an ice-water bath. MeMgBr (33.9 mL, 1 mol/L in THF, 33.9 mmol) was added dropwise into the mixture at the rate of 3 mmol/min. Then the mixture was warmed to room temperature slowly and allowed to react for 2 hrs. The reaction was monitored by TLC until completion, the mixture was cooled to 0°C with an ice-water bath. The mixture was quenched with the saturated ammonium chloride solution (100 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound E-6 (3.9 g, yield 99%) as a white solid. ESI[M + H]+ = 233.1
    • 7. Preparation of (R)-2-(4-fluoro-1-(1-phenylethyl)-1H-imidazol-5-yl)-2,2-dimeth oxyethan-1-ol(E)
  • Figure imgb0344
  • At room temperature, (R)-1-(4-fluoro-1-(1-phenylethyl)-1H-imidazol-5-yl)eth an-1-one E-6 (3.9 g, 16.8 mmol) and PhI(OAc)2 (8.1 g, 25.1 mmol) were dissolved in MeOH (30 mL). The mixture was cooled to -10°C with an ice-brine bath. KOH (11.3 g, 201.4 mol) was added in portions into the mixture within 30 minutes. Then the mixture was stirred at -10°C for 3 hrs. The reaction was monitored by TLC until completion, the saturated brine (200 mL) was added slowly into the mixture and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/5), with TLC (ethyl acetate/petroleum ether (v/v) = 1/3) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound A-4 (684 mg, yield 14%) as a white solid. ESI[M + H]+ = 295.2
    • 8.Preparation of Compounds C68 ~ C83
  • Figure imgb0345
  • The target compounds C68 ~ C83 were prepared according to the operation method of preparing compound C1. Compound E reacted with corresponding halides under NaH condition to give intermediate compounds 68-1 ~ 83-1, which were deprotected with PTSA.H2O to give target compounds C68 ~ C83.
  • The compound C68: 30 mg, ESI[M + H]+ = 331.2
  • 1H NMR (400 MHz, CDCl3) δ 7.41 (s, 1H), 7.36 - 7.11 (m, 5H), 6.40 (q, J= 7.1 Hz, 1H), 3.38 (s, 2H), 3.34 (s, 3H), 2.35 - 2.14 (m, 2H), 1.97 - 1.81 (m, 9H).
  • The compound C69: 59 mg, ESI[M + H]+ = 301.0
  • 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 1.1 Hz, 1H), 7.38 - 7.28 (m, 3H), 7.25 - 7.21 (m, 2H), 6.37 (d, J = 7.0 Hz, 1H), 4.57 (qd, J = 17.1, 2.3 Hz, 2H), 4.25 (q, J = 2.3 Hz, 2H), 1.86 - 1.81 (m, 6H).
  • The compound C70: 52 mg, ESI[M + H]+ = 317.1
  • 1H NMR (400 MHz, CDCl3) δ 7.43 (s, 1H), 7.39 - 7.28 (m, 3H), 7.26 - 7.18 (m, 2H), 6.37 (q, J = 7.0 Hz, 1H), 4.52 - 4.32 (m, 2H), 3.45 (p, J = 9.3 Hz, 2H), 2.68 - 2.51 (m, 1H), 2.10 - 2.01 (m, 2H), 1.98 - 1.88 (m, 2H), 1.85 (d, J = 7.1 Hz, 3H), 1.78 - 1.66 (m, 2H).
  • The compound C71: 64 mg, ESI[M + H]+ = 263.0
  • 1H NMR (400 MHz, CDCl3) δ 7.42 (s, 1H), 7.39 - 7.28 (m, 3H), 7.26 - 7.18 (m, 2H), 6.38 (q, J = 7.0 Hz, 1H), 4.52 - 4.32 (m, 2H), 3.44 (s, 3H), 1.83 (d, J = 7.1 Hz, 3H). The compound C72: 56 mg, ESI[M + H]+ = 277.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 (s, 1H), 7.37 - 7.28 (m, 3H), 7.26 - 7.18 (m, 2H), 6.39 (q, J = 6.9 Hz, 1H), 4.60 - 4.36 (m, 2H), 3.58 (q, J = 7.0 Hz, 2H), 1.83 (d, J = 7.0 Hz, 3H), 1.26 (t, J = 7.0 Hz, 3H).
  • The compound C73: 60 mg, ESI[M + H]+ = 287.0
  • 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 1.2 Hz, 1H), 7.39 - 7.28 (m, 3H), 7.26 - 7.18 (m, 2H), 6.36 (q, J = 70 Hz, 1H), 4.69 - 4.51 (m, 2H), 4.30 (d, J = 2.3 Hz, 2H), 2.45 (t, J= 2.4 Hz, 1H), 1.83 (d, J= 7.1 Hz, 3H).
  • The compound C74: 29 mg, ESI[M + H]+ = 331.1
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.28 (m, 4H), 7.26 - 7.19 (m, 2H), 6.39 (q, J= 7.1 Hz, 1H), 4.52 - 4.35 (m, 2H), 3.42 (t, J = 6.9 Hz, 2H), 2.43 - 2.29 (m, 1H), 2.11 - 1.97 (m, 2H), 1.91 - 1.84 (m, 1H), 1.82 (d, J = 7.0Hz, 3H), 1.81 - 1.77 (m, 1H), 1.76 - 1.69 (m, 2H), 1.68 - 1.58 (m, 2H).
  • The compound C75: 19 mg, ESI[M + H]+ = 351.0
  • 1H NMR (400 MHz, CDCl3) δ 7.43 (s, 1H), 7.38 - 7.28 (m, 3H), 7.27 - 7.18 (m, 2H), 6.38 (q, J= 7.0 Hz, 1H), 4.33 (s, 2H), 3.72- 3.68 (m, 1H), 3.51- 3.46 (m, 4H), 3.31 (s, 6H), 1.87 (d, J = 7.0 Hz, 3H).
  • The compound C76: 108 mg, ESI[M + H]+ = 303.2
  • 1H NMR (400 MHz, CDCl3) δ 7.44 - 7.27 (m, 4H), 7.26 - 7.20 (m, 2H), 6.39 (q, J= 7.0 Hz, 1H), 4.70 - 4.33 (m, 2H), 3.36 (d, J = 7.0 Hz, 2H), 1.83 (d, J = 7.1 Hz, 3H), 1.19 - 1.00 (m, 1H), 0.63 - 0.43 (m, 2H), 0.26 - 0.09 (m, 2H).
  • The compound C77: 39 mg, ESI[M + H]+ = 343.0
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (s, 1H), 7.39 - 7.29 (m, 3H), 7.26 - 7.18 (m, 2H), 6.39 (q, J = 70 Hz, 1H), 5.61 (t, J = 6.9 Hz, 1H), 5.11 - 4.69 (m, 6H), 4.35 (s, 2H), 1.86 (d, J = 7.1 Hz, 3H).
  • The compound C78: 22 mg, ESI[M + H]+ = 319.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 (s, 1H), 7.36 - 7.28 (m, 3H), 7.27 - 7.18 (m, 2H), 6.54 - 6.25 (m, 1H), 4.60 - 4.24 (m, 2H), 3.20 (p, J = 5.8 Hz, 1H), 1.82 (d, J = 7.0 Hz, 3H), 1.55 - 1.47 (m, 4H), 0.98 - 0.79 (m, 6H).
  • The compound C79: 29 mg, ESI[M + H]+ = 291.0
  • 1H NMR (400 MHz, CDCl3) δ 7.42 (s, 1H), 7.39 - 7.28 (m, 3H), 7.26 - 7.18 (m, 2H), 6.38 (q, J = 7.0 Hz, 1H), 4.52 - 4.32 (m, 2H), 3.31 - 3.19 (m, 1H), 1.82 (d, J= 7.1 Hz, 3H), 1.41 - 1.27 (m, 6H).
  • The compound C80: 32 mg, ESI[M + H]+ = 305.0
  • 1H NMR (400 MHz, CDCl3) δ 7.43 (s, 1H), 7.36 - 7.28 (m, 3H), 7.26 - 7.18 (m, 2H), 6.36 (q, J= 7.0 Hz, 1H), 4.52 - 4.32 (m, 2H), 3.52 - 3.38 (m, 2H), 1.84 (d, J= 7.1 Hz, 3H), 1.81 - 1.67 (m, 1H), 1.01 - 0.88 (m, 6H).
  • The compound C81: 39 mg, ESI[M + H]+ = 319.1
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (s, 1H), 7.38 - 7.28 (m, 3H), 7.27 - 7.18 (m, 2H), 6.38 (q, J= 7.0 Hz, 1H), 4.52 - 4.32 (m, 2H), 3.51 - 3.39 (m, 2H), 1.83 (d, J= 7.1 Hz, 3H), 1.80 - 1.69 (m, 1H), 1.69 - 1.39 (m, 2H), 1.01 - 0.90 (m, 6H).
  • The compound C82: 24 mg, ESI[M + H]+ = 305.0
  • 1H NMR (400 MHz, CDCl3) δ 7.43 (s, 1H), 7.37 - 7.28 (m, 3H), 7.26 - 7.18 (m, 2H), 6.39 (q, J= 7.0 Hz, 1H), 5.11 - 4.69 (m, 5H), 4.51 - 4.32 (m, 2H), 1.83 (d, J= 7.1 Hz, 3H).
  • The compound C83: 32 mg, ESI[M + H]+ = 319.0
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (s, 1H), 7.39 - 7.28 (m, 3H), 7.26 - 7.18 (m, 2H), 6.36 (q, J = 7.0 Hz, 1H), 4.52 - 4.32 (m, 6H), 3.47 - 3.37 (m, 2H), 2.96 - 2.88 (m, 1H), 1.83 (d, J = 7.1 Hz, 3H).
    • Example 15 Preparation of Compound C84
  • Figure imgb0346
  • At room temperature, compound C73 (100 mg, 0.35 mmol) and Hg2SO4/H2SO4/Silica gel (200 mg) was dissolved in CH2Cl2 (5 mL). Then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion, the saturated NaHCO3 solution was added into the mixture and extracted with CH2Cl2 (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) ~ 1/3), collecting the fraction with Rf = 0.4 ~ 0.5 to give the product C84 (53 mg, yield 50%) as colorless oil. ESI[M + H]+ = 305.0
  • 1H NMR (400 MHz, CDCl3) δ 7.41 (s, 1H), 7.39 - 7.28 (m, 3H), 7.25 - 7.19 (m, 2H), 6.41 - 6.20 (m, 1H), 4.58 (q, J= 17.5 Hz, 2H), 4.16 (s, 2H), 2.18 (s, 3H), 1.83 (d, J= 6.8 Hz, 3H).
    • Example 16 Preparation of Compound C85
  • Figure imgb0347
    • 1. Preparation of (R)-2-bromo-1-(4-fluoro-1-(1-phenylethyl)-1H-imidazol-5-yl)eth an -1-one (85-1)
  • Figure imgb0348
  • At room temperature, CuBr2(1.9 g, 8.5 mmol) was added into the solution of (R)-1-(4-fluoro-1-(1-phenylethyl)-1H-imidazol-5-yl)ethan-1-one E-6 (1.0 g, 4.3 mmol) in EtOH (50 mL). Then the mixture was stirred at 60°C for 1 hour. The reaction was monitored by TLC until completion, cooled to room temperature and quenched with H2O (30 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/5), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the compound 85-1 (703 mg, yield 53%) as colorless oil. ESI[M + H]+ = 311.1
    • 2. Preparation of compound C85
  • Figure imgb0349
  • At an ice bath, NaSEt (49 mg, 0.58 mmol) was added into the solution of 85-1 (150 mg, 0.48 mmol) in DMF (5 mL) at 0°C. Then the mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC until completion. The mixture was quenched with the ice-water (10 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.4 ~ 0.6 to give the compound C85 (73 mg, yield 52%). ESI[M + H]+ = 293.1
  • 1H NMR (400 MHz, CDCl3) δ 7.41 (s, 1H), 7.37 - 7.28 (m, 3H), 7.26 - 7.18 (m, 2H), 6.35 (q, J= 7.0 Hz, 1H), 3.75 - 3.64 (m, 2H), 2.51 - 2.44 (m, 2H), 1.83 (d, J= 7.1 Hz, 3H), 1.21 - 1.14 (m, 3H).
  • Examples of Group D compounds are as follows:
    • Example 1 Preparation of Compound D1
  • Figure imgb0350
    Figure imgb0351
    Figure imgb0352
    • 1.Preparation of ethyl (R)-1-(1-phenylethyl)-1H-pyrazole-5-carboxylate (A-1)
  • Figure imgb0353
  • In an ice-water bath, (S)-1-phenylethan-1-ol (8.38 g, 68.6 mmol) was added into the mixture of ethyl 1H-pyrazole-5-carboxylate (7.4 g, 52.8 mmol) and PPh3 (20.8 g, 79.3 mmol in THF (50 mL), then solution of DEAD (13.8 g, 79.2 mmol) in THF (150 mL) was added slowly into the mixture at the rate of 2 mmol/min. After addition, the reaction mixture was warmed slowly to room temperature and stirred overnight. The reaction was monitored by TLC until completion. The reaction mixture was quenched with the saturated brine (100 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give crude product. The crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound A-1 (9.5 g, yield 74%) as colorless oil. ESI[M + H]+ = 245.1
  • 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 1.9 Hz, 1H), 7.33 - 7.27 (m, 4H), 7.25 - 7.18 (m, 1H), 6.86 (d, J = 2.0 Hz, 1H), 6.59 (q, J = 7.1 Hz, 1H), 4.42 - 4.16 (m, 2H), 1.92 (d, J= 7.1 Hz, 3H), 1.33 (t, J= 7.1 Hz, 3H).
    • 2.Preparation of (R)-1-(1-phenylethyl)-1H-pyrazole-5-carboxylic acid (A-2)
  • Figure imgb0354
  • At room temperature, the solution of NaOH (3.1 g, 77.5 mmol) in water (12 mL) was added into the solution of A-1 (9.5 g, 38.9 mmol) in ethanol (12 mL), then the mixture was stirred at 60°C for 1 hour. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. Water (20 mL) was poured into the residue. The mixture was adjusted pH to 4 ~ 5 using IN HCl and extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the compound A-2 (6.70 g g, yield 80%) as a white solid. ESI[M + H]+ = 217.1
  • 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J= 2.0 Hz, 1H), 7.39 - 7.16 (m, 5H), 7.00 (d, J = 2.0 Hz, 1H), 6.56 (q, J= 7.0 Hz, 1H), 1.93 (d, J= 7.1 Hz, 3H).
    • 3. Preparation of (R)-N-methoxy-N-methyl-1-(1-phenylethyl)-1H-pyrazole-5-carboxamide (A-3)
  • Figure imgb0355
  • At room temperature, A-2 (3.5 g, 16.2 mmol), N, O-dimethylhydroxylamine hydrochloride (2.4 g, 24.6 mmol), DIEA (3.2 g, 24.8 mmol) and HATU (9.2 g, 24.2 mmol) were dissolved in DMF (100 mL), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was quenched with water (100 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound A-3 (4.10 g, yield 64%) as a white solid. ESI[M + H]+ = 260.2
    • 4. Preparation of (R)-1-(1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-one (A-4)
  • Figure imgb0356
  • At room temperature, A-3 (4.1 g, 15.8 mmol) was dissolved in anhydrous THF (20 mL). The mixture was cooled to 0°C with an ice-water bath. Methylmagnesium bromide (23.7 mL, 1 mol/L in THF, 23.7 mmol) was added dropwise into the mixture at the rate of 2 mmol/min, then the mixture was reacted at room temperature for 2 hrs. The reaction was monitored by TLC until completion. The reaction mixture was cooled to 0°C, quenched with saturated ammonium chloride solution (50 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound A-4 (3.10 g, yield 92%) as a white solid. ESI[M + H]+ = 215.1
    • 5. Preparation of (R)-2-bromo-1-(1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-one (A-6)
  • Figure imgb0357
  • At room temperature, CuBr2 (4.17 g, 18.7 mmol) was added into the solution of A-4 (2.0 g, 9.3 mmol) in ethanol (50 mL), then the mixture was stirred at 60°C for 1 hour. The reaction was monitored by TLC until completion. The reaction mixture was cooled to 0°C, quenched with water (50 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound A-6 (2.2 g, yield 81%) as a white solid. ESI[M + H]+ = 293.0
    • 6. Preparation of (R)-2-(ethylthio)-1-(1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-one
  • Figure imgb0358
  • In an ice-water bath, NaSEt (631 mg, 7.5 mmol) was added into the solution of A-6 (2.2 g, 7.5 mmol) in DMF (30 mL) at 0°C, then the mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC until completion. The reaction mixture was quenched with ice-water (10 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3) and collecting the fraction with Rf = 0.4 ~ 0.6 to give the title compound A-7 (1.26 g, yield 61%). ESI[M + H]+ = 275.2
  • 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J= 1.9 Hz, 1H), 7.34 - 7.20 (m, 5H), 6.88 (d, J = 2.0 Hz, 1H), 6.59 (q, J = 7.0 Hz, 1H), 3.60 (s, 2H), 2.49 - 2.35 (m, 2H), 1.94 (d, J= 7.1 Hz, 3H), 1.18 (t, J = 7.4 Hz, 3H).
    • 7. Preparation of (R)-2,2-dichloro-2-(ethylthio)-1-(1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-one (A-8)
  • Figure imgb0359
  • In an ice-water bath, SO2Cl2 (1.24 g, 9.18 mmol) was added into the solution of A-7 (1.26 g, 4.59 mmol) in dichloromethane (30 mL) at 0°C, then the mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure to give A-8 (1.4 g, crude), which was used for next step directly without further purification.
    • 8. Preparation of Compound D1
  • Figure imgb0360
  • At room temperature, A-4 (3.1 g, 14.5 mmol) and PhI(OAc)2 (7.0 g, 21.7 mmol) were dissolved in methanol (50 mL), then the mixture was cooled to -10°C with an ice-salt bath. KOH (9.8 g, 175 mmol) was added in portions into the mixture within 30 mins, then the reaction mixture was reacted at -10°C for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (100 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/5) and the fraction with Rf = 0.5 ~ 0.6 was collected to give the title compound D1 (196 mg, yield 4%). The fraction with Rf = 0.2 ~ 0.3 was collected to give the title compound A-5 (3.6 g, yield 87%).
    Figure imgb0361
  • At room temperature, crude compound A-8 (150 mg, 0.44 mmol) and Na2CO3 (70 mg, 0.66 mmol) were dissolved methanol (10 mL), then the mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC until completion. In an ice-water bath, the reaction mixture was quenched with saturated sodium bicarbonate solution (10 mL) at 0°C and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/5) and the fraction with Rf = 0.5 ~ 0.6 was collected to give the title compound D1 (89 mg, yield 66%). ESI[M + H]+ = 305.0
  • 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 2.1 Hz, 0.2H), 7.60 (d, J = 2.1 Hz, 0.8H), 7.35 - 7.11 (m, 6H), 6.78 - 5.98 (m, 1H), 3.92 (s, 0.7H), 3.49 (s, 1.3H), 3.13 (s, 7H), 1.99 - 1.87 (m, 3H).
    • Example 2 Preparation of Compounds D2 ~ D10
  • Figure imgb0362
    • 1. Preparation of Compound D2
  • Figure imgb0363
  • At room temperature, crude compound A-8 (1.4 g, 4.08 mmol) and Na2CO3 (865 mg, 8.16 mmol) were dissolved methanol (10 mL), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was quenched with saturated brine (20 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/8), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give title compound D2 (1.30 g, yield 95%). ESI[M + H]+ = 335.0
  • 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 2.0 Hz, 1H), 7.34 - 7.16 (m, 6H), 6.61 - 6.50 (m, 1H), 3.35 (s, 3H), 3.24 (s, 3H), 2.31 - 2.17 (m, 1H), 2.14 - 2.01 (m, 1H), 1.96 (d, J= 7.0 Hz, 3H), 0.99 (t, J= 7.5 Hz, 3H).
    • 2. Preparation of Compound D3
  • Figure imgb0364
    Figure imgb0365
  • Method A:
    At room temperature, A-4 (1.0 g, 4.67 mmol) and PhI(OAc)2 (2.3 g, 7.14 mmol) were dissolved in MeOH/EtOH (10 mL, v/v = 1/1), then the mixture was cooled to -10°C with an ice-salt bath. KOH (3.14 g, 56 mmol) was added in portions into the mixture within 30 mins, then the reaction mixture was reacted at -10°C for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (50 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/8) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound D3 (89 mg, yield 6%) and the title compound D9 (28 mg, yield 1.8%).
  • Method B:
    At room temperature, D2 (100 mg, 0.30 mmol) and Hg(OAc)2 (143 mg, 0.45 mmol) were dissolved in EtOH (2 mL), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (10 mL) and extracted with ethyl acetate (3 × 5 mL).
  • The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/5) and the fraction with Rf = 0.5 ~ 0.6 was collected to give the title compound D3 (39 mg, yield 41%). ESI[M + H]+ = 319.1
  • 1H NMR (400 MHz, CDCl3) δ 7.66 (s, 1H), 7.35 - 7.30 (m, 5H), 7.29 - 7.26 (m, 1H), 6.54 (d, J = 7.1 Hz, 1H), 4.43 - 4.40 (m, 2H), 3.95 (s, 1H), 3.78 - 3.71 (m, 1.5H), 3.52 (s, 3.5H), 1.95 (d, J= 7.0 Hz, 3H), 1.42 (t, J= 7.1 Hz, 1.5H), 1.27 (t, J= 7.0 Hz, 1.5H).
    • 3.Preparation of compounds D4 ~ D8
  • Figure imgb0366
  • The title compounds D4 ~ D8 were prepared according to the operation method B of preparing compound D3. Compound D2, Hg(OAc)2 and corresponding alcohols were stirred at room temperature overnight. The crude product was purified by Prep-TLC to give the title compounds.
  • Compound D4: 34 mg, ESI[M + H]+ = 333.1
  • 1H NMR (400 MHz, CDCl3) δ 7.66 (d, J= 2.1 Hz, 1H), 7.37 - 7.30 (m, 5H), 7.28 - 7.21 (m, 1H), 6.56 - 6.52 (m, 1H), 5.35 - 5.30 (m, 1H), 3.95 (s, 1H), 3.52 (s, 5H), 1.95 (d, J= 7.0 Hz, 3H), 1.55 (d, J= 6.5 Hz, 1H), 1.46 - 1.40 (m, 3H), 1.25 (t, J= 10.2 Hz, 2H).
  • Compound D5: 28 mg, ESI[M + H]+ = 361.0
  • 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J= 2.0 Hz, 1H), 7.38 - 7.32 (m, 4H), 7.29 - 7.22 (m, 1H), 6.57 (dd, J= 14.4, 7.3 Hz, 1H), 4.87 (s, 1H), 3.95 (s, 1H), 3.51 (s, 5H), 1.92 (dd, J= 7.0, 3.5 Hz, 3H), 1.65 - 1.62 (m, 2.5H), 1.60 - 1.55 (m, 1.5H), 1.50 - 1.45 (m, 1.5H), 1.40 - 1.35 (m, 3.5H), 1.25 - 1.20 (m, 1H).
  • Compound D6: 27 mg, ESI[M + H]+ = 361.1
  • 1H NMR (400 MHz, CDCl3) δ 7.66 (s, 1H), 7.32 - 7.19 (m, 6H), 6.59 - 6.52 (m, 1H), 4.04 (s, 1.5H), 3.95 (s, 1H), 3.52 (s, 4.5H), 3.32 (s, 1H), 1.95 (d, J= 7.0 Hz, 3H), 1.02 (s, 5.5H), 0.94 (s, 3.5H).
  • Compound D7: 41 mg, ESI[M + H]+ = 331.1
  • 1H NMR (400 MHz, CDCl3) δ 7.72 - 7.44 (m, 2H), 7.39 - 7.30 (m, 4H), 7.26 - 7.16 (m, 1H), 6.65 - 6.49 (m, 1H), 6.17 - 5.89 (m, 1H), 5.51 - 4.83 (m, 2H), 4.21 - 4.18 (m, 1.5H), 3.94 (s, 1.5H), 3.45 (m, 3H), 3.26 - 3.09 (m, 2H), 2.06 - 1.87 (m, 3H). Compound D8: 48 mg, ESI[M + H]+ = 343.1
  • 1H NMR (400 MHz, CDCl3) δ 7.75 - 7.46 (m, 2H), 7.38 - 7.32 (m, 3H), 7.28 - 7.19 (m, 2H), 6.66 - 6.47 (m, 1H), 4.22 - 4.18 (m, 1.5H), 3.96 (s, 2H), 3.48 (s, 3H), 3.28 - 3.08 (m, 1.5H), 2.04 - 1.82 (m, 6H).
    • 4.Preparation of Compound D9
  • Figure imgb0367
  • At room temperature, A-4 (1.0 g, 4.67 mmol) and PhI(OAc)2 (2.3 g, 7.14 mmol) were dissolved in MeOH/EtOH (10 mL, v/v = 1/1), then the mixture was cooled to -10°C with an ice-salt bath. KOH (3.14 g, 56 mmol) was added in portions into the mixture within 30 mins, then the reaction mixture was stirred at -10°C for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (50 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/8) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound D3 (89 mg, yield 6%) and the title compound D9 (28 mg, yield 1.8%).
  • Method B:
    At room temperature, crude compound A-8 (1.4 g, 4.08 mmol) and Na2CO3 (865 mg, 8.16 mmol) were dissolved ethanol (10 mL), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was quenched with saturated brine (20 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/8), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give title compound 9-1 (1.0 g, yield 68%). ESI[M + H]+ = 363.1 At room temperature, 9-1 (100 mg, 0.28 mmol) and Hg(OAc)2 (131 mg, 0.41 mmol) were dissolved in methanol (2 mL), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (10 mL) and extracted with ethyl acetate (3 × 5 mL).
  • The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/5) and the fraction with Rf = 0.5 ~ 0.6 was collected to give the title compound D9 (27 mg, yield 29%). ESI[M + H]+ = 333.1
  • 1H NMR (400 MHz, CDCl3) δ 7.63 (s, 1H), 7.31 - 7.27 (m, 5H), 7.26 - 7.24 (m, 1H), 6.52 (d, J = 7.1 Hz, 2H), 4.43 - 4.40 (m, 2H), 3.95 (s, 1H), 3.77 - 3.71 (m, 1.5H), 3.54 (s, 2.5H), 1.94 (d, J = 7.0 Hz, 3H), 1.44 - 1.40 (m, 3H), 1.28 - 1.24 (m, 3H).
    • 5.Preparation of compound D10
  • Figure imgb0368
  • The title compound D10 was prepared according to the operation method A and B of preparing compound D1 described in Example 1, using A-4 and A-8 as the raw materials respectively.
  • 34 mg of compound D10 was obtained in 34% yield by using method B. ESI[M + H]+ = 347.1
  • 1H NMR (400 MHz, CDCl3) δ 7.61 (s, 1H), 7.30 - 7.26 (m, 5H), 7.24 - 7.22 (m, 1H), 6.50 (d, J = 7.1 Hz, 2H), 4.42 - 4.40 (m, 1H), 3.94 (s, 1H), 3.75 - 3.70 (m, 1.5H), 3.52 (s, 2.5H), 1.92 (d, J= 7.0 Hz, 3H), 1.43 - 1.41 (m, 4.5H), 1.25 - 1.22 (m, 4.5H).
    • Example 3 Preparation of Compounds D11 ~ D12
  • Figure imgb0369
    • 1.Preparation of Compound D11
  • Figure imgb0370
  • At room temperature, PTSA.H2O (1.2 g, 6.31 mmol) was added into the solution of D1 (600 mg, 1.97 mmol) in acetone (15 mL), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was quenched with ice-water (10 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/3) and the fraction with Rf = 0.4 ~ 0.6 was collected to give the title compound D11 (305 mg, yield 60%). ESI[M + H]+ = 259.0
  • 1H NMR (400 MHz, CDCl3) δ 7.67 (d, J= 2.1 Hz, 1H), 7.44 - 7.16 (m, 6H), 6.54 (q, J = 7.0 Hz, 1H), 3.94 (s, 3H), 1.95 (d, J = 7.0 Hz, 3H).
    • 2.Preparation of Compound D12
  • Figure imgb0371
  • At room temperature, LiOH.H2O (81 mg, 1.93 mmol) was added into the solution of D11 (250 mg, 0.97 mmol) in MeOH/THF/H2O (7 mL, v/v/v = 1/1/1.5), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The reaction mixture was adjusted pH to 4 ~ 5 using IN HCl and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give the compound 12-1 (162 mg, yield 68%). ESI[M + H]+ = 245.0
  • At room temperature, 12-1 (150 mg, 0.61 mmol) and 2,2-dimethylpropan-1-ol (162 mg, 1.84 mmol) were dissolved in chloroform (5 mL). Five drops of concentrated hydrochloric acid were added into the mixture using a syringe, and then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/3) and the fraction with Rf = 0.4 ~ 0.6 was collected and dried to give the title product D12 (74 mg, yield 39%). ESI[M + H]+ = 315.1
  • 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J= 2.1 Hz, 1H), 7.46 - 7.18 (m, 6H), 6.55 (q, J = 7.0 Hz, 1H), 4.23 (s, 2H), 1.94 (d, J = 7.0 Hz, 3H), 1.23 (s, 9H).
    • Example 4 Preparation of Compounds D13 ~ D16
  • Figure imgb0372
    • 1. Preparation of Compounds D13 and D14
  • Figure imgb0373
  • A-4 (214 mg, 1.0 mmol) and 1,2-diphenyldiselane (1.56 g, 5.0 mmol) were dissolved in methanol or ethanol (10 mL), then the mixture was heated to reflux for 12 hrs. The reaction was monitored by TLC until completion. The reaction mixture was quenched with water (30 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by Prep-TLC (methyl tert-butyl ether /petroleum ether (v/v) = 1/30) and the fraction with Rf = 0.4 ~ 0.6 was collected to give the title compound D13 and the title compound D14.
  • Compound D13: 91 mg, yield 33%, ESI[M + H]+ = 275.0
  • 1H NMR (400 MHz, CDCl3) δ 7.64 (s, 1H), 7.30 - 7.26 (m, 5H), 7.26 - 7.23 (m, 1H), 6.51 (d, J = 7.1 Hz, 2H), 5.08 (s, 1H), 3.35 (s, 3H), 3.30 (s, 3H), 1.92 (d, J= 7.0 Hz, 3H).
  • Compound D14: 138 mg, yield 46%, ESI[M + H]+ = 303.2
  • 1H NMR (400 MHz, CDCl3) δ 7.63 (s, 1H), 7.31 - 7.26 (m, 5H), 7.25 - 7.23 (m, 1H), 6.49 (d, J= 7.1 Hz, 2H), 5.04 (s, 1H), 3.50 - 3.46 (m, 4H), 1.92 (d, J= 7.0 Hz, 3H), 1.19 - 1.15 (m, 6H).
    • 2. Preparation of Compound D15
  • Figure imgb0374
  • At room temperature, A-4 (400 mg, 1.87 mmol) was dissolved in dichloromethane (10 mL), then the mixture was cooled to 0°C with an ice-water bath. The solution of Br2 (597 mg, 3.74 mmol) in dichloromethane (5 mL) was added slowly into the above mixture using a syringe. The reaction mixture was stirred at room temperature for 2 hrs. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure to give crude compound 15-1, which was used for next step directly without further purification.
  • At room temperature, NaSEt (472 mg, 5.61 mmol) was added into the solution of crude 15-1 (1.87 mmol) in ethanol (30 mL), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The reaction mixture was quenched with ice-water (10 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.4 ~ 0.6 to give the title compound D15 (46 mg, yield 7.4% for 2 steps). ESI[M + H]+ = 335.1
  • 1H NMR (400 MHz, CDCl3) δ 7.62 (s, 1H), 7.30 - 7.24 (m, 5H), 7.22 - 7.20 (m, 1H), 6.45 (d, J = 7.1 Hz, 2H), 5.13 (s, 1H), 2.79 - 2.40 (m, 4H), 1.90 (d, J = 7.0 Hz, 3H), 1.16 - 1.13 (m, 6H).
    • 3. Preparation of Compound D16
  • Figure imgb0375
  • At room temperature, PTSA.H2O (4.1 g, 21.6 mmol) was added into the solution of A-5 (3.0 g, 10.9 mmol) in acetone (50 mL), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was quenched with ice-water (50 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/5), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound 16-1 (1.7 g, yield 68%). ESI[M + H]+ = 231.1
  • At room temperature, active MnO2 (26.6 g, 91%, 278 mmol) was added in portions into the solution of 16-1 (1.6 g, 6.9 mmol) in dioxane (150 mL), then the mixture was heated to reflux for 8 hrs. The reaction was monitored by TLC until completion. The reaction mixture was cooled to room temperature and filtered. The filter cake was washed with dichloromethane (300 mL). The filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/5), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound 16-2 (1.2 g, yield 76%). ESI[M + H]+ = 229.1
  • At room temperature, acetylacetone (1.5 g, 15.0 mmol) and 4-methylbenzenesulfonyl azide (2.9 g, 14.7 mmol) were dissolved in acetonitrile (100 mL), then the mixture was cooled to 0°C with an ice-water bath. DBU (6.9 g, 45 mmol) was added into the mixture using a syringe within 10 mins. After addition, the ice-water bath was removed, and the mixture was allowed to react at room temperature for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was beated with ethyl acetate/petroleum ether (v/v = 1/1) and filtered. The filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound 16-3 (1.3 g, yield 29%).
  • At room temperature, 16-2 (500 mg, 2.2 mmol) and 16-3 (277 mg, 2.2 mmol) were dissolved in benzene (5 mL), then the mixture was stirred at 80°C for 10 hrs. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/3) and the fraction with Rf = 0.4 ~ 0.6 was collected to give the title compound D16 (79 mg, yield 11%). ESI[M + H]+ = 327.1
  • 1H NMR (400 MHz, CDCl3) δ 7.65 (s, 1H), 7.32 - 7.29 (m, 5H), 7.25 - 7.22 (m, 1H), 6.69 (s, 1H), 6.44 (d, J= 7.1 Hz, 1H), 2.21 (s, 6H), 1.91 (d, J= 7.0 Hz, 3H).
    • Example 5 Preparation of Compound D17
  • Figure imgb0376
    Figure imgb0377
    Figure imgb0378
    • 1. Preparation of ethyl 3-nitro-1H-pyrazole-5-carboxylate (B-1)
  • Figure imgb0379
  • At room temperature, 3-nitro-1H-pyrazole-5-carboxylic acid (50 g, 318.3 mmol was dissolved in ethanol (300 mL). In an ice-water bath, SOCl2 (49 g, 412 mmol) was added dropwise into the mixture. After addition, the mixture was heated to reflux for 8 hrs. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane (30 mL) and adjusted pH to 7 ~ 8 with saturated sodium bicarbonate solution. The mixture was extracted with dichloromethane (3 × 30 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound B-1 (58.7 g, yield 99.6%) as a white solid. ESI[M + H]+ = 186.1
    • 2. Preparation of ethyl 3-amino-1H-pyrazole-5-carboxylate (B-2)
  • Figure imgb0380
  • B-1 (58.7 g, 317 mmol) and 10% wet palladium carbon (6 g) were dissolved in ethanol (200 mL). The system was replaced three times with hydrogen, then the reaction mixture was allowed to react at room temperature for 18 hrs under hydrogen. The reaction was monitored by TLC until completion. The reaction mixture was filtered. The filter cake was washed with ethanol (3 × 30 mL). The filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/1), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.4 ~ 0.5 to give compound B-2 (43.5 g, yield 88%). ESI[M + H]+ = 156.1
    • 3. Preparation of ethyl 3-fluoro-1H-pyrazole-5-carboxylate (B-3)
  • Figure imgb0381
  • In an ice-salt bath, B-2 (43.5 g, 280 mmol) was dissolved in HBF4 (40%) at -10°C, and then the solution of NaNO2 (20.3 g, 294 mmol) in water (30 mL) was added into the mixture. The mixture was allowed to react under the irradiation of a mercury lamp (302 nm) for 12 hrs. The reaction was monitored by TLC until completion, and then the reaction solution was adjusted pH to 7 ~ 8 with IN NaOH solution in an ice-water bath. The mixture was extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.4 ~ 0.5 to give compound B-3 (3.4 g, yield 8%) as a grey solid compound.
    • 4. Preparation of ethyl (R)-3-fluoro-1-(1-phenylethyl)-1H-pyrazole-5-carboxylate (B-4)
  • Figure imgb0382
  • In an ice-water bath, (S)-1-phenylethan-1-ol (3.4 g, 27.8 mmol) was added into the mixture of B-3 (3.4 g, 21.5 mmol) and PPh3 (8.4 g, 32.0 mmol) in THF (50 mL) at 0°C, then the solution of DEAD (5.6 g, 32.2 mmol) in THF (15 mL) was added dropwise into the mixture at the rate of 1 mmol/min. After addition, the reaction mixture was warmed slowly to room temperature and stirred overnight. The reaction was monitored by TLC until completion. The reaction mixture was quenched with the saturated brine (100 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give crude product. The crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the product B-4 (4.2 g, yield 74%). ESI[M + H]+ = 263.1
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.21 (m, 5H), 6.56 - 6.47 (m, 1H), 6.33 (d, J = 6.3 Hz, 1H), 4.41 - 4.17 (m, 2H), 1.85 (d, J= 7.1 Hz, 3H), 1.33 (t, J= 7.1 Hz, 3H).
    • 5. Preparation of (R)-3-fluoro-1-(1-phenylethyl)-1H-pyrazole-5-carboxylic acid (B-5)
  • Figure imgb0383
  • At room temperature, the solution of NaOH (1.3 g, 32.5 mmol) in water (10 mL) was added into the solution of B-4 (4.2 g, 16.0 mmol) in ethanol (10 mL), then the mixture was stirred at 60°C for 1 hour. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. Water (20 mL) was poured into the residue. The mixture was adjusted pH to 4 ~ 5 with IN HCl and extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the compound B-5 (2.8 g, yield 75%) as a white solid. ESI[M + H]+ = 234.9
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.14 (m, 6H), 6.55 - 6.36 (m, 2H), 1.87 (d, J = 7.0 Hz, 3H).
    • 6. Preparation of (R)-3-fluoro-N-methoxy-N-methyl-1-(1-phenylethyl)-1H-pyrazole-5-carboxamide (B-6)
  • Figure imgb0384
  • At room temperature, B-5 (2.0 g, 8.5 mmol), N,O-dimethylhydroxylamine hydrochloride (1.2 g, 12.3 mmol), DIEA (1.7 g, 13.2 mmol) and HATU (4.7 g, 12.4 mmol) were dissolved in DMF (30 mL), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was quenched with water (100 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound B-6 (1.8 g, yield 76%) as a white solid. ESI[M + H]+ = 278.1
    • 7. Preparation of (R)-1-(3-fluoro-1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-one (B-7)
  • Figure imgb0385
  • At room temperature, B-6 (1.8 g, 6.5 mmol) was dissolved in anhydrous THF (20 mL). The mixture was cooled to 0°C with an ice-water bath. Methylmagnesium bromide (13 mL, 1 mol/L in THF, 13.0 mmol) was added dropwise into the mixture at the rate of 2 mmol/min, then the mixture was reacted at room temperature for 2 hrs. The reaction was monitored by TLC until completion. The mixture was cooled to 0°C with an ice-water bath, quenched with saturated ammonium chloride solution (50 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound B-7 (1.2 g, yield 79%) as a white solid. ESI[M + H]+ = 233.1
    • 8. Preparation of (R)-2-bromo-1-(3-fluoro-1-(1-phenylethyl)-1H-pyrazol-5-yl) ethan-1-one (B-9)
  • Figure imgb0386
  • At room temperature, CuBr2 (4.5 g, 20 mmol) was added into the solution of B-7 (2.3 g, 10 mmol) in ethanol (50 mL), then the mixture was stirred at 60°C for 1 hour. The reaction was monitored by TLC until completion. The mixture was cooled to room temperature, quenched with water (50 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound B-9 (2.3 g, yield 74%) as light-yellow oil. ESI[M + H]+ = 311.0
    • 9.Preparation of (R)-2-(ethylthio)- 1 -(3 -fluoro-1 -(1 -phenylethyl)- 1H-pyrazol-5-yl)ethan-1-one (B-10)
  • Figure imgb0387
  • In an ice-water bath, NaSEt (595 mg, 7.07 mmol) was added into the solution of B-9 (2.2 g, 7.07 mmol) in DMF (30 mL) at 0°C, then the mixture was reacted at room temperature for 1 hour. The reaction was monitored by TLC until completion. The mixture was quenched with ice-water (10 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with collecting the fraction with Rf = 0.4 ~ 0.6 to give the title compound B-10 (1.1 g, yield 53%). ESI[M + H]+ = 293.0
    • 10. Preparation of (R)-2,2-dichloro-2-(ethylthio)-1-(3-fluoro-1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-one (B-11)
  • Figure imgb0388
  • In an ice-water bath, SO2Cl2 (923 mg, 6.84 mmol) was added into the solution of B-10 (1.0 g, 3.42 mmol) in dichloromethane (10 mL) at 0°C, then the mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure to give the crude compound B-11 (1.2 g), which was used for next step directly without further purification.
    • 11.Preparation of Compound D17
  • Figure imgb0389
    Figure imgb0390
  • At room temperature, B-7 (1 g, 4.3 mmol) and PhI(OAc)2 (2.1 g, 6.5 mmol) were dissolved in methanol (20 mL), then the mixture was cooled to -10°C with an ice-salt bath. KOH (2.9 g, 52 mmol) was added in portions into the mixture within 30 mins, then the reaction mixture was reacted at -10°C for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (50 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/8) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give title compound D17 (36 mg, yield 2.6%).
    Figure imgb0391
  • At room temperature, B-11 (200 mg, 0.55 mmol) and Ag2CO3 (229 mg, 0.83 mmol) were dissolved methanol (10 mL), then the mixture was stirred at room temperature for 10 hrs. The reaction was monitored by TLC until completion. In an ice-water bath, the mixture was quenched with saturated sodium bicarbonate solution (10 mL) at 0°C and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/5) and the fraction with Rf = 0.5 ~ 0.6 was collected to give the title compound D17 (67 mg, yield 38%). ESI[M + H]+ = 323.0
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.21 (m, 5H), 6.79 (d, J = 6.2 Hz, 1H), 6.47 - 6.37 (m, 1H), 3.92 (s, 3H), 3.50 (s, 6H), 1.87 (d, J= 7.0 Hz, 3H).
    • Example 6 Preparation of Compounds D18 ~ D28 1. Preparation of compound D18
  • Figure imgb0392
    Figure imgb0393
  • The title compound D18 was prepared according to the operation method A and B of preparing compound D10 described in Example 2, using B-7 and B-11 as the raw materials respectively.
  • Compound D18: 43 mg, ESI[M + H]+ = 365.1
  • 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.20 (m, 5H), 6.75 (d, J = 6.2 Hz, 1H), 6.47 - 6.39 (m, 1H), 4.42 - 4.40 (m, 1H), 3.93 (s, 1H), 3.75 - 3.70 (m, 1.5H), 3.53 (s, 2.5H), 1.88 (d, J= 7.0 Hz, 3H), 1.43 - 1.40 (m, 4.5H), 1.25 - 1.22 (m, 4.5H).
    • 2.Preparation of compounds D19 ~ D24
  • The title compounds D19 ~ D24 were prepared according to the operation method of preparing compounds D2 ~ D10 described in Example 2.
  • Compound D19: 26 mg, ESI[M + H]+ = 321.0
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.25 (m, 5H), 6.77 (d, J = 6.2 Hz, 1H), 6.49 - 6.38 (m, 1H), 4.07 - 3.78 (m, 4H), 3.26 (s, 3H), 1.86 (d, J= 7.0 Hz, 3H).
  • Compound D20: 16 mg, ESI[M + H]+ = 361.0
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.21 (m, 5H), 6.79 (d, J = 6.2 Hz, 1H), 6.47 - 6.37 (m, 1H), 4.23 - 4.16 (m, 1.5H), 3.95 (s, 2H), 3.47 (m, 3H), 3.27 - 3.08 (m, 1.5H), 2.03 - 1.82 (m, 6H).
  • Compound D21: 22 mg, ESI[M + H]+ = 359.0
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.21 (m, 5H), 6.79 (d, J = 6.2 Hz, 1H), 6.47 - 6.37 (m, 1H), 4.07 - 3.78 (m, 6H), 2.03 - 1.82 (m, 6H).
  • Compound D22: 54 mg, ESI[M + H]+ = 379.1
  • 1H NMR (400 MHz, CDCl3) δ 7.32 - 7.21 (m, 5H), 6.75 (d, J = 6.2 Hz, 1H), 6.45 - 6.34 (m, 1H), 4.03 (s, 1.5H), 3.95 (s, 1H), 3.53 (s, 4.5H), 3.31 (s, 1H), 1.93 (d, J= 7.0 Hz, 3H), 1.01 (s, 5.5H), 0.94 (s, 3.5H).
  • Compound D23: 36 mg, ESI[M + H]+ = 377.1
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.25 (m, 5H), 6.75 (d, J = 6.2 Hz, 1H), 6.48 - 6.38 (m, 1H), 4.07 - 3.78 (m, 5H), 3.30 (s, 1H), 1.92 (d, J = 7.0 Hz, 3H), 1.03 (s, 5.5H), 0.95 (s, 3.5H).
  • Compound D24: 29 mg, ESI[M + H]+ = 351.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.21 (m, 5H), 6.79 (d, J = 6.2 Hz, 1H), 6.46 - 6.37 (m, 1H), 4.44 - 4.40 (m, 2H), 3.96 (s, 1H), 3.77 - 3.72 (m, 1.5H), 3.54 (s, 2.5H), 1.86 (d, J= 7.0 Hz, 3H), 1.45 - 1.41 (m, 3H), 1.27 - 1.24 (m, 3H).
    • 3.Preparation of Compounds D25 ~ D28
  • Figure imgb0394
  • The title compounds D25 ~ D27 were prepared according to the operation method of preparing compounds D13 ~ D15 described in Example 4, using B-7 as the raw material. Compound D25: 12 mg, ESI[M + H]+ = 293.0
  • 1H NMR (400 MHz, CDCl3) δ 7.32 - 7.19 (m, 5H), 6.61 (d, J = 6.2 Hz, 1H), 6.50-6.39 (m, 1H), 4.87 (s, 1H), 3.37 (s, 3H), 3.33 (s, 3H), 1.85 (d, J = 7.0 Hz, 3H). Compound D26: 37 mg, ESI[M + H]+ = 321.1
  • 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.20 (m, 5H), 6.75 (d, J = 6.2 Hz, 1H), 6.47-6.39 (m, 1H), 5.02 (s, 1H), 3.70 - 3. 61 (m, 4H), 1.87 (d, J= 7.0 Hz, 3H), 1.23 (t, J= 7.0 Hz, 6H).
  • Compound D27: 34 mg, ESI[M + H]+ = 353.1
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.21 (m, 5H), 6.77 (d, J = 6.2 Hz, 1H), 6.48 - 6.38 (m, 1H), 5.23 (s, 1H), 2.78 - 2.46 (m, 4H), 1.86 (d, J = 7.0 Hz, 3H), 1.25 (t, J = 7.1 Hz, 6H).
  • At room temperature, sulfur (10 g) was placed in a three-necked flask. The system was replaced with nitrogen three times, and then heated to reflux. Perfluorobut-2-yne (1.44 g, 8.9 mmol) was added slowly into the system within 5 minutes. The product was blown out from the system by nitrogen and cooled to give 28-1 (1.0 g, yield 50%).
  • 28-1 (905 mg, 4.0 mmol) and dry chlorine (284 mg, 4.0 mmol) were cooled to -190°C with liquid nitrogen, then the mixture was stirred at -70°C for about 30 hrs. The crude product was distilled under reduced pressure and cooled to give 28-2 (501 mg, yield 42%).
  • In an ice-water bath, 28-2 (297 mg, 1.0 mmol) was added slowly into B-7 (232 mg, 1.0 mmol) at 0°C. After addition, the mixture was stirred at room temperature for 1 hour. The crude product was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/5) and the fraction with Rf = 0.5 ~ 0.6 was collected to give the title compound D28 (27 mg, yield 6%). ESI[M + H]+ = 457.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.22 (m, 5H), 6.75 (d, J = 6.2 Hz, 1H), 6.47 - 6.34 (m, 1H), 5.50 (s, 1H), 1.85 (d, J = 7.0 Hz, 3H).
    • Example 7 Preparation of Compounds D29 ~ D41
  • Figure imgb0395
    Figure imgb0396
    Figure imgb0397
    • 1.Preparation of ethyl 4-nitro- 1H-pyrazole-5-carboxylate (C-1)
  • Figure imgb0398
  • At room temperature, 4-nitro-1H-pyrazole-5-carboxylic acid (50 g, 318.3 mmol) was dissolved in ethanol (300 mL). In an ice-water bath, SOCl2 (49 g, 412 mmol) was added dropwise into the mixture at 0°C. After addition, the mixture was heated to reflux for 8 hrs. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane (30 mL) and adjusted pH to 7 ~ 8 with saturated sodium bicarbonate solution. The mixture was extracted with dichloromethane (3 × 30 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound C-1 (54.8 g, yield 93%) as a white solid. ESI[M + H]+ = 186.1
    • 2. Preparation of ethyl 4-amino-1H-pyrazole-5-carboxylate (C-2)
  • Figure imgb0399
  • At room temperature, C-1 (54.8 g, 296 mmol) and 10% wet palladium carbon (5 g) were dissolved in ethanol (200 mL). The system was replaced three times with hydrogen, then the reaction mixture was allowed to react at room temperature for 18 hrs under hydrogen. The reaction was monitored by TLC until completion. The reaction mixture was filtered. The filter cake was washed with ethanol (3 × 30 mL). The filtrate was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/1), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.4 ~ 0.5 to give compound C-2 (41.1 g, yield 89%) as a grey solid. ESI[M + H]+ = 156.1
    • 3. Preparation of ethyl 4-fluoro-1H-pyrazole-5-carboxylate (C-3)
  • Figure imgb0400
  • In an ice-salt bath, C-2 (35 g, 226 mmol) was dissolved in HBF4 (40%) at -10°C, then the solution of NaNO2 (16.4 g, 238 mmol) in the water (30 mL) was added into the mixture. The mixture was allowed to react under the irradiation of a mercury lamp (302 nm) for 12 hrs. The reaction was monitored by TLC until completion, then the reaction solution was adjusted pH to 7 ~ 8 with IN NaOH solution in an ice-water bath. The mixture was extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/5), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.4 ~ 0.5 to give compound C-3 (6 g, yield 17%) as a grey solid compound.
    • 4. Preparation of ethyl (R)-4-fluoro-1-(1-phenylethyl)-1H-pyrazole-5-carboxylate (C-4)
  • Figure imgb0401
  • In an ice-water bath, (S)-1-phenylethan-1-ol (6.0 g, 49.1 mmol) was added into the mixture of C-3 (6 g, 37.9 mmol) and PPh3 (14.9 g, 56.8 mmol) in THF (50 mL) at 0°C, then the solution of DEAD (9.9 g, 56.8 mmol) in THF (15 mL) was added dropwise into the mixture at the rate of 1.5 mmol/min. After addition, the reaction mixture was warmed slowly to room temperature and stirred overnight. The reaction was monitored by TLC until completion. The reaction mixture was quenched with the saturated brine (30 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the product C-4 (5.9 g, yield 59%). ESI[M + H]+ = 263.1
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J= 4.5 Hz, 1H), 7.35 - 7.20 (m, 5H), 6.46 (q, J = 7.1 Hz, 1H), 4.53 - 4.09 (m, 2H), 1.88 (d, J = 7.1 Hz, 3H), 1.34 (t, J = 7.1 Hz, 3H).
    • 5. Preparation of (R)-4-fluoro-1-(1-phenylethyl)-1H-pyrazole-5-carboxylic acid (C-5)
  • Figure imgb0402
  • At room temperature, the solution of NaOH (3.1 g, 77.5 mmol) in water (12 mL) was added into the solution of C-4 (9.5 g, 38.9 mmol) in ethanol (12 mL), then the mixture was stirred at 60°C for 1 hour. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. Water (20 mL) was poured into the residue. The mixture was adjusted pH to 4 ~ 5 with IN HCl and extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the compound C-5 (6.7 g, yield 80%) as a white solid. ESI[M + H]+ = 217.1
  • 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J= 2.0 Hz, 1H), 7.39 - 7.16 (m, 5H), 7.00 (d, J = 2.0 Hz, 1H), 6.56 (q, J= 7.0 Hz, 1H), 1.93 (d, J= 7.1 Hz, 3H).
    • 6. Preparation of (R)-4-fluoro-N-methoxy-N-methyl-1-(1-phenylethyl)-1H-pyrazole-5-carboxamide (C-6)
  • Figure imgb0403
  • At room temperature, C-5 (2.0 g, 8.5 mmol), N, O-dimethylhydroxylamine hydrochloride (1.2 g, 12.3 mmol), DIEA (1.7 g, 13.2 mmol) and HATU (4.7 g, 12.4 mmol) were dissolved in DMF (30 mL), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was quenched with water (100 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound C-6 (1.8 g, yield 76%) as a white solid. ESI[M + H]+ = 278.1
    • 7.Preparation of (R)-1-(4-fluoro-1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-one (C-7)
  • Figure imgb0404
  • At room temperature, C-6 (1.8 g, 6.5 mmol) was dissolved in anhydrous THF (20 mL). The mixture was cooled to 0°C with an ice-water bath. Methylmagnesium bromide (13 mL, 1 mol/L in THF, 13.0 mmol) was added dropwise into the mixture at the rate of 2 mmol/min, then the mixture was reacted at room temperature for 2 hrs. The reaction was monitored by TLC until completion. The mixture was cooled to 0°C with an ice-water bath, quenched with saturated ammonium chloride solution (50 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound C-7 (1.2 g, yield 79%) as a white solid. ESI[M + H]+ = 233.1
    • 8.Preparation of (R)-2-bromo-1-(3-fluoro-1-(1-phenylethyl)-1H-pyrazol-5-yl) ethan-1-one (C-8)
  • Figure imgb0405
  • At room temperature, CuBr2 (3.8 g, 17.0 mmol) was added into the solution of C-7 (2.0 g, 8.6 mmol) in ethanol (50 mL), then the mixture was stirred at 60°C for 1 hour. The reaction was monitored by TLC until completion. The mixture was cooled to room temperature, quenched with water (50 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound C-8 (1.6 g, yield 60%) as a white solid. ESI[M + H]+ = 311.0
    • 9.Preparation of (R)-2-(ethylthio)-1 -(3 -fluoro-1 -(1 -phenylethyl)-1H-pyrazol-5-yl)ethan-1-one (C-9)
  • Figure imgb0406
  • In an ice-water bath, NaSEt (405 mg, 4.82 mmol) was added into the solution of C-8 (1.5 g, 4.82 mmol) in DMF (20 mL) at 0°C, then the mixture was reacted at room temperature for 1 hour. The reaction was monitored by TLC until completion. The mixture was quenched with ice-water (10 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with collecting the fraction with Rf = 0.4 ~ 0.6 to give the title compound C-9 (723 mg, yield 51%). ESI[M + H]+ = 293.0
    • 10.Preparation of (R)-2,2-dichloro-2-(ethylthio)-1-(3-fluoro-1-(1-phenylethyl)-1H-pyrazol-5-yl)ethan-1-one (C-10)
  • Figure imgb0407
  • In an ice-water bath, SO2Cl2 (646 mg, 4.79 mmol) was added into the solution of C-9 (700 mg, 2.39 mmol) in dichloromethane (20 mL) at 0°C, then the mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure to give the crude product C-10 (720 mg), which was used for next step directly without further purification.
    • 11. Preparation of compound D29
  • Figure imgb0408
  • At room temperature, C-7 (500 mg, 2.15 mmol) and PhI(OAc)2 (1.04 g, 3.23 mmol) were dissolved in methanol (20 mL), then the mixture was cooled to -10°C with an ice-salt bath. KOH (1.45 g, 25.84 mmol) was added in portions into the mixture within 30 mins, then the reaction mixture was reacted at -10°C for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (100 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/8) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give title compound D29 (19 mg, yield 2.7%).
    Figure imgb0409
  • At room temperature, crude compound C-10 (100 mg, 0.28 mmol) and Ag2CO3 (115 mg, 0.42 mmol) were dissolved methanol (10 mL), then the mixture was stirred at room temperature for 10 hrs. The reaction was monitored by TLC until completion. The mixture was quenched with saturated sodium bicarbonate solution (10 mL) at 0°C and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/5) and the fraction with Rf = 0.5 ~ 0.6 was collected to give the title compound D29 (47 mg, yield 52%). ESI[M + H]+ = 323.0
  • 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J= 4.5 Hz, 1H), 7.35 - 7.20 (m, 5H), 6.34 (q, J = 7.0 Hz, 1H), 3.92 (s, 3H), 3.49 (s, 6H), 1.89 (d, J= 7.1 Hz, 3H).
    • 12.Preparation of compounds D30 ~ D41
  • The title compounds D30 ~ D36 were prepared according to the operation method of preparing compounds D2 ~ D16 described in Example 2.
  • The title compounds D37 ~ D39 were prepared according to the operation method of preparing compounds D13 ~ D15 described in Example 4, using C-7 as the raw material.
  • The title compound D40 was prepared according to the operation method of preparing compound D28 described in Example 6, using C-7 as the raw material.
  • The title compound D41 was prepared according to the operation method of preparing compound D29, using ethyl 3,4-difluoro-1H-pyrazole-5-carboxylate as the raw material.
  • Compound D30: 38 mg, ESI[M + H]+ = 321.0
  • 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J= 4.5 Hz, 1H), 7.34 - 7.21 (m, 5H), 6.33 (q, J = 7.0 Hz, 1H), 4.07 - 3.78 (m, 4H), 3.26 (s, 3H), 1.86 (d, J= 7.0 Hz, 3H). Compound D31: 26 mg, ESI[M + H]+ = 361.0
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J= 4.5 Hz, 1H), 7.35 - 7.21 (m, 5H), 6.32 (q, J = 7.0 Hz, 1H), 4.22 - 4.16 (m, 1.5H), 3.94 (s, 2H), 3.47 (m, 3H), 3.28 - 3.08 (m, 1.5H), 2.02 - 1.82 (m, 6H).
  • Compound D32: 17 mg, ESI[M + H]+ = 359.0
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J= 4.5 Hz, 1H), 7.35 - 7.20 (m, 5H), 6.33 (q, J = 7.0 Hz, 1H), 4.08 - 3.78 (m, 6H), 2.02 - 1.82 (m, 6H).
  • Compound D33: 25 mg, ESI[M + H]+ = 379.1
  • 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J= 4.5 Hz, 1H), 7.37 - 7.20 (m, 5H), 6.34 (q, J = 7.0 Hz, 1H), 4.03 (s, 1.5H), 3.95 (s, 1H), 3.53 (s, 4.5H), 3.32 (s, 1H), 1.88 (d, J= 7.0 Hz, 3H), 1.04 (s, 5.5H), 0.96 (s, 3.5H).
  • Compound D34: 27 mg, ESI[M + H]+ = 377.1
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J= 4.5 Hz, 1H), 7.35 - 7.22 (m, 5H), 6.34 (q, J = 7.0 Hz, 1H), 4.05 - 3.78 (m, 5H), 3.31 (s, 1H), 1.89 (d, J = 7.0 Hz, 3H), 1.03 (s, 5.5H), 0.95 (s, 3.5H).
  • Compound D35: 31 mg, ESI[M + H]+ = 351.0
  • 1H NMR (400 MHz, CDCl3) δ 7.49 (d, J= 4.5 Hz, 1H), 7.34 - 7.20 (m, 5H), 6.32 (q, J = 7.0 Hz, 1H), 4.45 - 4.40 (m, 2H), 3.94 (s, 1H), 3.78 - 3.72 (m, 1.5H), 3.53 (s, 2.5H), 1.86 (d, J= 7.0 Hz, 3H), 1.46 - 1.41 (m, 3H), 1.28 - 1.24 (m, 3H).
  • Compound D36: 14 mg, ESI[M + H]+ = 365.1
  • 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J= 4.5 Hz, 1H), 7.36 - 7.20 (m, 5H), 6.33 (q, J = 7.0 Hz, 1H), 4.43 - 4.40 (m, 1H), 3.92 (s, 1H), 3.73 - 3.70 (m, 1.5H), 3.52 (s, 2.5H), 1.86 (d, J= 7.0 Hz, 3H), 1.45 - 1.40 (m, 4.5H), 1.28 - 1.22 (m, 4.5H).
  • Compound D37: 23 mg, ESI[M + H]+ = 293.0
  • 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J= 4.5 Hz, 1H), 7.35 - 7.20 (m, 5H), 6.34 (q, J = 7.0 Hz, 1H), 4.87 (s, 1H), 3.37 (s, 3H), 3.33 (s, 3H), 1.85 (d, J= 7.0 Hz, 3H). Compound D38: 24 mg, ESI[M + H]+ = 321.1
  • 1H NMR (400 MHz, CDCl3) δ 7.49 (d, J= 4.5 Hz, 1H), 7.36 - 7.20 (m, 5H), 6.35 (q, J = 7.0 Hz, 1H), 5.01 (s, 1H), 3.72 - 3. 61 (m, 4H), 1.87 (d, J= 7.0 Hz, 3H), 1.21 - 1.15 (m, 6H).
  • Compound D39: 26 mg, ESI[M + H]+ = 353.0
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J= 4.5 Hz, 1H), 7.35 - 7.23 (m, 5H), 6.31 (q, J = 7.0 Hz, 1H), 5.12 (s, 1H), 2.79 - 2.56 (m, 4H), 1.86 (d, J= 7.0 Hz, 3H), 1.25 - 1.14 (m, 6H).
  • Compound D40: 16 mg, ESI[M + H]+ = 457.2
  • 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J= 4.5 Hz, 1H), 7.36 - 7.20 (m, 5H), 6.32 (q, J = 7.0 Hz, 1H), 5.51 (s, 1H), 1.84 (d, J= 7.0 Hz, 3H).
  • Compound D41: 11 mg, ESI[M + H]+ = 341.0
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.20 (m, 5H), 6.24 (q, J = 7.0 Hz, 1H), 3.82 (s, 3H), 3.39 (s, 6H), 1.81 (d, J = 7.1 Hz, 3H).
    • Example 8 Preparation of Compounds D42 ~ D52
  • Preparation route of target compound D42:
    Figure imgb0410
    Figure imgb0411
    Figure imgb0412
    • 1. Preparation of (R)-(1-azidoethyl)benzene (D-1)
  • Figure imgb0413
  • In an ice-water bath, (S)-1-phenylethan-1-ol (20 g, 164 mmol) and PPh3 (85.9 g, 328 mmol) was dissolved in THF (300 mL) at 0°C, then the solution of DEAD (57.1 g, 328 mmol) in THF (50 ml) was added dropwise into the reaction mixture at the rate of 10 mmol/min, and then DPPA (54.1 g, 197 mmol) was added dropwise into the mixture at the rate of 6 mmol/min. After addition, the reaction mixture was warmed slowly to room temperature and stirred overnight. The reaction was monitored by TLC until completion. The reaction mixture was quenched with the saturated brine (150 mL) and extracted with hexane (3 × 50 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give crude product. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/100 ~ 1/50), with TLC (ethyl acetate/petroleum ether (v/v) = 1/10) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the product D-1 (20 g, yield 83%).
    • 2.Preparation of ethyl (R)-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylate (D-2)
  • Figure imgb0414
  • At room temperature, D-1 (4.8 g, 32.6 mmol) and ethyl propiolate (6.4 g, 65.2 mmol) were dissolved in toluene (100 mL), then the mixture was heated to reflux for 2 hrs. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (30 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/1), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give title compound D-2 (1.3 g, yield 16%). ESI[M + H]+ = 246.3
  • 1H NMR (400 MHz, CDCl3) δ 8.17 (s, 1H), 7.42 - 7.29 (m, 5H), 6.58 (q, J= 7.1 Hz, 1H), 4.45 - 4.26 (m, 2H), 2.08 (d, J = 7.1 Hz, 3H), 1.37 (t, J = 7.1 Hz, 3H).
    • 3.Preparation of (R)-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylic acid (D-3)
  • Figure imgb0415
  • At room temperature, LiOH.H2O (220 mg, 5.24 mmol) was added into the solution of D-2 (643 mg, 2.62 mmol) in MeOH/THF/H2O (3.5 mL, v/v/v = 1/1/1.5), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. Water (10 mL) was poured into the residue. The mixture was adjusted pH to 4 ~ 5 with IN HCl and extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the compound D-3 (545 mg, yield 96%) as a white solid. [M + H]+ = 218.2 1H NMR (400 MHz, CDCl3) δ 8.25 (s, 1H), 7.38 - 7.30 (m, 5H), 6.58 - 6.52 (m, 1H), 2.10 (d, J = 7.0 Hz, 3H).
    • 4.Preparation of (R)-N-methoxy-N-methyl-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxamide (D-4)
  • Figure imgb0416
  • At room temperature, D-3 (4.0 g, 18.4 mmol), N, O-dimethylhydroxylamine hydrochloride (2.7 g, 27.7 mmol), DIEA (3.6 g, 27.9 mmol) and HATU (10.5 g, 27.6 mmol) were dissolved in DMF (80 mL), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was quenched with water (100 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound D-4 (3.8 g, yield 79%) as a white solid. ESI[M + H]+ = 261.1
    • 5.Preparation of (R)-1-(1-(1-phenylethyl)-1H-1,2,3-triazol-5-yl)ethan-1-one (D-5)
  • Figure imgb0417
  • At room temperature, D-4 (3.7 g, 14.2 mmol) was dissolved in anhydrous THF (50 mL). The mixture was cooled to 0°C with ice-water bath. Methylmagnesium bromide (28 mL, 1 mol/L in THF, 28.0 mmol) was added dropwise into the mixture at the rate of 1.5 mmol/min, then the mixture was reacted at room temperature for 2 hrs. The reaction was monitored by TLC until completion. The mixture was cooled to 0°C with an ice-water bath, quenched with saturated ammonium chloride solution (100 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound D-5 (2.3 g, yield 75%) as a white solid. ESI[M + H]+ = 216.1
    • 6.Preparation of (R)-2-bromo-1-(1-(1-phenylethyl)-1H-1,2,3-triazol-5-yl)ethan-1-one (D-7)
  • Figure imgb0418
  • At room temperature, Br2 (2.2 g, 13.8 mmol) was added into the mixture of D-5 (2.0 g, 9.3 mmol) and hydrobromic acid solution (5 mL, 40%) in dioxane (20 mL), then the mixture was stirred at 50°C for 1 hour. The reaction was monitored by TLC until completion. The reaction mixture was cooled to room temperature, quenched with ice-water (30 mL) and saturated sodium bicarbonate solution (10 mL), extracted with ethyl acetate (3 × 10 mL). The combined organic layers washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude compound D-7, which was used for next step directly without further purification.
    • 7.Preparation of (R)-2-(ethylthio)-1 -(1 -(1 -phenylethyl)-1H-1,2,3 -triazol-5 -yl)ethan-1-one (D-8)
  • Figure imgb0419
  • In an ice-water bath, NaSEt (942 mg, 11.2 mmol) was added into the solution of the crude compound D-7 (calculated according to the theoretical amount of 9.3 mmol) in DMF (20 mL) at 0°C, then the mixture was reacted at room temperature for 1 hour. The reaction was monitored by TLC until completion. The mixture was quenched with ice-water (10 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with collecting the fraction with Rf = 0.4 ~ 0.6 to give the compound D-8 (478 mg, yield 19% for 2 steps). ESI[M + H]+ = 276.0
    • 8.Preparation of (R)-2,2-dichloro-2-(ethylthio)-1-(1-(1-phenylethyl)-1H-1,2,3-triazol-5-yl)ethan-1-one (D-9
  • Figure imgb0420
  • In an ice-water bath, SO2Cl2 (393 mg, 2.91 mmol) was added into the solution of D-8 (400 mg, 1.45 mmol) in dichloromethane (10 mL) at 0°C, then the mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure to give the crude product D-9 (439 mg), which was used for next step directly without further purification.
    • 9.Preparation of Compound D42
  • Figure imgb0421
  • At room temperature, D-5 (200 mg, 0.93 mmol) and PhI(OAc)2 (359 mg, 1.11 mmol) were dissolved in methanol (5 mL), then the mixture was cooled to -10°C with an ice-salt bath. KOH (626 mg, 11.2 mmol) was added in portions into the mixture within 5 mins, then the reaction mixture was reacted at -10°C for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (10 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/8) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give title compound D42 (7.3 mg, yield 2.6%).
    Figure imgb0422
  • At room temperature, D-9 (150 mg, 0.44 mmol) and Ag2CO3 (179 mg, 0.65 mmol) were dissolved methanol (5 mL), then the mixture was stirred at room temperature for 10 hrs. The reaction was monitored by TLC until completion. In an ice-water bath, the mixture was quenched with saturated sodium bicarbonate solution (10 mL) at 0°C and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/5) and the fraction with Rf = 0.5 ~ 0.6 was collected to give the title compound D42 (28 mg, yield 21%). ESI[M + H]+ = 306.0
  • 1H NMR (400 MHz, CDCl3) δ 8.68 (s, 0.61H), 8.51 (s, 0.39H), 7.35 - 7.28 (m, 3H), 7.26 - 7.18 (m, 2H), 6.55 - 6.46 (m, 1H), 3.95 (s, 2H), 3.49 (s, 3.5H), 3.13 (s, 3.5H), 2.13 - 2.03 (m, 3H).
    • 10.Preparation of Compounds D43 ~ D52
  • Figure imgb0423
  • The title compounds D43 ~ D49 were prepared according to the operation method of preparing compounds D2 ~ D10 described in Example 2, and the title compounds D50 ~ D52 were prepared according to the operation method of preparing compounds D14 ~ D16 described in Example 4.
  • Compound D43: 18 mg, ESI[M + H]+ = 336.0
  • 1H NMR (400 MHz, CDCl3) δ 8.69 (s, 0.61H), 8.52 (s, 0.39H), 7.34 - 7.29 (m, 3H), 7.27 - 7.18 (m, 2H), 6.55 - 6.46 (m, 1H), 3.35 (s, 3H), 3.24 (s, 3H), 2.31 - 2.17 (m, 1H), 2.14 - 2.01 (m, 4H), 0.99 (t, J = 7.5 Hz, 3H).
  • Compound D44: 32 mg, ESI[M + H]+ = 320.1
  • 1H NMR (400 MHz, CDCl3) δ 8.68 (s, 0.61H), 8.51 (s, 0.39H), 7.37 - 7.28 (m, 3H), 7.27 - 7.18 (m, 2H), 6.56 - 6.46 (m, 1H), 4.43 - 4.40 (m, 2H), 3.94 (s, 1H), 3.78 - 3.71 (m, 1.5H), 3.53 (s, 3.5H), 2.13 - 2.03 (m, 3H), 1.44 (t, J = 7.1 Hz, 1.5H), 1.27 (t, J = 7.0 Hz, 1.5H).
  • Compound D45: 22 mg, ESI[M + H]+ = 334.1
  • 1H NMR (400 MHz, CDCl3) δ 8.66 (s, 0.61H), 8.50 (s, 0.39H), 7.35 - 7.28 (m, 3H), 7.26 - 7.18 (m, 2H), 6.55 - 6.46 (m, 1H), 5.35 - 5.30 (m, 1H), 3.95 (s, 1H), 3.52 (s, 5H), 2.13 - 2.03 (m, 3H), 1.55 (d, J = 6.5 Hz, 1H), 1.46 - 1.40 (m, 3H), 1.25 (t, J = 10.2 Hz, 2H).
  • Compound D46: 16 mg, ESI[M + H]+ = 362.1
  • 1H NMR (400 MHz, CDCl3) δ 8.67 (s, 0.61H), 8.51 (s, 0.39H), 7.36 - 7.26 (m, 3H), 7.25 - 7.18 (m, 2H), 6.55 - 6.45 (m, 1H), 4.05 (s, 1.5H), 3.95 (s, 1H), 3.52 (s, 4.5H), 3.32 (s, 1H), 2.13 - 2.03 (m, 3H), 1.02 (s, 5.5H), 0.94 (s, 3.5H).
  • Compound D47: 19 mg, ESI[M + H]+ = 332.1
  • 1H NMR (400 MHz, CDCl3) δ 8.65 (s, 0.61H), 8.49 (s, 0.39H), 7.35 - 7.28 (m, 3H), 7.26 - 7.18 (m, 2H), 6.56 - 6.46 (m, 1H), 6.17 - 5.89 (m, 1H), 5.53 - 4.83 (m, 2H), 4.23 - 4.18 (m, 1.5H), 3.94 (s, 1.5H), 3.44 (m, 3H), 3.24 - 3.09 (m, 2H), 2.13 - 2.03 (m, 3H).
  • Compound D48: 35 mg, ESI[M + H]+ = 344.1
  • 1H NMR (400 MHz, CDCl3) δ 8.67 (s, 0.61H), 8.51 (s, 0.39H), 7.38 - 7.29 (m, 3H), 7.26 - 7.19 (m, 2H), 6.55 - 6.46 (m, 1H), 4.24 - 4.18 (m, 1.5H), 3.95 (s, 2H), 3.49 (s, 3H), 3.28 - 3.08 (m, 1.5H), 2.05 - 1.82 (m, 6H).
  • Compound D49: 33 mg, ESI[M + H]+ = 348.1
  • 1H NMR (400 MHz, CDCl3) δ 8.63 (s, 0.61H), 8.50 (s, 0.39H), 7.35 - 7.28 (m, 3H), 7.24 - 7.18 (m, 2H), 6.55 - 6.46 (m, 1H), 4.44 - 4.40 (m, 1H), 3.95 (s, 1H), 3.75 - 3.70 (m, 1.5H), 3.54 (s, 2.5H), 2.15 - 2.05 (m, 3H), 1.43 - 1.41 (m, 4.5H), 1.27 - 1.22 (m, 4.5H).
  • Compound D50: 24 mg, ESI[M + H]+ = 304.1
  • 1H NMR (400 MHz, CDCl3) δ 8.64 (s, 0.61H), 8.52 (s, 0.39H), 7.37 - 7.28 (m, 3H), 7.24 - 7.18 (m, 2H), 6.57 - 6.46 (m, 1H), 5.12 (s, 1H), 3.74 - 3.46 (m, 4H), 2.13 - 2.03 (m, 3H), 1.23 (t, J = 6.9 Hz, 6H).
  • Compound D51: 17 mg, ESI[M + H]+ = 336.0
  • 1H NMR (400 MHz, CDCl3) δ 8.68 (s, 0.61H), 8.52 (s, 0.39H), 7.35 - 7.27 (m, 3H), 7.24 - 7.18 (m, 2H), 6.55 - 6.47 (m, 1H), 5.23 (s, 1H), 2.78 - 2.39 (m, 4H), 2.14 - 2.03 (m, 3H), 1.27 (t, J = 7.0 Hz, 6H).
  • Compound D52: 20 mg, ESI[M + H]+ = 328.2
  • 1H NMR (400 MHz, CDCl3) δ 8.66 (s, 0.61H), 8.50 (s, 0.39H), 7.35 - 7.28 (m, 3H), 7.26 - 7.18 (m, 2H), 6.70 (s, 1H), 6.57 - 6.49 (m, 1H), 2.25 (s, 6H), 2.13 - 2.03 (m, 3H).
    • Example 9 Preparation of Compounds D53 ~ D62
  • Preparation route of target compound D53:
    Figure imgb0424
    Figure imgb0425
    Figure imgb0426
    • 1. Preparation of ethyl (R)-4-fluoro-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylate (E-1)
  • Figure imgb0427
  • At room temperature, (R)-(1-azidoethyl) benzene (5.1 g, 34.7 mmol) and ethyl 3-fluoropropiolate (8.1 g, 69.8 mmol) were dissolved in toluene (50 mL), and then the mixture was heated to reflux for 12 hrs. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/1), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound E-1 (890 mg, yield 10%). ESI[M + H]+ = 264.2
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.21 (m, 5H), 6.57 - 6.53 (m, 1H), 4.45 - 4.26 (m, 2H), 2.02 (d, J = 7.1 Hz, 3H), 1.37 (t, J = 7.1 Hz, 3H).
    • 2. Preparation of (R)-4-fluoro-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylic acid (E-2)
  • Figure imgb0428
  • At room temperature, LiOH.H2O (223 mg, 5.32 mmol) was added into the solution of E-1 (700 mg, 2.66 mmol) in MeOH/THF/H2O (3 mL, v/v/v = 1/1/1), then the mixture was stirred at room temperature for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. Water (10 mL) was poured into the residue. The mixture was adjusted pH to 4 ~ 5 with IN HCl and extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give compound E-2 (586 mg, yield 94%) as a white solid. ESI[M + H]+ = 236.0
  • 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.14 (m, 5H), 6.55 - 6.49 (m, 1H), 2.03 (d, J = 7.1 Hz, 3H).
    • 3. Preparation of (R)-4-fluoro-N-methoxy-N-methyl-1-(1-phenylethyl)-1H-1,2,3 -triazole-5-carboxamide (E-3)
  • Figure imgb0429
  • At room temperature, E-2 (4.0 g, 17.01 mmol), N, O-dimethylhydroxylamine hydrochloride (2.5 g, 25.63 mmol), DIEA (3.3 g, 25.51 mmol) and HATU (9.7 g, 27.6 mmol) were dissolved in DMF (80 mL), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was quenched with water (100 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound E-3 (3.1 g, yield 65%) as a white solid. ESI[M + H]+ = 279.0
    • 4. Preparation of (R)-1-(4-fluoro-1-(1-phenylethyl)-1H-1,2,3-triazol-5-yl)ethan-1-one (E-4)
  • Figure imgb0430
  • At room temperature, E-3 (2.6 g, 9.34 mmol) was dissolved in anhydrous THF (50 mL). The mixture was cooled to 0°C with an ice-water bath. Methylmagnesium bromide (18.7 mL, 1 mol/L in THF, 18.7 mmol) was added dropwise into the mixture at the rate of 1.5 mmol/min, and then the mixture was reacted at room temperature for 2 hrs. The reaction was monitored by TLC until completion. The mixture was cooled to 0°C, quenched with saturated ammonium chloride solution (100 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound E-4 (1.4 g, yield 64%) as a white solid. ESI[M + H]+ = 234.0
    • 5. Preparation of (R)-2-bromo-1-(4-fluoro-1-(1-phenylethyl)-1H-1,2,3-triazol-5-yl)ethan-1-one (E-6)
  • Figure imgb0431
  • At room temperature, Br2 (1.4 g, 8.76 mmol) was added into the mixture of E-4 (1.0 g, 4.29 mmol) and hydrobromic acid solution (5 mL, 40%) in dioxane (20 mL), then the mixture was stirred at 50°C for 1 hour. The reaction was monitored by TLC until completion. The reaction mixture was cooled to room temperature, quenched with ice-water (30 mL) and saturated sodium bicarbonate solution (10 mL), and extracted with ethyl acetate (3 × 10 mL). The combined organic layers washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude compound E-6, which was used for next step directly without further purification.
    • 6. Preparation of (R)-2-(ethylthio)-1-(4-fluoro-1-(1-phenylethyl)-1H-1,2,3-triazol-5-yl)ethan-1-one (E-7)
  • Figure imgb0432
  • In an ice-water bath, NaSEt (433 mg, 5.15 mmol) was added into the solution of the crude compound E-6 (calculated according to the theoretical amount of 4.29 mmol) in DMF (10 mL) at 0°C, and then the mixture was reacted at room temperature for 1 hour. The reaction was monitored by TLC until completion. The mixture was quenched with ice-water (10 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with collecting the fraction with Rf = 0.4 ~ 0.6 to give the compound E-7 (286 mg, yield 23% for 2 steps). ESI[M + H]+ = 294.0
    • 7. Preparation of (R)-2,2-dichloro-2-(ethylthio)-1-(4-fluoro-1-(1-phenylethyl)-1H-1,2,3-triazol-5-yl)ethan-1-one (E-8)
  • Figure imgb0433
  • In an ice-water bath, SO2Cl2 (184 mg, 1.36 mmol) was added into the solution of E-7 (200 mg, 0.68 mmol) in dichloromethane (5 mL) at 0°C, then the mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure to give the crude product E-8 (205 mg), which was used for next step directly without further purification.
    • 8. Preparation of compound D53
  • Figure imgb0434
  • At room temperature, E-4 (300 mg, 1.29 mmol) and PhI(OAc)2 (621 mg, 1.93 mmol) were dissolved in methanol (10 mL), then the mixture was cooled to -10°C with an ice-salt bath. KOH (869 mg, 15.49 mmol) was added in portions into the mixture within 5 mins, then the reaction mixture was reacted at -10°C for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (10 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/5) and the fraction with Rf = 0.5 ~ 0.6 was collected to give the title compound D53 (17 mg, yield 4%).
    Figure imgb0435
  • At room temperature, E-7 (150 mg, 0.41 mmol) and Ag2CO3 (171 mg, 0.62 mmol) were dissolved methanol (5 mL), then the mixture was stirred at room temperature for 10 hrs. The reaction was monitored by TLC until completion. The mixture was quenched with saturated sodium bicarbonate solution (10 mL) at 0°C and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/5) and the fraction with Rf = 0.5 ~ 0.6 was collected to give the title compound D53 (31 mg, yield 23%). ESI[M + H]+ = 324.0
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 3.92 (s, 0.7H), 3.49 (s, 1.3H), 3.13 (s, 7H), 2.07 (d, J= 7.1 Hz, 3H).
    • 9.Preparation of compounds D54 ~ D62
  • The title compounds D54 ~ D59 were prepared according to the operation method of preparing compounds D2 ~ D10 described in Example 2.
  • The title compounds D60 ~ D62 were prepared according to the operation method of preparing compounds D14 ~ D16 described in Example 4.
  • Compound D54: 42 mg, ESI[M + H]+ = 354.0
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.28 (m, 5H), 6.51 (q, J= 7.1 Hz, 1H), 3.35 (s, 3H), 3.24 (s, 3H), 2.33 - 2.17 (m, 1H), 2.15 - 2.01 (m, 4H), 0.99 (t, J = 7.5 Hz, 3H). Compound D55: 31 mg, ESI[M + H]+ = 338.0
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 4.43 - 4.40 (m, 2H), 3.95 (s, 1H), 3.78 - 3.71 (m, 1.5H), 3.52 (s, 3.5H), 2.07 (d, J = 7.1 Hz, 3H), 1.42 (t, J = 7.1 Hz, 1.5H), 1.27 (t, J = 7.0 Hz, 1.5H).
  • Compound D56: 12 mg, ESI[M + H]+ = 352.1
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.28 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H), 5.35 - 5.30 (m, 1H), 3.92 (s, 1H), 3.51 (s, 5H), 2.06 (d, J= 7.1 Hz, 3H), 1.56 (d, J= 6.5 Hz, 1H), 1.47 - 1.40 (m, 3H), 1.24 (t, J = 10.2 Hz, 2H).
  • Compound D57: 21 mg, ESI[M + H]+ = 366.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.27 (m, 5H), 6.50 (q, J = 7.1 Hz, 1H), 4.43-4.40 (m, 1H), 3.94 (s, 1H), 3.74 - 3.70 (m, 1.5H), 3.50 (s, 2.5H), 2.07 (d, J = 7.1 Hz, 3H), 1.42 - 1.40 (m, 4.5H), 1.25 - 1.21 (m, 4.5H).
  • Compound D58: 12 mg, ESI[M + H]+ = 350.0
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 6.17 - 5.89 (m, 1H), 5.51 - 4.83 (m, 2H), 4.21 - 4.18 (m, 1.5H), 3.94 (s, 1.5H), 3.46 (m, 3H), 3.26 - 3.09 (m, 2H), 2.08 (d, J = 7.1 Hz, 3H).
  • Compound D59: 35 mg, ESI[M + H]+ = 362.0
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.29 (m, 5H), 6.50 (q, J = 7.1 Hz, 1H), 4.22 - 4.18 (m, 1.5H), 3.96 (s, 2H), 3.49 (s, 3H), 3.28 - 3.08 (m, 1.5H), 2.07 (d, J= 7.1 Hz, 3H), 2.05 - 1.82 (m, 3H).
  • Compound D60: 24 mg, ESI[M + H]+ = 322.0
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.28 (m, 5H), 6.52 (q, J= 7.1 Hz, 1H), 5.17 (s, 1H), 3.80 - 3.55 (m, 4H), 2.05 (d, J= 7.1 Hz, 3H), 1.28 - 1.15 (m, 6H).
  • Compound D61: 34 mg, ESI[M + H]+ = 354.0
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.30 (m, 5H), 6.53 (q, J= 7.1 Hz, 1H), 5.35 (s, 1H), 2.79 - 2.47 (m, 4H), 2.07 (d, J= 7.1 Hz, 3H), 1.27 - 1.13 (m, 6H).
  • Compound D62: 21 mg, ESI[M + H]+ = 346.2
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.68 (s, 1H), 6.52 (q, J = 7.1 Hz, 1H), 2.27 (s, 6H), 2.07 (d, J = 7.1 Hz, 3H).
    • Example 10 Preparation of Compounds D63 ~ D72
  • Preparation route of target compound D63
    Figure imgb0436
    Figure imgb0437
  • Preparation route of compounds D64 ~ 67:
    Figure imgb0438
  • Preparation route of compound D68:
    Figure imgb0439
    Figure imgb0440
    Figure imgb0441
  • Preparation route of compounds D69 ~ 72:
    Figure imgb0442
    • 1. Preparation of ethyl 3-chloropropiolate (F-1)
  • Figure imgb0443
  • At room temperature, ethyl propiolate (9.0 g, 91.7 mmol) and tert-butyl hypochlorite (10 g, 92.1 mmol) were dissolved in t-BuOH (100 mL), then t-BuOK (2.0 g, 17.8 mmol) was added in two portions into the mixture within 5 mins. After addition, the reaction mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give the crude product F-1, which was used for next step directly without further purification.
    • 2. Preparation of ethyl (R)-4-chloro-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylate (F-2)
  • Figure imgb0444
  • At room temperature, the crude product F-1 from the previous step and D-1 (3.2 g, 21.7 mmol) were dissolved in toluene (100 mL), and then the mixture was heated to reflux for 14 hrs. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (30 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/1), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound F-2 (620 mg, yield 10%). ESI[M + H]+ = 280.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 4.43-4.33 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H), 1.38 (t, J = 7.1 Hz, 3H).
    • 3. Preparation of (R)-4-chloro-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylic acid
  • Figure imgb0445
  • At room temperature, LiOH.H2O (156 mg, 3.72 mmol) was added into the solution of F-2 (520 mg, 1.86 mmol) in MeOH/THF/H2O (3 mL, v/v/v = 1/1/1), then the mixture was stirred at room temperature for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. Water (10 mL) was poured into the residue. The mixture was adjusted pH to 4 ~ 5 with IN HCl and extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the compound F-3 (445 mg, yield 95%) as a white solid. ESI[M + Na]+ = 274.1, [M + H - 105]+ = 148.1
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 2.08 (d, J = 7.0 Hz, 3H).
    • 4. Preparation of Compounds D63 ~ D67
  • The intermediate compounds F-4 ~ F-9 were prepared according to the operation method of preparing intermediate compounds D-4 ~ D-9 described in Example 8. The title compounds D63 ~ D67 were prepared according to the operation method of preparing compounds D42 ~ D48 described in Example 8.
  • Compound D63: 30 mg, ESI[M + H]+ = 340.0
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.29 (m, 5H), 6.51 (q, J = 7.1 Hz, 1H), 3.91 (s, 0.7H), 3.48 (s, 1.3H), 3.12 (s, 7H), 2.07 (d, J = 7.1 Hz, 3H).
  • Compound D64: 18 mg, ESI[M + H]+ = 354.0
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.28 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 4.42 - 4.40 (m, 2H), 3.94 (s, 1H), 3.77 - 3.71 (m, 1.5H), 3.51 (s, 3.5H), 2.07 (d, J = 7.1 Hz, 3H), 1.42 (t, J = 7.1 Hz, 1.5H), 1.28 (t, J = 7.0 Hz, 1.5H).
  • Compound D65: 12 mg, ESI[M + H]+ = 368.0
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.29 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H), 5.36 - 5.30 (m, 1H), 3.91 (s, 1H), 3.53 (s, 5H), 2.07 (d, J = 7.1 Hz, 3H), 1.54 (d, J = 6.5 Hz, 1H), 1.45 - 1.40 (m, 3H), 1.24 (t, J = 10.2 Hz, 2H).
  • Compound D66: 10 mg, ESI[M + H]+ = 380.0
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 5.24 - 5.14 (m, 1H), 3.94 (s, 1H), 3.77 - 3.71 (m, 1.5H), 3.51 (s, 3.5H), 2.54 - 2.37 (m, 2H), 2.27 - 2.14 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H), 1.96 - 1.85 (m, 1H), 1.78 - 1.66 (m, 1H). Compound D67: 24 mg, ESI[M + H]+ = 366.0
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.29 (m, 5H), 6.52 (q, J = 7.1 Hz, 1H), 6.17 - 5.89 (m, 1H), 5.52 - 4.82 (m, 2H), 4.22 - 4.18 (m, 1.5H), 3.92 (s, 1.5H), 3.45 (m, 3H), 3.27 - 3.09 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H).
    • 5. Preparation of ethyl 3-bromopropiolate (G-1)
  • Figure imgb0446
  • At room temperature, ethyl propiolate (12.0 g, 122 mmol), NBS (26.2 g, 147 mmol) and AgNO3 (10.4 g, 61 mmol) were dissolved in acetone (400 mL), then the reaction mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give the crude product G-1, which was used for next step directly without further purification.
    • 6. Preparation of ethyl (R)-4-bromo-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylate
  • Figure imgb0447
  • At room temperature, the crude product G-1 from the previous step and D-1 (7.1 g, 48.2 mmol) were dissolved in toluene (100 mL), then the mixture was heated to reflux for 14 hrs. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (30 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/1), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give title compound G-2 (2.3 g, yield 15%). ESI[M + H]+ = 324.1
  • 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.29 (m, 5H), 6.53 (q, J = 7.1 Hz, 1H), 4.45 - 4.31 (m, 2H), 2.07 (d, J= 7.1 Hz, 3H), 1.39 (t, J= 7.1 Hz, 3H).
    • 7. Preparation of (R)-4-bromo-1-(1-phenylethyl)-1H-1,2,3-triazole-5-carboxylic acid
  • Figure imgb0448
  • At room temperature, LiOH.H2O (337 mg, 8.0 mmol) was added into the solution of G-2 (1.3 g, 4.0 mmol) in MeOH/THF/H2O (15 mL, v/v/v = 1/1/1), then the mixture was stirred at room temperature for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. Water (10 mL) was poured into the residue. The mixture was adjusted pH to 4 ~ 5 with IN HCl and extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the compound G-3 (445 mg, yield 95%) as a white solid. ESI[M + H - 105]+ = 191.0
  • 1H NMR (400 MHz, CD3OD) δ 7.48 - 7.13 (m, 5H), 6.76 - 6.65 (m, 1H), 2.00 (d, J = 5.5 Hz, 3H).
    • 8. Preparation of compounds D68 ~ D72
  • The intermediate compounds G-4 ~ G-9 were prepared according to the operation method of preparing intermediate compounds D-4 ~ D-9 described in Example 8. The title compounds D68 ~ D72 were prepared according to the operation method of preparing compounds D42 ~ D48 described in Example 8.
  • Compound D68: 22 mg, ESI[M + H]+ = 384.0
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.29 (m, 5H), 6.51 (q, J = 7.1 Hz, 1H), 3.92 (s, 0.7H), 3.49 (s, 1.3H), 3.13 (s, 7H), 2.06 (d, J = 7.1 Hz, 3H).
  • Compound D69: 54 mg, ESI[M + H]+ = 398.0
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.27 (m, 5H), 6.51 (q, J = 7.1 Hz, 1H), 4.41-4.38 (m, 2H), 3.92 (s, 1H), 3.76 - 3.71 (m, 1.5H), 3.52 (s, 3.5H), 2.06 (d, J = 7.1 Hz, 3H), 1.42 (t, J= 7.1 Hz, 1.5H), 1.25 (t, J = 7.0 Hz, 1.5H).
  • Compound D70: 16 mg, ESI[M + H]+ = 412.0
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.51 (q, J = 7.1 Hz, 1H), 5.35 - 5.30 (m, 1H), 3.95 (s, 1H), 3.52 (s, 5H), 2.06 (d, J = 7.1 Hz, 3H), 1.55 (d, J = 6.5 Hz, 1H), 1.46 - 1.40 (m, 3H), 1.25 (t, J = 10.2 Hz, 2H).
  • Compound D71: 18 mg, ESI[M + H]+ = 424.0
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.29 (m, 5H), 6.50 (q, J = 7.1 Hz, 1H), 5.25 - 5.14 (m, 1H), 3.94 (s, 1H), 3.78 - 3.71 (m, 1.5H), 3.51 (s, 3.5H), 2.52 - 2.37 (m, 2H), 2.28 - 2.12 (m, 2H), 2.07 (d, J = 7.1 Hz, 3H), 1.97 - 1.86 (m, 1H), 1.78 - 1.64 (m,1H). Compound D72: 22 mg, ESI[M + H]+ = 410.0
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.29 (m, 5H), 6.51 (q, J = 7.1 Hz, 1H), 6.17-5.89 (m, 1H), 5.51 - 4.83 (m, 2H), 4.24 - 4.18 (m, 1.5H), 3.94 (s, 1.5H), 3.45 (m, 3H), 3.28 - 3.09 (m, 2H), 2.06 (d, J = 7.1 Hz, 3H).
    • Example 11 Preparation of Compounds D73 ~ D92
  • Figure imgb0449
    Figure imgb0450
    • 1. Preparation of compound D77
  • Figure imgb0451
  • At room temperature, LiOH.H2O (6.9 g, 164.4 mmol) was added into the solution of ethyl (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylate (20.0 g, 81.9 mmol) in THF/MeOH/H2O (80 mL, v/v/v = 1/1/1.5), then the mixture was stirred at room temperature for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. Water (50 mL) was poured into the residue. The mixture was adjusted pH to 4 ~ 5 with IN HCl at 0°C and filtered. The filter cake was washed with water and methyl tert-butyl ether, transferred to a single mouth bottle and vacuum dried to give pure product H-1. The filtrate was extracted with dichloromethane (5 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was washed with methyl tert-butyl ether to give pure product H-1. A total of two batches gave white solid compound H-1 (15 g, yield 85%). ESI[M + H]+ = 217.3
  • 1H NMR (400 MHz, CDCl3) δ 9.73 (brs, 1H), 7.89 (s, 1H), 7.87 (s, 1H), 7.39 - 7.27 (m, 3H), 7.26 - 7.18 (m, 2H), 6.55 (q, J = 7.1 Hz, 1H), 1.87 (d, J = 7.1 Hz, 3H).
  • At room temperature, H-1 (13 g, 60 mmol), N, O-dimethylhydroxylamine hydrochloride (11.7 g, 120 mmol), DIEA (15.5 g, 120 mmol) and HATU (45.6 g, 120 mmol) were dissolved in DMF (200 mL), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was quenched with water (100 mL) and extracted with ethyl acetate (4 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound H-2 (13 g, yield 84%) as a white solid. ESI[M + H]+ = 260.1
  • At room temperature, H-2 (13 g, 50.1 mmol) was dissolved in anhydrous THF (100 mL). The mixture was cooled to 0°C with an ice-water bath. Methylmagnesium bromide (100.2 mL, 1 mol/L in THF, 100.2 mmol) was added dropwise into the mixture at the rate of 5 mmol/min, then the mixture was reacted at room temperature for 2 hrs. The reaction was monitored by TLC until completion. The mixture was cooled to 0°C, quenched with saturated ammonium chloride solution (100 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound H-3 (9.1 g, yield 85%) as a white solid. ESI[M + H]+ = 215.1
  • At room temperature, H-3 (22 g, 0.10 mol) and PhI(OAc)2 (49.6 g, 0.15 mol) were dissolved in methanol (300 mL), then the mixture was cooled to -10°C with an ice-salt bath. KOH (67.3 g, 1.2 mol) was added in portions into the mixture within 60 mins, then the reaction mixture was reacted at -10°C for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (500 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/5), with TLC (ethyl acetate/petroleum ether (v/v) = 1/3) monitoring, and collecting the fraction with Rf = 0.4 ~ 0.6 to give title compound D77 (5.1 g, yield 17%). ESI[M + H]+ = 305.0
  • 1H NMR (400 MHz, CDCl3) δ 8.28 (s, 1H), 7.99 (s, 1H), 7.34 - 7.27 (m, 2H), 7.26 - 7.21 (m, 1H), 7.16 - 7.09 (m, 2H), 6.40 (q, J= 6.9 Hz, 1H), 3.15 (s, 9H), 1.88 (d, J= 7.1 Hz, 3H).
    • 2. Preparation of compounds D73, D74 and D75
  • Figure imgb0452
  • In an ice-water bath, NaH (18 mg, 60% in mineral oil, 0.45 mmol) was added in portions into the mixture of H-4 (100 mg, 0.36 mmol) in DMF (5 mL) at 0°C, then the mixture was stirred at 0°C for 30 min. 1-bromobut-2-yne (72 mg, 0.54 mmol) was added slowly into the mixture with a syringe. The mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated ammonium chloride solution (10 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/5) and the fraction with Rf = 0.5 ~ 0.6 was collected to give the title compound D73 (65 mg, yield 51%). ESI[M + H - 28]+ = 357.3
  • 1H NMR (400 MHz, CDCl3) δ 7.74 (s, 1H), 7.40 - 7.28 (m, 3H), 7.22 - 7.11 (m, 3H), 6.04 (q, J = 7.0 Hz, 1H), 4.03 - 3.81 (m, 2H), 3.80 - 3.52 (m, 2H), 3.27 (s, 3H), 3.23 (s, 3H), 1.84 (d, J = 7.1 Hz, 3H), 1.80 (t, J = 2.3 Hz, 3H).
  • The title compounds D74 and D75 were prepared according to the operation method of preparing compound D73, using H-4 to react with compounds 3-bromoprop-1-yne and 3-bromoprop-1-ene respectively.
  • Compound D74: 85 mg, ESI[M + H]+ = 343.3
  • 1H NMR (400 MHz, CDCl3) δ 7.76 (s, 1H), 7.41 - 7.11 (m, 6H), 6.40 (q, J = 7.1 Hz, 1H), 4.00 - 3.50 (m, 4H), 3.28 (s, 3H), 3.21 (s, 3H), 2.45 (t, J = 2.4 Hz, 1H), 1.85 (d, J = 7.1 Hz, 3H).
  • Compound D75: 51 mg, ESI[M + H]+ = 345.3
  • 1H NMR (400 MHz, CDCl3) δ 7.74 (s, 1H), 7.45 - 7.11 (m, 6H), 6.41 (q, J = 7.0 Hz, 1H), 6.15 - 5.91 (m, 1H), 5.50 - 4.81 (m, 2H), 4.00 - 3.50 (m, 4H), 3.25 (s, 3H), 3.20 (s, 3H), 1.85 (d, J = 7.1 Hz, 3H).
    • 3. Preparation of Compounds D76, D78 and D79
  • Figure imgb0453
  • At room temperature, H-3 (1.0 g, 4.67 mmol) and PhI(OAc)2 (2.3 g, 7.14 mmol) were dissolved in methanol (20 mL), then the mixture was cooled to -10°C with an ice-salt bath. KOH (3.1 g, 55.25 mmol) was added in portions into the mixture within 20 mins, then the reaction mixture was reacted at -10°C for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (50 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/5) and the fraction with Rf = 0.5 ~ 0.6 was collected to give the title compound D76 (64 mg, yield 4%). ESI[M + H]+ = 347.0
  • 1H NMR (400 MHz, CDCl3) δ 8.34 (s, 1H), 7.91 (s, 1H), 7.32 - 7.27 (m, 2H), 7.26 - 7.22 (m, 1H), 7.13 - 7.06 (m, 2H), 6.41 (q, J = 7.1 Hz, 1H), 3.49 - 3.20 (m, 6H), 1.87 (d, J = 7.1 Hz, 3H), 1.14 (t, J = 7.1 Hz, 9H).
  • Replacing the above solvent with MeOH/EtOH (20 mL, v/v = 1/1) can separate the target compounds D78 and D79 at the same time.
  • Compound D78: 57 mg, yield 3.8%, ESI[M + H]+ = 319.0
  • 1H NMR (400 MHz, CDCl3) δ 8.31 (s, 1H), 8.03 (s, 1H), 7.41 - 7.19 (m, 3H), 7.17 - 7.07 (m, 2H), 6.41 (q, J = 6.9 Hz, 1H), 3.44 - 3.32 (m, 1H), 3.30 - 3.23 (m, 1H), 3.21 (s, 3H), 3.13 (s, 3H), 1.88 (d, J = 7.1 Hz, 3H), 1.12 (t, J = 7.1 Hz, 3H).
  • Compound D79: 18 mg, yield 1.2%, ESI[M + H]+ = 333.1
  • 1H NMR (400 MHz, CDCl3) δ 8.34 (s, 1H), 8.12 (s, 1H), 7.42 - 7.27 (m, 3H), 7.17 - 7.08 (m, 2H), 6.43 (q, J = 7.1 Hz, 1H), 3.46 - 3.32 (m, 3H), 3.22 (s, 3H), 3.20 - 3.09 (m, 1H), 1.89 (d, J = 7.1 Hz, 3H), 1.17 (t, J = 7.1 Hz, 3H), 1.10 (t, J = 7.1 Hz, 3H).
    • 4. Preparation of Compound D80
  • Figure imgb0454
  • At room temperature, PTSA.H2O (9.4 g, 49.4 mmol) was added into the solution of D79 (5.0 g, 16.4 mmol) in acetone (50 mL), then the mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC until completion. The mixture was quenched with ice-water (50 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/5), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give title compound D80 (2.5 g, yield 59%). ESI[M + H]+ = 259.1
  • 1H NMR (400 MHz, CDCl3) δ 8.42 (s, 1H), 8.10 (s, 1H), 7.42 - 7.30 (m, 3H), 7.25 - 7.20 (m, 2H), 6.39 (q, J = 6.8 Hz, 1H), 3.95 (s, 3H), 1.90 (d, J = 7.0 Hz, 3H).
    • 5. Preparation of Compounds D81 ~ D86
  • Figure imgb0455
  • At room temperature, LiOH.H2O (488 mg, 11.6 mmol) was added into the solution of D80 (1.5 g, 5.8 mmol) in THF/MeOH/H2O (14 mL, v/v/v = 1/1/1.5), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. Water (10 mL) was poured into the residue. The mixture was adjusted pH to 4 ~ 5 with IN HCl and extracted with dichloromethane (8 × 15 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to give the compound H-6 (1.1 g, yield 78%) as a grey solid. ESI[M + H]+ = 245.0
  • Compound H-6 (244 mg, 1 mmol) and EtOH were condensed under the condition of DCC and DMAP to give target compound D81 (86 mg, yield 32%). ESI[M + H]+ = 273.1
  • 1H NMR (400 MHz, CDCl3) δ 8.29 (s, 1H), 7.87 (s, 1H), 7.40 - 7.28 (m, 3H), 7.25 - 7.15 (m, 2H), 6.36 (q, J = 7.0 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 1.87 (d, J = 7.1 Hz, 3H), 1.40 (t, J = 7.1 Hz, 3H).
  • Compound H-6 (244 mg, 1 mmol) reacted with the corresponding alcohol under catalytic amount of concentrated hydrochloric acid to give target compounds D82, D83 and D86.
  • Compound D82: 84 mg, yield 27%, ESI[M + H]+ = 315.1
  • 1H NMR (400 MHz, CDCl3) δ 8.27 (d, J = 6.7 Hz, 1H), 7.89 (s, 1H), 7.42 - 7.28 (m, 3H), 7.25 - 7.16 (m, 2H), 6.37 (q, J = 7.0 Hz, 1H), 4.38 - 4.12 (m, 2H), 1.87 (d, J = 7.1 Hz, 3H), 1.80 - 1.69 (m, 1H), 1.69 - 1.39 (m, 2H), 1.01 - 0.90 (m, 6H).
  • Compound D83: 73 mg, yield 23%, ESI[M + H]+ = 315.0
  • 1H NMR (400 MHz, CDCl3) δ 8.25 (s, 1H), 7.90 (s, 1H), 7.42 - 7.28 (m, 3H), 7.26 - 7.21 (m, 2H), 6.38 (q, J = 7.0 Hz, 1H), 5.00 (p, J = 6.3 Hz, 1H), 1.88 (d, J = 7.1 Hz, 3H), 1.78 - 1.60 (m, 4H), 1.01 - 0.89 (m, 6H).
  • Compound D86: 133 mg, yield 42%, ESI[M + H]+ = 315.1
  • 1H NMR (400 MHz, CDCl3) δ 8.25 (s, 1H), 7.89 (s, 1H), 7.44 - 7.29 (m, 3H), 7.26 - 7.20 (m, 2H), 6.39 (q, J = 7.1 Hz, 1H), 4.11 - 3.98 (m, 2H), 1.88 (d, J = 7.1 Hz, 3H), 1.01 (s, 9H).
  • Compound H-6 (100 mg, 0.41 mmol) reacted with oxalyl chloride under catalytic amount DMF to give the corresponding acyl chloride, which was concentrated under reduced pressure to give the crude product. The crude product reacted with the corresponding alcohol using CH2Cl2 as solvent to give target compounds D84 and D85. Compound D84: 11 mg, yield 9%, ESI[M + H]+ = 297.1
  • 1H NMR (400 MHz, CDCl3) δ 7.94 (s, 1H), 7.92 (s, 1H), 7.42 - 7.28 (m, 3H), 7.24 - 7.12 (m, 2H), 6.42 (q, J = 6.9 Hz, 1H), 4.65 (q, J = 17.7 Hz, 2H), 2.01 - 1.84 (m, 6H). Compound D85: 16 mg, yield 12%, ESI[M + H]+ = 339.1
  • 1H NMR (400 MHz, CDCl3) δ 8.22 (s, 1H), 7.94 (s, 1H), 7.34 - 7.27 (m, 2H), 7.25 - 7.21 (m, 1H), 7.16 - 7.09 (m, 2H), 6.40 (q, J = 6.9 Hz, 1H), 5.64 (t, J = 6.6 Hz, 1H), 5.05 - 4.86 (m, 3H), 4.86 - 4.69 (m, 3H), 1.87 (d, J = 7.1 Hz, 3H).
    • 6. Preparation of compounds D87, D88 and D90
  • Figure imgb0456
  • The compounds D87, D88 and D90 were prepared according to the operation method of preparing compounds D13, D14 and D15. The target compounds D87 and D88 were prepared by the reaction of H-3 with MeOH or EtOH under the conditions of 1,2-diphenyldiselane and ammonium persulfate. After bromination, H-3 reacted with NaSEt to give compound D90.
  • Compound D87: 63 mg, ESI[M + H]+ = 275.0
  • 1H NMR (400 MHz, CDCl3) δ 8.16 (s, 1H), 7.95 (s, 1H), 7.39 - 7.28 (m, 3H), 7.23 - 7.15 (m, 2H), 6.41 (q, J = 7.1 Hz, 1H), 4.93 (s, 1H), 3.39 (s, 3H), 3.35 (s, 3H), 1.87 (d, J = 7.1 Hz, 3H).
  • Compound D88: 168 mg, ESI[M + H]+ = 303.0
  • 1H NMR (400 MHz, CDCl3) δ 8.17 (s, 1H), 7.83 (s, 1H), 7.36 - 7.27 (m, 3H), 7.21 - 7.14 (m, 2H), 6.40 (q, J = 7.1 Hz, 1H), 5.03 (s, 1H), 3.70 - 3.46 (m, 4H), 1.85 (d, J = 7.1 Hz, 3H), 1.20 (d, J = 7.1, 1.0 Hz, 6H).
  • Compound D90: 21 mg, ESI[M + H]+ = 335.0
  • 1H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H), 7.85 (s, 1H), 7.34 - 7.27 (m, 2H), 7.22 - 7.18 (m, 1H), 7.16 - 7.09 (m, 2H), 6.40 (q, J = 6.9 Hz, 1H), 5.23 (s, 1H), 2.79 - 2.39 (m, 4H), 1.86 (d, J = 7.1 Hz, 3H), 1.19 (t, J = 7.0 Hz, 6H ).
    • 7. Preparation of Compounds D89, D91 and D92
  • Figure imgb0457
  • At room temperature, PTSA.H2O (826 mg, 4.34 mmol) was added into the solution of H-4 (400 mg, 1.45 mmol) in acetone (10 mL), then the mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC until completion. The mixture was quenched with ice-water (10 mL) and extracted with ethyl acetate (3 × 5 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by Prep-TLC (ethyl acetate/petroleum ether (v/v) = 1/5) and the fraction with Rf = 0.5 ~ 0.6 was collected to give the title compound H-5 (250 mg, yield 75%). ESI[M + H]+ = 231.0
  • H-5 was oxidized by Cu(OAc)2 to give compound H-7, and then reacted with ethylene glycol or pinacol under the reflux condition of p-toluenesulfonic acid and toluene to give target compounds D89 and D91.
  • Compound D89: 42 mg, ESI[M + H]+ = 273.0
  • 1H NMR (400 MHz, CDCl3) δ 8.21 (s, 1H), 7.91 (s, 1H), 7.34 - 7.27 (m, 2H), 7.25 - 7.21 (m, 1H), 7.15 - 7.09 (m, 2H), 6.41 (q, J = 6.9 Hz, 1H), 5.01 (p, J = 6.3 Hz, 1H), 4.06 - 3.76 (m, 4H), 1.88 (d, J = 7.1 Hz, 3H).
  • Compound D91: 12 mg, ESI[M + H]+ = 329.3
  • 1H NMR (400 MHz, CDCl3) δ 8.18 (s, 1H), 7.90 (s, 1H), 7.34 - 7.27 (m, 2H), 7.26 - 7.24 (m, 1H), 7.16 - 7.09 (m, 2H), 6.41 (q, J = 6.9 Hz, 1H), 5.03 (s, 1H), 1.85 (d, J = 7.1 Hz, 3H), 1.20 (s, 12H).
  • Compound D92 was prepared according to the operation method of preparing compound D16 described in Example 4.
  • Compound D92: 24 mg, ESI[M + H]+ = 327.2
  • 1H NMR (400 MHz, CDCl3) δ 8.28 (s, 1H), 7.99 (s, 1H), 7.34 - 7.27 (m, 2H), 7.26 - 7.21 (m, 1H), 7.16 - 7.09 (m, 2H), 6.65 (s, 1H), 6.40 (q, J = 6.9 Hz, 1H), 2.21 (s, 6H), 1.85 (d, J = 7.1 Hz, 3H).
    • Example 12 Preparation of Compounds D93 ~ D107
  • Figure imgb0458
    Figure imgb0459
    • 1. Preparation of ethyl 4-amino-1H-imidazole-5-carboxylate (I-1)
  • Figure imgb0460
  • At room temperature, 4-amino-1H-imidazole-5-carboxamide (3.0 g, 23.8 mmol), ethanol (30 mL) and MeSO3H (6 mL) were successively added into the 200 mL sealed tube, then the reaction mixture was allowed to react at 120°C for 10 hrs. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure, adjusted pH to 7 ~ 8 with saturated sodium bicarbonate solution and extracted with ethyl acetate (3 × 150 mL). The combined organic layers were washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give compound I-1 (3.0 g, yield 81%) as a white solid.
    • 2. Preparation of ethyl 4-fluoro-1H-imidazole-5-carboxylate (I-2)
  • Figure imgb0461
  • In an ice-salt bat, I-1 (250 mg, 1.61 mmol) was dissolved in HBF4 (40%) at -10°C, and then the solution of NaNO2 (117 mg, 1.69 mmol) in water (0.15 mL) was added into the mixture. The mixture was allowed to react under the irradiation of a mercury lamp (302 nm) for 2 hrs. The reaction was monitored by TLC until completion, and then the reaction solution was adjusted pH to 7 ~ 8 with IN NaOH solution in an ice-water bath. The mixture was extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/1), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.4 ~ 0.5 to give compound I-2 (100 mg, yield 39%) as colorless oil.
    • 3. Preparation of (R)-Ethyl 4-fluoro-1-(1-phenylethyl)-1H-imidazole-5-carboxylate (I-3)
  • Figure imgb0462
  • In an ice-water bath, (S)-1-phenylethan-1-ol (134 mg, 1.1 mmol) was added into the mixture of I-2 (158 mg, 1.1 mmol) and PPh3 (346 mg, 1.32 mmol) in THF (10 mL) at 0°C, then the solution of DEAD (230 mg, 1.32 mmol) in THF (1 mL) was added dropwise into the mixture at the rate of 0.5 mmol/min. After addition, the reaction mixture was warmed slowly to room temperature and stirred for 5 hrs. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the product I-3 (70 mg, yield 27%) as colorless oil. ESI[M + H]+ = 263.0
  • 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.28 (m, 4H), 7.23 - 7.16 (m, 2H), 6.28 (q, J = 7.1 Hz, 1H), 4.39 - 4.17 (m, 2H), 1.84 (d, J = 7.1 Hz, 3H), 1.32 (t, J = 7.1 Hz, 3H).
    • 4. Preparation of (R)-4-fluoro-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid (I-4)
  • Figure imgb0463
  • At room temperature, the solution of NaOH (21.6 mg, 0.54 mmol) in water (5 mL) was added into the solution of I-3 (70 mg, 0.27mmol) in ethanol (5 mL), then the mixture was stirred at room temperature for 5 hrs. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure, cooled and adjusted pH to 4 ~ 5 with IN HCl. The mixture was extracted with ethyl acetate (3 × 20 mL). The combined organic layers were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give the compound I-4 (58 mg, yield 93%) as a grey solid. ESI[M + H]+ = 235.0
  • 1H NMR (400 MHz, CDCl3) δ 7.43 - 7.28 (m, 4H), 7.24 - 7.16 (m, 2H), 6.24 (q, J = 7.0 Hz, 1H), 1.85 (d, J = 7.1 Hz, 3H).
    • 5. Preparation of (R)-4-fluoro-N-methoxy-N-methyl-1-(1-phenylethyl)-1H-imidazole-5-carboxamide (I-5)
  • Figure imgb0464
  • At room temperature, I-4 (4.4 g, 18.8 mmol), N, O-dimethylhydroxylamine hydrochloride (2.8 g, 28.7 mmol), DIEA (3.7 g, 28.6 mmol) and HATU (10.9 g, 28.7 mmol) were dissolved in DMF (50 mL), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The mixture was quenched with water (100 mL) and extracted with ethyl acetate (4 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/10 ~ 1/3), with TLC (ethyl acetate/petroleum ether (v/v) = 1/1) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound I-5 (4.7 g, yield 90%) as a white solid. ESI[M + H]+ = 278.1
    • 6. Preparation of (R)-1-(4-fluoro-1-(1-phenylethyl)-1H-imidazol-5-yl)ethan-1-one (I-6)
  • Figure imgb0465
  • At room temperature, I-5 (4.7 g, 16.9 mmol) was dissolved in anhydrous THF (50 mL). The mixture was cooled to 0°C with an ice-water bath. Methylmagnesium bromide (33.9 mL, 1 mol/L in THF, 33.9 mmol) was added dropwise into the mixture at the rate of 3 mmol/min, then the mixture was reacted at room temperature for 2 hrs. The reaction was monitored by TLC until completion. The mixture was cooled to 0°C with ice-water bath, quenched with saturated ammonium chloride solution (100 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/5) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the title compound I-6 (3.9 g, yield 99%) as a white solid. ESI[M + H]+ = 233.1
    • 7. Preparation of D93 and intermediate I-7
  • Figure imgb0466
  • At room temperature, I-6 (3.9 g, 16.8 mmol) and PhI(OAc)2 (8.1 g, 25.1 mmol) were dissolved in methanol (30 mL), then the mixture was cooled to -10°C with an ice-salt bath. KOH (11.3 g, 201.4 mol) was added in portions into the mixture within 50 mins, then the reaction mixture was reacted at -10°C for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (100 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/5), with TLC (ethyl acetate/petroleum ether (v/v) = 1/3) monitoring, and collecting the fraction with Rf = 0.3 ~ 0.6 to give compound I-7 (684 mg, yield 14%) as colorless oil, ESI[M + H]+ = 295.2 and the title compound D93 (52 mg, yield 0.96%), ESI[M + H]+ = 323.0
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 1.5 Hz, 1H), 7.42 - 7.30 (m, 3H), 7.29 - 7.23 (m, 2H), 6.23 (q, J = 7.0 Hz, 1H), 3.93 (s, 3H), 3.49 (s, 6H), 1.86 (d, J = 7.0 Hz, 3H).
    • 8. Preparation of Compounds D94 ~ D107
  • Figure imgb0467
    Figure imgb0468
  • The title compounds D94 ~ D100 were prepared according to the operation method of preparing compounds D2 ~ D10 described in Example 2.
  • The title compounds D101 ~ D105 were prepared according to the operation method of preparing compounds D13 ~ D16 described in Example 4.
  • The title compounds D106 ~ D107 were prepared according to the operation method of preparing compounds D84 and D86 described in Example 11.
  • Compound D94: 19 mg, ESI[M + H]+ = 351.1
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 1.5 Hz, 1H), 7.41 - 7.30 (m, 3H), 7.28 - 7.23 (m, 2H), 6.23 (q, J = 7.0 Hz, 1H), 4.45 - 4.40 (m, 2H), 3.94 (s, 1H), 3.76 - 3.72 (m, 1.5H), 3.54 (s, 2.5H), 1.86 (d, J = 7.0 Hz, 3H), 1.43 - 1.41 (m, 3H), 1.27 - 1.24 (m, 3H).
  • Compound D95: 12 mg, ESI[M + H]+ = 365.1
  • 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 1.5 Hz, 1H), 7.45 - 7.30 (m, 3H), 7.27 - 7.23 (m, 2H), 6.25 (q, J = 7.0 Hz, 1H), 4.42 - 4.41 (m, 1H), 3.93 (s, 1H), 3.75 - 3.72 (m, 1.5H), 3.51 (s, 2.5H), 1.88 (d, J = 7.0 Hz, 3H), 1.43 - 1.40 (m, 4.5H), 1.25 - 1.20 (m, 4.5H).
  • Compound D96: 22 mg, ESI[M + H]+ = 321.0
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 1.5 Hz, 1H), 7.42 - 7.31 (m, 3H), 7.29 - 7.23 (m, 2H), 6.23 (q, J = 7.0 Hz, 1H), 4.07 - 3.78 (m, 4H), 3.26 (s, 3H), 1.86 (d, J = 7.0 Hz, 3H).
  • Compound D97: 32 mg, ESI[M + H]+ = 361.0
  • 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 1.5 Hz, 1H), 7.44 - 7.33 (m, 3H), 7.30 - 7.24 (m, 2H), 6.24 (q, J = 7.0 Hz, 1H), 4.22 - 4.18 (m, 1.5H), 3.97 (s, 2H), 3.48 (s, 3H), 3.28 - 3.09 (m, 1.5H), 2.05 - 1.82 (m, 6H).
  • Compound D98: 42 mg, ESI[M + H]+ = 359.0
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 1.5 Hz, 1H), 7.41 - 7.30 (m, 3H), 7.28 - 7.23 (m, 2H), 6.23 (q, J = 7.0 Hz, 1H), 4.04 - 3.78 (m, 6H), 2.03 - 1.82 (m, 6H). Compound D99: 18 mg, ESI[M + H]+ = 379.1
  • 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 1.5 Hz, 1H), 7.42 - 7.30 (m, 3H), 7.27 - 7.23 (m, 2H), 6.22 (q, J = 7.0 Hz, 1H), 4.03 (s, 1.5H), 3.95 (s, 1H), 3.54 (s, 4.5H), 3.30 (s, 1H), 1.86 (d, J = 7.0 Hz, 3H), 1.05 (s, 5.5H), 0.94 (s, 3.5H).
  • Compound D100: 16 mg, ESI[M + H]+ = 377.1
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 1.5 Hz, 1H), 7.43 - 7.32 (m, 3H), 7.29 - 7.23 (m, 2H), 6.24 (q, J = 7.0 Hz, 1H), 4.07 - 3.78 (m, 5H), 3.31 (s, 1H), 1.85 (d, J = 7.0 Hz, 3H), 1.03 (s, 5.5H), 0.96 (s, 3.5H).
  • Compound D101: 46 mg, ESI[M + H]+ = 321.1
  • 1H NMR (400 MHz, CDCl3) δ 7.42 (s, 1H), 7.37 - 7.28 (m, 3H), 7.24 - 7.17 (m, 2H), 6.34 (q, J = 6.9 Hz, 1H), 5.28 (d, J = 1.8 Hz, 1H), 3.88 - 3.24 (m, 4H), 1.83 (d, J = 7.1 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H), 1.12 (t, J = 7.1 Hz, 3H).
  • Compound D102: 27 mg, ESI[M + H]+ = 293.0
  • 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 1.5 Hz, 1H), 7.44 - 7.30 (m, 3H), 7.29 - 7.23 (m, 2H), 6.23 (q, J = 7.0 Hz, 1H), 4.87 (s, 1H), 3.36 (s, 3H), 3.32 (s, 3H), 1.85 (d, J = 7.0 Hz, 3H).
  • Compound D103: 31 mg, ESI[M + H]+ = 349.2
  • 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 1.5 Hz, 1H), 7.43 - 7.30 (m, 3H), 7.29 - 7.23 (m, 2H), 6.27 (q, J = 7.0 Hz, 1H), 5.00 (s, 1H), 3.98 - 3.90 (m, 2H), 1.87 (d, J = 7.0 Hz, 3H), 1.18 - 1.15 (m, 12H).
  • Compound D104: 28 mg, ESI[M + H]+ = 353.0
  • 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 1.5 Hz, 1H), 7.42 - 7.30 (m, 3H), 7.28 - 7.23 (m, 2H), 6.23 (q, J = 7.0 Hz, 1H), 5.35 (d, J = 1.8 Hz, 1H ), 2.78 - 2.39 (m, 4H), 1.85 (d, J = 7.0 Hz, 3H), 1.27 (t, J = 7.1 Hz, 3H), 1.20 (t, J = 7.1 Hz, 3H).
  • Compound D105: 37 mg, ESI[M + H]+ = 345.3
  • 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 1.5 Hz, 1H), 7.41 - 7.30 (m, 3H), 7.28 - 7.23 (m, 2H), 6.68 (s, 1H), 6.23 (q, J = 7.0 Hz, 1H), 2.23 (s, 6H), 1.86 (d, J = 7.0 Hz, 3H).
  • Compound D106: 28 mg, ESI[M + H]+ = 315.0
  • 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 1.5 Hz, 1H), 7.44 - 7.30 (m, 3H), 7.29 - 7.23 (m, 2H), 6.23 (q, J = 7.0 Hz, 1H), 4.65 (q, J = 17.7 Hz, 2H), 2.01 - 1.84 (m, 6H). Compound D107: 35 mg, ESI[M + H]+ = 333.0
  • 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 1.5 Hz, 1H), 7.40 - 7.30 (m, 3H), 7.29 - 7.23 (m, 2H), 6.21 (q, J = 7.0 Hz, 1H), 4.11 - 3.99 (m, 2H), 1.88 (d, J = 7.1 Hz, 3H), 1.00 (s, 9H).
    • Example 13 Preparation of Compound D108
  • Figure imgb0469
    • 1. Preparation of ethyl (R)-4-chloro-1-(1-phenylethyl)-1H-imidazole-5-carboxylate
  • Figure imgb0470
  • At room temperature, ethyl (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylate (5.0 g, 20.5 mmol) and NCS (3.3 g, 24.7 mmol) were dissolved in acetonitrile (50 mL), then the reaction mixture was heated to reflux for 3 hrs. The reaction was monitored by TLC until completion. The reaction mixture was cooled to room temperature, quenched with water (100 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the crude colorless oil. The oil was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/200 ~ 1/50), with TLC (ethyl acetate/petroleum ether (v/v) = 1/30) monitoring, and collecting the fraction to give compound 108-1 (1.56 g, yield 39%). ESI[M + H]+ = 279.0, 175.1
  • 1H NMR (400 MHz, CDCl3) δ 7.72 (s, 1H), 7.38 - 7.27 (m, 3H), 7.21 - 7.14 (m, 2H), 6.73 (q, J = 7.1 Hz, 1H), 4.29 (q, J = 7.1 Hz, 2H), 1.98 (d, J = 7.2 Hz, 3H), 1.34 (t, J = 7.1 Hz, 3H).
    • 2. Preparation of Compound D108
  • Figure imgb0471
  • The intermediate compounds 108-2 ~ 108-4 were prepared according to the operation method of preparing intermediate compounds I-4, I-5 and I-6 described in Example 12. The title compound D108 was prepared according to the operation method of preparing compound D93 described in Example 12, using 108-4 as the raw material.
  • 4.6 g of compound 108-1 was used as the starting material to finally obtain the target compound D108 (38 mg, yield 0.68% four steps). ESI[M + H]+ = 339.0
  • 1H NMR (400 MHz, CDCl3) δ 8.23 (s, 0.48H), 8.22 (s, 0.56H), 7.40 - 7.27 (m, 3H), 7.22 - 7.10 (m,2H), 6.73 - 6.62 (m, 0.50H), 6.62 - 6.52 (m, 0.48H), 3.94 (s, 1H), 3.49 (s, 3H), 3.22 (s, 5H), 2.02 (d, J = 7.1 Hz, 1.5H), 1.98 (d, J = 7.2 Hz, 1.5H).
    • Example 14 Preparation of Compounds D109 ~ 118
  • Figure imgb0472
    Figure imgb0473
    • 1. Preparation of (R)-2,2,2-trichloro-1-(1-(1-phenylethyl)-1H-pyrrol-2-yl)ethan-1-one
  • Figure imgb0474
  • At room temperature, (S)-1-phenylethan-1-ol (1.7 g, 14.1 mmol) was added into the mixture of 2,2,2-trichloro-1-(1H-pyrrol-2-yl)ethan-1-one (3.0 g, 14.1 mmol) and PPh3 (4.5 g, 17.0 mmol) in anhydrous THF (20 mL) under nitrogen protection, then the solution of DEAD (0.44 mL, 17.0 mmol) was added dropwise into the mixture at the rate of 1 mmol/min. After addition, the reaction mixture was stirred at room temperature for 5 hrs. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated ammonium chloride solution (20 mL) and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give crude product. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/100 ~ 1/15), with TLC (ethyl acetate/petroleum ether (v/v) = 1/15) monitoring, and collecting the fraction with Rf = 0.6 ~ 0.7 to give J-1 (2.66 g, yield 60%) as colorless oil.
    • 2. Preparation of methyl (R)-1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (J-2)
  • Figure imgb0475
  • At room temperature, J-1 (2.3 g, 7.3 mmol) and K2CO3 (4.0 g, 29.2 mmol) were dissolved in methanol (20 mL), then the mixture was stirred at room temperature for 10 mins. The reaction was monitored by TLC until completion. The reaction mixture was filtered. The filter cake was washed with methanol (10 mL). The filtrate was used for next step directly without further purification.
    • 3. Preparation of (R)-1-(1-phenylethyl)-1H-pyrrole-2-carboxylic acid (J-3)
  • Figure imgb0476
  • At room temperature, the solution of NaOH (584 mg, 29.2 mmol) in water (10 mL) was added into the solution of J-2 in methanol, then the mixture was stirred at 60°C for 2 hrs. The reaction was monitored by TLC until completion. The reaction mixture was cooled and adjusted pH to 4 ~ 5 with concentrated hydrochloric acid. The reaction mixture was extracted with dichloromethane (3 × 15 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/2), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.3 ~ 0.4 to give compound J-3 (1.2 g, yield 76% for two steps) as a grey solid. ESI[M + H]+ = 216.1
  • 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.27 (m, 1H), 7.26 - 7.21 (m, 1H), 7.18 - 7.10 (m, J = 5.7, 2.7, 1.1 Hz, 1H), 7.06 - 7.02 (m, J = 2.5, 1.9 Hz, 0H), 6.56 (q, J = 7.0 Hz, 0H), 6.21 (dd, J = 3.9, 2.7 Hz, 0H), 1.81 (d, J = 7.1 Hz, 2H).
    • 4. Preparation of compounds D109 ~ D118
  • The title compound D109 was prepared according to the operation method of preparing compound D1 described in Example 1.
  • The title compounds D110 ~ D116 were prepared according to the operation method of preparing compounds D2 ~ D8 described in Example 2.
  • The title compound D117 was prepared according to the operation method of preparing compound D11 described in Example 3.
  • The title compound D118 was prepared according to the operation method of preparing compound D16 described in Example 4.
  • Compound D109: 82 mg, ESI[M + H]+ = 304.0 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.27 (m, 2H), 7.26 - 7.20 (m, 1H), 7.15 (d, J = 7.3 Hz, 2H), 7.00 (d, J = 3.0 Hz, 2H), 6.61 (q, J = 7.0 Hz, 1H), 6.20 - 6.15 (m, 1H), 3.92 (s, 0.7H), 3.49 (s, 1.3H), 3.13 (s, 7H), 1.80 (d, J = 7.1 Hz, 3H).
  • Compound D110: 34 mg, ESI[M + H]+ = 334.0
  • 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.27 (m, 2H), 7.26 - 7.20 (m, 1H), 7.15 (d, J = 7.3 Hz, 2H), 7.00 (d, J = 3.0 Hz, 2H), 6.61 (q, J = 7.0 Hz, 1H), 6.20 - 6.15 (m, 1H), 3.35 (s, 3H), 3.24 (s, 3H), 2.31 - 2.17 (m, 1H), 2.14 - 2.01 (m, 1H), 1.80 (d, J = 7.1 Hz, 3H), 0.99 (t, J = 7.5 Hz, 3H).
  • Compound D111: 22 mg, ESI[M + H]+ = 318.1
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.28 (m, 2H), 7.26 - 7.20 (m, 1H), 7.12 (d, J = 7.3 Hz, 2H), 7.00 (d, J = 3.0 Hz, 2H), 6.63 (q, J = 7.0 Hz, 1H), 6.20 - 6.15 (m, 1H), 4.43 - 4.40 (m, 2H), 3.95 (s, 1H), 3.78 - 3.71 (m, 1.5H), 3.50 (s, 3.5H), 1.80 (d, J = 7.1 Hz, 3H), 1.42 (t, J = 7.1 Hz, 1.5H), 1.28 (t, J = 7.0 Hz, 1.5H).
  • Compound D112: 42 mg, ESI[M + H]+ = 332.1
  • 1H NMR (400 MHz, CDCl3) δ 7.30 - 7.26 (m, 2H), 7.25 - 7.20 (m, 1H), 7.14 (d, J = 7.3 Hz, 2H), 7.00 (d, J = 3.0 Hz, 2H), 6.61 (q, J = 7.0 Hz, 1H), 6.22 - 6.17 (m, 1H), 5.35 - 5.30 (m, 1H), 3.95 (s, 1H), 3.52 (s, 5H), 1.80 (d, J = 7.1 Hz, 3H), 1.55 (d, J = 6.5 Hz, 1H), 1.45 - 1.40 (m, 3H), 1.25 (t, J = 10.2 Hz, 2H).
  • Compound D113: 22 mg, ESI[M + H]+ = 360.1
  • 1H NMR (400 MHz, CDCl3) δ 7.32 - 7.27 (m, 2H), 7.26 - 7.20 (m, 1H), 7.13 (d, J = 7.3 Hz, 2H), 7.00 (d, J = 3.0 Hz, 2H), 6.61 (q, J = 7.0 Hz, 1H), 6.20 - 6.15 (m, 1H), 4.87 (s, 1H), 3.95 (s, 1H), 3.51 (s, 5H), 1.80 (d, J = 7.1 Hz, 3H), 1.65 - 1.62 (m, 2.5H), 1.60 - 1.55 (m, 1.5H), 1.50 - 1.45 (m, 1.5H), 1.40 - 1.35 (m, 3.5H), 1.24 - 1.20 (m, 1H).
  • Compound D114: 22 mg, ESI[M + H]+ = 360.1
  • 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.27 (m, 2H), 7.25 - 7.20 (m, 1H), 7.15 (d, J = 7.3 Hz, 2H), 7.02 (d, J = 3.0 Hz, 2H), 6.62 (q, J = 7.0 Hz, 1H), 6.20 - 6.15 (m, 1H), 4.04 (s, 1.5H), 3.95 (s, 1H), 3.52 (s, 4.5H), 3.32 (s, 1H), 1.82 (d, J = 7.1 Hz, 3H), 1.02 (s, 5.5H), 0.94 (s, 3.5H).
  • Compound D115: 32 mg, ESI[M + H]+ = 330.1
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.27 (m, 2H), 7.24 - 7.20 (m, 1H), 7.15 (d, J = 7.3 Hz, 2H), 7.01 (d, J = 3.0 Hz, 2H), 6.61 (q, J = 7.0 Hz, 1H), 6.20 - 5.89 (m, 2H), 5.51 - 4.83 (m, 2H), 4.21 - 4.18 (m, 1.5H), 3.92 (s, 1.5H), 3.45 (m, 3H), 3.26 - 3.09 (m, 2H), 1.80 (d, J = 7.1 Hz, 3H).
  • Compound D116: 42 mg, ESI[M + H]+ = 342.0
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.27 (m, 2H), 7.26 - 7.21 (m, 1H), 7.15 (d, J = 7.3 Hz, 2H), 7.05 (d, J = 3.0 Hz, 2H), 6.61 (q, J = 7.0 Hz, 1H), 6.21 - 6.15 (m, 1H), 4.22 - 4.18 (m, 1.5H), 3.96 (s, 2H), 3.49 (s, 3H), 3.28 - 3.08 (m, 1.5H), 2.04 - 1.82 (m, 3H), 1.81 (d, J = 7.1 Hz, 3H).
  • Compound D117: 122 mg, ESI[M + H]+ = 258.0
  • 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.27 (m, 2H), 7.26 - 7.20 (m, 1H), 7.17 (d, J = 7.3 Hz, 2H), 7.04 (d, J = 3.0 Hz, 2H), 6.61 (q, J = 7.0 Hz, 1H), 6.25 - 6.19 (m, 1H), 3.94 (s, 3H), 1.83 (d, J = 7.1 Hz, 3H).
  • Compound D118: 28 mg, ESI[M + H]+ = 326.2
  • 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.29 (m, 2H), 7.26 - 7.22 (m, 1H), 7.15 (d, J = 7.3 Hz, 2H), 7.06 (d, J = 3.0 Hz, 2H), 6.70 (s, 1H), 6.61 (q, J = 7.0 Hz, 1H), 6.20 - 6.15 (m, 1H), 2.24 (s, 6H), 1.83 (d, J = 7.1 Hz, 3H).
    • Example 15 Preparation of Compounds D119 ~ D129
  • Figure imgb0477
    Figure imgb0478
    • 1. Preparation of ethyl (R)-3-fluoro-1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (K-1)
  • Figure imgb0479
  • In an ice-water bath, (S)-1-phenylethan-1-ol (5.8 g, 47.5 mmol) was added into the mixture of ethyl 3-fluoro-1H-pyrrole-2-carboxylate (5.0 g, 31.8 mmol) and PPh3 (12.5 g, 47.7 mmol) in THF (50 mL) at 0°C, then the solution of DEAD (8.3 g, 47.7 mmol) in THF (100 mL) was added dropwise into the mixture at the rate of 2 mmol/min. After addition, the reaction mixture was warmed slowly to room temperature and stirred overnight. The reaction was monitored by TLC until completion. The reaction mixture was quenched with the saturated brine (30 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give crude product. The crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the product K-1 (7.0 g, yield 84%). ESI[M + H]+ = 262.2
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.21 (m, 3H), 7.12 (d, J = 7.2 Hz, 2H), 6.76 (dd, J = 5.1, 3.3 Hz, 1H), 6.45 (q, J = 7.1 Hz, 1H), 5.93 (d, J = 3.2 Hz, 1H), 4.37 - 4.11 (m, 2H), 1.76 (d, J = 7.1 Hz, 3H), 1.31 (t, J = 7.1 Hz, 3H).
    • 2. Preparation of compounds D119 ~ 129
  • The title compound D119 was prepared according to the operation method of preparing compounds D1 described in Example 1.
  • The title compounds D120 ~ D125 were prepared according to the operation method of preparing compounds D2 ~ D10 described in Example 2.
  • The title compounds D126 ~ D129 were prepared according to the operation method of preparing compounds D13 ~ D16 described in Example 4.
  • Compound D119: 111 mg, ESI[M + H]+ = 322.0
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.28 (m, 2H), 7.26 - 7.21 (m, 1H), 7.17 - 7.09 (m, 2H), 6.83 - 6.76 (m, 1H), 6.44 (q, J = 7.1 Hz, 1H), 5.94 (d, J = 3.2 Hz, 1H), 3.92 (s, 0.7H), 3.49 (s, 1.3H), 3.13 (s, 7H), 1.76 (d, J = 7.1 Hz, 3H).
  • Compound D120: 27 mg, ESI[M + H]+ = 358.0
  • 1H NMR (400 MHz, CDCl3) δ 7.33 - 7.28 (m, 2H), 7.26 - 7.21 (m, 1H), 7.15 - 7.09 (m, 2H), 6.83 - 6.76 (m, 1H), 6.44 (q, J = 7.1 Hz, 1H), 5.94 (d, J = 3.2 Hz, 1H), 4.07 - 3.78 (m, 6H), 2.03 - 1.82 (m, 3H), 1.74 (d, J = 7.1 Hz, 3H).
  • Compound D121: 33 mg, ESI[M + H]+ = 320.0
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.28 (m, 2H), 7.26 - 7.21 (m, 1H), 7.19 - 7.09 (m, 2H), 6.83 - 6.76 (m, 1H), 6.41 (q, J = 7.1 Hz, 1H), 5.94 (d, J = 3.2 Hz, 1H), 4.07 - 3.78 (m, 4H), 3.26 (s, 3H), 1.78 (d, J = 7.1 Hz, 3H).
  • Compound D122: 34 mg, ESI[M + H]+ = 360.0
  • 1H NMR (400 MHz, CDCl3) δ 7.32 - 7.28 (m, 2H), 7.25 - 7.21 (m, 1H), 7.17 - 7.09 (m, 2H), 6.83 - 6.76 (m, 1H), 6.41 (q, J = 7.1 Hz, 1H), 5.94 (d, J = 3.2 Hz, 1H), 4.23 - 4.16 (m, 1.5H), 3.95 (s, 2H), 3.47 (m, 3H), 3.27 - 3.08 (m, 1.5H), 2.03 - 1.82 (m, 3H),1.73 (d, J = 7.1 Hz, 3H).
  • Compound D123: 31 mg, ESI[M + H]+ = 352.0
  • 1H NMR (400 MHz, CDCl3) δ 7.30 - 7.27 (m, 2H), 7.25 - 7.21 (m, 1H), 7.17 - 7.09 (m, 2H), 6.83 - 6.76 (m, 1H), 6.45 (q, J = 7.1 Hz, 1H), 5.94 (d, J = 3.2 Hz, 1H), 3.35 (s, 3H), 3.24 (s, 3H), 2.31 - 2.17 (m, 1H), 2.11 - 2.01 (m, 1H), 1.74 (d, J = 7.1 Hz, 3H), 0.99 (t, J = 7.5 Hz, 3H).
  • Compound D124: 28 mg, ESI[M + H]+ = 350.1
  • 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.28 (m, 2H), 7.24 - 7.21 (m, 1H), 7.17 - 7.09 (m, 2H), 6.83 - 6.76 (m, 1H), 6.40 (q, J = 7.1 Hz, 1H), 5.92 (d, J = 3.2 Hz, 1H), 4.43 - 4.40 (m, 2H), 3.95 (s, 1H), 3.77 - 3.71 (m, 1.5H), 3.51 (s, 2.5H), 1.78 (d, J = 7.1 Hz, 3H), 1.44 - 1.40 (m, 3H), 1.28 - 1.24 (m, 3H).
  • Compound D125: 11 mg, ESI[M + H]+ = 364.0
  • 1H NMR (400 MHz, CDCl3) δ 7.32 - 7.28 (m, 2H), 7.25 - 7.21 (m, 1H), 7.18 - 7.09 (m, 2H), 6.83 - 6.76 (m, 1H), 6.44 (q, J = 7.1 Hz, 1H), 5.94 (d, J = 3.2 Hz, 1H), 4.42 - 4.40 (m, 1H), 3.94 (s, 1H), 3.75 - 3.70 (m, 1.5H), 3.52 (s, 2.5H), 1.74 (d, J = 7.1 Hz, 3H), 1.43 - 1.41 (m, 4.5H), 1.25 - 1.22 (m, 4.5H).
  • Compound D126: 27 mg, ESI[M + H]+ = 320.1
  • 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.28 (m, 2H), 7.26 - 7.21 (m, 1H), 7.16 - 7.08 (m, 2H), 6.83 - 6.76 (m, 1H), 6.42 (q, J = 7.1 Hz, 1H), 5.92 (d, J = 3.2 Hz, 1H), 5.25 (s, 1H), 3.70 - 3.46 (m, 4H), 1.76 (d, J = 7.1 Hz, 3H), 1.17 - 1.15 (m, 6H). Compound D127: 22 mg, ESI[M + H]+ = 292.0
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.27 (m, 2H), 7.25 - 7.21 (m, 1H), 7.17 - 7.09 (m, 2H), 6.83 - 6.76 (m, 1H), 6.41 (q, J = 7.1 Hz, 1H), 5.92 (d, J = 3.2 Hz, 1H), 5.05 (s, 1H), 3.35 (s, 3H), 3.31 (s, 3H), 1.75 (d, J = 7.1 Hz, 3H).
  • Compound D128: 34 mg, ESI[M + H]+ = 352.0
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.28 (m, 2H), 7.26 - 7.21 (m, 1H), 7.18 - 7.09 (m, 2H), 6.83 - 6.76 (m, 1H), 6.43 (q, J = 7.1 Hz, 1H), 5.92 (d, J = 3.2 Hz, 1H), 5.36 (s, 1H), 2.80 - 2.39 (m, 4H), 1.76 (d, J = 7.1 Hz, 3H), 1.27 - 1.13 (m, 6H). Compound D129: 33 mg, ESI[M + H]+ = 344.0
  • 1H NMR (400 MHz, CDCl3) δ 7.31 - 7.26 (m, 2H), 7.24 - 7.20 (m, 1H), 7.17 - 7.09 (m, 2H), 6.83 - 6.76 (m, 1H), 6.67 (s, 1H), 6.43 (q, J = 7.1 Hz, 1H), 5.91 (d, J = 3.2 Hz, 1H), 2.20 (s, 6H), 1.77 (d, J = 7.1 Hz, 3H).
    • Example 16 Preparation of Compounds D130 ~ D134
  • Figure imgb0480
    • 1. Preparation of ethyl (R)-1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (L-1)
  • Figure imgb0481
  • In an ice-water bath, (S)-1-phenylethan-1-ol (6.9 g, 56.5 mmol) was added into the mixture of ethyl 1H-pyrrole-2-carboxylate (5.0 g, 35.9 mmol) and PPh3 (14.8 g, 56.4 mmol) in THF (50 mL) at 0°C, then the solution of DEAD (9.8 g, 56.3 mmol) in THF (20 mL) was added dropwise into the mixture at the rate of 2 mmol/min. After addition, the reaction mixture was warmed slowly to room temperature and stirred overnight. The reaction was monitored by TLC until completion. The reaction mixture was quenched with the saturated brine (100 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give crude product. The crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the product L-1 (4.0 g, yield 46%). ESI[M + H]+ = 244.3
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.29 (m, 2H), 7.28 - 7.22 (m, 1H), 7.20 - 7.12 (m, 2H), 7.07 - 6.99 (m, 1H), 6.63 (q, J = 7.1 Hz, 1H), 6.25 - 6.17 (m, 1H), 4.36 - 4.16 (m, 2H), 1.83 (d, J = 7.1 Hz, 3H), 1.33 (t, J = 7.1 Hz, 3H).
    • 2. Preparation of ethyl (R)-5-fluoro-1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (L-2)
  • Figure imgb0482
  • At room temperature, L-1 (2.0 g, 8.2 mmol) and Selectfluor (6.4 g, 18.1 mmol) were dissolved in acetonitrile (50 mL), then the mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The reaction mixture was quenched with saturated brine (100 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give title compound L-2 (410 mg, yield 19%). ESI[M + H]+ = 262.1
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.29 (m, 2H), 7.26 - 7.20 (m, 3H), 6.89 (dd, J = 5.9, 4.4 Hz, 1H), 6.80 (q, J = 7.1 Hz, 1H), 5.60 - 5.52 (m, 1H), 4.33 - 4.19 (m, 2H), 1.89 (dd, J = 7.3, 2.3 Hz, 3H), 1.34 (t, J = 7.1 Hz, 3H).
    • 3. Preparation of compounds D130 ~ D13
  • The title compound D130 was prepared according to the operation method of preparing compounds D1 described in Example 1.
  • The title compounds D131 ~ D132 were prepared according to the operation method of preparing compounds D2 ~ D10 described in Example 2.
  • The title compounds D133 ~ D134 were prepared according to the operation method of preparing compounds D14 and D16 described in Example 4.
  • Compound D130: 32 mg, ESI[M + H]+ = 322.0
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.22 (m, 5H), 6.94 (dd, J = 6.0, 4.3 Hz, 1H), 6.80 (q, J = 7.3 Hz, 1H), 5.59 - 5.53 (m, 1H), 3.92 (s, 0.7H), 3.49 (s, 1.3H), 3.13 (s, 7H), 1.91 - 1.87 (m, 3H).
  • Compound D131: 41 mg, ESI[M + H]+ = 320.0
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.25 (m, 5H), 6.93 (dd, J = 6.0, 4.3 Hz, 1H), 6.82 (q, J = 7.3 Hz, 1H), 5.59 - 5.54 (m, 1H), 4.07 - 3.78 (m, 4H), 3.26 (s, 3H), 1.91 - 1.85 (m, 3H).
  • Compound D132: 37 mg, ESI[M + H]+ = 360.1
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.24 (m, 5H), 6.92 (dd, J = 6.0, 4.3 Hz, 1H), 6.83 (q, J = 7.3 Hz, 1H), 5.59 - 5.53 (m, 1H), 4.22 - 4.18 (m, 1.5H), 3.94 (s, 2H), 3.46 (s, 3H), 3.28 - 3.08 (m, 1.5H), 2.04 - 1.82 (m, 6H).
  • Compound D133: 22 mg, ESI[M + H]+ = 320.0
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.22 (m, 5H), 6.93 (dd, J = 6.0, 4.3 Hz, 1H), 6.81 (q, J = 7.3 Hz, 1H), 5.58 - 5.53 (m, 1H), 5.24 (s, 1H), 3.76 - 3.42 (m, 4H), 1.91 - 1.86 (m, 3H), 1.25 - 1.11 (m, 6H).
  • Compound D134: 32 mg, ESI[M + H]+ = 344.0
  • 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.24 (m, 5H), 6.94 (dd, J = 6.0, 4.3 Hz, 1H), 6.83 (q, J = 7.3 Hz, 1H), 6.65 (s, 1H), 5.57 - 5.53 (m, 1H), 2.27 (s, 6H), 1.92 - 1.86 (m, 3H).
    • Example 17 Preparation of Compounds D135 ~ D144
  • Figure imgb0483
    • 1. Preparation of ethyl 3,4-difluoro-1H-pyrrole-2-carboxylate (M-1)
  • Figure imgb0484
  • At room temperature, 3,4-difluoro-1H-pyrrole-2-carboxylic acid (1.0 g, 6.8 mmol), DCC (2.1 g, 10.2 mmol) and DMAP (1.3 g, 10.6 mmol) were dissolved in dichloromethane (10 mL), then the mixture was stirred at room temperature for 5 mins. Ethanol (470 mg, 10.2 mmol) was added slowly into the above mixture using a syringe and the reaction mixture was stirred at room temperature overnight. The reaction was monitored by TLC until completion. The reaction mixture was concentrated under reduced pressure. Methyl tert-butyl ether was added into the residue and stirred, filtered. The filter cake was washed with methyl tert-butyl ether, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give compound M-1 (800 mg, yield 67%). ESI[M + H]+ = 176.1
    • 2. Preparation of ethyl (R)-3,4-difluoro-1-(1-phenylethyl)-1H-pyrrole-2-carboxylate (M-2)
  • Figure imgb0485
  • In an ice-water bath, (S)-1-phenylethan-1-ol (6.9 g, 56.5 mmol) was added into the mixture of M-1 (800 mg, 35.9 mmol) and PPh3 (14.8 g, 56.4 mmol) in THF (50 mL) at 0°C, then the solution of DEAD (9.8 g, 56.3 mmol) in THF (20 mL) was added dropwise into the mixture at the rate of 2 mmol/min. After addition, the reaction mixture was warmed slowly to room temperature and stirred overnight. The reaction was monitored by TLC until completion. The reaction mixture was quenched with the saturated brine (100 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give crude product. The crude product was purified by silica gel column chromatography (ethyl acetate/petroleum ether (v/v) = 1/20 ~ 1/10), with TLC (ethyl acetate/petroleum ether (v/v) = 1/2) monitoring, and collecting the fraction with Rf = 0.5 ~ 0.6 to give the product M-2 (1.0 g, yield 46%). ESI[M + H]+ = 280.2
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.28 (m, 3H), 7.17 - 7.12 (m, 2H), 6.63 (dd, J = 4.6, 2.2 Hz, 1H), 6.53 - 6.46 (m, 1H), 4.33 - 4.23 (m, 2H), 1.72 (d, J = 7.1 Hz, 3H), 1.32 (t, J = 7.1 Hz, 3H).
    • 3. Preparation of Compounds D135 ~ 144
  • The title compound D135 was prepared according to the operation method of preparing compound D1 described in Example 1.
  • The title compounds D136 ~ D141 were prepared according to the operation method of preparing compounds D2 ~ D10 described in Example 2.
  • The title compounds D142 ~ D144 were prepared according to the operation method of preparing compounds D13 ~ D16 described in Example 4.
  • Compound D135: 27 mg, ESI[M + H]+ = 340.0
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.28 (m, 3H), 7.17 - 7.12 (m, 2H), 6.63 (dd, J = 4.7, 2.2 Hz, 1H), 6.53 - 6.46 (m, 1H), 3.92 (s, 0.7H), 3.49 (s, 1.3H), 3.13 (s, 7H), 1.72 (d, J = 7.1 Hz, 3H).
  • Compound D136: 28 mg, ESI[M + H]+ = 378.0
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.28 (m, 3H), 7.17 - 7.12 (m, 2H), 6.60 (dd, J = 4.7, 2.2 Hz, 1H), 6.53 - 6.46 (m, 1H), 4.22 - 4.18 (m, 1.5H), 3.96 (s, 2H), 3.48 (s, 3H), 3.28 - 3.08 (m, 1.5H), 2.04 - 1.82 (m, 3H), 1.70 (d, J = 7.1 Hz, 3H).
  • Compound D137: 40 mg, ESI[M + H]+ = 370.0
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.28 (m, 3H), 7.16 - 7.12 (m, 2H), 6.63 (dd, J = 4.7, 2.2 Hz, 1H), 6.52 - 6.46 (m, 1H), 3.35 (s, 3H), 3.25 (s, 3H), 2.33 - 2.17 (m, 1H), 2.14 - 2.01 (m, 1H), 1.75 (d, J = 7.1 Hz, 3H), 0.99 (t, J = 7.5 Hz, 3H).
  • Compound D138: 22 mg, ESI[M + H]+ = 368.1
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.28 (m, 3H), 7.17 - 7.12 (m, 2H), 6.61 (dd, J = 4.7, 2.2 Hz, 1H), 6.52 - 6.42 (m, 1H), 4.43 - 4.40 (m, 2H), 3.93 (s, 1H), 3.74 - 3.71 (m, 1.5H), 3.54 (s, 2.5H), 1.72 (d, J = 7.1 Hz, 3H), 1.44 - 1.41 (m, 3H), 1.29 - 1.24 (m, 3H).
  • Compound D139: 32 mg, ESI[M + H]+ = 382.1
  • 1H NMR (400 MHz, CDCl3) δ 7.34 - 7.28 (m, 3H), 7.15 - 7.10 (m, 2H), 6.63 (dd, J = 4.7, 2.2 Hz, 1H), 6.51 - 6.46 (m, 1H), 4.42 - 4.40 (m, 1H), 3.92 (s, 1H), 3.75 - 3.70 (m,
  • 1.5H), 3.52 (s, 2.5H), 1.73 (d, J= 7.1 Hz, 3H), 1.43 - 1.41 (m, 4.5H), 1.26 - 1.22 (m, 4.5H).
  • Compound D140: 42 mg, ESI[M + H]+ = 338.0
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.28 (m, 3H), 7.16 - 7.12 (m, 2H), 6.61 (dd, J = 4.7, 2.2 Hz, 1H), 6.52 - 6.46 (m, 1H), 4.07 - 3.78 (m, 4H), 3.26 (s, 3H), 1.71 (d, J = 7.1 Hz, 3H).
  • Compound D141: 23 mg, ESI[M + H]+ = 376.0
  • 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.28 (m, 3H), 7.15 - 7.12 (m, 2H), 6.63 (dd, J = 4.7, 2.2 Hz, 1H), 6.53 - 6.46 (m, 1H), 4.07 - 3.78 (m, 6H), 2.03 - 1.82 (m, 3H), 1.71 (d, J = 7.1 Hz, 3H).
  • Compound D142: 34 mg, ESI[M + H]+ = 338.0
  • 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.29 (m, 3H), 7.18 - 7.12 (m, 2H), 6.63 (dd, J = 4.7, 2.2 Hz, 1H), 6.53 - 6.46 (m, 1H), 5.24 (s, 1H), 3.80 - 3.46 (m, 4H), 1.71 (d, J = 7.1 Hz, 3H), 1.29 - 1.15 (m, 6H).
  • Compound D143: 31 mg, ESI[M + H]+ = 370.0
  • 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.28 (m, 3H), 7.16 - 7.11 (m, 2H), 6.62 (dd, J = 4.7, 2.2 Hz, 1H), 6.54 - 6.46 (m, 1H), 5.45 (s, 1H), 2.88 - 2.39 (m, 4H), 1.72 (d, J = 7.1 Hz, 3H), 1.26 - 1.13 (m, 6H).
  • Compound D144: 62 mg, ESI[M + H]+ = 362.2
  • 1H NMR (400 MHz, CDCl3) δ 7.36 - 7.28 (m, 3H), 7.17 - 7.10 (m, 2H), 6.71 (s, 1H), 6.61 (dd, J= 4.7, 2.2 Hz, 1H), 6.53 - 6.44 (m, 1H), 2.28 (s, 6H), 1.75 (d, J= 7.1 Hz, 3H).
  • The following examples illustrate the beneficial effects of the present invention:
    • Example 1 The anesthetic activity of group A compounds was assessed in rats using a loss of righting reflexes (LORR) assay
  • Adult male Sprague-Dawley rats (250-300 g) were selected for the experiment. The compounds in the above examples and the control drugs, etomidate and CPMM, were dissolved in dimethyl sulfoxide (DMSO), and the same volume of DMSO was given as the blank control group. The anesthesia effects of the compounds were assessed in rats using a LORR assay and a period >30 s was considered as an indicator of general anesthesia. Then the up and down method was used to determine 50% effective dose (ED50). The drugs were administered through the tail vein of rats in a volume of 0.6 mL and at a rate of 0.1 mL/s. As shown in Tables A1-E1, the results suggest that the compounds of the present invention, similar to the control etomidate and CPMM, provide a definite and transient effect of general anesthesia. Besides the compounds have the same or better potency as etomidate and CPMM. Table 1. The ED50 value with LORR and minimal lethal dose of the present invention compounds in rats
    Compound /drug ED50(mg/kg) Minimal lethal dose (mg/kg) Approximate therapeutic index
    Etomidate 0.75(0.72-0.77)* 12.75 17
    CPMM 0.78(0.74-0.82)* >7.8 >10
    Propofol 5.51(5.39-5.64)* 28 5
    DMSO / / /
    Compound A1 C >16 >8
    Compound A3 C >8 >6
    Compound A4 C >15 >11
    Compound A6 D >13 >5
    Compound A8 C >9 >7
    Compound A10 D >12 >5
    Compound A11 C >8 >4
    Compound A12 C >6 >4
    Compound A14 C >11 >8
    Compound A15 D >9 >4
    Compound A16 D >12 >4
    Compound A18 D >8 >3
    Compound A20 C >12 >10
    Compound A21 D >6 >16
    Compound A23 D >11 >5
    Compound A24 A >6 >31
    Compound A25 A >5 >21
    Compound A30 C >7 >6
    Compound A34 B >4 >6
    Compound A49 D >9 >2
    Compound A52 B >11 >16
    Compound A53 D >14 >6
    Compound A54 C >12 >9
    Compound A57 D >15 >7
    Compound A65 D >16 >7
    Compound A70 C >12 >6
    Compound A72 A >11 >100
    Compound A73 A >2 >25
    Compound A76 A >2 >10
    Compound A83 C >12 >10
    Compound A87 B >13 >18
    Compound A90 C >10 >5
    Compound A92 A >1 >14
    Compound A94 B >12 >12
    Compound A98 C >10 >7
    Compound A100 D >14 >6
    Compound A101 C >13 >8
    Compound A108 D >15 >5
    Notes:
    ∗ The values in brackets indicate 95% confidence limit (mg/kg);
    A indicates that the measured ED50 is in the range of 0.04-0.50 mg/kg (including 0.04 and 0.50 mg/kg);
    B means that the measured ED50 is in the range of 0.50-1.00 mg/kg (excluding 0.50 mg/kg, including 1.00 mg/kg);
    C indicates that the measured ED50 is in the range of 1.00-2.00 mg/kg (excluding 1.00 mg/kg, including 2.00 mg/kg);
    D indicates that the measured ED50 is in the range of 2.00-6.00 mg/kg (excluding 2.00 mg/kg, including 6.00 mg/kg).
    • Example 2 Comparison of pharmacological characteristics of the group A compounds at equivalent doses (2ED50) in rats
  • Adult male Sprague-Dawley rats (250-300 g) were selected for the experiment (n=8). The compounds and the control drugs, etomidate and CPMM, were dissolved in DMSO, and the same volume of DMSO was given as the blank control group. The drugs were administered at a dose twice their ED50 through the tail vein of rats in a volume of 0.6 mL and at a rate of 0.1 mL/s. In addition, the time of LORR was recorded as the onset time of anesthesia.
  • The results show that the compounds of the present invention, similar to the etomidate and CPMM, exhibit rapid onset and recovery (Tables 2). Furthermore, the duration of the pharmacological effects is sufficient to meet the time requirements for rapid induction of general anesthesia and for diagnostic examinations, some short invasive clinical examinations, or operations. In the experiment, the types and incidence of adverse reactions of the compounds of the present invention are less than those of etomidate and CPMM. Table 2 Comparison of pharmacological characteristics of the compounds at equivalent doses (2ED50) in rats
    Compound/drug 2ED50 (mg/k g) Onset time (min) Righting reflex duration (min) Sedation duration (mg/kg) Types and incidence of adverse reactions
    Etomidate 1.49 0.11±0.03 4.92±1.19 11.08±2.16 Tremor(10/10), Facial
    muscle twitching(4/10),Tongue stretching(8/10)
    CPMM 1.56 0.26±0.08 1.62±0.63 4.99±0.87 Convulsions(4/10), Tremor(5/10),Myoclonus( 5/10)
    Propofol 11.02 0.19±0.03 8.36±2 16.02±2.58 Intermittent Tremor(6/8), Bucking (5/8), Tongue stretching(4/8), Forelimb rigidity (2/8), Hindlimb rigidity(2/8)
    DMSO / / / / Red urine(10/10)
    Compound A1 2C 0.56±0.26 2.24±1.29 8.37±2.63 Red urine(8/8),Convulsions(7/ 8)
    Compound A3 2C 0.13±0.04 2.73±1.08 5.76±0.80 Red urine(8/8),Hindlimb rigidity (1/8)
    Compound A4 2C 0.52±0.21 1.39±0.66 6.75±1.43 Red urine(6/6), Euphoria(5/6),Hindlimb rigidity(1/6)
    Compound A6 2D 0.38±0.12 3.81±2.17 9.72±3.29 Red urine(8/8),Facial muscle twitching(2/8),Hindlimb rigidity (1/8)
    Compound A8 2C 0.57±0.20 2.70±2.52 14.81±5.21 Red urine(8/8), Tremor(2/8), Euphoria(1/8)
    Compound A10 2D 0.43±0.22 1.32±0.61 8.31±2.76 Red urine(8/8), Tremor(3/8), Forelimb clonic convulsion(2/8),Hindlimb rigidity(2/8), Facial muscle twitching(2/8), Nod(1/8)
    Compound All 2C 0.41±0.15 2.65±1.10 10.46±2.46 Red urine(6/6), General Tremor(4/6), Hindlimb rigidity (2/6), Convulsion(1/6), Euphoria(1/6)
    Compound A12 2C 0.69±0.22 3.16±2.13 8.71±1.57 Red urine(8/8), Tremor(3/8), Euphoria(1/8),Hindlimb rigidity (1/8), Clonic convulsion(1/8), Tetany convulsion (1/8), Apnea(1/8), Nod(1/8)
    Compound A14 2C 0.78±0.22 1.20±0.72 12.29±2.59 Red urine(5/5),Four limbs Tremor(1/5)
    Compound A15 2D 0.40±0.10 1.82±0.76 11.26±1.51 Red urine(8/8), Euphoria(2/8), Hindlimb rigidity(2/8), Hindlimb Tremor(1/8)
    Compound A16 2D 0.55±0.21 2.55±1.54 8.28±1.30 Red urine(8/8) Euphoria(2/8), Tremor(2/8), Apnea (1/8),Hindlimb rigidity
    (1/8)
    Compound A18 2D 0.73±0.10 1.19±0.64 10.44±1.49 Red urine(8/8), Hindlimb rigidity(5/8)
    Compound A20 2C 0.67±0.14 1.15±0.66 7.05±3.95 Red urine(8/8), Hindlimb rigidity(3/8), General Tremor(1/8)
    Compound A21 2D 0.51±0.10 1.16±0.39 8.65±2.38 Red urine(8/8) ,Euphoria(3/8), Four limbs Tremor(2/8), Hindlimb rigidity (2/8)
    Compound A23 2D 0.48±0.14 2.28±1.83 8.27±1.80 Red urine(8/8),Euphoria(6/8), Hindlimb rigidity (2/8), Tremor(1/8), Convul sions(1/8)
    Compound A24 2A 0.47±0.09 1.47±0.63 5.64±0.54 Red urine(8/8),Convulsions(5/ 8),Hindlimb rigidity (2/8)
    Compound A25 2A 0.50±0.12 2.6±0.83 7.27±0.80 Red urine(8/8),Hindlimb rigidity (2/8),Tremor(1/8)
    Compound A30 2C 0.3±0.22 2.6±0.83 6.40±1.20 Red urine(8/8),Euphoria(3/8), Tremor(1/8)
    Compound A34 2B 0.60±0.32 1.6±0.43 6.27±0.47 Red urine(8/8),Hindlimb rigidity(2/8), Tremor(1/8)
    Compound A49 2D 0.28±0.04 2.69±1.18 7.94±1.27 Red urine(8/8),Hindlimb rigidity (2/8),brokenwinded(1/8),Tremor(3/8)
    Compound A52 2B 0.50±0.08 2.01±1.00 9.59±3.37 Red urine(8/8),Euphoria(3/8), broken-winded(1/8)
    Compound A53 2D 0.53±0.28 3.01±1.22 6.59±2.17 Red urine(8/8), Tremor(2/8)
    Compound A54 2C 0.69±0.11 2.13±1.80 7.49±1.65 Red urine(8/8),Hindlimb rigidity (3/8),GeneralTremor(1/8)
    Compound A57 2D 0.42±0.16 1.48±0.51 6.31±2.55 Red urine (7/7),GeneralTremor (2/7),Tetany convulsion(2/7)
    Compound A65 2D 0.36±0.15 2.48±0.67 8.31±3.23 Red urine(8/8), Tremor(2/8)
    Compound A70 2C 0.31±0.08 2.51±1.03 10.18±3.27 Red urine(8/8),Hindlimb rigidity (2/8),Tremor(1/8),Clonic convulsion(1/8),Euphoria (1/8)
    Compound A72 2A 0.41±0.17 0.71±0.20 4.16±2.32 Red urine(8/8),Tremor(1/8),Hi ndlimb rigidity (1/8)
    Compound A73 2A 0.42±0.07 1.21±0.45 10.08±4.36 Red urine(8/8), Tremor(3/8),Fa cial muscle twitching(2/8),Euphoria(1 /8),Nod(1/8)
    Compound A76 2A 0.36±0.12 2.29±0.56 9.08±2.16 Red urine(8/8),
    Tremor(2/8), Euphoria(1/8)
    Compound A83 2C 0.43±0.32 3.21±0.41 10.08±4.36 Red urine(8/8),Facial muscle twitching (3/8),Euphoria(2 /8)
    Compound A87 2B 0.30±0.12 2.21±0.24 7.08±2.36 Red urine(8/8),Facial muscle twitching (4/8),Tremor(1/ 8)
    Compound A90 2C 0.51±0.07 5.21±1.45 5.06±1.36 Red urine(8/8), Convulsions(2/ 8),Nod(1/8)
    Compound A92 2A 0.43±0.22 2.03±0.33 6.08±1.26 Red urine(8/8),Tremor(2/8),E uphoria(1/8)
    Compound A94 2B 0.33±0.12 1.26±0.40 5.03±2.19 Red urine(8/8), Tremor(3/8),Fo ur limbs rigidity(2/8),Euphoria(1/8 )
    Compound A98 2C 0.30±0.06 1.89±0.23 7.12±1.37 Red urine(8/8),Facial muscle twitching(2/8),Hindlimb rigidity (1/8)
    Compound A100 2D 0.49±0.17 3.21±0.89 11.08±3.36 Red urine(8/8), Indirect tremor Tremor(4/8),Four limbs rigidity(2/8),Euphoria(2/8 )
    Compound A101 2C 0.39±0.21 2.29±0.65 9.11±2.36 Red urine(8/8),Euphoria(3/8), Nod(2/8)
    Compound A108 2D 0.26±0.20 3.29±1.20 8.22±1.36 Red urine(8/8),Hindlimb rigidity (7/8),the four limbs Tremor(3/8)
    • Example 3 The effects of the group A compounds on adrenocortical function in vitro test
  • The H295R cell line was selected and treated with vehicle (i.e., DMSO) and different concentrations of etomidate, CPMM, etomidate metabolite (i.e., etomidate acid), and the compounds of the present invention. Then secretion of the cortisol and corticosterone in the supernatant, was measured using HPLC-MS/MS method to determine whether the compounds of the present invention had adrenotoxic potential. The results show that the compounds of the present invention meet the design requirements (Table 3), and none of the compounds inhibit adrenocortical function in the experiment. Table 3. The effects of the compounds on adrenocortical function in vitro test
    Cell line:: H295R
    Cortisol and corticosterone determination: HPLC-MS/MS method
    The effect determination of compounds or drugs on adrenal function:
    No inhibition (using blank culture medium, or DMSO, or etomidate metabolite, i.e., etomidate acid, as a control), marked as "0" in the table.
    Mild inhibition (using CPMM as a control), marked as "1" in the table.
    Obvious inhibition (with etomidate as a control), marked as "2" in the table.
    Compound /drug EC50 (Cortisol) Cortisol as an indicator to determine the presence of inhibition EC50 (Corticoster one) Corticoste rone as an indicator to determine the presence of inhibition
    Etomidate >1nM 2 >10nM 2
    CPMM >10nM 1 > 100nM 1
    Propofol > 10000nM 0 > 10000nM 0
    Etomidate acid > 10000nM 0 > 10000nM 0
    DMSO > 10000nM 0 > 10000nM 0
    Blank medium > 10000nM 0 > 10000nM 0
    Compound A1 > 1000nM 0 > 1000nM 0
    Compound A3 > 1000nM 0 > 1000nM 0
    Compound A4 > 1000nM 0 > 1000nM 0
    Compound A6 > 1000nM 0 > 1000nM 0
    Compound A8 > 1000nM 0 > 1000nM 0
    Compound A10 > 1000nM 0 > 1000nM 0
    Compound All > 100nM 0 > 100nM 0
    Compound A12 > 100nM 0 > 100nM 0
    Compound A14 > 1000nM 0 > 1000nM 0
    Compound A15 > 100nM 0 > 100nM 0
    Compound A16 > 100nM 0 > 100nM 0
    Compound A18 > 100nM 0 > 100nM 0
    Compound A20 > 100nM 0 > 100nM 0
    Compound A21 > 100nM 0 > 100nM 0
    Compound A23 > 100nM 0 > 100nM 0
    Compound A24 > 1000nM 0 > 1000nM 0
    Compound A25 > 1000nM 0 > 1000nM 0
    Compound A30 > 1000nM 0 > 1000nM 0
    Compound A34 > 1000nM 0 > 1000nM 0
    Compound A49 > 100nM 0 > 100nM 0
    Compound A52 > 1000nM 0 > 1000nM 0
    Compound A53 > 100nM 0 > 100nM 0
    Compound A54 > 100nM 0 > 100nM 0
    Compound A57 > 100nM 0 > 100nM 0
    Compound A65 > 100nM 0 > 100nM 0
    Compound A70 > 100nM 0 > 100nM 0
    Compound A72 > 1000nM 0 > 1000nM 0
    Compound A73 > 1000nM 0 > 1000nM 0
    Compound A76 > 1000nM 0 > 1000nM 0
    Compound A83 > 1000nM 0 > 1000nM 0
    Compound A87 > 1000nM 0 > 1000nM 0
    Compound A90 > 1000nM 0 > 1000nM 0
    Compound A92 > 1000nM 0 > 1000nM 0
    Compound A94 > 1000nM 0 > 1000nM 0
    Compound A98 > 1000nM 0 > 1000nM 0
    Compound A100 > 100nM 0 > 100nM 0
    Compound A101 > 100nM 0 > 100nM 0
    Compound A108 > 100nM 0 > 100nM 0
    • Example 4 The effects of group A compounds on adrenal cortex function were measured in vivo.
  • The anesthetic activity of the compounds was assessed in rats using a LORR assay and the up and down method was used to determine ED50. The drugs were administered at a dose twice their ED50 through the tail vein of rats (n=8), The changes of serum corticosterone in rats before and after administration were measured. The serum corticosterone concentration (ng/ml) was used as the representative index to determine the effect of present invention compounds on adrenal cortex function in rats.
  • The main test equipment are as follows:
    Multifunctional ionmeter(METTLER TOLEDO, Types : SevenMulti), Pipette (Eppendorf, Specifications: 1000 ul, 200 ul, 100 ul, 10 ul), 22 G intravenous indwelling needle(BECTON DICKINSON), 1 ml micro injection needle (Germany BD), timer.
  • Administration procedure: The experiment was unified in the forenoon. 8:00 to 8:30 for the trial preparation stage. Rats were put into a restraint device with a 22G indwelling catheter placed into a lateral tail vein and retained with heparin, a pre-filled extension tube was attached and taped to the tail vein to secure the extension tube.
    • ① Dexamethasone suppression: intravenous injection of dexamethasone after the placement of the retaining needle(0.5 mg/kg).
    • ② The first blood collection was performed two hours after dexamethasone administration(S 1);
    • ③Dexamethasone is injected after blood collection(0.2 mg/kg)+ the present invention Compound(2ED50), all drugs or compounds had a constant volume of 0.6 ml, and the speed was 0. 1ml/s. Exogenous ACTH (25 ug / kg) was injected after 15 minutes. ④Blood samples were collected again 30 minutes after ACTH administration(S2);
    • ⑤After blood samples were collected, they were allowed to stand for 30-60 minutes at room temperature, then centrifuged at 3500 rpm for 10 minutes, the supernatant was centrifuged at 15000 rpm for 5 minutes, and then frozen in -20°C refrigerator.
  • Data collection: The concentration of corticosterone in serum of rats was measured by high performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) within 2-3 days after sampling.
  • The result: the compounds of this invention did not inhibit the synthesis of adrenal cortex hormone as compared with normal saline (0.9% NaCl) and propofol (PRO), while the control of etomidate (ET) showed obvious inhibitory effect on adrenal cortex function (Fig. 1).
    • Example 5 The effects of the group A compounds on the circulatory function were measured in rats using a small animal implanted physiological signal telemetry system
  • The anesthetic activity of the compounds was assessed in rats using a LORR assay and the up and down method was used to determine ED50. The drugs were administered at a dose twice their ED50 through the tail vein of rats (n=6). A small animal implantable physiological signal telemetry system from DSI (Data Science International, Inc.) was used to measure the changes in heart rate (HR) and blood pressure in rats during 30 min after administration. Then mean arterial pressure (MAP) and HR were used as representative indicators to determine hemodynamic stability of the compounds of the present invention in rats.
  • The main test equipment are as follows:
    A small animal implantable physiological signal telemetry system from DSI (Data Science International, Inc.) including implants (RATHD-S21, DSI, United States), receiver boards (RPC-1, DSI, United States), signal conversion devices (DEM, DSI, USA), perfusion glue (DSI, USA), fibrin membrane (DSI, USA), etc.
  • A small animal ventilator (HX-101E, Chengdu Taimeng Technology Co., Ltd.); An electronic balance (ME215S, Sartorius, Germany).
  • First, animal models were established. A left ventricular catheter, an abdominal aortic catheter and ECG wires were placed into rats. At least one week after surgery, data were recorded.
  • Administration procedure: rats were put into a restraint device with a 20G indwelling catheter placed into a lateral tail vein. After administration of 0.2 mL heparin, a pre-filled extension tube was attached and taped to the tail vein to secure the extension tube. Then the rats were removed from the restraint device to a cage before placing them together on the signal receiver. After the rats acclimatized for 30 min, the compounds were injected with a dose at 2-fold the ED50 via the catheter. Finally, the pharmacological effects, adverse reactions, and behavioural manifestations of the rats were observed and recorded
  • Data collection: After setting the data collection parameters on the software, the power of the implant was turned on to start data collection. In this experiment, data recording frequency was set to 15 s. Data collection was continuously recorded for 30 min before and after administration of the drugs in rats. After data acquisition, the test was stopped. The results: the compounds of the present invention had almost no inhibitory effect on the circulatory function as does the control etomidate, while the control propofol exihibit significant inhibition of the circulatory function (Fig. 2, Fig. 3, Fig. 4, Fig. 5).
    • Example 6 Pharmacological effects of the group A compounds on continuous infusion in rats
  • Adult male Sprague-Dawley rats with body weight ranging from 250 to 300 gm were selected for continuous infusion test. The compounds of the present invention and the control drugs, etomidate and CPMM, were prepared as emulsion before the test, which was continuously infused through the tail vein of the rats at 2 times the MIR (minimum infusion rate) and the LORR was maintained for 1 hour. Time to recovery of righting reflex from stopping infusion, and time to fully awake from stopping infusion were recorded. The results are shown in Table A.
  • The results are shown which illustrate that the recovery time after 1 hour of continuous infusion under 2 x MIR conditions is not significantly longer than that of the compounds of the present invention after a single intravenous injection of 2ED50, and the recovery time is considerably shorter than that of etomidate. Furthermore, the types and incidence of adverse reactions are also significantly less than etomidate and CPMM. Table 4 Pharmacological effects of the compounds on continuous infusion in rats
    Compound /drug Onset time (min) Recovery time after stopping infusion (min) Types and incidence of adverse reactions
    Etomidate 4-5 25-30 Tremor(6/6),Facial muscle twitching (4/6),Tongue stretching(5/6)
    CPMM 3-4 7-8 Convulsions(3/6),Tremor(5/6),Myoclonus(5/6),
    DMSO / / Hematuria(8/8)
    Compound A4 4-5 14-16 Tremor(3/6),Tongue stretching(4/6)
    Compound A14 6-7 10-14 Tremor(1/6),
    Compound A20 5-6 12-15 Tremor(5/6)
    Compound A24 4-5 8-12 Tremor(2/6),Tongue stretching(4/6)
    Compound A30 3-4 8-14 Tremor(2/6)
    Compound A52 5-6 13-18 Tongue stretching(4/6),Tremor(4/6)
    Compound A76 3-4 14-16 Tremor(1/6),Tongue stretching(2/6)
    Compound A90 5-6 2-15 Tremor(3/6)
    • Example 7 The anesthetic activity of the group B compounds was assessed in rats using a loss of righting reflexes (LORR) assay
  • Adult male Sprague-Dawley rats (250-300 g) were selected for the experiment. The compounds in the above examples and the control drugs, etomidate and CPMM, were dissolved in dimethyl sulfoxide (DMSO), and the same volume of DMSO was given as the blank control group. The anesthesia effects of the compounds were assessed in rats using a LORR assay and a period >30 s was considered as an indicator of general anesthesia. Then the up and down method was used to determine 50% effective dose (ED50). The drugs were administered through the tail vein of rats in a volume of 0.6 mL and at a rate of 0.1 mL/s. As shown in Tables A1-E1, the results suggest that the compounds of the present invention, similar to the control etomidate and CPMM, provide a definite and transient effect of general anesthesia. Besides the compounds have the same or better potency as etomidate and CPMM. Table 5 The ED50 value with LORR and minimal lethal dose of the compounds in rats
    Compound /drug ED50 (mg/kg) Minimal lethal dose (mg/kg) Approximate therapeutic index
    Etomidate 0.75(0.72-0.77)* 12.75 17
    CPMM 0.78(0.74-0.82)* >7.8 >10
    Propofol 5.51(5.39-5.64)* 28 5
    DMSO / / /
    Compound B1 A >8 >20
    Compound B3 A >6 >32
    Compound B6 A >10 >71
    Compound B7 B >24 >31
    Compound B8 B >8 >9
    Compound B10 B >11 >16
    Compound B11 B >6 >8
    Compound B12 A >5 >16
    Compound B13 B >1 >2
    Compound B14 C >7 >5
    Compound B15 B >9 >9
    Compound B17 A >16 >56
    Compound B18 C >14 >12
    Compound B21 B >8 >11
    Compound B26 C >12 >10
    Compound B30 B >10 >10
    Compound B35 A >8 >29
    Compound B36 B >5 >7
    Compound B40 B >6 >6
    Compound B47 C >13 >9
    Compound B51 C >14 >12
    Compound B65 B >9 >13
    Compound B70 D >15 >2
    Compound B80 D >16 >3
    Compound B99 A >8 >16
    Compound B100 D >18 >2
    Compound B101 C >13 >7
    Compound B104 C >11 >10
    Compound B108 B >14 >20
    Compound B110 D >16 >7
    Compound B115 B >18 >25
    Compound B116 C >12 >9
    Compound B118 C >17 >12
    Compound B120 B >15 >21
    Compound B121 D >20 >3
    Compound B127 B >16 >23
    Compound B132 B >12 >16
    Compound B133 B >14 >20
    Compound B136 D >18 >6
    Compound B137 C >12 >9
    Compound B140 E >30 >2
    Compound B144 E >24 >2
    Compound B145 D >18 >4
    Compound B146 C >14 >8
    Notes:
    ∗ The values in brackets indicate 95% confidence limit (mg/kg);
    A indicates that the measured ED50 is in the range of 0.04-0.50 mg/kg (including 0.04 and 0.50 mg/kg);
    B indicates that the measured ED50 is in the range of 0.50-1.00 mg/kg (excluding 0.50 mg/kg, including 1.00 mg/kg);
    C indicates that the measured ED50 is in the range of 1.00-2.00 mg/kg (excluding 1.00 mg/kg, including 2.00 mg/kg);
    D indicates that the measured ED50 is in the range of 2.00-10.00 mg/kg (excluding 2.00 mg/kg, including 10.00 mg/kg);
    E indicates that the measured ED50 is in the range of 10.00-20.00 mg/kg (excluding 10.00 mg/kg, including 20.00 mg/kg).
    • Example 8 Comparison of pharmacological characteristics of the group B compounds at equivalent doses (2ED50) in rats
  • Adult male Sprague-Dawley rats (250-300g) were selected for the experiment (n=8).
  • The compounds and the control drugs, etomidate and CPMM, were dissolved in DMSO, and the same volume of DMSO was given as the blank control group. The drugs were administered at a dose twice their ED50 through the tail vein of rats in a volume of 0.6 mL and at a rate of 0.1 mL/s. In addition, the time of LORR was recorded as the onset time of anesthesia. The results show that the compounds of the present invention, Similar to the etomidate and CPMM, exhibit rapid onset and recovery (Tables 2). Furthermore, the duration of the pharmacological effects is sufficient to meet the time requirements for rapid induction of general anesthesia and for diagnostic examinations, some short invasive clinical examinations, or operations. In the experiment, the types and incidence of adverse reactions of the compounds of the present invention are less than those of etomidate and CPMM. Table 6 Comparison of pharmacological characteristics of the compounds at equivalent doses (2ED50) in rats
    Compound /drug 2ED50 (mg/kg ) Minimal lethal dose (mg/kg) Approxima te therapeutic index Compoun d /drug ED50 (mg/kg)
    Etomidate 1.49 0.11±0.03 4.92±1.19 11.08±2.1 6 Tremor(10/10),Facial muscle twitching(4/10),Tongue stretching(8/10)
    CPMM 1.56 0.26±0.08 1.62±0.63 4.99±0.87 Convulsions(4/10),Tremo r(5/10),Myoclonus(5/10)
    Propofol 11.02 0.19±0.03 8.36±2 16.02±2.5 8 IntermittentTremor(6/8), Cough(5/8), Tongue stretching (4/8),Forelimb rigidity(2/8),Hindlimb rigidity(2/8)
    DMSO / / / / Red urine(10/10)
    Compound B1 2A 0.45±0.16 1.11±1.25 4.46±1.41 Red urine(8/8), Hindlimb rigidity(4/8),Euphoria(2/8 )
    Compound B3 2A 0.24±0.12 3.69±1.35 10.32±2.0 8 Red urine(8/8),Hindlimb rigidity(4/8),Tremor(1/8), Euphoria(1/8)
    Compound B6 2A 0.46±0.07 1.89±0.71 6.13±0.98 Red urine(8/8),Euphoria(1/8)
    Compound B7 2B 0.44±0.18 1.78±0.89 6.18±2.17 Red urine(8/8) ,Euphoria(3/8)
    Compound B8 2B 0.44±0.11 2.01±0.63 7.06±1.70 Red urine(10/10),Euphoria(1/ 10),
    Compound B10 2B 0.39±0.20 2.03±0.73 7.14±1.05 Red urine(8/8),Facial muscle twitching(2/8)
    Compound B11 2B 0.46±0.23 0.85±0.18 6.89±1.01 Red urine(8/8), Generalrigidity (1/8)
    Compound B12 2A 0.58±0.23 1.98±0.89 6.03±0.88 Red urine(8/8), Euphoria(4/8),Hindlimb rigidity(1/8),Tremor(1/8)
    Compound B13 2B 0.21±0.08 3.58±2.20 9.92±3.14 Red urine(8/8),Hindlimb rigidity(7/8),Tremor(1/8)
    Compound B14 2C 0.33±0.12 1.16±0.31 5.47±1.14 Red urine(8/8),Euphoria(4/8)
    Compound B15 2B 0.46±0.04 1.57±0.77 4.74±1.38 Red urine(3/3),Euphoria(3/3)
    Compound B17 2A 0.43±0.04 3.27±1.63 8.07±3.09 Red urine(8/8)
    Compound B18 2C 0.31±0.14 3.22±0.99 7.03±1.27 Red urine(8/8),Convulsions(4/ 8),Slower breathing(1/8),Hindlimb rigidity(1/8)
    Compound B21 2B 0.28±0.15 4.26±1.21 6.03±0.97 Red urine(8/8),Hindlimb rigidity(3/8)
    Compound B26 2C 0.33±0.05 3.26±1.23 5.67±2.03 Red urine(8/8), Tremor(2/8),Hi ndlimb rigidity(2/8)
    Compound B30 2B 0.27±0.04 4.50±1.32 6.32±1.15 Red urine(8/8),Facial muscle twitching(2/8),Hindlimb rigidity(1/8)
    Compound B35 2A 0.38±0.58 3.88±1.08 5.39±0.97 Red urine(8/8),Convulsions(4/ 8),Slower breathing(1/8),Hindlimb rigidity(1/8)
    Compound B36 2B 0.29±0.67 4.67±1.24 6.61±2.54 Red urine(8/8),Slower breathing(1/8),Tremor(1/ 8)
    Compound B40 2B 0.21±0.09 3.68±1.21 6.22±1.61 Red urine(8/8),Generalrigidity (1/8),Cough(1/8),
    Compound B47 2C 0.18±0.12 3.90±0.29 3.21±0.97 Red urine(8/8),brokenwinded(1/8),Forelimb rigidity(1/8)
    Compound B51 2C 0.29±0.33 2.98±0.28 4.20±1.62 Red urine(8/8),IntermittentTre mor(4/8),Hindlimb rigidity(2/8)
    Compound B65 2B 0.45±0.14 0.94±0.25 5.30±2.17 Red urine(8/8),Hindlimb rigidity(4/8),Tremor(2/8)
    Compound B70 2D 0.51±0.33 1.94±0.61 4.21±1.76 Red urine(8/8), Tremor(3/8)
    Compound B80 2D 0.39±0.21 3.20±0.31 4.90±1.27 Red urine(8/8),Hindlimb rigidity(4/8),Tremor(2/8)
    Compound B99 2A 0.78±0.24 1.02±0.58 6.34±1.04 Red urine(8/8),Euphoria(3/8), Hindlimb rigidity(2/8),Tremor(1/8)
    Compound B100 2D 0.13-0.45 0.75-1.12 7.27-10.52 Red urine(2/2),Euphoria(1/2)
    Compound B101 2C 0.44±0.12 3.02±1.32 5.32±1.76 Red urine(8/8),Euphoria(4/8), General rigidity(2/8),Tremor(1/8)
    Compound B104 2C 0.59±0.11 1.18±0.65 6.34±1.33 Red urine(8/8),Hindlimb rigidity(1/8),Tremor(1/8)
    Compound B108 2B 0.60±0.12 0.96±0.26 6.14±1.70 Red urine(8/8),Hindlimb rigidity(3/3)
    Compound B110 2D 0.44±0.32 3.83±0.69 5.32±1.09 Red urine(8/8),brokenwinded(3/8),Tremor(2/8)
    Compound B115 2B 0.62±0.25 1.95±1.55 6.39±2.85 Red urine(8/8),Hindlimb rigidity(2/8)
    Compound B116 2C 0.49±0.13 1.44±0.73 5.66±1.91 Red urine(8/8),Hindlimb rigidity(2/8),Tremor(1/8)
    Compound B118 2C 0.63±0.27 0.77±0.17 4.89±2.09 Red urine(8/8), Tremor(1/8)
    Compound B120 2B 0.53±0.17 1.26±0.44 7.46±1.51 Red urine(8/8),Hindlimb rigidity(8/8),Tremor(1/8)
    Compound B121 2D 0.7 1.53 7.83 Red urine(1/1),Tremor(1/1)
    Compound B127 2B 0.59±0.15 1.23±0.41 6.74±2.39 Red urine(8/8)
    Compound B132 2B 0.55±0.20 0.91±0.42 7.65±2.60 Red urine(8/8),Hindlimb rigidity(2/8)
    Compound B133 2B 0.63±0.14 2.10±1.17 8.34±0.90 Red urine(8/8),Hindlimb rigidity(4/8),Tremor(2/8)
    Compound B136 2D 0.71±0.15 1.60±0.70 7.22±2.06 Red urine(8/8)
    Compound B137 2C 0.50±0.20 0.73±0.13 6.65±3.03 Red urine(4/4),Hindlimb rigidity(2/4),Tremor(1/4)
    Compound B140 2E 0.55±0.43 3.90±0.43 6.56±1.87 Red urine(8/8) ,Euphoria(3/8)
    Compound B144 2E 0.43±0.12 4.43±0.12 5.07±1.42 Red urine(8/8), Tremor(4/8),E uphoria(1/8)
    Compound B145 2D 0.59±0.16 0.57±0.13 7.71±1.03 Red urine(8/8),Hindlimb rigidity(5/8),Euphoria(1/8 )
    Compound B146 2C 0.60±0.23 1.08±0.45 10.21±2.5 2 Red urine(8/8),Hindlimb rigidity(6/8), Tremor(1/8)
    • Example 9 The effects of the group B compounds on adrenocortical function in vitro test
  • The H295R cell line was selected and treated with vehicle (i.e., DMSO) and different concentrations of etomidate, CPMM, etomidate metabolite (i.e., etomidate acid), and the compounds of the present invention. Then secretion of the cortisol and corticosterone in the supernatant, was measured using HPLC-MS/MS method to determine whether the compounds of the present invention had adrenotoxic potential. The results show that the compounds of the present invention meet the design requirements (Tables 3), and none of the compounds inhibit adrenocortical function in the experiment. Table 7 The effects of the compounds on adrenocortical function in vitro test
    Cell line:: H295R
    Incubation concentration and concentration range: 0.1nM, InM, 10nM, 50nM, 100nM, 500nM, 1000nM, 10000nM
    Cortisol and corticosterone determination: HPLC-MS/MS method
    The effect determination of compounds or drugs on adrenal function:
    No inhibition (using blank culture medium, or DMSO, or etomidate metabolite, i.e., etomidate acid, as a control), marked as "0" in the table.
    Mild inhibition (using CPMM as a control), marked as "1" in the table.
    Obvious inhibition (with etomidate as a control), marked as "2" in the table.
    Compound /drug EC50 (Cortisol) Cortisol as an indicator to determine the presence of inhibition EC50 (Corticoster one) Corticosterone as an indicator to determine the presence of inhibition
    Etomidate > 1nM 2 > 10nM 2
    CPMM > 10nM 1 > 100nM 1
    Etomidate acid > 10000nM 0 > 10000nM 0
    Propofol > 10000nM 0 > 10000nM 0
    DMSO > 10000nM 0 > 10000nM 0
    Blank medium > 10000nM 0 > 10000nM 0
    Compound B1 > 50nM 0 > 100nM 0
    Compound B3 > 1000nM 0 > 1000nM 0
    Compound B6 > 100nM 0 > 100nM 0
    Compound B7 > 100nM 0 > 100nM 0
    Compound B8 > 1000nM 0 > 1000nM 0
    Compound B10 > 100nM 0 > 100nM 0
    Compound B11 > 1000nM 0 > 1000nM 0
    Compound B12 > 1000nM 0 > 1000nM 0
    Compound B13 > 1000nM 0 > 1000nM 0
    Compound B14 > 1000nM 0 > 1000nM 0
    Compound B15 > 1000nM 0 > 1000nM 0
    Compound B17 > 1000nM 0 > 1000nM 0
    Compound B18 > 100nM 0 > 100nM 0
    Compound B21 > 100nM 0 > 100nM 0
    Compound B26 > 100nM 0 > 100nM 0
    Compound B30 > 1000nM 0 > 1000nM 0
    Compound B35 > 1000nM 0 > 1000nM 0
    Compound B36 > 1000nM 0 > 1000nM 0
    Compound B40 > 100nM 0 > 100nM 0
    Compound B47 > 100nM 0 > 100nM 0
    Compound B51 > 1000nM 0 > 1000nM 0
    Compound B65 > 1000nM 0 > 1000nM 0
    Compound B70 > 1000nM 0 > 1000nM 0
    Compound B80 > 1000nM 0 > 1000nM 0
    Compound B99 > 3000nM 0 > 3000nM 0
    Compound B100 > 1000nM 0 > 1000nM 0
    Compound B101 > 1000nM 0 > 1000nM 0
    Compound B104 > 3000nM 0 > 3000nM 0
    Compound B108 > 3000nM 0 > 3000nM 0
    Compound B110 > 3000nM 0 > 3000nM 0
    Compound B115 > 3000nM 0 > 3000nM 0
    Compound B116 > 3000nM 0 > 3000nM 0
    Compound B118 > 1000nM 0 > 1000nM 0
    Compound B120 > 1000nM 0 > 1000nM 0
    Compound B121 > 1000nM 0 > 1000nM 0
    Compound B127 > 3000nM 0 > 3000nM 0
    Compound B132 > 1000nM 0 > 1000nM 0
    Compound B133 > 1000nM 0 > 1000nM 0
    Compound B136 > 1000nM 0 > 1000nM 0
    Compound B137 > 1000nM 0 > 1000nM 0
    Compound B140 > 1000nM 0 > 1000nM 0
    Compound B144 > 1000nM 0 > 1000nM 0
    Compound B145 > 3000nM 0 > 3000nM 0
    Compound B146 > 3000nM 0 > 3000nM 0
    • Example 10 The effects of group B compounds on adrenal cortex function were measured in vivo.
  • The anesthetic activity of the compounds was assessed in rats using a LORR assay and the up and down method was used to determine ED50. The drugs were administered at a dose twice their ED50 through the tail vein of rats (n=8), The changes of serum corticosterone in rats before and after administration were measured. The serum corticosterone concentration (ng/ml) was used as the representative index to determine the effect of present invention compounds on adrenal cortex function in rats.
  • The main test equipment are as follows:
    Multifunctional ionmeter (METTLER TOLEDO, type : SevenMulti), Pipette(Eppendorf, Specifications: 1000 ul, 200 ul, 100 ul, 10 ul), 22 G intravenous indwelling needle(BECTON DICKINSON), 1 ml micro injection needle (Germany BD), timer.
  • Administration procedure: The experiment was unified in the forenoon. 8:00 to 8:30 for the trial preparation stage. Rats were put into a restraint device with a 22G indwelling catheter placed into a lateral tail vein and retained with heparin, a pre-filled extension tube was attached and taped to the tail vein to secure the extension tube.
    • ① Dexamethasone suppression: intravenous injection of dexamethasone after the placement of the retaining needle(0.5 mg/kg).
    • ② The first blood collection was performed two hours after dexamethasone administration(S1);
    • ③Dexamethasone is injected after blood collection(0.2 mg/kg)+ the present invention Compound(2ED50), all drugs or compounds had a constant volume of 0.6 ml, and the speed was 0.1ml/s. Exogenous ACTH (25 ug / kg) was injected after 15 minutes.
    • ④Blood samples were collected again 30 minutes after ACTH administration(S2);
    • ⑤After blood samples were collected, they were allowed to stand for 30-60 minutes at room temperature, then centrifuged at 3500 rpm for 10 minutes, the supernatant was centrifuged at 15000 rpm for 5 minutes, and then frozen in -20°C refrigerator.
  • Data collection: The concentration of corticosterone in serum of rats was measured by high performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) within 2-3 days after sampling.
  • Result: the Compound of this invention did not inhibit the synthesis of adrenal cortex hormone as compared with normal saline (0.9% NaCl) and propofol (PRO), while the control of etomidate (ET) showed obvious inhibitory effect on adrenal cortex function. (Fig. 6).
    • Example 11 The effects of the group B compounds on the circulatory function were measured in rats using a small animal implanted physiological signal telemetry system
  • The anesthetic activity of the compounds was assessed in rats using a LORR assay and the up and down method was used to determine ED50. The drugs were administered at a dose twice their ED50 through the tail vein of rats (n=6). A small animal implantable physiological signal telemetry system from DSI (Data Science International, Inc.) was used to measure the changes in heart rate (HR) and blood pressure in rats during 30 min after administration. Then mean arterial pressure (MAP) and HR were used as representative indicators to determine hemodynamic stability of the compounds of the present invention in rats.
  • The main test equipment are as follows:
    A small animal implantable physiological signal telemetry system from DSI (Data Science International, Inc.) including implants (RATHD-S21, DSI, United States), receiver boards (RPC-1, DSI, United States), signal conversion devices (DEM, DSI, USA), perfusion glue (DSI, USA), fibrin membrane (DSI, USA), etc.
  • A small animal ventilator (HX-101E, Chengdu Taimeng Technology Co., Ltd.); An electronic balance (ME215S, Sartorius, Germany).
  • First, animal models were established. A left ventricular catheter, an abdominal aortic catheter and ECG wires were placed into rats. At least one week after surgery, data were recorded.
  • Administration procedure: rats were put into a restraint device with a 20G indwelling catheter placed into a lateral tail vein. After administration of 0.2 mL heparin, a pre-filled extension tube was attached and taped to the tail vein to secure the extension tube. Then the rats were removed from the restraint device to a cage before placing them together on the signal receiver. After the rats acclimatized for 30 min, the compounds were injected with a dose at 2-fold the ED50 via the catheter. Finally, the pharmacological effects, adverse reactions, and behavioral manifestations of the rats were observed and recorded
  • Data collection: After setting the data collection parameters on the software, the power of the implant was turned on to start data collection. In this experiment, data recording frequency was set to 15 s. Data collection was continuously recorded for 30 min before and after administration of the drugs in rats. After data acquisition, the test was stopped. Results: compounds of the present invention had almost no inhibitory effect on the circulatory function as does the control etomidate and CPMM, while the control propofol exhibit significant inhibition of the circulatory function (Fig. 7, Fig. 8, Fig. 9, Fig. 10).
    • Example 12 Pharmacological effects of the group B compounds on continuous infusion in rats
  • Adult male Sprague-Dawley rats with body weight ranging from 250 to 300 gm were selected for continuous infusion test. The compounds of the present invention and the control drugs, etomidate and CPMM, were prepared as emulsion before the test, which was continuously infused through the tail vein of the rats at 2 times the MIR (minimum infusion rate) and the LORR was maintained for 1 hour. Time to recovery of righting reflex from stopping infusion, and time to fully awake from stopping infusion were recorded. The results are shown in Table 8.
  • The results are shown which illustrate that the recovery time after 1 hour of continuous infusion under 2 × MIR conditions is not significantly longer than that of the compounds of the present invention after a single intravenous injection of 2 × ED50, and the recovery time is considerably shorter than that of etomidate. Furthermore, the types and incidence of adverse reactions are also significantly less than etomidate and CPMM. Table 8 Pharmacological effects of the compounds on continuous infusion in rats
    Compound /drug Onset time (min) Recovery time after stopping infusion (min) Types and incidence of adverse reactions
    Etomidate 4-5 25-30 Tremor (6/6), Facial muscle twitching (4/6), Tongue stretching (5/6)
    CPMM 3-4 7-8 Convulsions (3/6), Tremor (5/6), Myoclonus (5/6)
    DMSO / / Red urine (8/8)
    Compound B3 3-4 15-16 Tremor(4/6),Tongue stretching(3/6)
    Compound B6 4-6 14-16 Tremor(2/6),Tongue stretching(2/6)
    Compound B12 5-6 13-15 Tremor(3/6)
    Compound B14 5-6 19-12 Tremor(3/6)
    Compound B47 3-4 7-15 Tremor(4/6),Forelimbrigidity(l/6)
    Compound B80 3-5 12-16 Tremor(5/6)
    Compound B100 5-6 15-17 Tremor(2/6),Tongue stretching(3/6)
    Compound B118 6-7 13-15 Tremor(4/6), Tongue stretching(4/6)
    • Example 13 The group C compounds of the invention can produce definite general anesthesia in rats
  • Instruments and equipment: Multifunctional ionmeter(METTLER TOLEDO,types: SevenMulti),Pipette(Eppendorf,Specifications: 1000 ul,200 ul,100 ul,10 ul),22 G intravenous indwelling needle(BECTON DICKINSON),1 ml micro injection needle (Germany BD),timer.
  • Experimental Method: The anesthesia effects of the compounds were assessed in rats using a loss of righting reflexes (LORR) assay and a period >30 s was considered as an indicator of general anesthesia. Then the up and down method was used to determine 50% effective dose (ED50). Adult male Sprague-Dawley rats (250-300 g) were selected for the experiment. The compounds in the above examples and the control drugs, etomidate and CPMM, were dissolved in dimethyl sulfoxide (DMSO), and the same volume of DMSO was given as the blank control group. The drugs were administered through the tail vein of rats in a volume of 0.6 mL and at a rate of 0.1 mL/s.
  • Evaluating indicator: The end point of anesthesia: LORR was used as the end point of anesthesia; General anesthesia effect: the disappearance of forepaw righting reflex in rats lasting for 30 seconds is taken as the index of general anesthesia effect; Anesthesia recovery index: the recovery of rat forepaw righting reflex was used as the index of anesthesia recovery.
  • Experimental results are shown in Table 9:
    The compound of the invention can produce definite and transient general anesthesia like the control etomidate and CPMM, and the compound of the invention shows the same or better potency as etomidate and CPMM. Table 9 The effectiveness and safety window of the compound of the invention in rats
    Compound /drug ED50 (mg/kg) Minimal lethal dose (mg/kg) Approximate therapeutic index
    Etomidate 0.74(0.72-0.75)* 13.8 18.7
    CPMM 0.49(0.45-0.53)* 20.6 42.0
    Propofol 5.01(5.01-5.79)* 22.6 4.0
    DMSO / / /
    Compound C1 ++++ / /
    Compound C2 ++++ >12.4 >2.5
    Compound C9 ++++ >10.2 >2.1
    Compound C14 ++++ >14.5 >6.0
    Compound C15 ++++ >16.8 >3.4
    Compound C16 ++++ >17.0 >12.0
    Compound C27 ++ >13.6 >16.6
    Compound C28 ++++ >11.8 >2.4
    Compound C29 ++++ / /
    Compound C33 ++++ >14.2 >2.8
    Compound C34 ++++ >12.8 >2.6
    Compound C35 ++ >10.3 >12.9
    Compound C36 ++++ >15.2 >3.0
    Compound C40 ++ >8.3 >13.8
    Compound C45 ++++ >10.8 >2.2
    Compound C46 ++++ >11.8 >2.4
    Compound C51 +++ >12.5 >8.3
    Compound C53 +++++ / /
    Compound C54 ++++++ / /
    Compound C55 ++++ >13.61 >16.6
    Compound C56 ++++ >13.61 >16.6
    Compound C57 ++++ >13.61 >16.6
    Compound C69 + >4.2 >19.2
    Compound C70 + >6.4 >18.2
    Compound C71 ++ >6.6 >8.0
    Compound C72 + >8.9 >27.7
    Compound C73 + >4.0 >23.4
    Compound C74 + >6.0 >42.9
    Compound C76 ++ >15.6 >21.9
    Compound C78 ++ >11.5 >14.3
    Compound C84 +++++ / /
    Notes:
    ∗ The values in brackets indicate 95% confidence limit (mg/kg);
    + indicates that the measured ED50 is in the range of 0.04-0.50 mg/kg (including 0.04 and 0.50 mg/kg);
    ++ means that the measured ED50 is in the range of 0.50-1.00 mg/kg (excluding 0.50 mg/kg, including 1.00 mg/kg);
    +++ indicates that the measured ED50 is in the range of 1.00-2.00 mg/kg (excluding 1.00 mg/kg, including 2.00 mg/kg);
    ++++ indicates that the measured ED50 is in the range of 2.00-10.00 mg/kg (excluding 2.00 mg/kg, including 6.00 mg/kg);
    +++++ indicates that the measured ED50 is in the range of 10.00-20.00 mg/kg (excluding 10.00 mg/kg, including 20.00 mg/kg);
    ++++++ indicates that the measured ED50 is in the range of 20.00-30.00 mg/kg (excluding 20.00 mg/kg, including 30.00 mg/kg).
    • Example 14 The group C compounds of the invention shows the pharmacological effect of rapid onset and rapid recovery under the equivalent dose (2ED50).
  • Instruments and equipment: multi-function ion meter (METTLER TOLEDO, models:
    SevenMulti), pipetting gun (Eppendorf, specifications: 1000 ul, 200 ul, 100 ul, 10 ul), electronic balance (model: ME215S, manufacturers: Sartorius, Germany), the timer.
  • Experimental methods: Adult male Sprague-Dawley rats (250-300 g) were selected for the experiment (n=8). The compounds and the control drugs, etomidate and CPMM, were dissolved in DMSO, and the same volume of DMSO was given as the blank control group. The drugs were administered at a dose twice their ED50 through the tail vein of rats in a volume of 0.6 mL and at a rate of 0.1 mL/s.
  • Evaluation index: onset time: from the completion of drug injection to the disappearance of forepaw righting reflex in rats; Duration of anesthesia: the time from the disappearance of rat forepaw righting reflex to the recovery of rat forepaw righting reflex; Recovery time of anesthesia: the time from the disappearance of forepaw righting reflex to complete recovery;
  • Experimental results (table 10, 11):
    The compound of the invention, like the control etomidate and CPMM, shows the characteristics of rapid onset and rapid recovery. The duration of pharmacological action can meet the time needs of rapid induction of general anesthesia and diagnostic examination, short traumatic examination or operation. In the experiment, the types and incidence of adverse reactions of the compound of the invention are mostly less than those of the control etomidate and CPMM Table 10 Pharmacological effects of the present invention compound in rats
    Compound /drug Onset time (min) Righting reflex duration (min) Sedation duration (min)
    Etomidate < 30 s 6.03±1.93 15.35±3.57
    CPMM < 30 s 2.71±0.97 8.48±2.58
    Propofol < 30 s 8.53±1.52 14.77±3.50
    DMSO / / /
    Compound C1 < 1 min 0.90±0.30 9.06±1.21
    Compound C2 < 30 s 1.78±0.53 5.38±0.78
    Compound C9 < 30 s 1.56±0.89 6.62±0.72
    Compound C14 < 1 min 1.38±0.4 7 9.03±1.58
    Compound C15 < 30 s 2.13±0.59 5.3±0.92
    Compound C16 < 30 s 2.26±0.81 4.89±0.98
    Compound C27 < 30 s 1.48±0.14 4.39±0.94
    Compound C28 < 30 s 1.91±0.65 5.63±0.62
    Compound C29 / / /
    Compound C33 < 30 s 1.62±0.85 4.43±0.92
    Compound C34 < 30 s 2.26±0.81 4.89±0.98
    Compound C35 < 30 s 2.26±0.81 4.89±0.98
    Compound C36 < 30 s 4.02±1.09 15.57±4.94
    Compound C40 < 30 s 3.76±1.75 10.48±2.58
    Compound C45 < 30 s 3.00±1.02 7.74±0.85
    Compound C46 < 30 s 1.82±0.64 5.63±1.52
    Compound C51 < 30 s 2.89±0.68 4.62±1.02
    Compound C53 / / /
    Compound C54 / / /
    Compound C55 < 30 s 1.83±0.30 6.26±2.45
    Compound C56 < 1min 1.49±0.62 5.32±1.21
    Compound C57 < 1min 1.89±0.29 6.12±1.14
    Compound C69 < 30 s 1.91±0.68 6.28±1.62
    Compound C70 < 30 s 1.35±0.61 5.30±1.14
    Compound C71 < 30 s 2.00±0.81 5.11±1.64
    Compound C72 < 1min 1.29±0.64 5.70±1.51
    Compound C73 < 30 s 1.24±0.56 6.76±1.49
    Compound C74 < 1min 1.37±0.63 5.68±1.10
    Compound C76 < 30 s 1.72±0.61 4.32±0.96
    Compound C78 < 30 s 2.59±0.99 7.30±1.85
    Compound C84 / / /
    Table 11 Adverse reaction of the present invention compound of the under equivalent dose(2ED 50 )(n=8)
    Compound /drug Red urine Euph oria Tong ue stret ching Trem or the four limbs rigidity Slower breathing , Tetany convulsion Coug h, brok en-wind ed Co nvu lsio ns Systemic stiffness, Convulsi ons, Opisthot onus
    Etomidate / 0 4 6 0 0 0 0 0
    CPMM 8 0 4 5 4 3 0 0 0
    Propofol / 0 0 0 2 2 0 0 0
    DMSO 8 0 0 0 1 0 0 0 0
    Compound C1 8 2 1 0 0 0 0 0 0
    Compound C2 8 0 2 0 0 0 0 0 0
    Compound C9 8 0 0 0 0 0 0 0 0
    Compound C14 8 1 0 1 0 0 0 0 0
    Compound C15 8 0 0 1 0 0 0 0 0
    Compound C16 8 0 1 2 4 0 0 0 0
    Compound C27 8 0 2 0 0 0 0 0 1
    Compound C28 8 0 0 1 0 0 0 0 0
    Compound C29 / / / / / / / / /
    Compound C33 8 0 0 1 0 0 0 0 0
    Compound C34 8 1 1 0 0 0 0 0 6
    Compound C35 8 0 1 0 0 0 0 0 7
    Compound C36 8 0 0 0 3 0 0 0 0
    Compound C40 8 0 0 0 0 1 0 1 1
    Compound C45 8 0 0 0 1 0 0 0 7
    Compound C46 8 0 1 1 0 0 0 0 0
    Compound C51 8 0 0 2 0 0 0 0 0
    Compound C53 / / / / / / / / /
    Compound C54 / / / / / / / / /
    Compound C55 8 0 0 0 0 0 0 0 7
    Compound C56 8 0 1 1 0 0 0 0 0
    Compound C57 8 0 2 1 0 0 0 0 0
    Compound C69 8 0 0 0 0 0 0 0 1
    Compound C70 8 4 0 0 6 0 0 0 0
    Compound C71 8 0 0 1 1 0 0 2 0
    Compound C72 8 0 0 0 0 0 0 0 0
    Compound C73 8 0 0 0 1 0 0 0 2
    Compound C74 8 0 0 1 0 0 0 0 0
    Compound C76 8 0 0 1 1 0 0 0 0
    Compound C78 8 0 1 0 1 0 0 0 0
    Compound C84 / / / / / / / / /
    • Example 15 The group C compounds have no inhibition on adrenocortical function in vitro cell test
  • Instruments and Equipment: multi-function ion meter (METTLER TOLEDO, models:
    SevenMulti), pipetting gun (Eppendorf, specifications: 1000 ul, 200 ul, 100 ul, 10 ul), centrifuge (model: Allegra, manufacturers: BECKMAN COULTER, American).
  • Experimental methods: The H295R cell line was selected to evaluate the ability of compounds to inhibit steroid synthesis in vitro. Cells are treated with vehicle (i.e., DMSO) and different concentrations of etomidate, CPMM, etomidate metabolite (i.e., etomidate acid), and the compounds of the present invention. Incubation concentration and concentration range are 0.1nM, 1nM, 10nM, 50nM, 100nM, 500nM, 1000nM, 10000nM. Then secretion of the cortisol and corticosterone in the supernatant, was measured using HPLC-MS/MS method to determine whether the compounds of the present invention had adrenotoxic potential.
  • Evaluation indexes: EC50 (Cortisol): The drug concentration required to reduce the concentration of corticosterone in the culture medium by 50%; EC50 (Corticosterone):
    The drug concentration required to reduce the concentration of cortisol in the culture medium by 50%.
  • Experimental results (Fig. 11):
    The results show that the compounds of the present invention meet the design requirements. EC50 of all compounds is obvious greater then etomidate, little or obvious greater then CPMM, the compounds less inhibit adrenocortical function in the experiment.
    • Example 16 The present invention of group C Compounds have no inhibitory effect on the function of adrenocortical in rats
  • Instruments and equipment: multi-function ion meter (METTLER TOLEDO, models: SevenMulti), pipetting gun (Eppendorf, specifications: 1000 ul, 200 ul, 100 ul, 10 ul), electronic balance (model: ME215S, manufacturers: Sartorius, Germany), the timer.
  • Experimental Method: Adult male Sprague-Dawley rats (250-300 g) were selected for the experiment (n=8), all the experiment were started in the morning. Place indwelling needles in tail vein of rats and inject dexamethasone (0.5 mg/kg). The first time of blood collection(S1) is in two hours later, and give dexamethasone (0.2 mg/kg). The compounds and the control drugs, etomidate and PRO were given at a dose twice their ED50, and using the same volume of 0.9% NaCl as the blank control group. All the drugs were administered in a volume of 0.6 ml and at a rate of 0.1 ml/s. 15 min later, exogenous ACTH (25 ug/kg) was injected. Another blood sample was collected after 30 min(S2). The blood samples were left standing at room temperature for 30-60 min, followed by centrifugation at 3500 rpm for 10 min. The supernatant was taken and centrifuged again at 15000 rpm for 5 min before being frozen and stored in a -20°C refrigerator. The concentration of the corticosterone in the supernatant, was measured using HPLC-MS/MS method 2-3 days later, to determine whether the compounds of the present invention had inhibition of adrenal cortex function.
  • Evaluation indexes: The concentration of the corticosterone in the supernatant of rats before and after given drugs.
  • Result (Tables 12, Fig. 12): After given ACTH stimulation, the concentration of the corticosterone in the supernatant of rats obviously increased after given the compounds of the present invention, similar to the 0.9% NaCl and PRO; but didn't change and even going down after using etomidate. The results show that the compounds hardly inhibit adrenocortical function in the experiment. Table 12 The effects of the compounds on adrenocortical function in rats
    Group Baseline(S1) Give ACTH 30min later(S2)
    0.9% NaCl 130.10±56.00 268.12±34.77
    ET 142.31±45.33 124.34±23.11
    PRO 156.98±59.41 253.11±31.56
    Compound C2 163.22±35.11 242.12±46.22
    Compound C15 145.90±54.33 267.99±33.20
    Compound C27 180.33±46.70 253.11±34.56
    Compound C34 169.77±45.66 278.33±32.45
    Compound C40 159.54±34.52 268.56±29.46
    Compound C74 147.00±34.56 250.77±45.30
    • Example 17 The group C compound of the present invention has slight influence on the circulatory function of rats
  • Instruments and Equipment: A small animal implantable physiological signal telemetry system from DSI (Data Science International, Inc.), including implants (RATHD-S21, DSI, United States), receiver boards (RPC-1, DSI, United States), signal conversion devices (DEM, DSI, USA), perfusion glue (DSI, USA), fibrin membrane (DSI, USA), etc. A small animal ventilator (HX-101E, Chengdu Taimeng Technology Co., Ltd.); An electronic balance (ME215S, Sartorius, Germany).
  • Experimental Methods: The circulatory function of rats was monitored by A small animal implantable physiological signal telemetry system from DSI (Data Science International, Inc.). Adult male Sprague-Dawley rats (250-300g) were selected for the experiment (n=6). First, the animal model was established, and the left ventricular catheter, abdominal aorta catheter and electrocardiogram wire were placed. At least one week after the operation, the signal can be collected to start the test. At the beginning of the experiment, after the placement of the indwelling needle in the tail vein of rats, connect the extension tube, put the rats together with the feeding cage on the signal receiver and start collecting data. After 30 minutes, the compound in the example and the control drugs etomidate and propofol in the dose of 2ED50 were given respectively. All compounds or drugs were given at a constant volume of 0.6 ml at a uniform rate of 0.1 ml/s. The pharmacological effects, adverse reactions and behavior of rats were observed and recorded after drug injection.
  • Data Collection: After setting the data collection parameters on the software, the power of the implant was turned on to start data collection. In this experiment, data recording frequency was set to 15s once time. Data collection was continuously recorded for 15 min before and after administration of the drugs in rats. After data acquisition, the test was stopped.
  • Evaluation Indexes: Collect the blood pressure, heart rate and other data of rats during and 15 minutes after administration, and judge the effect of the compound of the invention on the circulatory function of rats with the indexes of mean arterial pressure (MAP) and heart rate (HR).
  • Experimental Results (Fig.13,14,15,16):
    Like the control etomidate, the compound of the invention has a slight inhibitory effect on the circulatory function after administration, but soon rises to near the baseline, while the control propofol shows a significant inhibition on the circulatory system function.
    • Example 18 The group C compounds of the present invention can still recover rapidly after continuous infusion in rats for 1 hour.
  • Instrument and Equipment: micro injection pump (model: SN-50F6, manufacturer:
    Shenzhen Shengnuo Medical Equipment Co., LTD.), multi-functional ion meter (METTLER TOLEDO, model: SevenMulti), pipette gun (Eppendorf, specification: 1000ul, 200ul, 100ul, 10ul), timer.
  • Experimental Methods: Adult male SD rats with body weight ranging from 250 g to 350 g were selected for continuous infusion test. The compound of the invention, the control drug etomidate and CPMM were continuously injected through the tail vein of rats at a dose of 2 times the MIR (minimum infusion speed), and the absence of righting reflex was maintained for 1 hour from the time of the disappearance of righting reflex, and the awakening time and complete recovery time of the experimental animals were recorded after stopping the infusion.
  • Evaluation indexes: the time from the beginning of continuous infusion to the disappearance of sedation in rats; the time from the cessation of infusion to the restoration of the forepaw turning reflex after 1 hour of continuous infusion; the time from the cessation of infusion to the complete restoration of rats after 1 hour of continuous infusion.
  • Experimental results (table 13):
    The recovery time of the compound in the invention is not significantly longer than or equal to etomidate in terms of recovery time after continuous infusion of 2 times the dose of MIR(minimum infusion rate) for 1 hour compared with a single intravenous injection of 2ED50 dose. The types and incidence of adverse reactions were significantly less than etomidate and CPMM. Table 13 Pharmacological effects of continuous infusion of the compounds of the present invention
    Compound /drug Sedation onset time(min) After the infusion is stopped Righting reflex recovery time(min) Recovery time after stopping infusion(min) Types and incidence of adverse reactions
    Etomidate <5 15-20 30-40 Tremor(6/6),Myocl onus(4/6),Tongue stretching(2/6),Hin dlimb rigidity(2/6)
    CPMM <5 8-10 10-15 Red urine(6/6), Tremor( 4/6),Hindlimb rigidity(4/6)
    DMSO / / / Red urine(6/6)
    Compound C2 <5 10-15 20-30 Red urine(6/6), Tremor( 3/6),Tongue stretching(4/6)
    Compound C15 <5 16-18 30-36 Red urine(6/6),Tremor( 1/6),
    Compound C27 <5 12-16 15-20 Red urine(6/6),Tremor( 5/6)
    Compound C34 <5 15-20 22-28 Red urine(6/6),Tremor( 2/6),Tongue stretching(4/6)
    Compound C40 <5 16-20 27-35 Red urine(6/6),Tremor( 2/6)
    Compound C74 <5 13-18 18-24 Red urine(6/6),Tremor( 4/6),Tongue stretching(4/6)
    • Example 19 The group D compounds of the present invention can produce definite general anesthesia in rats
  • Instrument and Equipment: Multifunctional ionmeter(METTLER TOLEDO, types:
    SevenMulti), Pipette(Eppendorf, Specifications: 1000 ul, 200 ul,100 ul,10 ul),22 G intravenous indwelling needle(BECTON DICKINSON), 1 ml micro injection needle (Germany BD),timer.
  • Experimental Method: The anesthesia effects of the compounds were assessed in rats using a LORR assay and a period >30 s was considered as an indicator of general anesthesia. Then the up and down method was used to determine 50% effective dose (ED50). Adult male Sprague-Dawley rats (250-300 g) were selected for the experiment.
  • The compounds in the above examples and the control drugs, etomidate and CPMM, were dissolved in dimethyl sulfoxide (DMSO), and the same volume of DMSO was given as the blank control group. The drugs were administered through the tail vein of rats in a volume of 0.6 mL and at a rate of 0.1 mL/s.
  • Evaluating indicator: The end point of anesthesia: the disappearance of forepaw righting reflex (lorr) was used as the end point of anesthesia; General anesthesia effect: the disappearance of forepaw righting reflex in rats lasting for 30 seconds is taken as the index of general anesthesia effect; Anesthesia recovery index: the recovery of rat forepaw righting reflex was used as the index of anesthesia recovery.
  • Experimental results (Table 14):
    The compound of the invention can produce definite and transient general anesthesia like the control etomidate and CPMM, and the compound of the invention shows the same or better potency as etomidate and CPMM. Table 14 The effectiveness and safety window of the compound of the present invention in rats
    Compound /drug ED50(mg/kg) Minimal lethal dose (mg/kg) Approximate therapeutic index
    Etomidate 0.74(0.72-0.75)∗ 13.8 18.7
    CPMM 0.49(0.45-0.53)∗ 20.6 42.0
    Propofol 5.01(5.01-5.79)∗ 22.6 4.0
    DMSO / / /
    Compound D1 ++ >11.2 >8.4
    Compound D2 ++++ >10.5 >6.6
    Compound D3 ++++ / /
    Compound D4 ++++ >10.1 >5.0
    Compound D6 ++++ >12.4 >7.3
    Compound D7 ++ >3.2 >5.4
    Compound D11 +++++ >30.2 >4.6
    Compound D17 ++ >11.9 >4.5
    Compound D25 ++ >8.4 >10.2
    Compound D29 + >3.6 >4.1
    Compound D42 + >1.8 >4.2
    Compound D73 +++++ / /
    Compound D74 +++++ >10.2 >16.6
    Compound D75 +++++ >11.2 >5.4
    Compound D76 ++ >11.5 >31.8
    Compound D77 + >1.4 >21.0
    Compound D78 ++ >6.8 >6.2
    Compound D79 ++ >2.7 >6.4
    Compound D80 +++++ >12.2 >2.9
    Compound D81 ++ >12.6 >15.2
    Compound D82 ++++ >7.8 >6.3
    Compound D83 +++++ / /
    Compound D84 ++++ / /
    Compound D86 +++ >9.8 >7.3
    Compound D87 +++ >13.2 >6.8
    Compound D88 +++ >2.6 >10.3
    Compound D93 + >1.8 >25.1
    Compound D101 + >9.3 >10.5
    Compound D108 ++++ >8.5 >10.2
    Notes:
    ∗ The values in brackets indicate 95% confidence limit (mg/kg);
    + indicates that the measured ED50 is in the range of 0.04-0.50 mg/kg (including 0.04 and 0.50 mg/kg);
    ++ indicates that the measured ED50 is in the range of 0.50-1.00 mg/kg (excluding 0.50 mg/kg, including 1.00 mg/kg);
    +++ indicates that the measured ED50 is in the range of 1.00-2.00 mg/kg (excluding 1.00 mg/kg, including 2.00 mg/kg);
    ++++ indicates that the measured ED50 is in the range of 2.00-6.00 mg/kg (excluding 2.00 mg/kg, including 6.00 mg/kg).
    +++++ indicates that the measured ED50 is greater than 6.00 mg/kg (excluding 6.00 mg/kg).
    • Example 20 The group D compound of the present invention shows the pharmacological effect of rapid onset and rapid recovery under the equivalent dose (2ED50).
  • Instruments and Equipment: multi-function ion meter (METTLER TOLEDO, models: SevenMulti), pipetting gun (Eppendorf, specifications: 1000 ul, 200 ul, 100 ul, 10 ul), electronic balance (model: ME215S, manufacturers: Sartorius, Germany), the timer. Experimental Methods: Adult male Sprague-Dawley rats (250-300 g) were selected for the experiment (n=8). The compounds and the control drugs, etomidate and CPMM, were dissolved in DMSO, and the same volume of DMSO was given as the blank control group. The drugs were administered at a dose twice their ED50 through the tail vein of rats in a volume of 0.6 mL and at a rate of 0.1 mL/s.
  • Evaluation index: onset time: from the completion of drug injection to the disappearance of forepaw righting reflex in rats; Duration of anesthesia: the time from the disappearance of rat forepaw righting reflex to the recovery of rat forepaw righting reflex; Recovery time of anesthesia: the time from the disappearance of forepaw righting reflex to complete recovery;
  • Experimental results (table 15, 16):
    The compound of the invention, like the control etomidate and CPMM, shows the characteristics of rapid onset and rapid recovery. The duration of pharmacological action can meet the time needs of rapid induction of general anesthesia and diagnostic examination, short traumatic examination or operation. In the experiment, the types and incidence of adverse reactions of the compound of the invention are mostly less than those of the control etomidate and CPMM. Table15 Pharmacological effects of the compound of the present invention in rats
    Compound /drug Onset time (min) Righting reflex duration (min) Sedation duration (min)
    Etomidate < 30 s 6.03±1.93 15.35±3.57
    CPMM < 30 s 2.71±0.97 8.48±2.58
    Propofol < 30 s 8.53±1.52 14.77±3.50
    DMSO / / /
    Compound D1 < 1 min 1.18±0.43 7.96±2.14
    Compound D2 < 1 min 5.82±1.87 13.71±3.89
    Compound D3 < 1 min 1.25±0.27 6.26±1.50
    Compound D4 < 1 min 0.98±0.35 7.28±1.56
    Compound D6 < 1 min 1.33±0.19 7.35±1.45
    Compound D7 < 1 min 0.55±0.59 8.52±2.29
    Compound D11 / / /
    Compound D17 < 1 min 0.86±0.23 5.48±0.50
    Compound D25 < 1 min 1.52±0.26 6.82±0.27
    Compound D29 < 30 s 1.24±0.06 2.26±0.59
    Compound D42 < 1 min 1.38±0.15 3.83±0.74
    Compound D73 / / /
    Compound D74 < 1 min 1.29±0.49 4.78±1.24
    Compound D75 < 30 s 1.59±0.67 5.28±0.68
    Compound D76 < 1 min 1.67±1.32 6.44±1.82
    Compound D77 < 30 s 1.43±0.22 3.68±0.56
    Compound D78 < 30 s 4.02±1.35 7.29±1.20
    Compound D79 < 30 s 1.75±0.76 5.84±1.46
    Compound D80 < 30 s 1.58±0.61 6.42±1.68
    Compound D81 < 1 min 1.35±0.12 4.87±0.39
    Compound D82 < 1 min 0.98±0.31 6.70±1.46
    Compound D83 / / /
    Compound D84 / / /
    Compound D86 < 1 min 1.24±0.12 7.88±1.94
    Compound D87 < 30 s 4.34±0.54 8.26±2.74
    Compound D88 < 30 s 1.86±1.02 7.08±1.06
    Compound D93 < 30 s 2.50±0.30 6.89±0.80
    Compound D101 < 30 s 1.80±0.58 7.20±3.21
    Compound D108 < 30 s 2.30±1.76 5.90±2.13
    Table 16 Adverse reaction of the compound of the invention under equivalent dose(2 × ED50)(n=8)
    Compound /drug Re d uri ne Euph oria Tong ue stret ching Trem or Four limbs rigidity Slower breathing , Tetany convulsio n Cough, broken-winded Conv ulsio ns Systemic stiffness ,Conv ulsions, opisthotonus
    Etomidate / 0 4 3 2 0 0 0 0
    CPMM / 0 4 2 2 0 0 0 0
    Propofol / 0 0 2 1 2 0 0 0
    DMSO 8 0 0 1 1 0 0 0 0
    Compound D1 8 0 1 0 0 0 0 0 0
    Compound D2 8 3 2 8 0 1 2 0 0
    Compound D3 8 0 0 1 1 0 0 0 0
    Compound D4 8 0 0 0 0 0 0 0 0
    Compound D6 8 0 0 2 1 0 0 0 0
    Compound D7 8 0 1 1 1 0 0 0 0
    Compound D11 / / / / / / / / /
    Compound D17 8 0 0 0 1 0 0 0 0
    Compound D25 8 0 0 2 1 0 0 0 0
    Compound D29 8 0 0 4 3 0 0 0 0
    Compound D42 8 0 1 1 0 0 0 6 0
    Compound D73 / / / / / / / / /
    Compound D74 8 0 0 1 1 0 0 0 0
    Compound D75 8 0 0 0 0 0 0 0 0
    Compound D76 8 0 0 0 2 0 0 0 8
    Compound D77 8 0 1 0 0 0 0 0 8
    Compound D78 8 0 1 0 0 0 0 0 2
    Compound D79 8 0 0 1 0 0 0 6 0
    Compound D80 8 0 0 0 4 0 0 0 0
    Compound D81 8 0 0 1 1 0 0 0 0
    Compound D82 8 0 1 0 2 0 0 0 0
    Compound D83 / / / / / / / / /
    Compound D84 / / / / / / / / /
    Compound D86 8 0 0 0 0 0 0 0 2
    Compound D87 8 0 0 0 0 0 0 0 5
    Compound D88 8 0 1 1 1 0 0 0 7
    Compound D93 8 0 1 0 0 0 0 0 8
    Compound D101 8 0 0 0 0 0 0 0 2
    Compound D108 8 2 0 0 0 0 0 0 0
    • Example 21 The effects of the group D compounds on adrenocortical function in vitro test
  • Instruments and Equipment: multi-function ion meter (METTLER TOLEDO, models: SevenMulti), pipetting gun (Eppendorf, specifications: 1000 ul, 200 ul, 100 ul, 10 ul), centrifuge (model: Allegra, manufacturers: BECKMAN COULTER, American).
  • Experimental Methods: The H295R cell line was selected to evaluate the ability of compounds to inhibit steroid synthesis in vitro. Cells are treated with vehicle (i.e., DMSO) and different concentrations of etomidate, CPMM, etomidate metabolite (i.e., etomidate acid), and the compounds of the present invention. Incubation concentration and concentration range are 0.1nM, 1nM, 10nM, 50nM, 100nM, 500nM, 1000nM, 10000nM. Then secretion of the cortisol and corticosterone in the supernatant, was measured using HPLC-MS/MS method to determine whether the compounds of the present invention had adrenotoxic potential.
  • Evaluation Indexes: EC50 (Cortisol): The drug concentration required to reduce the concentration of corticosterone in the culture medium by 50%; EC50 (Corticosterone): The drug concentration required to reduce the concentration of cortisol in the culture medium by 50%.
  • Experimental Results (Fig. 17 ):
    The results show that the compounds of the present invention meet the design requirements. EC50 of all compounds is obvious greater then etomidate, little or obvious greater then CPMM, the compounds less inhibit adrenocortical function in the experiment.
    • Example 22 Compounds D hardly inhibit adrenocortical function
  • Instruments and Equipment: multi-function ion meter (METTLER TOLEDO, models: SevenMulti), pipetting gun (Eppendorf, specifications: 1000 ul, 200 ul, 100 ul, 10 ul), electronic balance (model: ME215S, manufacturers: Sartorius, Germany), the timer. Experimental Method: Adult male Sprague-Dawley rats (250-300 g) were selected for the experiment (n=8), all the experiment were started in the morning. Place indwelling needles in tail vein of rats and inject dexamethasone (0.5 mg/kg). The first time of blood collection(S1) is in two hours later, and give dexamethasone (0.2 mg/kg) . The compounds and the control drugs, etomidate and PRO were given at a dose twice their ED50, and using the same volume of 0.9% NaCl as the blank control group. All the drugs were administered in a volume of 0.6 ml and at a rate of 0.1 ml/s. 15 min later, exogenous ACTH (25 ug/kg) was injected. Another blood sample was collected after 30 min(S2). The blood samples were left standing at room temperature for 30-60 min, followed by centrifugation at 3500 rpm for 10 min. The supernatant was taken and centrifuged again at 15000 rpm for 5 min before being frozen and stored in a -20°C refrigerator. The concentration of the corticosterone in the supernatant, was measured using HPLC-MS/MS method 2-3 days later, to determine whether the compounds of the present invention had inhibition of adrenal cortex function.
  • Evaluation indexes: The concentration of the corticosterone in the supernatant of rats before and after given drugs.
  • Experimental Results (Tables17, Figure18): After given ACTH stimulation, the concentration of the corticosterone in the supernatant of rats obviously increased after given the compounds of the present invention, similar to the 0.9% NaCl and PRO; but didn't change and even going down after using etomidate. The results show that the compounds hardly inhibit adrenocortical function in the experiment. Table 17 The effects of the compounds on adrenocortical function in rats
    Group Baseline(S1) Give ACTH 30min later(S2)
    0.9%NaCl 130.10±43.28 268.12±34.77
    ET 142.31±45.33 124.34±23.11
    PRO 156.98±59.41 253.11±31.56
    Compound D1 165.43±15.99 247.90±43.21
    Compound D17 160.98±33.09 248.55±32.33
    Compound D25 171.66±24.66 259.09±36.77
    Compound D29 163.98±22.11 279.76±24.67
    Compound D76 153.23±30.91 277.88±34.56
    Compound D79 151.11±21.00 277.88±30.56
    Compound D81 147.99±46.90 260.99±21.77
    Compound D87 163.22±35.11 242.12±40.22
    Compound D88 172.33±46.70 253.11±33.20
    • Example 23 The group D compound of the present invention has slight influence on the circulatory function of rats
  • Instruments and Equipment: A small animal implantable physiological signal telemetry system from DSI (Data Science International, Inc.) including implants (RATHD-S21, DSI, United States), receiver boards (RPC-1, DSI, United States), signal conversion devices (DEM, DSI, USA), perfusion glue (DSI, USA), fibrin membrane (DSI, USA), etc. A small animal ventilator (HX-101E, Chengdu Taimeng Technology Co., Ltd.); An electronic balance (ME215S, Sartorius, Germany).
  • Experimental Methods: The circulatory function of rats was monitored by A small animal implantable physiological signal telemetry system from DSI (Data Science International, Inc.). Adult male Sprague-Dawley rats (250-300g) were selected for the experiment (n=6). First, the animal model was established, and the left ventricular catheter, abdominal aorta catheter and electrocardiogram wire were placed. At least one week after the operation, the signal can be collected to start the test. At the beginning of the experiment, after the placement of the indwelling needle in the tail vein of rats, connect the extension tube, put the rats together with the feeding cage on the signal receiver and start collecting data. After 30 minutes, the compound in the example and the control drugs etomidate and propofol in the dose of 2ed50 were given respectively. All compounds or drugs were given at a constant volume of 0.6 ml at a uniform rate of 0.1 ml / s. The pharmacological effects, adverse reactions and behavior of rats were observed and recorded after drug injection.
  • Data collection: After setting the data collection parameters on the software, the power of the implant was turned on to start data collection. In this experiment, data recording frequency was set to 15 s. Data collection was continuously recorded for 15 min before and after administration of the drugs in rats. After data acquisition, the test was stopped. Evaluation indexes: Collect the blood pressure, heart rate and other data of rats during and 15 minutes after administration, and judge the effect of the compound of the invention on the circulatory function of rats with the indexes of mean arterial pressure (MAP) and heart rate (HR).
  • Experimental results (Fig. 19,20,21,22):
    Like the control etomidate, the compound of the invention has a slight inhibitory effect on the circulatory function after administration, but soon rises to near the baseline, while the control propofol shows a significant inhibition on the circulatory system function.
    • Example 24 The group D compounds of the present invention can still recover rapidly after continuous infusion in rats for 1 hour.
  • Instrument and Equipment: micro injection pump (model: SN-50F6, manufacturer:
    Shenzhen Shengnuo Medical Equipment Co.,LTD.), multi-functional ion meter (METTLER TOLEDO, model: SevenMulti), pipette gun (Eppendorf, specification: 1000 ul, 200 ul, 100 ul, 10 ul), timer.
  • Experimental Methods: Adult male SD rats with body weight ranging from 250 g to 350 g were selected for continuous infusion test. The compound of the invention, the control drug etomidate and CPMM were continuously injected through the tail vein of rats at a dose of 2 times the MIR (minimum infusion speed), and the absence of righting reflex was maintained for 1 hour from the time of the disappearance of righting reflex, and the awakening time and complete recovery time of the experimental animals were recorded after stopping the infusion.
  • Evaluation indexes: the time from the beginning of continuous infusion to the disappearance of sedation in rats; the time from the cessation of infusion to the restoration of the forepaw turning reflex after 1 hour of continuous infusion; the time from the cessation of infusion to the complete restoration of rats after 1 hour of continuous infusion.
  • Experimental results (Table 18):
    The recovery time of the compound in the invention is not significantly longer than or equal to etomidate in terms of recovery time after continuous infusion of 2 times the dose of MIR(minimum infusion rate) for 1 hour compared with a single intravenous injection of 2ED50 dose. The types and incidence of adverse reactions were significantly less than etomidate and CPMM. Table 17 The effects of the compounds on adrenocortical function in rats
    Group Baseline (S1) Give ACTH 30min later (S2)
    0.9%NaCl 130.10±43.28 268.12±34.77
    ET 142.31±45.33 124.34±23.11
    PRO 156.98±59.41 253.11±31.56
    Compound D1 165.43±15.99 247.90±43.21
    Compound D17 160.98±33.09 248.55±32.33
    Compound D25 171.66±24.66 259.09±36.77
    Compound D29 163.98±22.11 279.76±24.67
    Compound D76 153.23±30.91 277.88±34.56
    Compound D79 151.11±21.00 277.88±30.56
    Compound D81 147.99±46.90 260.99±21.77
    Compound D87 163.22±35.11 242.12±40.22
    Compound D88 172.33±46.70 253.11±33.20
    • Example 23 The group D compound of the present invention has slight influence on the circulatory function of rats
  • Instruments and Equipment: A small animal implantable physiological signal telemetry system from DSI (Data Science International, Inc.) including implants (RATHD-S21, DSI, United States), receiver boards (RPC-1, DSI, United States), signal conversion devices (DEM, DSI, USA), perfusion glue (DSI, USA), fibrin membrane (DSI, USA), etc. A small animal ventilator (HX-101E, Chengdu Taimeng Technology Co., Ltd.); An electronic balance (ME215S, Sartorius, Germany).
  • Experimental Methods: The circulatory function of rats was monitored by A small animal implantable physiological signal telemetry system from DSI (Data Science International, Inc.). Adult male Sprague-Dawley rats (250-300g) were selected for the experiment (n=6). First, the animal model was established, and the left ventricular catheter, abdominal aorta catheter and electrocardiogram wire were placed. At least one week after the operation, the signal can be collected to start the test. At the beginning of the experiment, after the placement of the indwelling needle in the tail vein of rats, connect the extension tube, put the rats together with the feeding cage on the signal receiver and start collecting data. After 30 minutes, the compound in the example and the control drugs etomidate and propofol in the dose of 2ed50 were given respectively. All compounds or drugs were given at a constant volume of 0.6 ml at a uniform rate of 0.1 ml / s. The pharmacological effects, adverse reactions and behavior of rats were observed and recorded after drug injection.
  • Data collection: After setting the data collection parameters on the software, the power of the implant was turned on to start data collection. In this experiment, data recording frequency was set to 15 s. Data collection was continuously recorded for 15 min before and after administration of the drugs in rats. After data acquisition, the test was stopped. Evaluation indexes: Collect the blood pressure, heart rate and other data of rats during and 15 minutes after administration, and judge the effect of the compound of the invention on the circulatory function of rats with the indexes of mean arterial pressure (MAP) and heart rate (HR).
  • Experimental results (Fig. 19, 20,21,22):
    Like the control etomidate, the compound of the invention has a slight inhibitory effect on the circulatory function after administration, but soon rises to near the baseline, while the control propofol shows a significant inhibition on the circulatory system function.
    • Example 24 The group D compound of the present invention can still recover rapidly after continuous infusion in rats for 1 hour.
  • Instrument and Equipment: micro injection pump (model: SN-50F6, manufacturer:
    Shenzhen Shengnuo Medical Equipment Co.,LTD.), multi-functional ion meter (METTLER TOLEDO, model: SevenMulti), pipette gun (Eppendorf, specification: 1000 ul, 200 ul, 100 ul, 10 ul), timer.
  • Experimental Methods: Adult male SD rats with body weight ranging from 250 g to 350 g were selected for continuous infusion test. The compound of the invention, the control drug etomidate and CPMM were continuously injected through the tail vein of rats at a dose of 2 times the MIR (minimum infusion speed), and the absence of righting reflex was maintained for 1 hour from the time of the disappearance of righting reflex, and the awakening time and complete recovery time of the experimental animals were recorded after stopping the infusion.
  • Evaluation indexes: the time from the beginning of continuous infusion to the disappearance of sedation in rats; the time from the cessation of infusion to the restoration of the forepaw turning reflex after 1 hour of continuous infusion; the time from the cessation of infusion to the complete restoration of rats after 1 hour of continuous infusion.
  • Experimental results (table 18):
    The recovery time of the compound in the invention is not significantly longer than or equal to etomidate in terms of recovery time after continuous infusion of 2 times the dose of MIR(minimum infusion rate) for 1 hour compared with a single intravenous injection of 2ED50 dose. The types and incidence of adverse reactions were significantly less than etomidate and CPMM. Table 18 Pharmacological effects of continuous infusion of the compound of present the invention
    Compound /drug Sedati on onset time( min) After the infusion is stopped Righting reflex recovery time(min) Recovery time after stopping infusion(min ) Types and incidence of adverse reactions
    Etomidate <5 15-20 30-40 Tremor(6/6),Myoclonus(4/ 6),Tongue stretching(2/6),Hindlimb rigidity(2/6)
    CPMM <5 8-10 10-15 Red urine(6/6),Tremor(4/6),Hin dlimb rigidity(4/6)
    DMSO / / / Red urine(6/6)
    Compound D1 <5 18-24 35-45 Red urine(6/6),Tremor(2/6),Ton gue stretching(2/6)
    Compound D17 <5 15-22 25-35 Red urine(6/6),Tremor(1/6),
    Compound D25 <5 16-24 30-40 Red urine(6/6),Tremor(2/6),Hin dlimb rigidity(1/6)
    Compound D29 <5 12-20 20-25 Red urine(6/6),Tongue stretching(4/6)
    Compound D76 <5 15-25 25-40 Red urine(6/6),Hindlimb rigidity(2/6)
    Compound D77 < 5 12-16 20-30 Red urine(6/6),Tongue stretching(3/6),Tremor(3/6 )
    Compound D81 <5 13-14 15-25 Red urine(6/6),Tremor(2/6),the four limbs rigidity(2/6)
  • In summary, the present invention discloses a class of structurally novel substituted nitrogen heterocyclic compounds. The substituted nitrogen heterocyclic compounds have better depressant effects on the central nervous system and produce sedative, hypnotic and/or anesthetic action as well as control of epilepsy persistence; The substituted nitrogen heterocyclic compounds not only maintains excellent anesthetic activity, but also has the characteristics of rapid onset and rapid recovery; At the same time, the substituted nitrogen heterocyclic compounds have almost no inhibitory effect on the function of adrenal cortex and has little side effects, which solves the technical problems in the field. The present invention provides a new choice for clinically screening and /or preparing sedative, hypnotic and/or general anesthesia drugs and drugs for controlling status epilepticus.

Claims (18)

  1. Compounds of formula I, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof:
    Figure imgb0486
    R1 is independently selected from the group consisting of deuterium, halogen, - CN, -NO2, -OR32, -C(O)R31, -CO2R31, -CON(R32)2, -N(R32)2, -OC(O)R31, -SO2R31, substituted or unsubstituted 3~8-membered heterocyclic groups, substituted or unsubstituted C1-8 alkyls, substituted or unsubstituted C1-8 alkoxyl, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls;
    Wherein, R31 is independently of each other selected from the group consisting of deuterium, R32, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls; R32 is independently of each other selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyls, substituted or unsubstituted C3-8 cycloalkyls, substituted or unsubstituted 3~8-membered heterocyclic groups, substituted or unsubstituted aryls, and substituted or unsubstituted heteroaryls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclic groups or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, and heteroaryls or their halogenated or deuterated derivatives;
    For above R1, R31, R32, said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclic groups or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    n is an integer of 0~5;
    R2 is selected from the group consisting of hydrogen, deuterium, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C1-8 alkoxyl or their halogenated or deuterated derivatives, C2-8 alkenyls or their halogenated or deuterated derivatives, C2-8 alkynyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclic groups or their halogenated or deuterated derivatives;
    K1 is selected from N or CRk1, K2 is selected from N or CRk2;
    K3 is CRk3, R is selected from
    Figure imgb0487
    or, K3 is CRk0, R is Rk3, Rk0 is selected from
    Figure imgb0488
    Figure imgb0489
    Rk1, Rk2, Rk3 are independently selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-8 alkyls, N(R3k)2; said substituents are deuterium, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C1-8 alkoxyls or their halogenated or deuterated derivatives, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclic groups or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives, -N(R3k)2, R3k is H or C1-8 alkyls;
    X is selected from O, S or NR30, wherein, R30 is selected from hydrogen or C1-8 alkyl;
    L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-8 alkylenyls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C2-8 alkenyls or their halogenated or deuterated derivatives, C2-8 alkynyls or their halogenated or deuterated derivatives, C1-8 alkoxyls or their halogenated or deuterated derivatives, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclic groups or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    L1 and L2 can be connected to the homotopic or heterotopic atoms on the A ring; m is an integer of 0~4;
    Ring A is none, or, ring A is selected from 3~8-membered saturated carbocycles, 3~8-membered unsaturated carbocycles, 3~8-membered saturated heterocycles or 3~8-membered unsaturated heterocycles;
    R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl,
    Figure imgb0490
     substituted or unsubstituted C1-8 alkyls, -OR33, -SR33, -OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls aryls, heteroaryls, -N(R33)2, - C(O)R34, -C(S)R34, -S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls, cyano, isocyano, isothiocyano, nitro, -L33-R36 or =R39;
    L33 is selected from C1-4 alkylenyls;
    R36 is selected from cyano, nitro, -OC(O) R34, -C(O)R34, -S(O)R34, -C(O)N(R33)2;
    R33 is selected from the group consisting of hydrogen, methylsulfonyl, -L31-COO-L32, and the following substituted or unsubstituted groups: C1-8 alkyls, C3-8 cycloalkyls, 3~8-membered heterocyclylss, aryls, heteroaryls;
    R34 is selected from the group consisting of R33, deuterium, and the following substituted or unsubstituted groups: C1-8 alkoxyl, C2-8 alkenyls, C2-8 alkynyls, or - S-C1-8 alkyls;
    L31 is selected from the substituted or unsubstituted C1-8 alkylenyls; L32 is selected from the substituted or unsubstituted C1-8 alkyls;
    For above R5, R33, R34, said substituents are selected from group consisting of deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives, -S-C1-4 alkyls, di-substituted cyclic carbonyls, =R39, C2-8 alkenyls or C2-8 alkynyls;
    R39 is selected from O, S, NR40 or C(R41)2; R40 is selected from hydrogen, halogen, C1-4 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
    R0 is selected from LC3RC4, LC1XCLC2RC5;
    LC3 is selected from none, substituted or unsubstituted C1~4 alkylenyls, said substituents in C1~4 alkylenyls are selected from the group consisting of C1-5 alkyls, C1~5 alkoxyl, halogen, hydroxyl;
    RC4 is selected from the group consisting of substituted or unsubstituted C2~6 alkenyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted 3~6-membered saturated or unsaturated heterocyclyls, substituted or unsubstituted 3~6-membered saturated or unsaturated cycloalkyls, COR4d; said substituents are independently of each other selected from LC4R4e; R4d is selected from C1~6 alkyls;
    LC4 is selected from the group consisting of none, substituted or unsubstituted C1-4 alkylenyls; R4e is selected from the group consisting of C1~5 alkyls, C1~5 alkoxyl, halogen, hydroxyl;
    LC1 is selected from substituted or unsubstituted C1~3 alkylenyls, said substituents is selected from C1-5 alkyls;
    XC is O or S;
    LC2 is selected from none, substituted or unsubstituted C1-3 alkylenyls, said substituents are selected from the group consisting of C1-4 alkyls, C1~4 alkoxyl, L2aR5g; L2a is selected from none, C1~2 alkylenyls; R5g is selected from halogen, C1~4 alkoxyls;
    RC5 is selected from the group consisting of hydrogen, halogen, C1~5 alkyls, C2~4 alkenyls, C2~4 alkynyls, COR4d, C3~6 di-alkenyls, C1~5 alkoxyl, 3~6-membered saturated or unsaturated heterocyclyls all of which are substituted by one or more R5c, 3~6-membered saturated or unsaturated cycloalkyls all of which are substituted by one or more R5c; R4d is selected C1~6 alkyls, R5c is selected from the group consisting of halogen, =R5d, L1aR5e, C3~6di-alkenyls; R5d is d CH2, O or S, L1a is C1~3 alkylenyls, R5e is C1~5 alkyls, C1~5 alkoxyl;
    MD is selected from CO or CRD6RD7, RD6 is selected from hydrogen, XDbRD4b, RD7 is selected from hydrogen, XDcRD4c;
    XD is O or S; XDb is O or S; XDc is O or S;
    Ra is selected from the group consisting of substituted or unsubstituted C1~6 alkyls, substituted or unsubstituted C2~6 alkynyls, substituted or unsubstituted C2~6 alkenyls, substituted or unsubstituted 3~6-membered saturated or unsaturated heterocyclyls, substituted or unsubstituted 3~6-membered saturated or unsaturated cycloalkyls; said substituents are independently of each other selected from the group consisting of C3~6 di-alkenyls, C1~3 alkyls, C1~5 alkoxyl, halogen, hydroxyl;
    RD4b, RD4c are independently of each other selected from the group consisting of substituted or unsubstituted C1~6 alkyls, substituted or unsubstituted C2~6 alkynyls, substituted or unsubstituted C2~6 alkenyls, CORDf, substituted or unsubstituted 3~6-membered saturated or unsaturated heterocyclyls groups, substituted or unsubstituted 3~6-membered saturated or unsaturated cycloalkyls; said substituents are independently of each other selected from the group consisting of C3~6 dialkenyls, C1~5 alkyls, C1~5 alkoxyl, halogen, hydroxyl; RDf is selected from C1~5 alkyls; Or, when MD is CRD6RD7 and RD6 is XDbRD4b, RD4b and Ra is connected to get the substituted or unsubstituted 3~6-membered saturated or unsaturated heterocyclyls said saturated or unsaturated heterocyclic substituents is selected from the group consisting of halogenated or un-halogenated C1~6 alkyls, halogenated or un-halogenated C2~6 alkynyls, halogenated or un-halogenated C2~6 alkenyls, CORDf; RD7 is selected from the group consisting of hydrogen, XDcRD4c, XDc is O or S, RD4c is selected from the group consisting of substituted or unsubstituted C1~6 alkyls, substituted or unsubstituted C2~6 alkynyls, substituted or unsubstituted C2~6 alkenyls, CORDf, substituted or unsubstituted 3~6-membered saturated or unsaturated heterocycyls, substituted or unsubstituted 3~6-membered saturated or unsaturated cycloalkyls; said substituents are independently of each other selected from the group consisting of C3~6 di-alkenyl, C1~5 alkyls, C1~5 alkoxyl, halogen, hydroxyl; RDf is selected from C1~5 alkyls.
  2. Compounds according to claim 1, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, characterized in that: said compound has a structure of formula A-I:
    Figure imgb0491
    R1 is independently of each other selected from the group consisting of deuterium, halogen, -CN, -NO2, -OR32, -C(O)R31, -CO2R31, -CON(R32)2, -N(R32)2, -OC(O)R31, -SO2R31, substituted or unsubstituted 3~8-membered heterocyclyls, substituted or unsubstituted C1-8 alkyls, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls;
    Wherein, R31 is independently of each other selected from the group consisting of deuterium, R32, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls, R32 is independently of each other selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyls, substituted or unsubstituted C3-8 cycloalkyls, substituted or unsubstituted 3~8-membered heterocyclyls, substituted or unsubstituted aryls, and substituted or unsubstituted heteroaryls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    For above R1, R31, R32, said substituents are selected from the group consisting of deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclylss or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    n is an integer of 0~5;
    R2 is selected from the group consisting of hydrogen, deuterium, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C1-8 alkoxyl or their halogenated or deuterated derivatives, C2-8 alkenyls or their halogenated or deuterated derivatives, C2-8 alkynyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives;
    R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-8 alkyls; said substituents is deuterium, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C1-8 alkoxyl or their halogenated or deuterated derivatives, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    X is selected from O, S or NR30, wherein, R30 is selected from hydrogen, deuterium or C1-8 alkyls;
    L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-8 alkylenyls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C2-8 alkenyls or their halogenated or deuterated derivatives, C2-8 alkynyls or their halogenated or deuterated derivatives, C1-8 alkoxyls or their halogenated or deuterated derivatives, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    L1 and L2 can be connected to thehomotopic or heterotopic atoms on the A ring; m is an integer of 0~4;
    Ring A is none, or, ring A is selected from 3~8-membered saturated carbocycles, 3~8-membered unsaturated carbocycles, 3~8-membered saturated heterocycles or 3~8-membered unsaturated heterocycles;
    R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl,
    Figure imgb0492
     substituted or unsubstituted C1-8 alkyls, -OR33, -SR33, -OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocycyls, aryls, heteroaryls, -N(R33)2, - C(O)R34, -C(S)R34, -S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls, cyano, isocyano, isothiocyano, nitro, -L33-R36 or =R39;
    L33 is selected from C1-4 alkylenyls;
    R36 is selected from cyano, nitro, -OC(O)R34, -C(O)R34, -S(O)R34, -C(O)N(R33)2;
    R33 is selected from the group consisting of hydrogen, methylsulfonyl, -L31-COO-L32, the following substituted or unsubstituted groups:C1-8 alkyls, C3-8 cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls;
    R34 is selected from the group consisting of R33, deuterium, the following substituted or unsubstituted groups: C1-8 alkoxyl, C2-8 alkenyls, C2-8 alkynyls or - S-C1-8 alkyls;
    L31 is selected from the substituted or unsubstituted C1-8 alkylenyls; L32 is selected from the substituted or unsubstituted C1-8 alkyls;
    For above R5, R33, R34, said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives, -S-C1-4 alkyls, di-substituted cyclic carbonyl, =R39, C2-8 alkenyls or C2-8 alkynyls;
    R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-4 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
    Preferably:
    Above R1 is independently of each other selected from the group consisting of deuterium, halogen, -CN, -NO2, -OR32, -C(O)R31, -CO2R31, -CON(R32)2, -N(R32)2, -OC(O)R31, C1-3 alkyls, C2-3 alkenyls, C2-3 alkynyls;
    Wherein, R31 is independently of each other selected from the group consisting of deuterium, R32, C2-3 alkenyls, C2-3 alkynyls; R32 is independently of each other selected from the group consisting of hydrogen, C1-3 alkyls;
    Or, n is an integer of 0~2;
    Or, R2 is selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyls or their halogenated or deuterated derivatives.
  3. Compounds according to claim 2, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, characterized in that: said compound is represented by formula A-II:
    Figure imgb0493
    R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-4 alkyls; said substituents is deuterium, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-6 cycloalkyls or their halogenated or deuterated derivatives, 3~6-membered heterocyclyls or their halogenated or deuterated derivatives;
    X is selected from O or S;
    L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-4 alkylenyls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C2-4 alkenyls or their halogenated or deuterated derivatives, C2-4 alkynyls or their halogenated or deuterated derivatives, C1-4 alkoxyls or their halogenated or deuterated derivatives, C3-5 cycloalkyls or their halogenated or deuterated derivatives, 3~5-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    L1 and L2 can be connected to the homotopic or heterotopic atoms on the A ring; m is an integer of 0~4;
    Ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles, 3~6-membered saturated heterocycles or 3~6-membered unsaturated heterocycles;
    R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl,
    Figure imgb0494
     substituted or unsubstituted C1-8 alkyls, -OR33, -SR33, -OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, -C(O)R34, -C(S)R34, -S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls, cyano, isocyano, isothiocyano, nitro, -L33-R36 or =R39;
    L33 is selected from C1-4 alkylenyls;
    R36 is selected from cyano, nitro, -OC(O)R34, -C(O)R34, -S(O)R34, -C(O)N(R33)2;
    R33 is selected from the group consisting of hydrogen, methyl sulfonyl, the following substituted or unsubstituted groups:C1-8 alkyls, C3-8 cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls;
    R34 is selected from the group consisting of R33, deuterium, the following substituted or unsubstituted groups: C1-8 alkoxyl, C2-8 alkenyls, C2-8 alkynyls; For above R5, R33, R34, said substituents thereof are selected from the group consisting of deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives, -S-C1-4 alkyls, di-substituted cyclic carbonyl, =R39, C2-6 alkenyls or C2-6 alkynyls;
    R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-4 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
  4. Compounds according to claim 3, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, characterized in that:
    R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-4 alkyls; said substituents is deuterium, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-6 cycloalkyls or their halogenated or deuterated derivatives, 3~6-membered heterocycles or their halogenated or deuterated derivatives;
    Or, L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-4 alkylenyls; said substituents are deuterium, cyano, hudroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C2-4 alkenyls or their halogenated or deuterated derivatives, C2-4 alkynyls or their halogenated or deuterated derivatives, C1-4 alkoxyls or their halogenated or deuterated derivatives, C3-5 cycloalkyls or their halogenated or deuterated derivatives, 3~5-membered heterocycles or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    m is an integer of 0~4;
    Or, ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles, 3~6-membered saturated heterocycles or 3~6-membered unsaturated heterocycles;
    or, R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl ,
    Figure imgb0495
     substituted or unsubstituted C1-6 alkyls, -OR33, -SR33, - OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, -C(O)R34, -C(S)R34, -S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-6 alkenyls, substituted or unsubstituted C2-6 alkynyls, cyano, isocyano, isothiocyano, =R39;
    R33 is selected from the group consisting of hydrogen, methylsulfonyl, the following substituted or unsubstituted groups: C1-4 alkyls, C3-8 cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls;
    R34 is selected from the group consisting of R33, deuterium, the following substituted or unsubstituted groups: C1-4 alkoxyl, C2-4 alkenyls, C2-4 alkynyls;
    For above R5, R33, R34, said substituents are selected from the group consisting of deuterium, cyano, hudroxyl, carboxyl, halogen, C1-4 alkyls, C1-4 alkoxyl, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -S-C1-4 alkyls, di-substituted carbonyls, =R39, C2-4 alkenyls or C2-4 alkynyls;
    R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen,
    C1-4 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
    Preferably:
    For above R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-2 alkyls; said substituents are deuterium, halogen, C1-2 alkyls or their halogenated or deuterated derivatives, C1-2 alkoxyl or their halogenated or deuterated derivatives;
    Or, L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-3 alkylenyls; said substituents are deuterium, halogen, C1-3 alkyls or their halogenated or deuterated derivatives, C2-3 alkenyls or their halogenated or deuterated derivatives, C2-3 alkynyls or their halogenated or deuterated derivatives, C1-3 alkoxyl or their halogenated or deuterated derivatives;
    m is an integer of 0~3;
    Or, ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles, 3~6-membered saturated heterocycles; or, R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl ,
    Figure imgb0496
     substituted or unsubstituted C1-4 alkyls, -OR33, -SR33, - OC(O)R34, C3-8-membered cycloalkyls, C3-8-membered cycloalkyls, 3~8-membered heterocyclylss, aryls, heteroaryls, -N(R33)2, -C(O)R34, -C(S)R34, -S(O)R34, - CON(R33)2, -SO2R34, substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, cyano, isocyano, isothiocyano, =R39;
    R33 is selected from the group consisting of hydrogen, methylsulfonyl, the following substituted or unsubstituted groups: C1-3 alkyls, C3-6 cycloalkyls, 3~6-membered heterocyclyls, aryls, heteroaryls;
    R34 is selected from the group consisting of R33, deuterium, substituted or unsubstituted C1-3 alkoxyl;
    For above R5 ,R33,R34, said substituents are selected from the group consisting of deuterium, halogen, cyano, C1-2 alkyls, C1-2 alkoxyl, C3-6-membered cycloalkyls, 3~6-membered heterocycyls, aryls, heteroaryls, -S-C1-2 alkyls, di-substituted cyclic carbonyl, =R39, C2-4 alkenyls or C2-4 alkynyls;
    R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-3 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
    More Preferably:
    For above R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyl groups;
    Or, L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-2 alkylenyls; said substituents are deuterium, halogen, C1-2 alkyls, C2-3 alkenyls, C2-3 alkynyls;
    m is an integer of 0~2;
    Or, ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles or 3~6-membered saturated heterocycles; or, R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl ,
    Figure imgb0497
     , substituted or unsubstituted C1-3 alkyls, -OR33, -SR33, - OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, -C(O)R34, -C(S)R34, -S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-3 alkenyls, substituted or unsubstituted C2-3 alkynyls, cyano, isocyano, isothiocyano, =R39;
    R33 is selected from the group consisting of hydrogen, methylsulfonyl, acetyl, C1-3 alkyls;
    R34 is selected from the group consisting of R33, deuterium, C1-3 alkoxyl;
    For above R5, said substituents are selected from the group consisting of deuterium, halogen, cyano, C1-2 alkyls, 3~5-membered heterocyclyls, -S-CH3, di-substituted carbonyl, =R39, C2-4 alkenyls or C2-4 alkynyls;
    R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-3 alkyls; R41 is selected from R40 or deuterium;
  5. Compounds according to anyone of claims 2~4, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, characterized in that: said compound is represented by formula A-II:
    Figure imgb0498
     In formula A-II:
    Ring A is 3~6-membered saturated carbocycles;
    X is selected from O, S; m is an integer of 0~2;
    R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyl, preferably,
    R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, F, Cl, CF3;
    L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted methylene; said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
    L1 and L2 can be connected to the homotopic or heterotopic atoms on the A ring;
    R5 is selected from the group consisting of hydrogen, deuterium, C1-2 alkyls, propadienyl, substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, -OR33, -C(O)R34, halogen, =R39;
    R33 is selected from the C1-3 alkyls;
    R34 is selected from the group consisting of R33, deuterium, C1-3 alkoxyl;
    Said substituents of R5 are selected from the group consisting of =R39, C2-4 alkenyls or C2-4 alkynyls;
    R39 is selected from O, S, CH2;
    or, in formula A-II:
    Ring A is selected from 3~6-membered saturated heterocycles; preferably, ring A is
    Figure imgb0499
     , M is O or S;
    X is selected from O or S; m is an integer of 0~2;
    R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyl, preferably, R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, F, Cl, CF3;
    L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted methylene; said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
    R5 is selected from the group consisting of hydrogen, deuterium, C1-2 alkyls, propadienyl, substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, -OR33, -C(O)R34, halogen, =R39;
    R33 is selected from C1-3 alkyls;
    R34 is selected from the group consisting of R33, deuterium, C1-3 alkoxyl;
    Said substituents R5 are selected from the group consisting of =R39, C2-4 alkenyls or C2-4 alkynyls;
    R39 is selected from O, S, CH2;
    Or, in formula A-II:
    Ring A is 5~6-membered unsaturated carbocycles; preferably, ring A is
    Figure imgb0500
     or
    Figure imgb0501
    X is selected from O, S; m is an integer of 0~1;
    R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyl, preferably, R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, F, Cl, CF3;
    L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted methylene; said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
    R5 is selected from -C(O)R34, R34 is selected from the group consisting of deuterium, R33, C1-2 alkoxyl, R33 is selected from the group consisting hydrogen, C1-2 alkyl; Or, in formula formula A-II:
    Ring A is none;
    X is selected from O, S; m is an integer of 0~1;
    R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyl, preferably, R3 and R4 are independently of each other selected from the group consisting of hydrogen, deuterium, F, Cl, CF3;
    L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted methylene; said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
    R5 is selected from the group consisting of hydrogen, deuterium, C1-4 alkyls, propadienyl ,
    Figure imgb0502
     substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, -OR33, -OC(O)R34;
    R33 is selected from C1-3 alkyls;
    R34 is selected from the group consisting of deuterium, R33, C1-3 alkoxyl;
    Said substituents of R5 are selected from the group consisting ofdi-substituted cyclic carbonyls, =R39, C2-4 alkenyls or C2-4 alkynyls, R39 is selected from O, S, CH2;
  6. Compounds according to claim 1, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, characterized in that: said compound is represented by formula B-1:
    Figure imgb0503
    R1 is independently of each other selected from the group consisting of deuterium, halogen, -CN, -NO2, -OR32, -C(O)R31, -CO2R31, -CON(R32)2, -N(R32)2, -OC(O)R31, -SO2R31, substituted or unsubstituted 3~8-membered heterocyclyls, substituted or unsubstituted C1-8 alkyls, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls;
    Wherein, R31 is independently of each other selected from the group consisting of deuterium, R32, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls, R32 is independently of each other selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyls, substituted or unsubstituted C3-8 cycloalkyls, substituted or unsubstituted 3~8-membered heterocyclyls, substituted or unsubstituted aryls, substituted or unsubstituted heteroaryls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    For above R1, R31, R32, said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    n is an integer of 0~5;
    R2 is selected from the group consisting of hydrogen, deuterium, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C1-8 alkoxyl or their halogenated or deuterated derivatives, C2-8 alkenyls or their halogenated or deuterated derivatives, C2-8 alkynyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives;
    In R4a and R4b, one is R4, other is
    Figure imgb0504
    Wherein, R4 is selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-8 alkyls, N(R3)2; said substituents are deuterium, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C1-8 alkoxyls or their halogenated or deuterated derivatives, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyl or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives, - N(R3)2, R3 is H or C1-8 alkyls;
    X is selected from O, S, or NR30, wherein, R30 is selected from hydrogen or C1-8 alkyls;
    L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-8 alkylenyls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-8 alkyls or their halogenated or deuterated derivatives, C2-8 alkenyls or their halogenated or deuterated derivatives, C2-8 alkynyls or their halogenated or deuterated derivatives, C1-8 alkoxyls or their halogenated or deuterated derivatives, C3-8 cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    L1 and L2 can be connected to the homotopic or heterotopic atoms on the A ring; m is an integer of 0~4;
    Ring A is none, or, ring A is selected from 3~8-membered saturated carbocycles, 3~8-membered unsaturated carbocycles, 3~8-membered saturated heterocycles or 3~8-membered unsaturated heterocycles;
    R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl,
    Figure imgb0505
     substituted or unsubstituted C1-8 alkyls, -OR33, -SR33, -OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, - C(O)R34, -C(S)R34, -S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls, cyano, isocyano, isothiocyano, nitro, -L33-R36 or =R39;
    L33 is selected from C1-4 alkylenyls;
    R36 is selected from cyano, nitro, -OC(O)R34, -C(O)R34, -S(O)R34, -C(O)N(R33)2;
    R33 is selected from the group consisting of hydrogen, methylsulfonyl, -L31-COO-L32,
    the following substituted or unsubstituted groups: C1-8 alkyls, C3-8 cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls;
    R34 is selected from the group consisting of R33, deuterium, the following substituted or unsubstituted groups: C1-8 alkoxyl, C2-8 alkenyls, C2-8 alkynyls, or - S-C1-8 alkyls;
    L31 is selected from the substituted or unsubstituted C1-8 alkylenyls; L32 is selected from the substituted or unsubstituted C1-8 alkyls;
    For above R5, R33, R34, said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives, -S-C1-4 alkyls, di-substituted cyclic carbonyl, =R39, C2-8 alkenyls or C2-8 alkynyls;
    R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-4 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
    Preferably:
    For above R1 is independently of each other selected from the group consisting of deuterium, halogen, -CN, -NO2, -OR32, -C(O)R31, -CO2R31, -CON(R32)2, -N(R32)2, -OC(O)R31, C1-3 alkyls, C2-3 alkenyls, C2-3 alkynyls;
    Wherein, R31 is independently of each other selected from the group consisting of deuterium, R32, C2-3 alkenyls, C2-3 alkynyls; R32 is independently of each other selected from of hydrogen, C1-3 alkyls;
    Or, n is an integer of 0~2;
    Or, R2 is selected from the group consisting of hydrogen, deuterium, halogen, C1-3 alkyls or their halogenated or deuterated derivatives;
  7. Compounds according to claim 6, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, characterized in that: said compound is represented by formula B-II-1 or B-II-2:
    Figure imgb0506
    R4 is selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-4 alkyls, N(R3)2; Said substituents are deuterium, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-6 cycloalkyls or their halogenated or deuterated derivatives, 3~6-membered heterocyclyls or their halogenated or deuterated derivatives, -N(R3)2, R3 is H or C1-4 alkyls;
    X is selected from O or S;
    L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-4 alkylenyls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C2-4 alkenyls or their halogenated or deuterated derivatives, C2-4 alkynyls or their halogenated or deuterated derivatives, C1-4 alkoxyls or their halogenated or deuterated derivatives, C3-5 cycloalkyls or their halogenated or deuterated derivatives, 3~5-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    L1 and L2 can be connected to the homotopic or heterotopic atoms on the A ring; m is an integer of 0~4;
    Ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles, 3~6-membered saturated heterocycles or 3~6-membered unsaturated heterocycles;
    R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl,
    Figure imgb0507
     substituted or unsubstituted C1-8 alkyls, -OR33, -SR33, -OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, - C(O)R34, -C(S)R34, -S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-8 alkenyls, substituted or unsubstituted C2-8 alkynyls, cyano, isocyano, isothiocyano, nitro, -L33-R36 or =R39;
    L33 is selected from C1-4 alkylenyls;
    R36 is selected from cyano, nitro, -OC(O) R34, -C(O)R34, -S(O)R34, -C(O)N(R33)2;
    R34 is selected from the group consisting of deuterium or R33, R33 is selected from the group consisting of hydrogen, methyl sulfonyl, the following substituted or unsubstituted groups: C1-8 alkyls, C3-8 cycloalkyls, 3~8-membered heterocyclyls, heteroaryls;
    R34 is selected from the group consisting of R33, deuterium, the following substituted or unsubstituted groups: C1-8 alkoxyl, C2-8 alkenyls, C2-8 alkynyls; For above R5, R33, R34, said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-8-membered cycloalkyls or their halogenated or deuterated derivatives, 3~8-membered heterocyclyls or their halogenated or deuterated derivatives, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives, -S-C1-4 alkyls, si-substituted carbonyl, =R39, C2-6 alkenyls or C2-6 alkynyls;
    R39 is selected from O, S, NR40 or C(R41)2; R40 is selected from hydrogen, halogen, C1-4 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium.
  8. Compounds according to claim 7, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, characterized in that:
    R4 is selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-4 alkyls, N(R3)2; Said substituents is deuterium, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C3-6 cycloalkyls or their halogenated or deuterated derivatives, 3~6-membered heterocyclyls or their halogenated or deuterated derivatives, -N(R3)2, R3 is H or C1-4 alkyls;
    Or, L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-4 alkylenyls; said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C1-4 alkoxyl or their halogenated or deuterated derivatives, C2-4 alkenyls or their halogenated or deuterated derivatives, C2-4 alkynyls or their halogenated or deuterated derivatives, C3-5 cycloalkyls or their halogenated or deuterated derivatives, 3~5-membered heterocyclyls or their halogenated or deuterated derivative, aryls or their halogenated or deuterated derivatives, heteroaryls or their halogenated or deuterated derivatives;
    m is an integer of 0~4;
    Or, ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles, 3~6-membered saturated heterocycles or 3~6-membered unsaturated heterocycles;
    Or, R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl,
    Figure imgb0508
     substituted or unsubstituted C1-6 alkyls, -OR33, -SR33, - OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, -C(O)R34, -C(S)R34, -S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-6 alkenyls, substituted or unsubstituted C2-6 alkynyls, cyano, isocyano, isothiocyano, =R39;
    R33 is selected from the group consisting of hydrogen, methyl sulfonyl, the following substituted or unsubstituted groups: C1-4 alkyls, C3-8 cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls;
    R34 is selected from the group consisting of R33, deuterium, the following substituted or unsubstituted groups: C1-4 alkoxyl, C2-4 alkenyls, C2-4 alkynyls;
    For above R5, R33, R34, said substituents are deuterium, cyano, hydroxyl, carboxyl, halogen, C1-4 alkyls, C1-4 alkoxyl, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -S-C1-4 alkyls, di-substituted cyclic carbonyl, =R39, C2-4 alkenyls or C2-4 alkynyls;
    R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen,
    C1-4 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
    Preferably:
    For above R4 is selected from the group consisting of hydrogen, deuterium, halogen, substituted or unsubstituted C1-2 alkyls, -N(R3)2; Said substituents is deuterium, halogen, C1-2 alkyls or their halogenated or deuterated derivatives, C1-2 alkoxyl or their halogenated or deuterated derivatives, -N(R3)2, R3 is H or C1-4 alkyls;
    Or, L1 and L2 are independently of each other selected from the group consisting of none, substituted or unsubstituted C1-3 alkylenyls; said substituents is deuterium, halogen, C1-4 alkyls or their halogenated or deuterated derivatives, C2-3 alkenyls or their halogenated or deuterated derivatives, C2-3 alkynyls or their halogenated or deuterated derivatives, C1-3 alkoxyl or their halogenated or deuterated derivatives; m is an integer of 0~3;
    Or, ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles or 3~6-membered saturated heterocycles; or, R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl.
    Figure imgb0509
     , substituted or unsubstituted C1-4 alkyls, -OR33, -SR33, - OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, -C(O)R34, -C(S)R34, -S(O)34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, cyano, isocyano, isothiocyano, =R39;
    R33 is selected from the group consisting of hydrogen, methylsulfonyl, the following substituted or unsubstituted groups: C1-3 alkyls, C3-6 cycloalkyls, 3~6-membered heterocyclyls, aryls, heteroaryls;
    R34 is selected from the group consisting of R33, deuterium, substituted or unsubstituted C1-3 alkoxyl;
    For above R5, R33 and R34, said substituents are deuterium, halogen, cyano, C1-2 alkyls, C1-2 alkoxyls, C3-6-membered cycloalkyls, 3~6-membered heterocyclyls, aryls, heteroaryls, -S-C1-2 alkyls, di-substituted cyclic carbonyl, =R39, C2-4 alkenyls or C2-4 alkynyls;
    R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-3 alkyls or their halogenated or deuterated derivatives; R41 is selected from R40 or deuterium;
    More Preferably:
    For above R4 is selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyl, - N(R3)2, R3 is H or C1-2 alkyl;
    Or, L1 and L2 are independently of each other selected from none, substituted or unsubstituted C1-2 alkylenyls; said substituents are deuterium, halogen, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
    m is an integer of 0~2;
    Or, ring A is none, or, ring A is selected from 3~6-membered saturated carbocycles, 3~6-membered unsaturated carbocycles, 3~6-membered saturated heterocycles; or, R5 is selected from the group consisting of hydrogen, deuterium, halogen, propadienyl ,
    Figure imgb0510
     substituted or unsubstituted C1-3 alkyls, -OR33, -SR33, - OC(O)R34, C3-8-membered cycloalkyls, 3~8-membered heterocyclyls, aryls, heteroaryls, -N(R33)2, -C(O)R34, -C(S)R34, -S(O)R34, -CON(R33)2, -SO2R34, substituted or unsubstituted C2-3 alkenyls, substituted or unsubstituted C2-3 alkynyls, cyano, isocyano, isothiocyano, =R39;
    R33 is selected from the group consisting of hydrogen, methyl sulfonyl, acetyl, C1-3 alkyls;
    R34 is selected from the group consisting of R33, deuterium, C1-3 alkoxyl;
    For above R5 is selected from of the group deuterium, halogen, cyano, C1-2 alkyls, 3~5-membered heterocyclyls, -S-CH3, di-substituted cyclic carbonyl, =R39, C2-4 alkenyls or C2-4 alkynyls;
    R39 is selected from O, S, NR40 or C(R41)2, R40 is selected from hydrogen, halogen, C1-3 alkyls; R41 is selected from R40 or deuterium;
  9. Compounds according to anyone of claims 6~8, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, characterized in that: said compound is represented by formula B-II-1 or B-II-2:
    Figure imgb0511
     Wherein:
    Ring A is 3~6-membered saturated carbocycles;
    X is selected from O, S; m is an integer of 0~2;
    R4 is selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyls, N(R3)2; R3 is H or C1-2 alkyls; preferably, R4 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, CF3, -N(CH3)2;
    L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted methylenes; said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
    L1 and L2 can be connected to the homotopic or heterotopic atoms on the A ring;
    R5 is selected from the group consisting of hydrogen, deuterium, C1-2 alkyls, propadienyl, substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, -OR33, -SR33, -C(O)R34, halogen, =R39;
    R33 is selected from the C1-3 alkyls;
    R34 is selected from the group consisting of R33, deuterium, C1-3 alkoxyls;
    R5 said substituents are selected from the group consisting of =R39, C2-4 alkenyls or
    C2-4 alkynyls;
    Or, wherein:
    Ring A is selected from 3~6-membered saturated heterocycles; preferably, ring A is
    Figure imgb0512
     M is s O or S;
    X is selected from O or S; m is an integer of 0~2;
    R4 is selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyls, N(R3)2, R3 is H or C1-2 alkyls; preferably, R4 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, CF3, -N(CH3)2;
    L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted C1-2 methylene; said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
    R5 is selected from the group consisting of hydrogen, deuterium, C1-2 alkyls, propadienyl, substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, -OR33, -SR33, -C(O)R34, halogen, =R39;
    R33 is selected from the C1-3 alkyls;
    R34 is selected from the group consisting of R33, deuterium, C1-3 alkoxyl;
    R5 said substituents is selected from the group consisting of =R39, C2-4 alkenyls or
    C2-4 alkynyls;
    R39 is selected from the O, S, CH2;
    Or, wherein:
    Ring A is selected from 5~6-membered unsaturated carbocycles; preferably, Ring A is
    Figure imgb0513
    X is selected from O or S; m is an integer of 0~1;
    R4 is selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyls, N(R3)2; R3 is H or C1-2 alkyls; Preferably, R4 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, CF3, -N(CH3)2;
    L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted C1-2 methylene; said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
    R5 is selected from -C(O)R34, R34 is selected from the group consisting of deuterium, R33, C1-2 alkoxyl; R33 is selected from hydrogen, C1-2 alkyls;
    or, wherein:
    Ring A is none,
    X is selected from O, S; m is an integer of 0~1;
    R4 is independently of each other selected from the group consisting of hydrogen, deuterium, halogen, halogenated or un-halogenated methyl, -N(R3)2, R3 is H or C1-2 alkyls; Preferably, R4 is selected from the group consisting of hydrogen, deuterium, F, Cl, Br, I, CF3, -N(CH3)2;
    L1 and L2 are independently of each other selected from the group consisting of none, substituted by 1~2 substituents or unsubstituted C1-2 methylene; said substituents are deuterium, C1-4 alkyls, C2-3 alkenyls, C2-3 alkynyls;
    R5 is selected from the group consisting of hydrogen, deuterium, C1-4 alkyls , substituted by 1~3 halogens alkyls, propadienyl,
    Figure imgb0514
     substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, -OR33, -SR33, -C(O)R34;
    R33 is selected from the C1-3 alkyls;
    R34 is selected from the group consisting of deuterium, R33, C1-3 alkoxyls;
    Said substituents of R5 are selected from the group consisting of di-substituted cyclopentanoyls, =R39, C2-4 alkenyls or C2-4 alkynyls, R39 is selected from O, S, CH2;
  10. Compounds according to claim 1, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, characterized in that: said compound is represented by formula C-I:
    Figure imgb0515
     Wherein, n is an integer of 0~3;
    R1 is selected from the group consisting of halogens, C1-5 alkyls , C1-5 alkoxyls;
    R2 is selected from the group consisting of halogens, C1-5 alkyls, C1-5 alkoxyls;
    Y1 is selected from N or CRc5a, Y2 is selected from N or CRc5b;
    Rc5a, Rc5b, Rc3 are independently selected from the group consisting of hydrogen, halogens, C1-5 alkyls;
    R0 is selected from LC3RC4, LC1XCLC2RC5;
    LC3 is selected from the group consisting of none, substituted or unsubstituted C1-4 alkylenyls; said substituents of C1-4 alkylenyls are selected from the group consisting of C1-5 alkyls, C1-5 alkoxyls, halogens, hydroxyl;
    RC4 is selected from the group consisting of substituted or unsubstituted C2-6 alkenyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted 3~6-membered saturated or unsaturated heterocyclyls, substituted or unsubstituted 3~6-membered saturated or unsaturated cycloalkyls, COR4d; said substituents independently of each other selected from LC4R4e; R4d is selected C1-6 alkyls; LC4 is selected from the group consisting of none, substituted or unsubstituted C1-4 alkylenyl; R4e is selected from the group consisting of C1-5 alkyls, C1-5 alkoxyl, halogen, hydroxyl;
    LC1 is selected from the substituted or unsubstituted C1-3 alkylenyls, said substituents are selected from the C1-5 alkyls;
    XC is O or S;
    LC2 is selected from the group consisting of none, substituted or unsubstituted C1-3 alkylenyls, said substituents are selected from the C1-4 alkyls, alkoxyls, L2aR5g;
    L2a is selected from the group consisting of none, C1-2 alkylenyls, R5g is selected from halogen, alkoxyls;
    Rc5 is selected from the group consisting of hydrogen, halogen, C1-5 alkyls, C2-4 alkenyls, C2-4 alkynyls, COR4d, C3-6 dienyls, C1∼5 alkoxyl, substituted by one or more R5c 3~6-membered saturated or unsaturated heterocyclyls; substituted by one or more R5c 3~6-membered saturated or unsaturated cycloalkyls; R4d is selected from C1-6 alkyls, R5, is selected from the group consisting of halogen, =R5d, L1aR5e, C3-6 dienyls;
    R5D is CH2, O or S; L1a is C1-3 alkylenyls; R5e is C1-5 alkyls, C1-5 alkoxyls.
  11. Compounds according to claim 10, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, characterized in that: said compound is represented by formula C-II:
    Figure imgb0516
     In formula C- II, RC4a is selected from the group consisting of substituted or unsubstituted C2-6 alkenyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted 3~6-membered saturated or unsaturated heterocyclyls, substituted or unsubstituted 3~6-membered saturated or unsaturated cycloalkyls; Said substituents are independently of each other selected from the group consisting of C1-5 alkyls, C1-5 alkoxyl, halogen, hydroxyl;
    Y1 is selected from N or CRC5a, Y2 is selected from N or CRC5b; Preferably, Y1 and Y2 aren't N at the same time;
    RC5a, RC5b, RC3 are independently of each other selected from the group consisting of hydrogen, halogen, C1-5 alkyls;
    Or, said the compounds are represented by formula C-III-a or formula C-III-b:
    Figure imgb0517
    Wherein, XC is O or S;
    LC1 is selected from substituted or unsubstituted C1-3 alkylenyls, said substituents are selected from the C1-3 alkyls; preferably, LC1 is methylene;
    LC2 is selected from the group consisting of none, substituted or unsubstituted C1-2 alkylenyls, said substituents are selected from the C1-3 alkyls;
    Ring C is selected from 3~4-membered saturated heterocyclyls, 3~4-membered saturated cycloalkyls;
    m1 is selected from 0, 1, 2; R5c is selected from the group consisting of halogen, =R5d, L1aR5e, propadienyl; R5d is CH2; L1a is C1∼3 alkylenyls, R5e is C1∼3 alkyls, C1∼3 alkoxyls; said halogen is selected to be F preferably;
    RC5a, RC5b, RC3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼3 alkyls; said halogen is selected to be F preferably;
    or, said the compounds are represented by formula C-III-c or formula C-III-d:
    Figure imgb0518
    Wherein, XC is O or S;
    LC1 is selected from substituted or unsubstituted C1-3 alkylenyls, said substituents are selected from the C1-3 alkyls, preferably, LC1 is selected from C1∼2 alkylenyls;
    LC2 is selected from the group consisting of none, substituted or unsubstituted C1-2 alkylenyls, said substituents are selected from the alkyls, alkoxyls, L2aR5g;
    L2a is selected from none, C1-2 alkylenyls; R5g is selected from halogen, alkoxyls;
    R5f is selected from the group consisting of hydrogen, halogen, alkyls, C2-3 alkenyls, C2-3 alkynyls, COR4d, propadienyl, C1∼4 alkoxyls; R4d is selected from C1∼4 alkyls;
    RC5a, RC5b, RC3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼3 alkyls; said halogen is selected to be F preferably;
    Or, said the compounds are represented by formula C-IV:
    Figure imgb0519
    In formula C-IV, LC3 is selected from substituted or unsubstituted alkylenyls, said substituents are selected from the group consisting of C1-5 alkyls, C1∼3 alkoxyl, halogen, hydroxyl;
    R4c is selected from the group consisting of substituted or unsubstituted C2-6 alkenyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted 3~6-membered saturated cycloalkyls, substituted or unsubstituted 3~6-membered saturated heterocyclyls, COR4d; said substituents are independently of each other selected from LC4R4e; R4d is selected from C1∼5 alkyls, LC4 is selected from none or C1-3 alkylenyls; R4e is selected from the group consisting of C1∼3 alkyls, C1∼3 alkoxyls, halogen, hydroxyl;
    Y1 is selected from N or CRC5a, Y2 is selected from N or CRC5b; preferably, Y1 and Y2 aren't N at the same time.
    RC5a, RC5b, RC3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼3 alkyls;
  12. Compounds according to anyone of claims 11, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, characterized in that: said the compound C-IV is represented by formula C- II-a or formula C- II -b
    Figure imgb0520
     Wherein, RC4a is selected from the group consisting of substituted or unsubstituted C2-3 alkenyls, substituted or unsubstituted C2-3 alkynyls, substituted or unsubstituted 3~4-membered saturated epoxyls; said substituents areindependently of each other selected from C1-3 alkyls;
    RC5a, RC5b, RC3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼3 alkyls; said halogen is selected to be F preferably;
    Or, the said compound C-IV is represented by formula C-IV-a or formula C-IV-b:
    Figure imgb0521
    wherein, LC3 is selected from substituted or unsubstituted C1-3 alkylenyls, said substituents is selected from the group consisting of C1-3 alkyls, C1∼3 alkoxyl;
    R4c is selected from the group consisting of substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted C2-4 alkynyls, substituted or unsubstituted 4-membered saturated cycloalkyls, COR4d; Said substituents are independently of each other selected from LC4R4e; R4d is selected from C1∼3 alkyls, LC4 is selected from the group consisting of none or C1-2 alkylenyls; R4e is selected from C1∼3 alkyls, C1∼3 alkoxyl;
    RC5a, RC5b, RC3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼3 alkyls; said halogen is selected to be F preferably.
  13. Compounds according to anyone of claims 11, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, characterized in that: the said compound is represented by formula D-I:
    Figure imgb0522
     Wherein, n is an integer of 0~3;
    R1 is selected from the group consisting of halogen, C1-5 alkyls, C1-5 alkoxyls;
    R2 is selected from the group consisting of halogen, C1-5 alkyls, C1-5 alkoxyls;
    Y1 is selected from N or CRD5a, Y2 is selected from N or CRD5b;
    RD5a, RD5b, RD3 are independently selected from the group consisting of hydrogen, halogen, C1-5 alkyls;
    MD is selected from CO or CRD6 RD7; RD6 is selected from hydrogen, XDbRD4b; R7 is selected from hydrogen, XDcRD4c;
    XD is O or S; XDb is O or S; XDc is O or S;
    Ra is selected from the group consisting of substituted or unsubstituted C1-6 alkyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted C2-6 alkenyls, substituted or unsubstituted 3~6-membered saturated or unsatutated hererocyclyls, substituted or unsubstituted 3~6-membered saturated or unsatutated cycloalkyls; said substituents are independently of each other selected from the group consisting of C3-6dienyls, C1∼3 alkyls, C1∼3 alkoxyl, halogen, hydroxyl;
    RD4b, RD4c are independently of each other selected from the group consisting of substituted or unsubstituted C1∼6 alkyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted C2-6 alkenyls, CORDf, substituted or unsubstituted 3∼6-membered saturated or unsatutated hererocyclyls, substituted or unsubstituted 3∼6-membered saturated or unsatutated cycloalkyls; said substituents are independently of each other selected from the group consisting of C3-6dienyls, C1∼3 alkyls, C1∼3 alkoxyl, halogen, hydroxyl; RDf is selected from C1∼3 alkyls;
    Or, when MD is CRD6RD7 and RD6 is XDbRD4b, RD4b and Ra are connected to get substituted or unsubstituted 3~6-membered saturated or unsatutated hererocyclyls,
    said substituents of saturated or unsatutated hererocyclyls are selected from halogenated or unhalogenated C1∼6 alkyls, halogenated or unhalogenated C2-6 alkynyls, halogenated or unhalogenated C2-6 alkenyls, CORDf;
    RD7 is selected from hydrogen, XDcRD4c; XDc is O or S, RD4c is selected from the group consisting of substituted or unsubstituted C1-6 alkyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted C2-6 alkenyls, CORDf, substituted or unsubstituted 3~6-membered saturated or unsatutated hererocyclyls, substituted or unsubstituted 3~6-membered saturated or unsatutated cycloalkyls, said substituents are independently of each other selected from the group consisting of C3-6dienyls, C1∼3 alkyls, C1∼3 alkoxyl, halogen, hydroxyl; RDf is selected from C1∼3 alkyls;
  14. Compounds according to anyone of claims 13, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, characterized in that: said the compound is represented by formula D-II:
    Figure imgb0523
     In formula D-II, XD is O or S;
    Ra is selected from the group consisting of substituted or unsubstituted C1-6 alkyls, substituted or unsubstituted C2-6 alkynyls, substituted or unsubstituted C2-6 alkenyls, substituted or unsubstituted 3~6-membered saturated or unsatutated hererocyclyls, substituted or unsubstituted 3~6-membered saturated or unsatutated cycloalkyls; said substituents are independently of each other selected from the group consisting of C3-6dienyls, C1∼3 alkyls, C1∼3 alkoxyls, halogen, hydroxyl;
    Y1 is selected from N or CRC5a, Y2 is selected from N or CRC5b;
    RD5a, RD5b, RD3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼3 alkyls;
    Or, said the compound is represented by formula D-III:
    Figure imgb0524
    Wherein, RD7 is selected from hydrogen or XDcRD4c;
    XD, XDb, XDc are independently selected from O or S;
    Ra, RD4b, RD4c are independently of each other selected from the group consisting of C1-6 alkyls, C2-6 alkynyls, C2-6 alkenyls, substituted or unsubstituted 3~6-membered saturated or unsatutated hererocyclyls, substituted or unsubstituted 3~6-membered saturated or unsatutated cycloalkyls; said substituents are independently of each other selected from the group consisting of C1∼3 alkyls, C1∼3 alkoxyl, halogen, hydroxyl;
    Y1 is selected from N or CRD5a, Y2 is selected from N or CRD5b;
    RD5a, RD5b, RD3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼3 alkyls;
    Or, said the compound is represented by formula D-IV:
    Figure imgb0525
    In formula D-IV, RD7 is selected from hydrogen, XDcRD4c;
    XDb, XD, XD4c are independently selected from O or S;
    RD4c is selected from the group consisting of C1-6 alkyls, C2-6 alkynyls, C2-6 alkenyls, CORDf; RDf is selected from C1-5 alkyls;
    Rd1 and Re1 are independently of each other selected from the group consisting of hydrogen, halogenated or un-halogenated C1-6 alkyls, C2-6 alkynyls, C2-6 alkenyls, CORDf; RDf is selected from C1-5 alkyls;
    Rd2 and Re2 are independently of each other selected from the group consisting of none, hydrogen, halogenated or un-halogenated C1-6 alkyls, C2-6 alkynyls, C2-6 alkenyls, CORDf; RDf is selected from C1-5 alkyls;
    Figure imgb0526
     is single bond or double bond;when
    Figure imgb0527
     is double bond, Rd2 and Re2 are none;
    Y1 is selected from N or CRD5a, Y2 is selected from N or CRD5b;
    RD5a, RD5b, RD3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼3 alkyls.
  15. Compounds according to anyone of claims 14, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, characterized in that: Said the compound D-II is represented by formula D-II-1, formula D-II-2, formula D-II-3 or formula D-II-4:
    Figure imgb0528
    Figure imgb0529
     Wherein, X is O or S, preferable selection is O;
    Ra is selected from the group consisting of substituted or unsubstituted C1-5 alkyls, substituted or unsubstituted C2-4 alkynyls, substituted or unsubstituted C2-4 alkenyls, substituted or unsubstituted 4-membered saturated epoxyls groups , substituted or unsubstituted 4-membered saturated cycloalkyls; Said substituents are independently of each other selected from the group consisting of propadienyl,
    C1∼3 alkyls, C1∼3 alkoxys;
    RD5a, RD5b, RD3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼3 alkyls; Said halogen is selected to be F, Cl, Br preferably;
    Or, said the compound D-III is represented by formula D-III-1, formula D-III-2, formula D-III-3 or formula D-III-4:
    Figure imgb0530
    Figure imgb0531
    Wherein, RD7 is selected from hydrogen or XDcRD4c;
    XD, XDb, XDc are independently selected from O or S;
    Ra, RD4b, RD4c are independently of each other selected from the group consisting of C1-5 alkyls, C2-4 alkynyls, C2-3 alkenyls, 4-membered saturated cycloalkyls;
    RD5a, RD5b, RD3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼3 alkyls; Said halogen is selected to be F, Cl, Br preferably;
    Or, said the compound D-IV is represented by formula D-IV-1, formula D-IV-2, formula D-IV-3 or formula D-IV-4 :
    Figure imgb0532
    Figure imgb0533
    wherein, RD7 is selected from hydrogen, XDcRD4c;
    XDb, XD, XDc are independently of each other selected from O or S;
    RD4c is selected from the group consisting of C1-5 alkyls, C2-4 alkynyls, C2-3 alkenyls;
    Rd1and Re1 are independently of each other selected from the group consisting of hydrogen, halogenated or un-halogenated C1-5 alkyls, CORDf; RDf is selected from C1-3 alkyls; Preferably, said halogenated C1-5 alkyls are CF3;
    Rd2 and Re2 are independently of each other selected from the group consisting of none, hydrogen, halogenated or un-halogenated C1-5 alkyls, CORDf; RDf is selected from C1-3 alkyls; Preferably, said halogenated C1-5 alkyls are CF3;
    Figure imgb0534
     is single bond or double bond; when is double bond,
    Figure imgb0535
     is double, Rd2 and Re2 are none;
    RD5a, RD5b, RD3 are independently of each other selected from the group consisting of hydrogen, halogen, C1∼3 alkyls; said halogen is selected to be F, Cl, Br preferably.
  16. Compounds according to anyone of claims 1~15, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, characterized in that, said compounds are:
    Figure imgb0536
    Figure imgb0537
    Figure imgb0538
    Figure imgb0539
    Figure imgb0540
    Figure imgb0541
    Figure imgb0542
    Figure imgb0543
    Figure imgb0544
    Figure imgb0545
    Figure imgb0546
    Figure imgb0547
    Figure imgb0548
    Figure imgb0549
    Figure imgb0550
    Figure imgb0551
    Figure imgb0552
    Figure imgb0553
    Figure imgb0554
    Figure imgb0555
    Figure imgb0556
    Figure imgb0557
    Figure imgb0558
    Figure imgb0559
    Figure imgb0560
    Figure imgb0561
    Figure imgb0562
    Figure imgb0563
    Figure imgb0564
    Figure imgb0565
    Figure imgb0566
    Figure imgb0567
    Figure imgb0568
    Figure imgb0569
    Figure imgb0570
    Figure imgb0571
    Figure imgb0572
    Figure imgb0573
    Figure imgb0574
    Figure imgb0575
    Figure imgb0576
    Figure imgb0577
    Figure imgb0578
    Figure imgb0579
    Figure imgb0580
    Figure imgb0581
    Figure imgb0582
    Figure imgb0583
    Figure imgb0584
    Figure imgb0585
    Figure imgb0586
    Figure imgb0587
    Figure imgb0588
    Figure imgb0589
    Figure imgb0590
    Figure imgb0591
    Figure imgb0592
    Figure imgb0593
    Figure imgb0594
    Figure imgb0595
    Figure imgb0596
    Figure imgb0597
    Figure imgb0598
    Figure imgb0599
    Figure imgb0600
    Figure imgb0601
    Figure imgb0602
    Figure imgb0603
    Figure imgb0604
    Figure imgb0605
    Figure imgb0606
    Figure imgb0607
    Figure imgb0608
    Figure imgb0609
    Figure imgb0610
    Figure imgb0611
    Figure imgb0612
    Figure imgb0613
    Figure imgb0614
    Figure imgb0615
    Figure imgb0616
    Figure imgb0617
    Figure imgb0618
    Figure imgb0619
    Figure imgb0620
    Figure imgb0621
    Figure imgb0622
    Figure imgb0623
    Figure imgb0624
    Figure imgb0625
    Figure imgb0626
    Figure imgb0627
    Figure imgb0628
    Figure imgb0629
    Figure imgb0630
    Figure imgb0631
    Figure imgb0632
    Figure imgb0633
    Figure imgb0634
    Figure imgb0635
    Figure imgb0636
    Figure imgb0637
    Figure imgb0638
    Figure imgb0639
    Figure imgb0640
    Figure imgb0641
    Figure imgb0642
    Figure imgb0643
    Figure imgb0644
    Figure imgb0645
    Figure imgb0646
    Figure imgb0647
    Figure imgb0648
    Figure imgb0649
    Figure imgb0650
    Figure imgb0651
    Figure imgb0652
    Figure imgb0653
    Figure imgb0654
    Figure imgb0655
    Figure imgb0656
    Figure imgb0657
    Figure imgb0658
    Figure imgb0659
    Figure imgb0660
    Figure imgb0661
    Figure imgb0662
    Figure imgb0663
    Figure imgb0664
    Figure imgb0665
    Figure imgb0666
    Figure imgb0667
    Figure imgb0668
    Figure imgb0669
    Figure imgb0670
    Figure imgb0671
    Figure imgb0672
    Figure imgb0673
    Figure imgb0674
    Figure imgb0675
    Figure imgb0676
    Figure imgb0677
    Figure imgb0678
    Figure imgb0679
    Figure imgb0680
    Figure imgb0681
    Figure imgb0682
    Figure imgb0683
    Figure imgb0684
    Figure imgb0685
    Figure imgb0686
    Figure imgb0687
    Figure imgb0688
    Figure imgb0689
    Figure imgb0690
    Figure imgb0691
    Figure imgb0692
    Figure imgb0693
    Figure imgb0694
    Figure imgb0695
    Figure imgb0696
    Figure imgb0697
    Figure imgb0698
    Figure imgb0699
  17. A drug, characterized in that it is prepared by using compounds according to anyone of claims 1~16, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, or their combinations as active ingredients, with addition of pharmaceutically acceptable excipients.
  18. The use of above compounds according to anyone of claims 1~16, or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or solvates thereof, or prodrugs thereof, or metabolites thereof, or deuterated derivatives thereof, or their combinations in preparation of drugs having sedative, hypnotic, and/or anesthetic effects and/or drugs that can be used to control epileptic status is applied.
EP20875415.0A 2019-10-11 2020-10-10 Substituted nitrogen heterocyclic compound and anesthetic effect thereof Pending EP4043440A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910964601.7A CN110724106B (en) 2019-10-11 2019-10-11 Substituted pyrazole formate derivative and application thereof
CN201910965229.1A CN110669017B (en) 2019-10-11 2019-10-11 Polysubstituted triazole formate derivative and application thereof
CN202011074987.3A CN112239428B (en) 2020-10-09 2020-10-09 Ketone-substituted heterocyclic compounds and their anesthetic action
CN202011073826.2A CN112174890B (en) 2020-10-09 2020-10-09 Ketone-substituted heterocyclic compounds and their anesthetic action
PCT/CN2020/120218 WO2021068943A1 (en) 2019-10-11 2020-10-10 Substituted nitrogen heterocyclic compound and anesthetic effect thereof

Publications (2)

Publication Number Publication Date
EP4043440A1 true EP4043440A1 (en) 2022-08-17
EP4043440A4 EP4043440A4 (en) 2023-11-08

Family

ID=75437006

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20875415.0A Pending EP4043440A4 (en) 2019-10-11 2020-10-10 Substituted nitrogen heterocyclic compound and anesthetic effect thereof

Country Status (4)

Country Link
US (1) US20230026724A1 (en)
EP (1) EP4043440A4 (en)
JP (1) JP2022551176A (en)
WO (1) WO2021068943A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113549013A (en) * 2021-07-29 2021-10-26 守恒(厦门)医疗科技有限公司 N-cyclopropyl methoxy imidazole amide derivatives and application thereof in antitumor drugs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2802325T3 (en) * 2012-01-13 2017-03-13 Massachusetts Gen Hospital ANESTHETIC RELATIONS AND RELATED APPLICATIONS THEREOF
EP3360863B1 (en) * 2015-10-10 2022-04-20 Jiangsu Nhwaluokang Pharmaceutical Research and Development Co., Ltd. Etomidate derivative and intermediate, preparation method and use thereof
CN107382870A (en) * 2016-05-17 2017-11-24 四川海思科制药有限公司 N substituted imidazole carboxylic acid ester compounds and preparation method thereof and purposes in medicine
CN107445898A (en) * 2016-05-30 2017-12-08 四川海思科制药有限公司 N substituted imidazole carboxylic acid ester compounds and preparation method thereof and purposes in medicine
CN107522662A (en) * 2016-06-16 2017-12-29 四川海思科制药有限公司 N substituted imidazole carboxylic acid ester compounds and preparation method thereof and purposes in medicine
CN107641105A (en) * 2016-07-22 2018-01-30 四川海思科制药有限公司 N substituted imidazole carboxylic acid ester compounds and preparation method thereof and purposes in medicine
CN109776510B (en) * 2018-01-30 2023-08-18 成都麻沸散医药科技有限公司 N-substituted imidazole formate derivative and application thereof
CN111153851B (en) 2019-02-01 2022-02-08 四川大学华西医院 Quaternary ammonium salt compound and preparation method and application thereof
CN109761906B (en) * 2019-03-02 2023-08-11 成都麻沸散医药科技有限公司 Substituted imidazole formate derivative and application thereof
CN110003188B (en) * 2019-03-27 2022-08-26 成都麻沸散医药科技有限公司 Substituted pyrrole formate derivative and application thereof
CN110724106B (en) * 2019-10-11 2023-05-05 成都麻沸散医药科技有限公司 Substituted pyrazole formate derivative and application thereof
CN110669017B (en) * 2019-10-11 2023-08-04 成都麻沸散医药科技有限公司 Polysubstituted triazole formate derivative and application thereof

Also Published As

Publication number Publication date
WO2021068943A1 (en) 2021-04-15
EP4043440A4 (en) 2023-11-08
US20230026724A1 (en) 2023-01-26
JP2022551176A (en) 2022-12-07

Similar Documents

Publication Publication Date Title
EP4043464A1 (en) Fused pyridone compound, and preparation method therefor and use thereof
EP3466431B1 (en) Crystalline forms and methods for preparing sglt2 inhibitors
KR102252649B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
US11434205B2 (en) Substituted imidazole carboxylate derivatives and the use thereof
EP3068785A1 (en) Substituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine derivatives as casein kinase 1 d/e inhibitors
JP2015508408A (en) Crystal forms of prostaglandin analogues and their production and use
WO2020007322A1 (en) Compound targeted to degrade bet protein and application thereof
EP3088394B1 (en) Chiral methoxyethyl etomidate compound, its prepartion and application as anesthesia
EP3415519A1 (en) Thiazolopyrimidinones as modulators of nmda receptor activity
TW200944527A (en) Pyrrolopyrimidinecarboxamides
EP4043440A1 (en) Substituted nitrogen heterocyclic compound and anesthetic effect thereof
EP3438108A1 (en) Phenyl [a]indole[2,3-g]quinolizine compounds, preparation method therefor, pharmaceutical composition, and applications thereof
CN109761906B (en) Substituted imidazole formate derivative and application thereof
CN110669017B (en) Polysubstituted triazole formate derivative and application thereof
CN110003188B (en) Substituted pyrrole formate derivative and application thereof
JPH05262766A (en) Piperidylmethyl-substituted chroman derivative
CN110724106A (en) Substituted pyrazole formate derivative and application thereof
EP4365170A1 (en) Amide compound and use thereof
RU2478630C2 (en) Intermediate compounds and methods for preparing zearalene macrolide analogues
EP4289842A1 (en) Phenyldihydropyrimidine compound and use thereof
AU2018323528B2 (en) Indene derivatives and uses thereof
CN107540677B (en) Sitagliptin derivative or pharmaceutically acceptable salt thereof, and preparation method and application thereof
EP3805225A1 (en) SELECTIVE A2a RECEPTOR ANTAGONIST
WO2022135390A1 (en) Ketohexokinase inhibitor and use thereof
JP2024517906A (en) Sulfonimidoyl-containing ATR inhibitor compounds

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220429

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231010

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4155 20060101ALI20231004BHEP

Ipc: A61K 31/415 20060101ALI20231004BHEP

Ipc: A61P 25/08 20060101ALI20231004BHEP

Ipc: A61P 23/00 20060101ALI20231004BHEP

Ipc: A61P 25/20 20060101ALI20231004BHEP

Ipc: C07D 409/12 20060101ALI20231004BHEP

Ipc: C07D 405/12 20060101ALI20231004BHEP

Ipc: C07D 249/04 20060101ALI20231004BHEP

Ipc: C07D 231/14 20060101AFI20231004BHEP